,symbol,name,description__profile,ceo__profile,industry__profile,price__profile,currency__profile,mktCap__profile,image__profile,volAvg__profile,pe__quote,change__quote,volume__quote,ebitda__income_statement,netIncome__income_statement,annual_earnings,quaterly_earnings,eps__income_statement,epsdiluted__income_statement,totalAssets__balance_sheet_statement,totalCurrentAssets__balance_sheet_statement,cashAndShortTermInvestments__balance_sheet_statement,totalLiabilities__balance_sheet_statement,netReceivables__balance_sheet_statement,longTermInvestments__balance_sheet_statement,totalCurrentLiabilities__balance_sheet_statement,cashAndCashEquivalents__balance_sheet_statement,freeCashFlow__cash_flow_statement,growthEBITDA__income_statement_growth,growthNetIncome__income_statement_growth,growthEPS__income_statement_growth,dividend__historical-price-full/stock_dividend,date__historical-price-full/stock_dividend,derived__netIncomeMargin,derived__debtRatio
0,AACG,ATA Creativity Global American Depositary Shares,"ATA Creativity Global, together with its subsidiaries, provides educational services to individual students through its training center network in China and internationally. Its educational services include portfolio training, research-based learning, overseas study counselling, in-school art classes through cooperation with high schools, foreign language training services, junior art education, and other related educational services to its students. The company also offers online courses for students. As of December 31, 2021, it operated through 21 training centers in 20 cities in China. The company was formerly known as ATA Inc. and changed its name to ATA Creativity Global in September 2019. ATA Creativity Global was founded in 1999 and is headquartered in Beijing, China.",Mr. Xiaofeng  Ma,Education & Training Services,0.9199,USD,14545689,https://images.financialmodelingprep.com/symbol/AACG.png,38691,-5.75,-0.0201,48675,-18817684,-36097777,"[{'period': '2024', 'revenue': 268.06, 'unit': 'M', 'net_profit': -36.1}, {'period': '2023', 'revenue': 221.62, 'unit': 'M', 'net_profit': -33.66}, {'period': '2022', 'revenue': 206.82, 'unit': 'M', 'net_profit': -48.59}, {'period': '2021', 'revenue': 202.21, 'unit': 'M', 'net_profit': -36.41}]","[{'period': ""Q4 '24"", 'revenue': 100.92, 'unit': 'M', 'net_profit': 13.26}, {'period': ""Q3 '24"", 'revenue': 67.25, 'unit': 'M', 'net_profit': -14.65}, {'period': ""Q2 '24"", 'revenue': 51.76, 'unit': 'M', 'net_profit': -16.75}, {'period': ""Q1 '24"", 'revenue': 48.13, 'unit': 'M', 'net_profit': -17.95}, {'period': ""Q4 '23"", 'revenue': 83.61, 'unit': 'M', 'net_profit': 8.56}, {'period': ""Q3 '23"", 'revenue': 59.45, 'unit': 'M', 'net_profit': -7.25}]",-2.3,-2.3,456927265,66639674,36523995,377281073,17887213,38000000,354495409,36523995,-23370073,0.03556042424573542,-0.07241575336127233,-0.06481481481481466,"[0.5980000000000001, 0.43]","['2018-08-27', '2011-06-28']",__nan__,0.8256917498674543
1,AACQ,Artius Acquisition Inc. Class A Common Stock,,,,,,,,,,,,,,[],"[{'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 62.53}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 16.18}, {'period': ""Q2 '20"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]",,,726060750,1344274,1123407,721060740,0,0,220,1123407,,,,,__nan__,__nan__,__nan__,0.9931135101298342
2,AACQU,Artius Acquisition Inc. Unit ,,,,11.05,USD,1581255000,https://images.financialmodelingprep.com/symbol/AACQU.png,12570,0,0.5,4352,-71942000,-83697000,"[{'period': '2024', 'revenue': 31.28, 'unit': 'M', 'net_profit': -83.7}, {'period': '2023', 'revenue': 28.8, 'unit': 'M', 'net_profit': 23.8}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 78.57}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -37.05}]","[{'period': ""Q1 '25"", 'revenue': 5.43, 'unit': 'M', 'net_profit': -26.44}, {'period': ""Q4 '24"", 'revenue': 9.22, 'unit': 'M', 'net_profit': -13.52}, {'period': ""Q3 '24"", 'revenue': 8.2, 'unit': 'M', 'net_profit': -36.76}, {'period': ""Q2 '24"", 'revenue': 7.03, 'unit': 'M', 'net_profit': -19.5}, {'period': ""Q1 '24"", 'revenue': 6.83, 'unit': 'M', 'net_profit': -13.91}, {'period': ""Q4 '23"", 'revenue': 13.06, 'unit': 'M', 'net_profit': -10.44}]",-0.0006,-0.0006,378027000,139174000,102920000,39662000,21705000,0,12549000,56307000,-59783000,-3.682401193139448,-4.51697621648878,-1.0035294117647058,__nan__,__nan__,__nan__,0.10491843175222934
3,AACQW,Artius Acquisition Inc Warrant,,,,,,,,,,,,0,0,"[{'period': '2020', 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]","[{'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 62.53}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]",0,0,726060750,1344274,725839883,25357720,0,0,0,1123407,-562274,0,0,0,__nan__,__nan__,__nan__,0.0349250665319672
4,AAL,American Airlines Group Inc. Common Stock,"American Airlines Group Inc., through its subsidiaries, operates as a network air carrier. The company provides scheduled air transportation services for passengers and cargo through its hubs in Charlotte, Chicago, Dallas/Fort Worth, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C., as well as through partner gateways in London, Madrid, Seattle/Tacoma, Sydney, and Tokyo. As of December 31, 2021, it operated a mainline fleet of 865 aircraft. The company was formerly known as AMR Corporation and changed its name to American Airlines Group Inc. in December 2013. American Airlines Group Inc. was founded in 1930 and is headquartered in Fort Worth, Texas.",Mr. Robert D. Isom Jr.,"Airlines, Airports & Air Services",11.86,USD,7821812320,https://images.financialmodelingprep.com/symbol/AAL.png,67364132.6,11.86,0.1,46253945,5014000000,846000000,"[{'period': '2024', 'revenue': 54210.0, 'unit': 'M', 'net_profit': 846.0}, {'period': '2023', 'revenue': 52790.0, 'unit': 'M', 'net_profit': 822.0}, {'period': '2022', 'revenue': 48970.0, 'unit': 'M', 'net_profit': 127.0}, {'period': '2021', 'revenue': 29.88, 'unit': 'B', 'net_profit': -1.99}]","[{'period': ""Q1 '25"", 'revenue': 12550.0, 'unit': 'M', 'net_profit': -473.0}, {'period': ""Q4 '24"", 'revenue': 13660.0, 'unit': 'M', 'net_profit': 590.0}, {'period': ""Q3 '24"", 'revenue': 13650.0, 'unit': 'M', 'net_profit': -149.0}, {'period': ""Q2 '24"", 'revenue': 14330.0, 'unit': 'M', 'net_profit': 717.0}, {'period': ""Q1 '24"", 'revenue': 12570.0, 'unit': 'M', 'net_profit': -312.0}, {'period': ""Q4 '23"", 'revenue': 13060.0, 'unit': 'M', 'net_profit': 19.0}]",1.29,1.17,61783000000,13154000000,6984000000,65760000000,2006000000,161000000,24295000000,804000000,1300000000,-0.03613994617454825,0.029197080291970802,0.02380952380952383,"[0.1, 0.1]","['2020-02-04', '2014-07-31']",__nan__,1.0643704578929478
5,AAME,Atlantic American Corporation Common Stock,"Atlantic American Corporation, through its subsidiaries, provides life and health, and property and casualty insurance products in the United States. The company operates through American Southern and Bankers Fidelity segments. It offers property and casualty insurance products, including business automobile insurance coverage for state governments, local municipalities, and other motor pools and fleets; and inland marine and general liability insurance products. The company also provides surety bond coverage for subdivision construction, school bus contracts, as well as performance and payment bonds. In addition, the company provides individual and group whole life insurance, as well as medicare supplement insurance products; and other accident and health insurance coverages, include various individual and group policies for the payment of standard benefits for the treatment of diagnosed cancer and other critical illnesses, as well as various other policies, such as short-term nursing facility care, accident expense, hospital indemnity, and disability coverages. It markets its products through independent agents and brokers. The company was founded in 1937 and is headquartered in Atlanta, Georgia.",Mr. Hilton Hatchett Howell Jr.,Insurance - Life,1.72,USD,35083184,https://images.financialmodelingprep.com/symbol/AAME.png,12490,-17.2,-0.06,5232,-1479000,-4268000,"[{'period': '2024', 'revenue': 188.23, 'unit': 'M', 'net_profit': -4.27}, {'period': '2023', 'revenue': 186790.0, 'unit': 'K', 'net_profit': -171.0}, {'period': '2022', 'revenue': 187.85, 'unit': 'M', 'net_profit': 1.52}, {'period': '2021', 'revenue': 199.55, 'unit': 'M', 'net_profit': 4.28}]","[{'period': ""Q1 '25"", 'revenue': 50120.0, 'unit': 'K', 'net_profit': 802.0}, {'period': ""Q4 '24"", 'revenue': 49040.0, 'unit': 'K', 'net_profit': 412.0}, {'period': ""Q3 '24"", 'revenue': 44.52, 'unit': 'M', 'net_profit': -2.0}, {'period': ""Q2 '24"", 'revenue': 47670.0, 'unit': 'K', 'net_profit': -684.0}, {'period': ""Q1 '24"", 'revenue': 47.0, 'unit': 'M', 'net_profit': -2.0}, {'period': ""Q4 '23"", 'revenue': 46.74, 'unit': 'M', 'net_profit': -2.23}]",-0.2,-0.19,393428000,35570000,35570000,293815000,50400000,193255000,71972000,35570000,4575000,-1.4407032181168058,-23.95906432748538,-6.168458781362007,"[0.02, 0.2]","['2025-04-09', '1984-12-24']",__nan__,0.7468075480138678
6,AAOI,Applied Optoelectronics Inc. Common Stock,"Applied Optoelectronics, Inc. designs, manufactures, and sells various fiber-optic networking products worldwide. It offers optical modules, lasers, subassemblies, transmitters and transceivers, and turn-key equipment, as well as headend, node, and distribution equipment. The company sells its products to internet data center operators, cable television and telecom equipment manufacturers, and internet service providers through its direct and indirect sales channels. Applied Optoelectronics, Inc. was incorporated in 1997 and is headquartered in Sugar Land, Texas.",Dr. Chih-Hsiang  Lin Ph.D.,Semiconductors,18.69,USD,1038124836,https://images.financialmodelingprep.com/symbol/AAOI.png,4840032.4,-4.58,-0.18,3044747,-159256000,-186733000,"[{'period': '2024', 'revenue': 249.37, 'unit': 'M', 'net_profit': -186.73}, {'period': '2023', 'revenue': 217.65, 'unit': 'M', 'net_profit': -56.05}, {'period': '2022', 'revenue': 222.82, 'unit': 'M', 'net_profit': -66.4}, {'period': '2021', 'revenue': 211.56, 'unit': 'M', 'net_profit': -54.16}]","[{'period': ""Q1 '25"", 'revenue': 99.86, 'unit': 'M', 'net_profit': -9.17}, {'period': ""Q4 '24"", 'revenue': 100.27, 'unit': 'M', 'net_profit': -119.69}, {'period': ""Q3 '24"", 'revenue': 65.15, 'unit': 'M', 'net_profit': -17.76}, {'period': ""Q2 '24"", 'revenue': 43.27, 'unit': 'M', 'net_profit': -26.11}, {'period': ""Q1 '24"", 'revenue': 40.67, 'unit': 'M', 'net_profit': -23.17}, {'period': ""Q4 '23"", 'revenue': 60.45, 'unit': 'M', 'net_profit': -13.86}]",-4.5,-4.5,547032000,301268000,67428000,317920000,116801000,0,170069000,67428000,-112932000,-5.082187595478155,-2.331662146731373,-1.5714285714285714,__nan__,__nan__,__nan__,0.581172582225537
7,AAON,AAON Inc. Common Stock,"AAON, Inc., together with its subsidiaries, engages in engineering, manufacturing, marketing, and selling air conditioning and heating equipment in the United States and Canada. The company operates through three segments: AAON Oklahoma, AAON Coil Products, and BasX. It offers rooftop units, data center cooling solutions, cleanroom systems, chillers, packaged outdoor mechanical rooms, air handling units, makeup air units, energy recovery units, condensing units, geothermal/water-source heat pumps, coils, and controls. The company markets and sells its products to retail, manufacturing, educational, lodging, supermarket, data centers, medical and pharmaceutical, and other commercial industries. It sells its products through a network of independent manufacturer representative organizations and internal sales force. The company was incorporated in 1987 and is based in Tulsa, Oklahoma.","Mr. Matthew J. Tobolski Ph.D., SE",Construction,106.87,USD,8695595107,https://images.financialmodelingprep.com/symbol/AAON.png,962596,55.95,2.76,433173,209118000,168559000,"[{'period': '2024', 'revenue': 1200.0, 'unit': 'M', 'net_profit': 168.56}, {'period': '2023', 'revenue': 1170.0, 'unit': 'M', 'net_profit': 177.62}, {'period': '2022', 'revenue': 888.79, 'unit': 'M', 'net_profit': 100.38}, {'period': '2021', 'revenue': 534.52, 'unit': 'M', 'net_profit': 58.76}]","[{'period': ""Q1 '25"", 'revenue': 322.05, 'unit': 'M', 'net_profit': 29.29}, {'period': ""Q4 '24"", 'revenue': 297.72, 'unit': 'M', 'net_profit': 24.69}, {'period': ""Q3 '24"", 'revenue': 327.25, 'unit': 'M', 'net_profit': 52.62}, {'period': ""Q2 '24"", 'revenue': 313.57, 'unit': 'M', 'net_profit': 52.23}, {'period': ""Q1 '24"", 'revenue': 262.1, 'unit': 'M', 'net_profit': 39.02}, {'period': ""Q4 '23"", 'revenue': 306.64, 'unit': 'M', 'net_profit': 47.05}]",2.07,2.02,1175234000,488212000,14000,350652000,286970000,0,174905000,14000,-3128000,-0.08077575672325424,-0.051029427495313105,-0.05479452054794526,"[0.1, 0.2]","['2025-06-06', '2006-06-08']",__nan__,0.29836781440972604
8,AAPL,Apple Inc. Common Stock,"Apple Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide. The company offers iPhone, a line of smartphones; Mac, a line of personal computers; iPad, a line of multi-purpose tablets; and wearables, home, and accessories comprising AirPods, Apple TV, Apple Watch, Beats products, and HomePod. It also provides AppleCare support and cloud services; and operates various platforms, including the App Store that allow customers to discover and download applications and digital content, such as books, music, video, games, and podcasts, as well as advertising services include third-party licensing arrangements and its own advertising platforms. In addition, the company offers various subscription-based services, such as Apple Arcade, a game subscription service; Apple Fitness+, a personalized fitness service; Apple Music, which offers users a curated listening experience with on-demand radio stations; Apple News+, a subscription news and magazine service; Apple TV+, which offers exclusive original content; Apple Card, a co-branded credit card; and Apple Pay, a cashless payment service, as well as licenses its intellectual property. The company serves consumers, and small and mid-sized businesses; and the education, enterprise, and government markets. It distributes third-party applications for its products through the App Store. The company also sells its products through its retail and online stores, and direct sales force; and third-party cellular network carriers, wholesalers, retailers, and resellers. Apple Inc. was founded in 1976 and is headquartered in Cupertino, California.",Mr. Timothy D. Cook,Consumer Electronics,211.252,USD,3155217621600,https://images.financialmodelingprep.com/symbol/AAPL.png,60872590,29.8,-0.198,53164417,134661000000,93736000000,"[{'period': '2024', 'revenue': 391.04, 'unit': 'B', 'net_profit': 93.74}, {'period': '2023', 'revenue': 383.29, 'unit': 'B', 'net_profit': 97.0}, {'period': '2022', 'revenue': 394.33, 'unit': 'B', 'net_profit': 99.8}, {'period': '2021', 'revenue': 365.82, 'unit': 'B', 'net_profit': 94.68}]","[{'period': ""Q2 '25"", 'revenue': 95.36, 'unit': 'B', 'net_profit': 24.78}, {'period': ""Q1 '25"", 'revenue': 124.3, 'unit': 'B', 'net_profit': 36.33}, {'period': ""Q4 '24"", 'revenue': 94.93, 'unit': 'B', 'net_profit': 14.74}, {'period': ""Q3 '24"", 'revenue': 85.78, 'unit': 'B', 'net_profit': 21.45}, {'period': ""Q2 '24"", 'revenue': 90.75, 'unit': 'B', 'net_profit': 23.64}, {'period': ""Q1 '24"", 'revenue': 119.58, 'unit': 'B', 'net_profit': 33.92}]",6.11,6.08,364980000000,152987000000,65171000000,308030000000,66243000000,91479000000,176392000000,29943000000,108807000000,0.07026704816404387,-0.033599670086086914,-0.008116883116883088,"[0.26, 0.12]","['2025-05-12', '1987-05-11']",__nan__,0.8439640528248123
9,AAWW,Atlas Air Worldwide Holdings NEW Common Stock,"Atlas Air Worldwide Holdings, Inc., through its subsidiaries, provides outsourced aircraft and aviation operating services. It operates through two segments, Airline Operations and Dry Leasing. The company offers outsourced cargo and passenger aircraft operating solutions, including contractual service arrangements, such as the provision of aircraft; and value-added services, including crew, maintenance, and insurance to aircraft and other customers. It also provides cargo and passenger aircraft charter services to the U.S. Military Air Mobility Command, charter brokers, freight forwarders, direct shippers, airlines, manufacturers, sports teams and fans, and private charter customers; and cargo and passenger aircraft and engines dry leasing services. In addition, the company offers administrative and management support services, and flight simulator training services. It also serves express delivery providers, e-commerce retailers, and airlines. The company has operations in Africa, Asia, Australia, Europe, the Middle East, North America, and South America. Atlas Air Worldwide Holdings, Inc. was founded in 1992 and is headquartered in Purchase, New York.",Mr. John W. Dietrich,"Airlines, Airports & Air Services",102.48,USD,2934330336,https://images.financialmodelingprep.com/symbol/AAWW.png,552884,9.732193732193732,0.02,1527211,914532000,355880000,"[{'period': '2022', 'revenue': 4550.0, 'unit': 'M', 'net_profit': 355.88}, {'period': '2021', 'revenue': 4030.0000000000005, 'unit': 'M', 'net_profit': 493.32}, {'period': '2020', 'revenue': 3210.0, 'unit': 'M', 'net_profit': 360.29}, {'period': '2019', 'revenue': 2740.0, 'unit': 'M', 'net_profit': -293.11}]","[{'period': ""Q4 '22"", 'revenue': 1210.0, 'unit': 'M', 'net_profit': 126.01}, {'period': ""Q3 '22"", 'revenue': 1120.0, 'unit': 'M', 'net_profit': 60.1}, {'period': ""Q2 '22"", 'revenue': 1180.0, 'unit': 'M', 'net_profit': 88.26}, {'period': ""Q1 '22"", 'revenue': 1040.0, 'unit': 'M', 'net_profit': 81.51}, {'period': ""Q4 '21"", 'revenue': 1160.0, 'unit': 'M', 'net_profit': 176.74}, {'period': ""Q3 '21"", 'revenue': 1020.0, 'unit': 'M', 'net_profit': 119.53}]",12.5,10.53,6696316000,1124918000,763314000,3631540000,253738000,0,1171283000,763314000,-8538000,-0.17628949641480052,-0.27859773735752064,-0.26729191090269633,__nan__,__nan__,__nan__,0.5423190900787836
10,ABCB,Ameris Bancorp Common Stock,"Ameris Bancorp operates as the bank holding company for Ameris Bank that provides range of banking services to retail and commercial customers primarily in Georgia, Alabama, Florida, North Carolina, and South Carolina. The company operates through five segments: Banking Division, Retail Mortgage Division, Warehouse Lending Division, SBA Division, and Premium Finance Division. It offers commercial and retail checking, regular interest-bearing savings, money market, individual retirement, and certificates of deposit accounts. The company also provides commercial real estate, residential real estate mortgage, agricultural, and commercial and industrial loans; consumer loans, including motor vehicle, home improvement, and home equity loans, as well as loans secured by savings accounts and small unsecured personal credit lines. In addition, it originates, administers, and services commercial insurance premium loans and small business administration loans. The company operates 165 full service domestic banking offices and 35 mortgage and loan production offices. Ameris Bancorp was founded in 1971 and is headquartered in Atlanta, Georgia.",Mr. H. Palmer Proctor Jr.,Banks - Regional,63.45,USD,4372396351,https://images.financialmodelingprep.com/symbol/ABCB.png,477958,11.79,0.17,286117,522588000,358685000,"[{'period': '2024', 'revenue': 1630.0, 'unit': 'M', 'net_profit': 358.69}, {'period': '2023', 'revenue': 1040.0, 'unit': 'M', 'net_profit': 269.11}, {'period': '2022', 'revenue': 1050.0, 'unit': 'M', 'net_profit': 346.54}, {'period': '2021', 'revenue': 990.85, 'unit': 'M', 'net_profit': 376.91}]","[{'period': ""Q1 '25"", 'revenue': 333.78, 'unit': 'M', 'net_profit': 87.94}, {'period': ""Q4 '24"", 'revenue': 281.21, 'unit': 'M', 'net_profit': 94.38}, {'period': ""Q3 '24"", 'revenue': 275.25, 'unit': 'M', 'net_profit': 99.21}, {'period': ""Q2 '24"", 'revenue': 290.0, 'unit': 'M', 'net_profit': 90.78}, {'period': ""Q1 '24"", 'revenue': 257.34, 'unit': 'M', 'net_profit': 74.31}, {'period': ""Q4 '23"", 'revenue': 253.3, 'unit': 'M', 'net_profit': 65.93}]",5.21,5.19,26262050000,2620198000,2620198000,22510528000,0,0,21722448000,1220377000,140716000,0,0.3328812173686851,0.3358974358974359,"[0.2, 0.095]","['2025-03-31', '1994-07-11']",__nan__,0.8571504509358561
11,ABCL,AbCellera Biologics Inc. Common Shares,"AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.",Dr. Carl L.G. Hansen Ph.D.,Biotechnology,2.03,USD,605924550,https://images.financialmodelingprep.com/symbol/ABCL.png,4503606,-3.62,0.01,3382653,-204148000,-162857000,"[{'period': '2024', 'revenue': 28.83, 'unit': 'M', 'net_profit': -162.86}, {'period': '2023', 'revenue': 38.02, 'unit': 'M', 'net_profit': -146.4}, {'period': '2022', 'revenue': 485.42, 'unit': 'M', 'net_profit': 158.52}, {'period': '2021', 'revenue': 375.2, 'unit': 'M', 'net_profit': 153.46}]","[{'period': ""Q1 '25"", 'revenue': 4.24, 'unit': 'M', 'net_profit': -45.62}, {'period': ""Q4 '24"", 'revenue': 5.05, 'unit': 'M', 'net_profit': -34.21}, {'period': ""Q3 '24"", 'revenue': 6.51, 'unit': 'M', 'net_profit': -51.11}, {'period': ""Q2 '24"", 'revenue': 7.32, 'unit': 'M', 'net_profit': -36.93}, {'period': ""Q1 '24"", 'revenue': 9.95, 'unit': 'M', 'net_profit': -40.61}, {'period': ""Q4 '23"", 'revenue': 9.18, 'unit': 'M', 'net_profit': -47.15}]",-0.55,-0.55,1360553000,751370000,625614000,304469000,92130000,82297000,76612000,156325000,-186952000,-0.06239656948969077,-0.11242639926774955,-0.07843137254901968,__nan__,__nan__,__nan__,0.22378327047898905
12,ABCM,Abcam plc American Depositary Shares,"Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools. The company serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. It has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. The company sells its products online. Abcam plc was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom.","Mr. Alan Thomas Hirzel BS, M.B.A., M.S.",Biotechnology,23.99,USD,5521322682,https://images.financialmodelingprep.com/symbol/ABCM.png,5816355,2399,0.01,7430229,42700000,-8500000,"[{'period': '2022', 'revenue': 361.7, 'unit': 'M', 'net_profit': -8.5}, {'period': '2021', 'revenue': 636.63, 'unit': 'M', 'net_profit': 23.66}, {'period': '2020', 'revenue': 297.7, 'unit': 'M', 'net_profit': 14.6}, {'period': '2019', 'revenue': 260.0, 'unit': 'M', 'net_profit': 12.5}]","[{'period': ""Q2 '23"", 'revenue': 203.2, 'unit': 'M', 'net_profit': 16.8}, {'period': ""Q4 '22"", 'revenue': 166.7, 'unit': 'M', 'net_profit': -9.38}, {'period': ""Q2 '22"", 'revenue': 185.2, 'unit': 'M', 'net_profit': 5.8}, {'period': ""Q4 '21"", 'revenue': 225.11, 'unit': 'M', 'net_profit': 2.04}, {'period': ""Q4 '20"", 'revenue': 167.7, 'unit': 'M', 'net_profit': 8.35}, {'period': ""Q2 '20"", 'revenue': 130.0, 'unit': 'M', 'net_profit': 6.25}]",-0.0372,-0.0372,1056600000,255400000,89000000,329700000,90300000,3200000,201800000,89000000,-12600000,-0.09915611814345991,-2.9318181818181817,-2.9375,"[0.044272, 0.035769]","['2020-03-19', '2014-03-19']",__nan__,0.31203861442362296
13,ABEO,Abeona Therapeutics Inc. Common Stock,"Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.","Dr. Vishwas  Seshadri M.B.A., Ph.D.",Biotechnology,6.1,USD,297679390,https://images.financialmodelingprep.com/symbol/ABEO.png,1456540,-3.94,0.31,1374904,-64211000,-63734000,"[{'period': '2024', 'revenue': 0.0, 'unit': 'M', 'net_profit': -63.73}, {'period': '2023', 'revenue': 3.5, 'unit': 'M', 'net_profit': -54.19}, {'period': '2022', 'revenue': 1.41, 'unit': 'M', 'net_profit': -31.81}, {'period': '2021', 'revenue': 3.0, 'unit': 'M', 'net_profit': -88.61}]","[{'period': ""Q1 '25"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -12.03}, {'period': ""Q4 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -9.29}, {'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -30.27}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.41}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -31.58}, {'period': ""Q4 '23"", 'revenue': 2.82, 'unit': 'M', 'net_profit': -16.59}]",-1.55,-1.55,108931000,100853000,97720000,64900000,1652000,0,16587000,23357000,-58461000,-0.2696946927153365,-0.17616446445707537,0.3873517786561264,"[0.593, 0.593]","['2000-03-31', '2000-03-31']",__nan__,0.5957899955017396
14,ABGI,ABG Acquisition Corp. I Class A Ordinary Shares,"ABG Acquisition Corp. I does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. ABG Acquisition Corp. I was incorporated in 2020 and is based in New York, New York.",Mr. Fan  Yu,Shell Companies,10.19,USD,196999184,https://images.financialmodelingprep.com/symbol/ABGI.png,42875,1019,-0.03,2114,-750584,-742688,"[{'period': '2021', 'revenue': 0.0, 'unit': 'K', 'net_profit': -742.69}]","[{'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.33}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 2.42}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -300.23}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -149.87}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -215.82}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -212.62}]",-0.0432,-0.0432,151524679,866783,510896,5469874,0,150657896,197124,510896,-979168,0,0,0,__nan__,__nan__,__nan__,0.03609889845072696
15,ABIO,ARCA biopharma Inc. Common Stock,"ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.",Mr. Thomas A. Keuer,Biotechnology,28.8,USD,34817184,https://images.financialmodelingprep.com/symbol/ABIO.png,13857,-4.8979591836734695,26.3,290850,-7296000,-5339000,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.34}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -9.26}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -19.23}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -9.74}]","[{'period': ""Q4 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -21.0}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.68}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.01}, {'period': ""Q3 '23"", 'revenue': 0.176, 'unit': 'M', 'net_profit': -1.09}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.42}]",-0.37,-0.37,37861000,37592000,37431000,841000,0,0,637000,37431000,-5014000,0.3114382785956965,0.42318496110630943,0.421875,"[1.613, 0.1325]","['2024-08-29', '2024-08-26']",__nan__,0.02221283114550593
16,ABMD,ABIOMED Inc. Common Stock,"Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.",Mr. Michael Minogue,Medical - Devices,381.02,USD,17180649405,https://images.financialmodelingprep.com/symbol/ABMD.png,1703123,65.35506003430531,0,15702662,400781000,136505000,"[{'period': '2022', 'revenue': 1030.0, 'unit': 'M', 'net_profit': 136.5}, {'period': '2021', 'revenue': 847.52, 'unit': 'M', 'net_profit': 225.53}, {'period': '2020', 'revenue': 840.88, 'unit': 'M', 'net_profit': 203.01}, {'period': '2019', 'revenue': 769.43, 'unit': 'M', 'net_profit': 259.02}]","[{'period': ""Q2 '23"", 'revenue': 265.92, 'unit': 'M', 'net_profit': 106.13}, {'period': ""Q1 '23"", 'revenue': 277.15, 'unit': 'M', 'net_profit': 54.55}, {'period': ""Q4 '22"", 'revenue': 269.85, 'unit': 'M', 'net_profit': 60.33}, {'period': ""Q3 '22"", 'revenue': 261.18, 'unit': 'M', 'net_profit': 45.75}, {'period': ""Q2 '22"", 'revenue': 248.14, 'unit': 'M', 'net_profit': 56.95}, {'period': ""Q1 '22"", 'revenue': 252.59, 'unit': 'M', 'net_profit': -26.52}]",3,2.98,1673393000,976473000,758607000,170067000,90608000,351938000,138457000,132818000,249627000,0.6230091075861455,-0.3947234231238222,-0.4,__nan__,__nan__,__nan__,0.10163004147860066
17,ABNB,Airbnb Inc. Class A Common Stock,"Airbnb, Inc., together with its subsidiaries, operates a platform that enables hosts to offer stays and experiences to guests worldwide. The company's marketplace model connects hosts and guests online or through mobile devices to book spaces and experiences. It primarily offers private rooms, primary homes, or vacation homes. The company was formerly known as AirBed & Breakfast, Inc. and changed its name to Airbnb, Inc. in November 2010. Airbnb, Inc. was founded in 2007 and is headquartered in San Francisco, California.",Mr. Brian  Chesky,Travel Services,138,USD,86444958810,https://images.financialmodelingprep.com/symbol/ABNB.png,5899662,35.03,1.21,3658953,2553000000,2648000000,"[{'period': '2024', 'revenue': 11.1, 'unit': 'B', 'net_profit': 2.65}, {'period': '2023', 'revenue': 9.92, 'unit': 'B', 'net_profit': 4.79}, {'period': '2022', 'revenue': 8.4, 'unit': 'B', 'net_profit': 1.89}, {'period': '2021', 'revenue': 5990.0, 'unit': 'M', 'net_profit': -352.0}]","[{'period': ""Q1 '25"", 'revenue': 2270.0, 'unit': 'M', 'net_profit': 154.0}, {'period': ""Q4 '24"", 'revenue': 2480.0, 'unit': 'M', 'net_profit': 461.0}, {'period': ""Q3 '24"", 'revenue': 3.73, 'unit': 'B', 'net_profit': 1.37}, {'period': ""Q2 '24"", 'revenue': 2750.0, 'unit': 'M', 'net_profit': 555.0}, {'period': ""Q1 '24"", 'revenue': 2140.0, 'unit': 'M', 'net_profit': 264.0}, {'period': ""Q4 '23"", 'revenue': 2220.0, 'unit': 'M', 'net_profit': -349.0}]",4.19,4.11,20959000000,17180000000,10611000000,12547000000,5931000000,0,10161000000,6864000000,4518000000,0.14535666218034993,-0.44741235392320533,-0.44281914893617014,__nan__,__nan__,__nan__,0.598644973519729
18,ABST,Absolute Software Corporation Common Stock,"Absolute Software Corporation develops, markets, and provides software services that support the management and security of computing devices, applications, data, and networks for various organizations. The company's Absolute platform offer Absolute Visibility that provides information on device hardware, software, and location; Absolute Control that provide remediation capabilities, such as the ability to remotely freeze devices and delete data; Absolute Resilience, which offer remote scripting, self-healing for critical apps, investigation and recovery services, and sensitive data identification; Absolute Ransomware Response that enables organizations to assess their ransomware preparedness for endpoints, monitors their endpoint cyber hygiene across the entire device fleet and allows for an expedited endpoint recovery; Absolute VPN an enterprise solution; Absolute ZTNA that protects networks and employees with real time risk analysis; and Absolute Insights for Network provides real-time data about device, application, and network performance in a single pane of glass. The company markets its solutions through device original equipment manufacturers, distributors, and value added resellers, as well as directly to healthcare organizations, educational institutions, governmental agencies, and individual consumers. It operates in North America, the United Kingdom, Vietnam, Germany, Australia, Japan, and Latin America. Absolute Software Corporation was incorporated in 1993 and is headquartered in Vancouver, Canada.",Ms. Christy  Wyatt,Software - Application,11.49,USD,610809526,https://images.financialmodelingprep.com/symbol/ABST.png,1570934,-22.98,-0.01,704052,18016000,-24485000,"[{'period': '2021', 'revenue': 197.31, 'unit': 'M', 'net_profit': -24.48}, {'period': '2020', 'revenue': 120.78, 'unit': 'M', 'net_profit': 3.73}, {'period': '2019', 'revenue': 104.67, 'unit': 'M', 'net_profit': 10.63}, {'period': '2018', 'revenue': 98.91, 'unit': 'M', 'net_profit': 7.58}]","[{'period': ""Q3 '22"", 'revenue': 58.77, 'unit': 'M', 'net_profit': -3.97}, {'period': ""Q2 '22"", 'revenue': 57.19, 'unit': 'M', 'net_profit': -7.0}, {'period': ""Q1 '22"", 'revenue': 53.56, 'unit': 'M', 'net_profit': -9.49}, {'period': ""Q4 '21"", 'revenue': 52.53, 'unit': 'M', 'net_profit': -5.34}, {'period': ""Q3 '21"", 'revenue': 51.98, 'unit': 'M', 'net_profit': -6.46}, {'period': ""Q2 '21"", 'revenue': 49.05, 'unit': 'M', 'net_profit': -5.12}]",-0.49,-0.49,555618000,136384000,64029000,552419000,63269000,0,174323000,63669000,37963000,0.5894133215703573,-7.560825294748124,-7.124999999999999,"[0.08, 0.05]","['2023-05-10', '2013-02-05']",__nan__,0.9942424471489405
19,ABTX,Allegiance Bancshares Inc. Common Stock,"Allegiance Bancshares, Inc. operates as the bank holding company for Allegiance Bank that provides a range of commercial banking services primarily to small and medium-sized businesses, professionals, and individual customers. It accepts deposit products, including checking accounts, commercial accounts, money market accounts, savings accounts, and other time deposits; and certificates of deposit. The company's loan portfolio comprises commercial and industrial loans; commercial real estate loans, including multi-family residential loans; commercial real estate construction and land development loans; residential real estate loans, such as 1-4 family residential mortgage loans; residential construction loans; and consumer and other loans. In addition, it offers automated teller machine services, drive-through services, and depository facilities; mobile banking services; and telephone, mail, and Internet banking services. Further, the company provides safe deposit boxes, debit cards, cash management and wire transfer services, night depository services, direct deposits, cashier's checks, and letters of credit. As of December 31, 2021, it operated 27 full-service banking locations, including 26 bank offices in the Houston metropolitan area and one office in Beaumont. The company was founded in 2007 and is headquartered in Houston, Texas.",Mr. Steven Retzloff,Banks - Regional,41.63,USD,0,https://images.financialmodelingprep.com/symbol/ABTX.png,0,11.190860215053764,-0.36,1609047,132064000,81553000,"[{'period': '2021', 'revenue': 237.13, 'unit': 'M', 'net_profit': 81.55}, {'period': '2020', 'revenue': 210.84, 'unit': 'M', 'net_profit': 45.53}, {'period': '2019', 'revenue': 192.96, 'unit': 'M', 'net_profit': 52.96}, {'period': '2018', 'revenue': 136.29, 'unit': 'M', 'net_profit': 37.31}]","[{'period': ""Q2 '22"", 'revenue': 60.19, 'unit': 'M', 'net_profit': 16.44}, {'period': ""Q1 '22"", 'revenue': 59.19, 'unit': 'M', 'net_profit': 18.66}, {'period': ""Q4 '21"", 'revenue': 60.56, 'unit': 'M', 'net_profit': 21.56}, {'period': ""Q3 '21"", 'revenue': 60.27, 'unit': 'M', 'net_profit': 19.06}, {'period': ""Q2 '21"", 'revenue': 58.87, 'unit': 'M', 'net_profit': 22.93}, {'period': ""Q1 '21"", 'revenue': 57.43, 'unit': 'M', 'net_profit': 18.01}]",3.97,3.97,7104954000,5029181000,2531274000,6288486000,33392000,1773765000,1753000,757509000,104449000,0.2860704269242755,0.7910352703474327,0.7882882882882882,"[0.14, 0.1]","['2022-08-30', '2020-02-28']",__nan__,0.8850846887960148
20,ABUS,Arbutus Biopharma Corporation Common Stock,"Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.","Ms. Lindsay  Androski J.D., M.B.A.",Biotechnology,3.08,USD,589903160,https://images.financialmodelingprep.com/symbol/ABUS.png,1071420,-8.11,-0.04,1014468,-68403000,-69920000,"[{'period': '2024', 'revenue': 6.17, 'unit': 'M', 'net_profit': -69.92}, {'period': '2023', 'revenue': 18.14, 'unit': 'M', 'net_profit': -72.85}, {'period': '2022', 'revenue': 39.02, 'unit': 'M', 'net_profit': -69.46}, {'period': '2021', 'revenue': 10.99, 'unit': 'M', 'net_profit': -77.35}]","[{'period': ""Q1 '25"", 'revenue': 1.76, 'unit': 'M', 'net_profit': -24.53}, {'period': ""Q4 '24"", 'revenue': 1.57, 'unit': 'M', 'net_profit': -12.53}, {'period': ""Q3 '24"", 'revenue': 1.34, 'unit': 'M', 'net_profit': -19.72}, {'period': ""Q2 '24"", 'revenue': 1.73, 'unit': 'M', 'net_profit': -19.8}, {'period': ""Q1 '24"", 'revenue': 1.53, 'unit': 'M', 'net_profit': -17.88}, {'period': ""Q4 '23"", 'revenue': 2.15, 'unit': 'M', 'net_profit': -19.31}]",-0.38,-0.38,131707000,127316000,122623000,34341000,2409000,0,15618000,36330000,-65032000,0.036387456681599185,0.04020645444686955,0.13636363636363635,__nan__,__nan__,__nan__,0.26073784992445354
21,ACAC,Acies Acquisition Corp. Class A Ordinary Share,"Acri Capital Acquisition Corporation focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. It intends to complete a business combination with technology-enabled companies operating in the areas of Software-as-a-Service, artificial intelligence, cloud computing, and Internet of Things. The company was incorporated in 2022 and is based in Austin, Texas.",Ms. Yi  Hua,Shell Companies,11.2,USD,44482256,https://images.financialmodelingprep.com/symbol/ACAC.png,9876,-18.06451612903226,-0.52,4112,-801150,886366,"[{'period': '2023', 'revenue': 0.0, 'unit': 'K', 'net_profit': 886.37}, {'period': '2022', 'revenue': 0.0, 'unit': 'K', 'net_profit': 217.22}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -213.23}]","[{'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -245.3}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 102.65}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 158.9}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 272.86}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 90.94}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 363.66}]",0.14,0.14,36732926,60080,54289,5171858,0,36672846,2550421,54289,-849990,-0.12130657444095627,3.0804238942289985,5.9306930693069315,__nan__,__nan__,__nan__,0.14079624367522478
22,ACACU,Acies Acquisition Corp. Unit,"Acri Capital Acquisition Corporation focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. It intends to complete a business combination with technology-enabled companies operating in the areas of Software-as-a-Service, artificial intelligence, cloud computing, and Internet of Things. The company was incorporated in 2022 and is based in Austin, Texas.",Ms. Yi  Hua,Shell Companies,12.94,USD,44482246,https://images.financialmodelingprep.com/symbol/ACACU.png,1165,0,-0.01,404,-801150,886366,"[{'period': '2023', 'revenue': 0.0, 'unit': 'K', 'net_profit': 886.37}, {'period': '2022', 'revenue': 0.0, 'unit': 'K', 'net_profit': 217.22}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -213.23}]","[{'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -245.3}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 102.65}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 158.9}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 272.86}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 90.94}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 363.66}]",0.14,0.14,36732926,60080,54289,5171858,0,36672846,2550421,54289,-849990,-0.12130657444095627,3.0804238942289985,5.9306930693069315,__nan__,__nan__,__nan__,0.14079624367522478
23,ACACW,Acies Acquisition Corp. Warrant,"Acri Capital Acquisition Corp. operates as a blank check company. The company was founded on January 7, 2022 and is headquartered in Austin, TX.",Ms. Yi  Hua,Shell Companies,0.26,USD,44482256,https://images.financialmodelingprep.com/symbol/ACACW.png,0,0,0.08,13089,-801150,886366,"[{'period': '2023', 'revenue': 0.0, 'unit': 'K', 'net_profit': 886.37}, {'period': '2022', 'revenue': 0.0, 'unit': 'K', 'net_profit': 217.22}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -213.23}]","[{'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -245.3}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 102.65}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 158.9}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 272.86}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 90.94}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 363.66}]",0.14,0.14,36732926,60080,54289,5171858,0,36672846,2550421,54289,-849990,-0.12130657444095627,3.0804238942289985,5.9306930693069315,__nan__,__nan__,__nan__,0.14079624367522478
24,ACAD,ACADIA Pharmaceuticals Inc. Common Stock,"ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.",Ms. Catherine E. Owen Adams,Biotechnology,22.26,USD,3725478120,https://images.financialmodelingprep.com/symbol/ACAD.png,1790848,16.25,4.66,17704772,100162000,226451000,"[{'period': '2024', 'revenue': 957.8, 'unit': 'M', 'net_profit': 226.45}, {'period': '2023', 'revenue': 726.44, 'unit': 'M', 'net_profit': -61.29}, {'period': '2022', 'revenue': 517.24, 'unit': 'M', 'net_profit': -215.97}, {'period': '2021', 'revenue': 484.14, 'unit': 'M', 'net_profit': -167.87}]","[{'period': ""Q1 '25"", 'revenue': 244.32, 'unit': 'M', 'net_profit': 18.99}, {'period': ""Q4 '24"", 'revenue': 259.6, 'unit': 'M', 'net_profit': 143.74}, {'period': ""Q3 '24"", 'revenue': 250.4, 'unit': 'M', 'net_profit': 32.77}, {'period': ""Q2 '24"", 'revenue': 241.96, 'unit': 'M', 'net_profit': 33.39}, {'period': ""Q1 '24"", 'revenue': 205.83, 'unit': 'M', 'net_profit': 16.55}, {'period': ""Q4 '23"", 'revenue': 231.04, 'unit': 'M', 'net_profit': 45.8}]",1.37,1.36,1187756000,938318000,755993000,454963000,104695000,0,394870000,319589000,157196000,2.476727556872632,4.694987435956009,4.7027027027027035,__nan__,__nan__,__nan__,0.3830441605851707
25,ACAH,Atlantic Coastal Acquisition Corp. Class A Common Stock,"Atlantic Coastal Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in mobility sector. The company was incorporated in 2020 and is based in New York, New York.",Mr. Anthony  Porcheron,Shell Companies,10.45,USD,127046920,https://images.financialmodelingprep.com/symbol/ACAH.png,1254,40.19230769230769,-0.18,37960,-4849950,17994321,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 17.99}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -9.21}, {'period': '2020', 'revenue': 0.0, 'unit': '', 'net_profit': -12.0}]","[{'period': ""Q3 '23"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.81}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.95}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.9}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.25}]",0.42,0.42,350656275,1353445,1252410,19858039,0,0,6904706,1252410,393036,0.03128831194355928,2.953135886402763,2.5555555555555554,__nan__,__nan__,__nan__,0.056631066990031766
26,ACAHU,Atlantic Coastal Acquisition Corp. Unit,"Atlantic Coastal Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in mobility sector. The company was incorporated in 2020 and is based in New York, New York.",Mr. Anthony  Porcheron,Shell Companies,10.66,USD,127046914,https://images.financialmodelingprep.com/symbol/ACAHU.png,514,-2132,-0.05,3002,-4849950,17994321,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 17.99}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -9.21}, {'period': '2020', 'revenue': 0.0, 'unit': '', 'net_profit': -12.0}]","[{'period': ""Q3 '23"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.81}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.95}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.9}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.25}]",0.42,0.42,350656275,1353445,1252410,19858039,0,0,6904706,1252410,393036,0.03128831194355928,2.953135886402763,2.5555555555555554,__nan__,__nan__,__nan__,0.056631066990031766
27,ACAHW,Atlantic Coastal Acquisition Corp. Warrant,"Atlantic Coastal Acquisition Corp. focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in San Francisco, California.",Mr. Anthony  Porcheron,Shell Companies,0.0161,USD,195077,https://images.financialmodelingprep.com/symbol/ACAHW.png,0,0,,0,-4849950,17994321,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 17.99}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -9.21}, {'period': '2020', 'revenue': 0.0, 'unit': '', 'net_profit': -12.0}]","[{'period': ""Q3 '23"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.81}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.95}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.9}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.25}]",0.42,0.42,350656275,1353445,1252410,19858039,0,0,6904706,1252410,393036,0.03128831194355928,2.953135886402763,2.5555555555555554,__nan__,__nan__,__nan__,0.056631066990031766
28,ACBAU,Ace Global Business Acquisition Limited Unit,"Ace Global Business Acquisition Limited does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses. It intends to focus on businesses in the gaming and e-commerce sectors in Greater China, Japan, and Southeast Asia regions. The company was incorporated in 2020 and is based in Central, Hong Kong.",Mr. Eugene Tu  Wong,Shell Companies,12,USD,41124600,https://images.financialmodelingprep.com/symbol/ACBAU.png,3,-57.69230769230769,-0.69,202,-1462820,-227215,"[{'period': '2023', 'revenue': 0.0, 'unit': 'K', 'net_profit': -227.22}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 4.93}, {'period': '2021', 'revenue': 0.0, 'unit': 'K', 'net_profit': -981.06}, {'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -15.81}]","[{'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -23.64}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -5.47}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 117.33}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -589.09}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 609.09}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.86}]",-0.0611,-0.0611,23399064,68541,68541,6951262,0,23330523,5103586,68541,-1355983,0.470359280353089,-1.0460850009309692,-1.0754320987654322,__nan__,__nan__,__nan__,0.2970743616069429
29,ACBAW,Ace Global Business Acquisition Limited Warrant,"Ace Global Business Acquisition Limited focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The company was founded in 2020 and is based in Central, Hong Kong.",Mr. Eugene Tu  Wong,Shell Companies,0.02,USD,68541,https://images.financialmodelingprep.com/symbol/ACBAW.png,0,0,-0.0136,210387,-1462820,-227215,"[{'period': '2023', 'revenue': 0.0, 'unit': 'K', 'net_profit': -227.22}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 4.93}, {'period': '2021', 'revenue': 0.0, 'unit': 'K', 'net_profit': -981.06}, {'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -15.81}]","[{'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -23.64}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -5.47}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 117.33}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -589.09}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 609.09}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.86}]",-0.0611,-0.0611,23399064,68541,68541,6951262,0,23330523,5103586,68541,-1355983,0.470359280353089,-1.0460850009309692,-1.0754320987654322,__nan__,__nan__,__nan__,0.2970743616069429
30,ACBI,Atlantic Capital Bancshares Inc. Common Stock,"Atlantic Capital Bancshares, Inc. operates as the bank holding company for Atlantic Capital Bank, N.A. that provides banking products and services. The company offers non-interest and interest bearing demand, savings and money market, time, and brokered deposits. It also provides working capital and equipment loans, loans supported by owner-occupied real estate, revolving lines of credit, term loans, and letters of credit; secured installments and home equity lines of credit; and commercial real estate loans, including secured construction loans, secured mini-permanent loans, and secured or unsecured lines of credit, as well as small business administration and franchise finance loans. In addition, the company offers cash and treasury management, capital market, payment processing, commercial and not-for-profit banking, payroll, electronic payment, and online and mobile banking services. It serves small and medium sized businesses and commercial enterprises, franchisees, not for profit enterprises, commercial real estate developers and individual clients, and professional services businesses. The company primarily operates 5 additional locations located in Cobb County, Fulton County, and Athens-Clarke County, Georgia; and Hamilton County, Tennessee. Atlantic Capital Bancshares, Inc. was incorporated in 2006 and is headquartered in Atlanta, Georgia.",Mr. Douglas Williams,Banks - Regional,32.34,USD,0,https://images.financialmodelingprep.com/symbol/ACBI.png,106420,0,-0.03,81866,46330000,22540000,"[{'period': '2020', 'revenue': 97.26, 'unit': 'M', 'net_profit': 22.54}, {'period': '2019', 'revenue': 91.59, 'unit': 'M', 'net_profit': 49.85}, {'period': '2018', 'revenue': 84.61, 'unit': 'M', 'net_profit': 28.53}, {'period': '2017', 'revenue': 97.03, 'unit': 'M', 'net_profit': -3.73}]","[{'period': ""Q3 '21"", 'revenue': 29.38, 'unit': 'M', 'net_profit': 13.3}, {'period': ""Q2 '21"", 'revenue': 29.24, 'unit': 'M', 'net_profit': 11.82}, {'period': ""Q1 '21"", 'revenue': 26.91, 'unit': 'M', 'net_profit': 13.36}, {'period': ""Q4 '20"", 'revenue': 25.66, 'unit': 'M', 'net_profit': 9.95}, {'period': ""Q3 '20"", 'revenue': 24.22, 'unit': 'M', 'net_profit': 8.62}, {'period': ""Q2 '20"", 'revenue': 23.97, 'unit': 'M', 'net_profit': 1.85}]",1.05,1.05,3615617000,3009901000,988825000,3277031000,0,561471000,0,653402000,80963000,-0.472407588767167,-0.5478888777454618,-0.5047169811320755,__nan__,__nan__,__nan__,0.9063545724007825
31,ACCD,Accolade Inc. Common Stock,"Accolade, Inc., together with its subsidiaries, develops and provides technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including nurses, physician medical directors, and behavioral health specialists. It also provides second opinion consultation and health care decision support services. The company serves employers who provide their employees and their employees' families a single place to turn for their health, healthcare, and benefits needs. Accolade, Inc. was incorporated in 2007 and is headquartered in Plymouth Meeting, Pennsylvania.",Mr. Rajeev  Singh,Medical - Healthcare Information Services,7.02,USD,575591590,https://images.financialmodelingprep.com/symbol/ACCD.png,1565611,-3.08,0,4543947,-69289000,-99805000,"[{'period': '2024', 'revenue': 414.29, 'unit': 'M', 'net_profit': -99.81}, {'period': '2023', 'revenue': 363.14, 'unit': 'M', 'net_profit': -459.65}, {'period': '2022', 'revenue': 310.02, 'unit': 'M', 'net_profit': -123.12}, {'period': '2021', 'revenue': 170.36, 'unit': 'M', 'net_profit': -50.65}]","[{'period': ""Q3 '25"", 'revenue': 105.06, 'unit': 'M', 'net_profit': -121.26}, {'period': ""Q2 '25"", 'revenue': 106.36, 'unit': 'M', 'net_profit': -23.93}, {'period': ""Q1 '25"", 'revenue': 110.47, 'unit': 'M', 'net_profit': -27.59}, {'period': ""Q4 '24"", 'revenue': 124.83, 'unit': 'M', 'net_profit': -7.51}, {'period': ""Q3 '24"", 'revenue': 99.37, 'unit': 'M', 'net_profit': -21.06}, {'period': ""Q2 '24"", 'revenue': 96.86, 'unit': 'M', 'net_profit': -32.83}]",-1.33,-1.33,788151000,284912000,237033000,342686000,27702000,0,107850000,185718000,-28651000,0.37206941864153337,0.782867399108017,0.7937984496124031,__nan__,__nan__,__nan__,0.4347973928853735
32,ACER,Acer Therapeutics Inc. Common Stock (DE),"Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts.",Mr. Christopher  Schelling,Biotechnology,0.6601,USD,0,https://images.financialmodelingprep.com/symbol/ACER.png,2387245,-0.342020725388601,-0.1444,574675,-24548224.000000004,-27860371,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -27.86}, {'period': '2021', 'revenue': 1.26, 'unit': 'M', 'net_profit': -14.73}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -22.9}, {'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': -28.88}]","[{'period': ""Q3 '23"", 'revenue': 0.37179, 'unit': 'M', 'net_profit': -14.73}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.09}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -26.86}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -11.24}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.99}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.67}]",-1.77,-1.77,11624226,3516698,2329218,28385498,0,0,18951700,2329218,-30423068,-0.5461036754204512,-0.8915723224152273,-0.7184466019417476,__nan__,__nan__,__nan__,2.4419258538159876
33,ACET,Adicet Bio Inc. Common Stock ,"Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.","Mr. Chen  Schor BA, CPA, M.B.A.",Biotechnology,0.7772,USD,64281901,https://images.financialmodelingprep.com/symbol/ACET.png,510777,-0.6,0.1392,1929517,-110650000,-117122000,"[{'period': '2024', 'revenue': 0.0, 'unit': 'M', 'net_profit': -117.12}, {'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -142.66}, {'period': '2022', 'revenue': 24.99, 'unit': 'M', 'net_profit': -67.03}, {'period': '2021', 'revenue': 9.73, 'unit': 'M', 'net_profit': -62.0}]","[{'period': ""Q1 '25"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -28.21}, {'period': ""Q4 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -28.73}, {'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -30.48}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -29.9}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -28.02}, {'period': ""Q4 '23"", 'revenue': 12.89, 'unit': 'M', 'net_profit': -29.49}]",-1.33,-1.33,220219000,180136000,176303000,33610000,0,0,19392000,56495000,-93496000,0.18958508807265537,0.17900152813021353,0.5981873111782477,"[0.0014, 0.0143]","['2018-09-21', '2009-06-11']",__nan__,0.15262080020343385
34,ACEV,ACE Convergence Acquisition Corp. Class A Ordinary Shares,"ACE Convergence Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses. It intends to focus on businesses in the IT infrastructure software and semiconductor sectors. ACE Convergence Acquisition Corp. was incorporated in 2020 and is based in Wilmington, Delaware.",Mr. Behrooz  Abdi,Shell Companies,9.78,USD,258126474,https://images.financialmodelingprep.com/symbol/ACEV.png,39409,3.7906976744186047,0.65,31566,-81556000,-144851000,"[{'period': '2023', 'revenue': 12.05, 'unit': 'M', 'net_profit': -144.85}, {'period': '2022', 'revenue': 17.36, 'unit': 'M', 'net_profit': -48.01}, {'period': '2021', 'revenue': 17.36, 'unit': 'M', 'net_profit': -51.7}, {'period': '2020', 'revenue': 18.13, 'unit': 'M', 'net_profit': -16.97}]","[{'period': ""Q4 '23"", 'revenue': 2.77, 'unit': 'M', 'net_profit': -7.39}, {'period': ""Q3 '23"", 'revenue': 2.9, 'unit': 'M', 'net_profit': -48.33}, {'period': ""Q2 '23"", 'revenue': 2.39, 'unit': 'M', 'net_profit': -76.51}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 5.96}, {'period': ""Q4 '22"", 'revenue': 0.0039, 'unit': 'B', 'net_profit': 80.39}, {'period': ""Q3 '22"", 'revenue': 4.01, 'unit': 'M', 'net_profit': -23.62}]",-16.378998706763443,-16.378998706763443,20589000,13301000,7113000,46612000,2866000,0,44357000,7113000,-28827000,0.12731970218913213,0.2487838524649677,-750.3761467889908,__nan__,__nan__,__nan__,2.263927339841663
35,ACEVU,ACE Convergence Acquisition Corp. Unit,"ACE Convergence Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses. It intends to focus on businesses in the IT infrastructure software and semiconductor sectors. ACE Convergence Acquisition Corp. was incorporated in 2020 and is based in Wilmington, Delaware.",Mr. Behrooz  Abdi,Shell Companies,9.769,USD,0,https://images.financialmodelingprep.com/symbol/ACEVU.png,1975,15.531001589825118,-0.011,858,-81556000,-144851000,"[{'period': '2023', 'revenue': 12.05, 'unit': 'M', 'net_profit': -144.85}, {'period': '2022', 'revenue': 17.36, 'unit': 'M', 'net_profit': -48.01}, {'period': '2021', 'revenue': 17.36, 'unit': 'M', 'net_profit': -51.7}, {'period': '2020', 'revenue': 18.13, 'unit': 'M', 'net_profit': -16.97}]","[{'period': ""Q4 '23"", 'revenue': 2.77, 'unit': 'M', 'net_profit': -7.39}, {'period': ""Q3 '23"", 'revenue': 2.9, 'unit': 'M', 'net_profit': -48.33}, {'period': ""Q2 '23"", 'revenue': 2.39, 'unit': 'M', 'net_profit': -76.51}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 5.96}, {'period': ""Q4 '22"", 'revenue': 0.0039, 'unit': 'B', 'net_profit': 80.39}, {'period': ""Q3 '22"", 'revenue': 4.01, 'unit': 'M', 'net_profit': -23.62}]",-16.378998706763443,-16.378998706763443,20589000,13301000,7113000,46612000,2866000,0,44357000,7113000,-28827000,0.12731970218913213,0.2487838524649677,-750.3761467889908,__nan__,__nan__,__nan__,2.263927339841663
36,ACEVW,ACE Convergence Acquisition Corp. Warrant,,,Shell Companies,0.1699,USD,0,https://images.financialmodelingprep.com/symbol/ACEVW.png,0,0,0.0199,132016,-81556000,-144851000,"[{'period': '2023', 'revenue': 12.05, 'unit': 'M', 'net_profit': -144.85}, {'period': '2022', 'revenue': 17.36, 'unit': 'M', 'net_profit': -48.01}, {'period': '2021', 'revenue': 17.36, 'unit': 'M', 'net_profit': -51.7}, {'period': '2020', 'revenue': 18.13, 'unit': 'M', 'net_profit': -16.97}]","[{'period': ""Q4 '23"", 'revenue': 2.77, 'unit': 'M', 'net_profit': -7.39}, {'period': ""Q3 '23"", 'revenue': 2.9, 'unit': 'M', 'net_profit': -48.33}, {'period': ""Q2 '23"", 'revenue': 2.39, 'unit': 'M', 'net_profit': -76.51}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 5.96}, {'period': ""Q4 '22"", 'revenue': 0.0039, 'unit': 'B', 'net_profit': 80.39}, {'period': ""Q3 '22"", 'revenue': 4.01, 'unit': 'M', 'net_profit': -23.62}]",-16.378998706763443,-16.378998706763443,20589000,13301000,7113000,46612000,2866000,0,44357000,7113000,-28827000,0.12731970218913213,0.2487838524649677,-750.3761467889908,__nan__,__nan__,__nan__,2.263927339841663
37,ACGL,Arch Capital Group Ltd. Common Stock,"Arch Capital Group Ltd., together with its subsidiaries, provides insurance, reinsurance, and mortgage insurance products worldwide. The company's Insurance segment offers primary and excess casualty coverages; loss sensitive primary casualty insurance programs; collateral protection, debt cancellation, and service contract reimbursement products; directors' and officers' liability, errors and omissions liability, employment practices and fiduciary liability, crime, professional indemnity, and other financial related coverages; medical professional and general liability insurance coverages; and workers' compensation and umbrella liability, as well as commercial automobile and inland marine products. It also provides property, energy, marine, and aviation insurance; travel insurance; accident, disability, and medical plan insurance coverages; captive insurance programs; employer's liability; and contract and commercial surety coverages. This segment markets its products through a group of licensed independent retail and wholesale brokers. Its Reinsurance segment provides casualty reinsurance for third party liability and workers' compensation exposures; marine and aviation; surety, accident and health, workers' compensation catastrophe, agriculture, trade credit, and political risk products; reinsurance protection for catastrophic losses, and personal lines and commercial property exposures; life reinsurance; casualty clash; and risk management solutions. This segment markets its reinsurance products through brokers. The company's Mortgage segment offers direct mortgage insurance and mortgage reinsurance. The company was incorporated in 1995 and is based in Pembroke, Bermuda.",Mr. Nicolas Alain Emmanuel Papadopoulo,Insurance - Diversified,94.59,USD,35448075450,https://images.financialmodelingprep.com/symbol/ACGL.png,1710122,9.7,1.05,1058104,4850000000,4312000000,"[{'period': '2024', 'revenue': 17.44, 'unit': 'B', 'net_profit': 4.31}, {'period': '2023', 'revenue': 13.63, 'unit': 'B', 'net_profit': 4.44}, {'period': '2022', 'revenue': 9.6, 'unit': 'B', 'net_profit': 1.48}, {'period': '2021', 'revenue': 8.93, 'unit': 'B', 'net_profit': 2.16}]","[{'period': ""Q1 '25"", 'revenue': 4620.0, 'unit': 'M', 'net_profit': 574.0}, {'period': ""Q4 '24"", 'revenue': 4510.0, 'unit': 'M', 'net_profit': 935.0}, {'period': ""Q3 '24"", 'revenue': 4550.0, 'unit': 'M', 'net_profit': 988.0}, {'period': ""Q2 '24"", 'revenue': 4.06, 'unit': 'B', 'net_profit': 1.27}, {'period': ""Q1 '24"", 'revenue': 3.84, 'unit': 'B', 'net_profit': 1.12}, {'period': ""Q4 '23"", 'revenue': 3.87, 'unit': 'B', 'net_profit': 2.33}]",11.47,11.19,70906000000,6613000000,979000000,50086000000,5634000000,38791000000,0,979000000,6622000000,0.4542728635682159,-0.029484582489309026,-0.03936348408710209,"[5, 5]","['2024-11-18', '2024-11-18']",__nan__,0.7063718162073731
38,ACGLO,Arch Capital Group Ltd. Depositary Shares Each Representing 1/1000th Interest in a Share of 5.45% Non-Cumulative Preferred Shares Series F,"Arch Capital Group Ltd., together with its subsidiaries, provides insurance, reinsurance, and mortgage insurance products worldwide. The company's Insurance segment offers primary and excess casualty coverages; loss sensitive primary casualty insurance programs; collateral protection, debt cancellation, and service contract reimbursement products; directors' and officers' liability, errors and omissions liability, employment practices and fiduciary liability, crime, professional indemnity, and other financial related coverages; medical professional and general liability insurance coverages; and workers' compensation and umbrella liability, as well as commercial automobile and inland marine products. It also provides property, energy, marine, and aviation insurance; travel insurance; accident, disability, and medical plan insurance coverages; captive insurance programs; employer's liability; and contract and commercial surety coverages. This segment markets its products through a group of licensed independent retail and wholesale brokers. Its Reinsurance segment provides casualty reinsurance for third party liability and workers' compensation exposures; marine and aviation; surety, accident and health, workers' compensation catastrophe, agriculture, trade credit, and political risk products; reinsurance protection for catastrophic losses, and personal lines and commercial property exposures; life reinsurance; casualty clash; and risk management solutions. This segment markets its reinsurance products through brokers. The company's Mortgage segment offers direct mortgage insurance and mortgage reinsurance. The company was incorporated in 1995 and is based in Pembroke, Bermuda.",Mr. Nicolas Alain Emmanuel Papadopoulo,Insurance - Diversified,20.56,USD,34190960600,https://images.financialmodelingprep.com/symbol/ACGLO.png,27296,4.38,0.02,16315,4850000000,4312000000,"[{'period': '2024', 'revenue': 17.44, 'unit': 'B', 'net_profit': 4.31}, {'period': '2023', 'revenue': 13.63, 'unit': 'B', 'net_profit': 4.44}, {'period': '2022', 'revenue': 9.6, 'unit': 'B', 'net_profit': 1.48}, {'period': '2021', 'revenue': 8.93, 'unit': 'B', 'net_profit': 2.16}]","[{'period': ""Q1 '25"", 'revenue': 4620.0, 'unit': 'M', 'net_profit': 574.0}, {'period': ""Q4 '24"", 'revenue': 4510.0, 'unit': 'M', 'net_profit': 935.0}, {'period': ""Q3 '24"", 'revenue': 4550.0, 'unit': 'M', 'net_profit': 988.0}, {'period': ""Q2 '24"", 'revenue': 4.06, 'unit': 'B', 'net_profit': 1.27}, {'period': ""Q1 '24"", 'revenue': 3.84, 'unit': 'B', 'net_profit': 1.12}, {'period': ""Q4 '23"", 'revenue': 3.87, 'unit': 'B', 'net_profit': 2.33}]",11.47,11.19,70906000000,6613000000,979000000,50086000000,5634000000,38791000000,0,979000000,6622000000,0.4542728635682159,-0.029484582489309026,-0.03936348408710209,"[0.34063, 0.507]","['2025-09-15', '2017-12-14']",__nan__,0.7063718162073731
39,ACGLP,Arch Capital Group Ltd. Depositary Shares Representing Interest in 5.25% Non-Cumulative Preferred Series E Shrs,"Arch Capital Group Ltd., together with its subsidiaries, provides insurance, reinsurance, and mortgage insurance products worldwide. The company's Insurance segment offers primary and excess casualty coverages; loss sensitive primary casualty insurance programs; collateral protection, debt cancellation, and service contract reimbursement products; directors' and officers' liability, errors and omissions liability, employment practices and fiduciary liability, crime, professional indemnity, and other financial related coverages; medical professional and general liability insurance coverages; and workers' compensation and umbrella liability, as well as commercial automobile and inland marine products. It also provides property, energy, marine, and aviation insurance; travel insurance; accident, disability, and medical plan insurance coverages; captive insurance programs; and contract and commercial surety coverages. This segment markets its products through a group of licensed independent retail and wholesale brokers. Its Reinsurance segment provides reinsurance for third party liability and workers' compensation exposures; marine and aviation reinsurance; surety, accident and health, workers' compensation catastrophe, agriculture, trade credit, and political risk products; reinsurance protection for catastrophic losses, and personal lines and commercial property exposures; life reinsurance; casualty clash; and risk management solutions. This segment markets its reinsurance products through brokers. The company's Mortgage segment offers private mortgage insurance covering one-to-four family residential mortgages; mortgage insurance to cover previously originated residential loans; quota share reinsurance; and credit risk-sharing products. This segment sells its products through direct basis and through brokers to mortgage originators. The company was founded in 1995 and is based in Pembroke, Bermuda.",Mr. Marc Grandisson,Insurance - Diversified,24.99,USD,15165357055,https://images.financialmodelingprep.com/symbol/ACGLP.png,29439,5.027157513578757,0.01,40244,4850000000,4312000000,"[{'period': '2024', 'revenue': 17.44, 'unit': 'B', 'net_profit': 4.31}, {'period': '2023', 'revenue': 13.63, 'unit': 'B', 'net_profit': 4.44}, {'period': '2022', 'revenue': 9.6, 'unit': 'B', 'net_profit': 1.48}, {'period': '2021', 'revenue': 8.93, 'unit': 'B', 'net_profit': 2.16}]","[{'period': ""Q1 '25"", 'revenue': 4620.0, 'unit': 'M', 'net_profit': 574.0}, {'period': ""Q4 '24"", 'revenue': 4510.0, 'unit': 'M', 'net_profit': 935.0}, {'period': ""Q3 '24"", 'revenue': 4550.0, 'unit': 'M', 'net_profit': 988.0}, {'period': ""Q2 '24"", 'revenue': 4.06, 'unit': 'B', 'net_profit': 1.27}, {'period': ""Q1 '24"", 'revenue': 3.84, 'unit': 'B', 'net_profit': 1.12}, {'period': ""Q4 '23"", 'revenue': 3.87, 'unit': 'B', 'net_profit': 2.33}]",11.47,11.19,70906000000,6613000000,979000000,50086000000,5634000000,38791000000,0,979000000,6622000000,0.4542728635682159,-0.029484582489309026,-0.03936348408710209,"[0.32813, 0.343]","['2021-09-14', '2016-12-13']",__nan__,0.7063718162073731
40,ACHC,Acadia Healthcare Company Inc. Common Stock,"Acadia Healthcare Company, Inc. provides behavioral healthcare services in the United States and Puerto Rico. The company offers behavioral healthcare services to its patients in various settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers, and outpatient clinics. As of March 31, 2022, it operated a network of 238 behavioral healthcare facilities with approximately 10,600 beds. The company was founded in 2005 and is headquartered in Franklin, Tennessee.",Mr. Christopher Howal Hunter,Medical - Care Facilities,26.15,USD,2408995530,https://images.financialmodelingprep.com/symbol/ACHC.png,3142229.1,9.41,0.51,2079272,607842000,255612000,"[{'period': '2024', 'revenue': 3150.0, 'unit': 'M', 'net_profit': 255.61}, {'period': '2023', 'revenue': 2930.0, 'unit': 'M', 'net_profit': -21.67}, {'period': '2022', 'revenue': 2610.0, 'unit': 'M', 'net_profit': 273.14}, {'period': '2021', 'revenue': 2310.0, 'unit': 'M', 'net_profit': 190.63}]","[{'period': ""Q1 '25"", 'revenue': 770.5, 'unit': 'M', 'net_profit': 8.37}, {'period': ""Q4 '24"", 'revenue': 774.24, 'unit': 'M', 'net_profit': 32.62}, {'period': ""Q3 '24"", 'revenue': 815.63, 'unit': 'M', 'net_profit': 68.13}, {'period': ""Q2 '24"", 'revenue': 796.04, 'unit': 'M', 'net_profit': 78.48}, {'period': ""Q1 '24"", 'revenue': 768.05, 'unit': 'M', 'net_profit': 76.38}, {'period': ""Q4 '23"", 'revenue': 742.8, 'unit': 'M', 'net_profit': 57.73}]",2.79,2.78,5956915000,577492000,76305000,2766084000,421975000,0,577919000,76305000,-560692000,2.2141565404993813,12.797295426224212,12.625000000000002,__nan__,__nan__,__nan__,0.46434840853025433
41,ACHL,Achilles Therapeutics plc American Depositary Shares,"Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.",Dr. Iraj  Ali Ph.D.,Biotechnology,1.48,USD,60828000,https://images.financialmodelingprep.com/symbol/ACHL.png,1281745,-0.891566265060241,0.01,1204120,-70442000,-69665000,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -69.67}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -71.18}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -61.1}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -33.2}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -19.59}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -16.38}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -12.27}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -18.79}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -16.68}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -16.85}]",-1.74,-1.74,161456000,145633000,131539000,19087000,10351000,33000,16996000,131539000,-49549000,0.10131023308625595,0.02122906597729572,0.043956043956043994,__nan__,__nan__,__nan__,0.11821796650480626
42,ACHV,Achieve Life Sciences Inc. Common Shares,"Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.",Dr. Richard A. B. Stewart,Biotechnology,3.08,USD,106830108,https://images.financialmodelingprep.com/symbol/ACHV.png,179925,-2.48,0.35,563133,-37418000,-39827000,"[{'period': '2024', 'revenue': 0.0, 'unit': 'M', 'net_profit': -39.83}, {'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -29.82}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -41.88}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -32.9}]","[{'period': ""Q1 '25"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -12.83}, {'period': ""Q4 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -12.36}, {'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -12.51}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.46}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -6.49}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.48}]",-1.24,-1.24,38633000,36467000,34360000,17734000,0,0,6682000,12753000,-29770000,-0.39964090671055585,-0.33580412544021465,0.17333333333333334,__nan__,__nan__,__nan__,0.4590376103331349
43,ACIU,AC Immune SA Common Stock,"AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.",Dr. Andrea  Pfeifer Ph.D.,Biotechnology,1.71,USD,169192701,https://images.financialmodelingprep.com/symbol/ACIU.png,175416,-2.71,0.14,90066,-48618000,-50916000,"[{'period': '2024', 'revenue': 27.31, 'unit': 'M', 'net_profit': -50.92}, {'period': '2023', 'revenue': 14.8, 'unit': 'M', 'net_profit': -54.23}, {'period': '2022', 'revenue': 3.94, 'unit': 'M', 'net_profit': -70.75}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -73.0}]","[{'period': ""Q1 '25"", 'revenue': 0.99, 'unit': 'M', 'net_profit': -19.03}, {'period': ""Q4 '24"", 'revenue': 1.14, 'unit': 'M', 'net_profit': -15.8}, {'period': ""Q3 '24"", 'revenue': 25.48, 'unit': 'M', 'net_profit': 5.5}, {'period': ""Q2 '24"", 'revenue': 0.687, 'unit': 'M', 'net_profit': -22.76}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -17.86}, {'period': ""Q4 '23"", 'revenue': 14.8, 'unit': 'M', 'net_profit': -4.74}]",-0.51,-0.51,230913000,171994000,165489000,118643000,2203000,415000,100838000,36275000,65266000,0.062008025929927456,0.06116202312245312,0.203125,__nan__,__nan__,__nan__,0.5137995695348465
44,ACIW,ACI Worldwide Inc. Common Stock,"ACI Worldwide, Inc., a software company, develops, markets, installs, and supports a range of software products and solutions for facilitating digital payments to banks, merchants, and billers worldwide. The company offers ACI Acquiring, a merchant management system to deliver digital innovation, improve fraud prevention, and reduce interchange fees; ACI Issuing, a digital payments issuing solution; and ACI Enterprise Payments Platform that provides payment processing and orchestration capabilities for digital payments. It also provides ACI Low Value Real-Time Payments, a platform for processing real-time payments; and ACI High Value Real-Time Payments, a payments engine that offers multi-bank, multi-currency, 24x7 payment processing, and SWIFT messaging. In addition, the company offers ACI Omni Commerce, a scalable, omni-channel payment processing platform; ACI Secure eCommerce solution; ACI Fraud Management, a real-time approach to fraud management; ACI Digital Business Banking, a cloud-based digital banking platform; and ACI Speedpay, an integrated suite of digital billing, payment, disbursement, and communication services. The company offers electronic bill presentment and payment services to consumer finance, insurance, healthcare, higher education, utility, government, and mortgage sectors; implementation services, including product installations and configurations, and custom software modifications; and business and technical consultancy, on-site support, product education, and testing services, as well as distributes or acts as a sales agent for software developed by third parties. It markets its products under the ACI Worldwide brand. The company was formerly known as Transaction Systems Architects, Inc. and changed its name to ACI Worldwide, Inc. in July 2007. The company was founded in 1975 and is based in Coral Gables, Florida.",Mr. Thomas Woodrow Warsop III,Software - Infrastructure,48.87,USD,5126463000,https://images.financialmodelingprep.com/symbol/ACIW.png,808706,19.32,0.1,699817,443548000,203118000,"[{'period': '2024', 'revenue': 1590.0, 'unit': 'M', 'net_profit': 203.12}, {'period': '2023', 'revenue': 1450.0, 'unit': 'M', 'net_profit': 121.51}, {'period': '2022', 'revenue': 1420.0, 'unit': 'M', 'net_profit': 142.18}, {'period': '2021', 'revenue': 1370.0, 'unit': 'M', 'net_profit': 127.79}]","[{'period': ""Q1 '25"", 'revenue': 394.56, 'unit': 'M', 'net_profit': 58.87}, {'period': ""Q4 '24"", 'revenue': 453.04, 'unit': 'M', 'net_profit': 98.56}, {'period': ""Q3 '24"", 'revenue': 451.75, 'unit': 'M', 'net_profit': 81.43}, {'period': ""Q2 '24"", 'revenue': 373.48, 'unit': 'M', 'net_profit': 30.89}, {'period': ""Q1 '24"", 'revenue': 316.02, 'unit': 'M', 'net_profit': -7.75}, {'period': ""Q4 '23"", 'revenue': 476.56, 'unit': 'M', 'net_profit': 122.62}]",1.93,1.91,3025293000,990822000,216394000,1600966000,414399000,0,602628000,216394000,343346000,0.2317151061076461,0.6716292620299731,0.7232142857142855,__nan__,__nan__,__nan__,0.5291937012381941
45,ACKIT,Ackrell SPAC Partners I Co. Subunits,"Ackrell SPAC Partners I Co. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company intends to focus on alcoholic and non-alcoholic beverage and wellness sectors. Ackrell SPAC Partners I Co. was founded in 2018 and is Claymont, Delaware.",Mr. Jason M. Roth,Shell Companies,10.3801,USD,0,https://images.financialmodelingprep.com/symbol/ACKIT.png,0,-324.378125,0.0101004,8435,-1198210,-842789,"[{'period': '2021', 'revenue': 0.0, 'unit': 'K', 'net_profit': -842.79}, {'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -115.54}, {'period': '2019', 'revenue': 0.0, 'unit': 'K', 'net_profit': -3.75}]","[{'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -53.56}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -333.55}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.68}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -243.02}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -353.3}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 120.14}]",-0.0611,-0.0611,140981542,158964,86792,2777250,0,0,2492480,86792,-590338,-9.37016201620162,-6.294095755729419,-6.273809523809525,__nan__,__nan__,__nan__,0.01969938731412088
46,ACKIU,Ackrell SPAC Partners I Co. Units,"Ackrell SPAC Partners I Co. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company intends to focus on alcoholic and non-alcoholic beverage and wellness sectors. Ackrell SPAC Partners I Co. was founded in 2018 and is Claymont, Delaware.",Mr. Stephen N. Cannon,Shell Companies,10.36,USD,0,https://images.financialmodelingprep.com/symbol/ACKIU.png,0,-323.75,0.009999275,300,-1198210,-842789,"[{'period': '2021', 'revenue': 0.0, 'unit': 'K', 'net_profit': -842.79}, {'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -115.54}, {'period': '2019', 'revenue': 0.0, 'unit': 'K', 'net_profit': -3.75}]","[{'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -53.56}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -333.55}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.68}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -243.02}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -353.3}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 120.14}]",-0.0611,-0.0611,140981542,158964,86792,2777250,0,0,2492480,86792,-590338,-9.37016201620162,-6.294095755729419,-6.273809523809525,__nan__,__nan__,__nan__,0.01969938731412088
47,ACKIW,Ackrell SPAC Partners I Co. Warrants,"Ackrell SPAC Partners I Co., a blank check company, focuses on effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, and other similar business combination. The company was formerly known as Able Acquisition Corp. and changed its name to Ackrell SPAC Partners I Co. in September 2019. The company was incorporated in 2018 and is based in Claymont, Delaware.",Mr. Jason M. Roth,Shell Companies,0.0004,USD,0,https://images.financialmodelingprep.com/symbol/ACKIW.png,0,0,-0.0108,317451,-1198210,-842789,"[{'period': '2021', 'revenue': 0.0, 'unit': 'K', 'net_profit': -842.79}, {'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -115.54}, {'period': '2019', 'revenue': 0.0, 'unit': 'K', 'net_profit': -3.75}]","[{'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -53.56}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -333.55}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.68}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -243.02}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -353.3}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 120.14}]",-0.0611,-0.0611,140981542,158964,86792,2777250,0,0,2492480,86792,-590338,-9.37016201620162,-6.294095755729419,-6.273809523809525,__nan__,__nan__,__nan__,0.01969938731412088
48,ACLS,Axcelis Technologies Inc. Common Stock,"Axcelis Technologies, Inc. designs, manufactures, and services ion implantation and other processing equipment used in the fabrication of semiconductor chips in the United States, Europe, and Asia. The company offers high energy, high current, and medium current implanters for various application requirements. It also provides aftermarket lifecycle products and services, including used tools, spare parts, equipment upgrades, maintenance services, and customer training. It sells its equipment and services to semiconductor chip manufacturers through its direct sales force. The company was founded in 1978 and is headquartered in Beverly, Massachusetts.",Dr. Russell J. Low Ph.D.,Semiconductors,61.58,USD,1978534610,https://images.financialmodelingprep.com/symbol/ACLS.png,709314,11.28,-1.09,375764,251545000,200992000,"[{'period': '2024', 'revenue': 1020.0, 'unit': 'M', 'net_profit': 200.99}, {'period': '2023', 'revenue': 1130.0, 'unit': 'M', 'net_profit': 246.26}, {'period': '2022', 'revenue': 920.0, 'unit': 'M', 'net_profit': 183.08}, {'period': '2021', 'revenue': 662.43, 'unit': 'M', 'net_profit': 98.65}]","[{'period': ""Q1 '25"", 'revenue': 192.56, 'unit': 'M', 'net_profit': 28.58}, {'period': ""Q4 '24"", 'revenue': 252.42, 'unit': 'M', 'net_profit': 49.96}, {'period': ""Q3 '24"", 'revenue': 256.56, 'unit': 'M', 'net_profit': 48.58}, {'period': ""Q2 '24"", 'revenue': 256.51, 'unit': 'M', 'net_profit': 50.87}, {'period': ""Q1 '24"", 'revenue': 252.37, 'unit': 'M', 'net_profit': 51.59}, {'period': ""Q4 '23"", 'revenue': 310.29, 'unit': 'M', 'net_profit': 71.06}]",6.17,6.15,1348781000,1123608000,571343000,335991000,203149000,0,207522000,123512000,128637000,-0.1530899112839419,-0.183831919533182,-0.17952127659574466,__nan__,__nan__,__nan__,0.24910715675858422
49,ACMR,ACM Research Inc. Class A Common Stock,"ACM Research, Inc., together with its subsidiaries, develops, manufactures, and sells single-wafer wet cleaning equipment for enhancing the manufacturing process and yield for integrated chips worldwide. It offers space alternated phase shift technology for flat and patterned wafer surfaces, which employs alternating phases of megasonic waves to deliver megasonic energy in a uniform manner on a microscopic level; timely energized bubble oscillation technology for patterned wafer surfaces at advanced process nodes, which provides cleaning for 2D and 3D patterned wafers; Tahoe technology for delivering cleaning performance using less sulfuric acid and hydrogen peroxide; and electro-chemical plating technology for advanced metal plating. The company markets and sells its products under the Ultra C brand name through direct sales force and third-party representatives. ACM Research, Inc. was incorporated in 1998 and is headquartered in Fremont, California.",Dr. Hui  Wang Ph.D.,Semiconductors,23.73,USD,1515504585,https://images.financialmodelingprep.com/symbol/ACMR.png,1878906,15.11,-0.6,1086366,180418000,103627000,"[{'period': '2024', 'revenue': 782.12, 'unit': 'M', 'net_profit': 103.63}, {'period': '2023', 'revenue': 557.72, 'unit': 'M', 'net_profit': 77.35}, {'period': '2022', 'revenue': 388.83, 'unit': 'M', 'net_profit': 39.26}, {'period': '2021', 'revenue': 259.75, 'unit': 'M', 'net_profit': 37.76}]","[{'period': ""Q1 '25"", 'revenue': 172.35, 'unit': 'M', 'net_profit': 20.38}, {'period': ""Q4 '24"", 'revenue': 223.47, 'unit': 'M', 'net_profit': 31.08}, {'period': ""Q3 '24"", 'revenue': 203.98, 'unit': 'M', 'net_profit': 30.9}, {'period': ""Q2 '24"", 'revenue': 202.48, 'unit': 'M', 'net_profit': 24.21}, {'period': ""Q1 '24"", 'revenue': 152.19, 'unit': 'M', 'net_profit': 17.43}, {'period': ""Q4 '23"", 'revenue': 170.32, 'unit': 'M', 'net_profit': 17.7}]",1.66,1.55,1855721000,1483379000,444095000,759815000,428904000,50338000,641233000,407445000,69987000,0.4207372292088291,0.3397328989385771,0.2868217054263565,__nan__,__nan__,__nan__,0.40944463095476097
50,ACNB,ACNB Corporation Common Stock,"ACNB Corporation, a financial holding company, provides banking, insurance, and financial services to individual, business, and government customers in the United States. The company offers checking, savings, and money market deposit accounts, as well as time deposits and debit cards. It also provides commercial lending products, such as commercial mortgages, real estate development and construction loans, accounts receivable and inventory financing, and agricultural and governmental loans; consumer lending products, including home equity loans and lines of credit, automobile and recreational vehicle loans, manufactured housing loans, and personal lines of credit; and mortgage lending programs include personal residential mortgages, and residential construction and investment mortgage loans. In addition, the company provides other services that are related to testamentary trusts, life insurance trusts, charitable remainder trusts, guardianships, powers of attorney, custodial accounts, and investment management and advisory accounts; and retail brokerage services. Further, it acts as a trustee to invest in, protect, manage, and distribute financial assets. Additionally, the company offers property and casualty, health, life, and disability insurance products to commercial and individual clients; and online, telephone, and mobile banking, as well as automated teller machine services. As of December 31, 2021, it operated through a network of 19 community banking offices located in Pennsylvania, including 12 offices in Adams county, five offices in York county, one office in Cumberland County, and one office in Franklin County; five community banking offices located in Frederick County; six community banking offices located in Carroll county, Maryland; and loan offices located in Lancaster and York, Pennsylvania, and Hunt Valley, Maryland. The company was founded in 1857 and is headquartered in Gettysburg, Pennsylvania.",Mr. James P. Helt,Banks - Regional,44,USD,460842800,https://images.financialmodelingprep.com/symbol/ACNB.png,36874,15.17,-0.17,19343,0,31846000,"[{'period': '2024', 'revenue': 107.47, 'unit': 'M', 'net_profit': 31.85}, {'period': '2023', 'revenue': 105.92, 'unit': 'M', 'net_profit': 31.69}, {'period': '2022', 'revenue': 104.81, 'unit': 'M', 'net_profit': 35.75}, {'period': '2021', 'revenue': 93.93, 'unit': 'M', 'net_profit': 27.83}]","[{'period': ""Q1 '25"", 'revenue': 43470.0, 'unit': 'K', 'net_profit': -272.0}, {'period': ""Q4 '24"", 'revenue': 26.91, 'unit': 'M', 'net_profit': 6.59}, {'period': ""Q3 '24"", 'revenue': 27.77, 'unit': 'M', 'net_profit': 7.2}, {'period': ""Q2 '24"", 'revenue': 27.39, 'unit': 'M', 'net_profit': 11.28}, {'period': ""Q1 '24"", 'revenue': 26.26, 'unit': 'M', 'net_profit': 6.77}, {'period': ""Q4 '23"", 'revenue': 22.46, 'unit': 'M', 'net_profit': 4.1}]",3.75,3.73,2394830000,410327000,410327000,2091557000,0,83966000,15826000,47262000,38822000,0,0.004986114617520828,0.008064516129032206,"[0.34, 0.29]","['2025-05-30', '1994-05-27']",__nan__,0.8733634537733367
51,ACOR,Acorda Therapeutics Inc. Common Stock,"Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.",Dr. Ron  Cohen M.D.,Drug Manufacturers - Specialty & Generic,0.661,USD,821028,https://images.financialmodelingprep.com/symbol/ACOR.png,125680,-0.00324704033010758,-0.209,321668,8402000,-252854000,"[{'period': '2023', 'revenue': 117.63, 'unit': 'M', 'net_profit': -252.85}, {'period': '2022', 'revenue': 118.57, 'unit': 'M', 'net_profit': -65.92}, {'period': '2021', 'revenue': 129.07, 'unit': 'M', 'net_profit': -103.95}, {'period': '2020', 'revenue': 152.97, 'unit': 'M', 'net_profit': -99.59}]","[{'period': ""Q1 '24"", 'revenue': 20.29, 'unit': 'M', 'net_profit': -27.39}, {'period': ""Q4 '23"", 'revenue': 37.98, 'unit': 'M', 'net_profit': -217.76}, {'period': ""Q3 '23"", 'revenue': 27.71, 'unit': 'M', 'net_profit': -8.89}, {'period': ""Q2 '23"", 'revenue': 29.68, 'unit': 'M', 'net_profit': -9.38}, {'period': ""Q1 '23"", 'revenue': 22.26, 'unit': 'M', 'net_profit': -16.82}, {'period': ""Q4 '22"", 'revenue': 31.47, 'unit': 'M', 'net_profit': 19.14}]",-203.59,-203.59,117745000,74794000,30360000,275701000,17298000,255000,227773000,30360000,-14248000,1.8376869391824526,-2.8360033982644577,-2.043198804185351,__nan__,__nan__,__nan__,2.3415091935963313
52,ACQR,Independence Holdings Corp. Class A Ordinary Share,"Independence Holdings Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses or entities. The company was incorporated in 2020 and is based in New York, New York.",Mr. John Lawrence Furlong,Shell Companies,10.19,USD,631663803,https://images.financialmodelingprep.com/symbol/ACQR.png,522498,32.87096774193548,-0.015,100,-983472,1966648,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.97}]","[{'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.2}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 10.53}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 16.04}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 5.8}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 837.39}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.33}]",0.0376,0.0376,498026595,2077765,1260014,34355832,0,495948830,91714,1260014,-1821586,0,0,0,__nan__,__nan__,__nan__,0.0689839304666049
53,ACQRU,Independence Holdings Corp. Units,"Independence Holdings Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses or entities. The company was incorporated in 2020 and is based in New York, New York.",Mr. John Lawrence Furlong,Shell Companies,10.19,USD,606006943,https://images.financialmodelingprep.com/symbol/ACQRU.png,1283,78.38461538461539,0,69,-983472,1966648,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.97}]","[{'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.2}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 10.53}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 16.04}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 5.8}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 837.39}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.33}]",0.0376,0.0376,498026595,2077765,1260014,34355832,0,495948830,91714,1260014,-1821586,0,0,0,__nan__,__nan__,__nan__,0.0689839304666049
54,ACQRW,Independence Holdings Corp. Warrant,"Independence Holdings Corp. a blank check company, intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses or entities. The company was founded in 2020 and is based in New York, New York.",Mr. John Lawrence Furlong,Shell Companies,0.0003,USD,631663803,https://images.financialmodelingprep.com/symbol/ACQRW.png,0,0,0,64030,-983472,1966648,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.97}]","[{'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.2}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 10.53}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 16.04}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 5.8}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 837.39}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.33}]",0.0376,0.0376,498026595,2077765,1260014,34355832,0,495948830,91714,1260014,-1821586,0,0,0,__nan__,__nan__,__nan__,0.0689839304666049
55,ACRS,Aclaris Therapeutics Inc. Common Stock,"Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.","Dr. Neal S. Walker D.O., M.D.",Medical - Diagnostics & Research,1.31,USD,141848110,https://images.financialmodelingprep.com/symbol/ACRS.png,880841,-0.82,0.09,491142,-51720000,-132065000,"[{'period': '2024', 'revenue': 18.72, 'unit': 'M', 'net_profit': -132.06}, {'period': '2023', 'revenue': 31.25, 'unit': 'M', 'net_profit': -88.48}, {'period': '2022', 'revenue': 29.75, 'unit': 'M', 'net_profit': -88.66}, {'period': '2021', 'revenue': 6.76, 'unit': 'M', 'net_profit': -114.28}]","[{'period': ""Q1 '25"", 'revenue': 1.46, 'unit': 'M', 'net_profit': -15.09}, {'period': ""Q4 '24"", 'revenue': 9.21, 'unit': 'M', 'net_profit': -96.55}, {'period': ""Q3 '24"", 'revenue': 4.35, 'unit': 'M', 'net_profit': -7.59}, {'period': ""Q2 '24"", 'revenue': 2.77, 'unit': 'M', 'net_profit': -10.99}, {'period': ""Q1 '24"", 'revenue': 2.4, 'unit': 'M', 'net_profit': -16.94}, {'period': ""Q4 '23"", 'revenue': 17.57, 'unit': 'M', 'net_profit': -1.49}]",-1.71,-1.71,220327000,125951000,113594000,64773000,318000,90302000,31596000,24570000,-20196000,0.5600731510228384,-0.49258032798001833,-0.34645669291338577,__nan__,__nan__,__nan__,0.29398575753312123
56,ACRX,AcelRx Pharmaceuticals Inc. Common Stock,"AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is based in Hayward, California.",Mr. Vincent J. Angotti,Drug Manufacturers - Specialty & Generic,0.86,USD,14578978,https://images.financialmodelingprep.com/symbol/ACRX.png,138824,-0.31272727272727274,0.06,240995,-15252000,-13004000,"[{'period': '2024', 'revenue': 0.0, 'unit': 'M', 'net_profit': -13.0}, {'period': '2023', 'revenue': 0.651, 'unit': 'M', 'net_profit': -10.29}, {'period': '2022', 'revenue': 1.77, 'unit': 'M', 'net_profit': 47.76}, {'period': '2021', 'revenue': 2.82, 'unit': 'M', 'net_profit': -35.1}]","[{'period': ""Q1 '25"", 'revenue': 0.027, 'unit': 'M', 'net_profit': -2.59}, {'period': ""Q4 '24"", 'revenue': -0.37, 'unit': 'M', 'net_profit': -12.61}, {'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.35}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.83}, {'period': ""Q4 '23"", 'revenue': 0.281, 'unit': 'M', 'net_profit': -4.52}, {'period': ""Q3 '23"", 'revenue': 0.117, 'unit': 'M', 'net_profit': -1.36}]",-0.5,-0.5,18236000,9417000,8863000,10235000,0,0,2647000,8863000,-12683000,0.09692699390135591,-0.26411976280742683,-713.2857142857143,__nan__,__nan__,__nan__,0.5612524676464137
57,ACST,Acasti Pharma Inc. Class A Common Stock,"Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.",Mr. Prashant  Kohli,Biotechnology,3.37,USD,34171463,https://images.financialmodelingprep.com/symbol/ACST.png,33247,-2.3566433566433567,0.13,27682,-14619000,-12853000,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -12.85}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -42.43}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -9.82}, {'period': '2020', 'revenue': 0.196, 'unit': 'M', 'net_profit': -19.68}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.76}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.43}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.62}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.17}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.39}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.72}]",-1.35,-1.35,73300000,24010000,23005000,11557000,722000,0,1684000,23005000,-12355000,-1.9225089922382785,0.6970703999622899,0.7635726795096321,__nan__,__nan__,__nan__,0.15766712141882674
58,ACTC,ArcLight Clean Transition Corp. Class A Ordinary Shares,,,,,,,,,,,,-1284331,-1284331,"[{'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.28}]","[{'period': ""Q2 '21"", 'revenue': 58.5, 'unit': 'M', 'net_profit': -189.03}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.28}]",-0.18,-0.18,278826627,1278085,278422424,10920462,0,0,1207962,873882,,0,0,0,__nan__,__nan__,__nan__,0.039165778812078805
59,ACTCU,ArcLight Clean Transition Corp. Unit,,,,,,,,,,,,-1284331,-1284331,"[{'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.28}]","[{'period': ""Q2 '21"", 'revenue': 58.5, 'unit': 'M', 'net_profit': -189.03}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.28}]",-0.18,-0.18,278826627,1278085,278422424,10920462,0,0,1207962,873882,,0,0,0,__nan__,__nan__,__nan__,0.039165778812078805
60,ACTCW,ArcLight Clean Transition Corp. Warrant,,,,,,,,,,,,-1284331,-1284331,"[{'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.28}]","[{'period': ""Q2 '21"", 'revenue': 58.5, 'unit': 'M', 'net_profit': -189.03}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.28}]",-0.18,-0.18,278826627,1278085,278422424,10920462,0,0,1207962,873882,-543727,0,0,0,__nan__,__nan__,__nan__,0.039165778812078805
61,ACTDU,ArcLight Clean Transition Corp. II Unit,"ArcLight Clean Transition Corp. II intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities in energy and natural resources sectors. ArcLight Clean Transition Corp. II was incorporated in 2021 and is based in Boston, Massachusetts.",,Shell Companies,7.655,USD,0,https://images.financialmodelingprep.com/symbol/ACTDU.png,0,-25.687919463087248,-2.595,6040,-15732042,-26982181,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -26.98}]","[{'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 8.31}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 9.16}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 8.21}]",-0.69,-0.69,312848614,1513189,811526,40766115,0,311175471,113261,811526,-1944632,0,0,0,__nan__,__nan__,__nan__,0.13030620298672635
62,ACTDW,ArcLight Clean Transition Corp. II Warrant,"ArcLight Clean Transition Corp. II intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2021 and is based in Boston, Massachusetts.",Mr. John F. Erhard J.D.,Shell Companies,0.875,USD,0,https://images.financialmodelingprep.com/symbol/ACTDW.png,0,0,-0.10699999,24511,-15732042,-26982181,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -26.98}]","[{'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 8.31}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 9.16}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 8.21}]",-0.69,-0.69,312848614,1513189,811526,40766115,0,311175471,113261,811526,-1944632,0,0,0,__nan__,__nan__,__nan__,0.13030620298672635
63,ACTG,Acacia Research Corporation (Acacia Tech) Common Stock,"Acacia Research Corporation, together with its subsidiaries, invests in intellectual property and related absolute return assets; and engages in the licensing and enforcement of patented technologies. The company operates through two segments, Intellectual Property Operations and Industrial Operations. The company owns or controls the rights to various patent portfolios, which include U.S. patents and foreign counterparts covering technologies used in a range of industries. It has executed approximately 1,600 license agreements, and approximately 200 patent portfolio licensing and enforcement programs. It also designs manufactures printers and parts, and consumable products through dealers and distributors for various industrial printing applications. In addition, the company offers supply-chain printing solutions for manufacturing, transportation and logistics, retail distribution, food and beverage distribution, and pharmaceutical distribution industries; and line matrix printers for mission critical applications within labeling and inventory management, build sheets, invoicing, manifests and bills of lading, and reporting industries. Acacia Research Corporation was incorporated in 1993 and is based in New York, New York.",Mr. Martin D. McNulty Jr.,Specialty Business Services,3.72,USD,357758724,https://images.financialmodelingprep.com/symbol/ACTG.png,302629,-33.82,0.01,214729,1866000,-36057000,"[{'period': '2024', 'revenue': 122.31, 'unit': 'M', 'net_profit': -36.06}, {'period': '2023', 'revenue': 125.1, 'unit': 'M', 'net_profit': 67.06}, {'period': '2022', 'revenue': 59.22, 'unit': 'M', 'net_profit': -110.94}, {'period': '2021', 'revenue': 88.05, 'unit': 'M', 'net_profit': 149.2}]","[{'period': ""Q1 '25"", 'revenue': 124.42, 'unit': 'M', 'net_profit': 24.29}, {'period': ""Q4 '24"", 'revenue': 48.84, 'unit': 'M', 'net_profit': -13.43}, {'period': ""Q3 '24"", 'revenue': 23.31, 'unit': 'M', 'net_profit': -14.0}, {'period': ""Q2 '24"", 'revenue': 25.84, 'unit': 'M', 'net_profit': -8.45}, {'period': ""Q1 '24"", 'revenue': 24320.0, 'unit': 'K', 'net_profit': -186.0}, {'period': ""Q4 '23"", 'revenue': 92.31, 'unit': 'M', 'net_profit': 74.76}]",-0.36,-0.36,756394000,420146000,333765000,203775000,26909000,0,47239000,273880000,-98545000,-0.9778723807942701,-1.5376826722338204,-1.5070422535211265,"[0.125, 0.125]","['2015-11-04', '2013-05-01']",__nan__,0.2694032475138618
64,ACVA,ACV Auctions Inc. Class A Common Stock,"ACV Auctions Inc. operates a digital marketplace that connects buyers and sellers for the online auction of wholesale vehicles. It also provides data services that offer insights into the condition and value of used vehicles, as well as offers customer financing services. ACV Auctions Inc. was incorporated in 2014 and is headquartered in Buffalo, New York.",Mr. George G. Chamoun,Auto - Dealerships,17.04,USD,3064950788,https://images.financialmodelingprep.com/symbol/ACVA.png,2732951,-38.73,0.11,2015859,-46571000,-79700000,"[{'period': '2024', 'revenue': 637.16, 'unit': 'M', 'net_profit': -79.7}, {'period': '2023', 'revenue': 481.23, 'unit': 'M', 'net_profit': -75.26}, {'period': '2022', 'revenue': 421.53, 'unit': 'M', 'net_profit': -102.19}, {'period': '2021', 'revenue': 358.44, 'unit': 'M', 'net_profit': -78.18}]","[{'period': ""Q1 '25"", 'revenue': 182.7, 'unit': 'M', 'net_profit': -14.82}, {'period': ""Q4 '24"", 'revenue': 159.51, 'unit': 'M', 'net_profit': -26.14}, {'period': ""Q3 '24"", 'revenue': 171.33, 'unit': 'M', 'net_profit': -16.03}, {'period': ""Q2 '24"", 'revenue': 160.62, 'unit': 'M', 'net_profit': -17.06}, {'period': ""Q1 '24"", 'revenue': 145.69, 'unit': 'M', 'net_profit': -20.47}, {'period': ""Q4 '23"", 'revenue': 118.38, 'unit': 'M', 'net_profit': -23.24}]",-0.48,-0.48,984149000,593197000,270101000,544145000,307815000,0,381166000,224065000,60858000,0.1357335065417092,-0.05898141135515074,-0.02127659574468087,__nan__,__nan__,__nan__,0.5529091631450116
65,ADAG,Adagene Inc. American Depositary Shares,"Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.",Dr. Peter P.  Luo Ph.D.,Biotechnology,1.77,USD,66707130,https://images.financialmodelingprep.com/symbol/ADAG.png,27458,-2.39,-0.0197,5029,-31663540,-33424111,"[{'period': '2024', 'revenue': 0.1032, 'unit': 'M', 'net_profit': -33.42}, {'period': '2023', 'revenue': 18.11, 'unit': 'M', 'net_profit': -18.95}, {'period': '2022', 'revenue': 9.29, 'unit': 'M', 'net_profit': -79.97}, {'period': '2021', 'revenue': 10.18, 'unit': 'M', 'net_profit': -73.18}]","[{'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.51}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.51}, {'period': ""Q4 '23"", 'revenue': 0.40787, 'unit': 'M', 'net_profit': -7.42}, {'period': ""Q3 '23"", 'revenue': 0.40787, 'unit': 'M', 'net_profit': -7.42}, {'period': ""Q2 '23"", 'revenue': 8.65, 'unit': 'M', 'net_profit': -2.05}, {'period': ""Q1 '23"", 'revenue': 8.65, 'unit': 'M', 'net_profit': -2.05}]",-0.95,-0.95,89268425,87778005,85194502,38744581,8309,0,38184938,85194502,-29734565,-1.1178513369030456,-0.7641432633269593,-0.7272727272727273,__nan__,__nan__,__nan__,0.43402335148178095
66,ADAP,Adaptimmune Therapeutics plc American Depositary Shares,"Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing a T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.",Mr. Adrian G.  Rawcliffe,Biotechnology,0.2779,USD,71656228,https://images.financialmodelingprep.com/symbol/ADAP.png,2028709,-0.93,0.0132,414148,-52665000,-70814000,"[{'period': '2024', 'revenue': 178.03, 'unit': 'M', 'net_profit': -70.81}, {'period': '2023', 'revenue': 60.28, 'unit': 'M', 'net_profit': -113.87}, {'period': '2022', 'revenue': 27.15, 'unit': 'M', 'net_profit': -165.46}, {'period': '2021', 'revenue': 6.15, 'unit': 'M', 'net_profit': -158.09}]","[{'period': ""Q1 '25"", 'revenue': 7.29, 'unit': 'M', 'net_profit': -47.58}, {'period': ""Q4 '24"", 'revenue': 3.22, 'unit': 'M', 'net_profit': -74.22}, {'period': ""Q3 '24"", 'revenue': 40.9, 'unit': 'M', 'net_profit': -17.62}, {'period': ""Q2 '24"", 'revenue': 128.23, 'unit': 'M', 'net_profit': 69.52}, {'period': ""Q1 '24"", 'revenue': 5.68, 'unit': 'M', 'net_profit': -48.5}, {'period': ""Q4 '23"", 'revenue': 0.23301, 'unit': 'M', 'net_profit': -48.33}]",-0.28,-0.28,245963000,188169000,151605000,234114000,15982000,0,64527000,91139000,-75926000,0.5891901589728389,0.3781208560564147,0.5042372881355932,__nan__,__nan__,__nan__,0.9518260876635917
67,ADBE,Adobe Inc. Common Stock,"Adobe Inc. operates as a diversified software company worldwide. It operates through three segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products, services, and solutions that enable individuals, teams, and enterprises to create, publish, and promote content; and Document Cloud, a unified cloud-based document services platform. Its flagship product is Creative Cloud, a subscription service that allows members to access its creative products. This segment serves content creators, workers, marketers, educators, enthusiasts, communicators, and consumers. The Digital Experience segment provides an integrated platform and set of applications and services that enable brands and businesses to create, manage, execute, measure, monetize, and optimize customer experiences from analytics to commerce. This segment serves marketers, advertisers, agencies, publishers, merchandisers, merchants, web analysts, data scientists, developers, and executives across the C-suite. The Publishing and Advertising segment offers products and services, such as e-learning solutions, technical document publishing, web conferencing, document and forms platform, web application development, and high-end printing, as well as Advertising Cloud offerings. The company offers its products and services directly to enterprise customers through its sales force and local field offices, as well as to end users through app stores and through its website at adobe.com. It also distributes products and services through a network of distributors, value-added resellers, systems integrators, software vendors and developers, retailers, and original equipment manufacturers. The company was formerly known as Adobe Systems Incorporated and changed its name to Adobe Inc. in October 2018. Adobe Inc. was founded in 1982 and is headquartered in San Jose, California.",Mr. Shantanu  Narayen,Software - Infrastructure,417.125,USD,177778675000,https://images.financialmodelingprep.com/symbol/ADBE.png,3838751,27.55,12.435,5345799,8029000000,5560000000,"[{'period': '2024', 'revenue': 21.5, 'unit': 'B', 'net_profit': 5.56}, {'period': '2023', 'revenue': 19.41, 'unit': 'B', 'net_profit': 5.43}, {'period': '2022', 'revenue': 17.61, 'unit': 'B', 'net_profit': 4.76}, {'period': '2021', 'revenue': 15.79, 'unit': 'B', 'net_profit': 4.82}]","[{'period': ""Q1 '25"", 'revenue': 5.71, 'unit': 'B', 'net_profit': 1.81}, {'period': ""Q4 '24"", 'revenue': 5.61, 'unit': 'B', 'net_profit': 1.68}, {'period': ""Q3 '24"", 'revenue': 5.41, 'unit': 'B', 'net_profit': 1.68}, {'period': ""Q2 '24"", 'revenue': 5.31, 'unit': 'B', 'net_profit': 1.57}, {'period': ""Q1 '24"", 'revenue': 5180.0, 'unit': 'M', 'net_profit': 620.0}, {'period': ""Q4 '23"", 'revenue': 5.05, 'unit': 'B', 'net_profit': 1.48}]",12.44,12.36,30230000000,11232000000,7886000000,16125000000,2072000000,0,10521000000,7613000000,7824000000,0.2073684210526316,0.02431834929992631,0.04713804713804703,"[0.0125, 0.05]","['2005-03-24', '1990-01-08']",__nan__,0.5334105193516374
68,ADER,26 Capital Acquisition Corp. Class A Common Stock,"26 Capital Acquisition Corp. does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Miami, Florida.",Mr. Jason N. Ader,Shell Companies,11.08,USD,114181616,https://images.financialmodelingprep.com/symbol/ADER.png,55398,-29.945945945945947,0.01,41942,-12035337,7258882,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.26}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.15}]","[{'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.09}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -692.92}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.67}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -519.52}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.94}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.17}]",0.21,0.21,35511910,805178,770820,21515475,0,34706732,5820854,770820,-1947734,0.10285697204853426,0.014834382459954354,-0.0454545454545455,__nan__,__nan__,__nan__,0.6058664543810794
69,ADERU,26 Capital Acquisition Corp. Unit,"26 Capital Acquisition Corp. does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Miami, Florida.",Mr. Jason N. Ader,Shell Companies,11.08,USD,111652606,https://images.financialmodelingprep.com/symbol/ADERU.png,108,50.593607305936075,0.08,2000,-12035337,7258882,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.26}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.15}]","[{'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.09}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -692.92}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.67}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -519.52}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.94}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.17}]",0.21,0.21,35511910,805178,770820,21515475,0,34706732,5820854,770820,-1947734,0.10285697204853426,0.014834382459954354,-0.0454545454545455,__nan__,__nan__,__nan__,0.6058664543810794
70,ADERW,26 Capital Acquisition Corp. Warrant,"26 Capital Acquisition Corp. is a blank check company that focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, and similar business combination with one or more businesses. The company was founded in 2020 and is based in Miami, Florida.",Mr. Jason N. Ader,Shell Companies,0.0065,USD,0,https://images.financialmodelingprep.com/symbol/ADERW.png,0,0,0.0013,36027,-12035337,7258882,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.26}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.15}]","[{'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.09}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -692.92}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.67}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -519.52}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.94}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.17}]",0.21,0.21,35511910,805178,770820,21515475,0,34706732,5820854,770820,-1947734,0.10285697204853426,0.014834382459954354,-0.0454545454545455,__nan__,__nan__,__nan__,0.6058664543810794
71,ADES,Advanced Emissions Solutions Inc. Common Stock,"Advanced Emissions Solutions, Inc., together with its subsidiaries, provides environmental technologies and specialty chemicals in the United States. It operates through two segments, Refined Coal and Advanced Purification Technologies. The company offers CyClean technology, a pre-combustion coal treatment process to enhance combustion, as well as to reduce emissions of nitrogen oxide and mercury from coals burned in cyclone boilers; and M-45 and M-45-PC technologies, which are pre-combustion coal treatment technologies used to control emissions from circulating fluidized bed boilers and pulverized coal boilers. It also provides mercury and other air contaminants controls; and activated carbon products, such as powdered activated carbon and granular activated carbon, as well as owns an associated lignite mine that supplies the raw material for the powdered activated carbon plant. The company's products are used in removal of heavy metal pollutants; treatment of drinking and waste waters; industrial acid gas and odor removal; automotive gasoline emission control; soil and ground water remediation; and food and beverage process and product purifications. It serves customers in the coal-fired power generation and industrial boiler processes. Advanced Emissions Solutions, Inc. was founded in 1996 and is headquartered in Greenwood Village, Colorado.",Mr. Robert E. Rasmus,Industrial - Pollution & Treatment Controls,3.36,USD,111716976,https://images.financialmodelingprep.com/symbol/ADES.png,100316,-4.602739726027397,0.1,100969,64000,-5109000,"[{'period': '2024', 'revenue': 108.96, 'unit': 'M', 'net_profit': -5.11}, {'period': '2023', 'revenue': 99.18, 'unit': 'M', 'net_profit': -12.25}, {'period': '2022', 'revenue': 102.99, 'unit': 'M', 'net_profit': -8.92}, {'period': '2021', 'revenue': 100.29, 'unit': 'M', 'net_profit': 60.4}]","[{'period': ""Q1 '25"", 'revenue': 27250.0, 'unit': 'K', 'net_profit': 203.0}, {'period': ""Q4 '24"", 'revenue': 30.58, 'unit': 'M', 'net_profit': 3.46}, {'period': ""Q3 '24"", 'revenue': 34.77, 'unit': 'M', 'net_profit': 1.62}, {'period': ""Q2 '24"", 'revenue': 25.41, 'unit': 'M', 'net_profit': -1.97}, {'period': ""Q4 '23"", 'revenue': 28.1, 'unit': 'M', 'net_profit': 3.29}, {'period': ""Q3 '23"", 'revenue': 29.83, 'unit': 'M', 'net_profit': -2.17}]",-0.14,-0.14,284368000,52356000,13516000,67092000,14876000,0,44653000,13516000,10477000,1.0518638573743921,0.582904726916483,0.6666666666666666,"[0.25, 0.25]","['2020-02-20', '2017-06-26']",__nan__,0.23593371968716592
72,ADI,Analog Devices Inc. Common Stock,"Analog Devices, Inc. designs, manufactures, tests, and markets integrated circuits (ICs), software, and subsystems that leverage analog, mixed-signal, and digital signal processing technologies. The company provides data converter products, which translate real-world analog signals into digital data, as well as translates digital data into analog signals; power management and reference products for power conversion, driver monitoring, sequencing, and energy management applications in the automotive, communications, industrial, and high-end consumer markets; and power ICs include performance, integration, and software design simulation tools for accurate power supply designs. It also offers high-performance amplifiers to condition analog signals; and radio frequency and microwave ICs to support cellular infrastructure; and microelectromechanical systems technology solutions, including accelerometers used to sense acceleration, gyroscopes for sense rotation, inertial measurement units to sense multiple degrees of freedom, and broadband switches for radio and instrument systems, as well as isolators. In addition, the company offers digital signal processing and system products for high-speed numeric calculations. It serves clients in the industrial, automotive, consumer, instrumentation, aerospace, and communications markets through a direct sales force, third-party distributors, and independent sales representatives in the United States, the rest of North and South America, Europe, Japan, China, and rest of Asia, as well as through its Website. Analog Devices, Inc. was incorporated in 1965 and is headquartered in Wilmington, Massachusetts.",Mr. Vincent T. Roche,Semiconductors,227.11,USD,112641109360,https://images.financialmodelingprep.com/symbol/ADI.png,4496067,72.56,-0.01,3596941,2032798000,1635273000,"[{'period': '2024', 'revenue': 9.43, 'unit': 'B', 'net_profit': 1.64}, {'period': '2023', 'revenue': 12.31, 'unit': 'B', 'net_profit': 3.31}, {'period': '2022', 'revenue': 12.01, 'unit': 'B', 'net_profit': 2.75}, {'period': '2021', 'revenue': 7.32, 'unit': 'B', 'net_profit': 1.39}]","[{'period': ""Q1 '25"", 'revenue': 2420.0, 'unit': 'M', 'net_profit': 391.32}, {'period': ""Q4 '24"", 'revenue': 2440.0, 'unit': 'M', 'net_profit': 478.07}, {'period': ""Q3 '24"", 'revenue': 2310.0, 'unit': 'M', 'net_profit': 392.23}, {'period': ""Q2 '24"", 'revenue': 2160.0, 'unit': 'M', 'net_profit': 302.24}, {'period': ""Q1 '24"", 'revenue': 2510.0, 'unit': 'M', 'net_profit': 462.73}, {'period': ""Q4 '23"", 'revenue': 2720.0, 'unit': 'M', 'net_profit': 498.43}]",3.3,3.28,48228277000,5484654000,2363164000,13051960000,1336331000,0,2988280000,1991342000,3122066000,-0.6695081815827367,-0.50664232169455,-0.5,"[0.99, 0.04]","['2025-03-04', '2003-11-25']",__nan__,0.2706287848516753
73,ADIL,Adial Pharmaceuticals Inc Common Stock,"Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.",Mr. Cary John Claiborne MBA,Biotechnology,0.6578,USD,4324765,https://images.financialmodelingprep.com/symbol/ADIL.png,1300882,-0.24,-0.0022,80654,-13196886,-13197451,"[{'period': '2024', 'revenue': 0.0, 'unit': 'M', 'net_profit': -13.2}, {'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -7.0}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -12.73}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -19.42}]","[{'period': ""Q1 '25"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.23}, {'period': ""Q4 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.07}, {'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.19}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.46}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -6.48}, {'period': ""Q4 '23"", 'revenue': 0.03225, 'unit': 'M', 'net_profit': -1.92}]",-0.71,-0.71,5043942,4058764,3750525,975858,0,981830,975858,3750525,-6922306,-0.8849118338692317,-0.8848412357234975,0.8556910569105691,__nan__,__nan__,__nan__,0.19347129685472197
74,ADILW,Adial Pharmaceuticals Inc Warrant,,None,,0.0009,USD,0,https://images.financialmodelingprep.com/symbol/ADILW.png,0,0,-0.0012,5182,-13196886,-13197451,"[{'period': '2024', 'revenue': 0.0, 'unit': 'M', 'net_profit': -13.2}, {'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -7.0}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -12.73}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -19.42}]","[{'period': ""Q1 '25"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.23}, {'period': ""Q4 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.07}, {'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.19}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.46}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -6.48}, {'period': ""Q4 '23"", 'revenue': 0.03225, 'unit': 'M', 'net_profit': -1.92}]",-0.71,-0.71,5043942,4058764,3750525,975858,0,981830,975858,3750525,-6922306,-0.8849118338692317,-0.8848412357234975,0.8556910569105691,__nan__,__nan__,__nan__,0.19347129685472197
75,ADMA,ADMA Biologics Inc Common Stock,"ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.",Mr. Adam S. Grossman,Biotechnology,19.69,USD,4700672460,https://images.financialmodelingprep.com/symbol/ADMA.png,3675474,23.44,0.49,2458705,147689000,197673000,"[{'period': '2024', 'revenue': 426.45, 'unit': 'M', 'net_profit': 197.67}, {'period': '2023', 'revenue': 258.21, 'unit': 'M', 'net_profit': -28.24}, {'period': '2022', 'revenue': 154.08, 'unit': 'M', 'net_profit': -85.18}, {'period': '2021', 'revenue': 80.94, 'unit': 'M', 'net_profit': -84.45}]","[{'period': ""Q1 '25"", 'revenue': 114.8, 'unit': 'M', 'net_profit': 26.9}, {'period': ""Q4 '24"", 'revenue': 117.55, 'unit': 'M', 'net_profit': 111.9}, {'period': ""Q3 '24"", 'revenue': 119.84, 'unit': 'M', 'net_profit': 35.91}, {'period': ""Q2 '24"", 'revenue': 107.19, 'unit': 'M', 'net_profit': 32.06}, {'period': ""Q1 '24"", 'revenue': 81.88, 'unit': 'M', 'net_profit': 17.81}, {'period': ""Q4 '23"", 'revenue': 73.9, 'unit': 'M', 'net_profit': -17.64}]",0.85,0.81,488678000,331410000,103147000,139660000,49999000,0,55542000,103147000,110097000,27.8455078125,8,7.538461538461538,__nan__,__nan__,__nan__,0.28579146186241244
76,ADMP,Adamis Pharmaceuticals Corporation Common Stock,"Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products for the treatment of asthma; and naloxone injection for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, and injectables; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.","Dr. Ebrahim  Versi M.D., Ph.D.",Drug Manufacturers - Specialty & Generic,0.775,USD,7253326,https://images.financialmodelingprep.com/symbol/ADMP.png,3113594,-0.07642998027613412,0.0065,119482,-24267629,-26199406,"[{'period': '2022', 'revenue': 4.76, 'unit': 'M', 'net_profit': -26.2}, {'period': '2021', 'revenue': 2.21, 'unit': 'M', 'net_profit': -34.6}, {'period': '2020', 'revenue': 16.53, 'unit': 'M', 'net_profit': -49.39}, {'period': '2019', 'revenue': 22.11, 'unit': 'M', 'net_profit': -29.31}]","[{'period': ""Q3 '23"", 'revenue': 9060.0, 'unit': 'K', 'net_profit': 348.2}, {'period': ""Q2 '23"", 'revenue': 0.0069500000000000004, 'unit': 'M', 'net_profit': -8.57}, {'period': ""Q1 '23"", 'revenue': 1450.0, 'unit': 'K', 'net_profit': 71.7}, {'period': ""Q4 '22"", 'revenue': 2.15, 'unit': 'M', 'net_profit': -3.4}, {'period': ""Q3 '22"", 'revenue': 1.51, 'unit': 'M', 'net_profit': -4.4}, {'period': ""Q2 '22"", 'revenue': 0.039850000000000003, 'unit': 'M', 'net_profit': -8.4}]",-12.24,-12.24,10930840,9272150,1081364,11738908,1085009,0,11395866,1081364,-26580923,0.20762511514149093,0.24279945930031407,0.27142857142857146,__nan__,__nan__,__nan__,1.0739255171606208
77,ADMS,Adamas Pharmaceuticals Inc. Common Stock,"Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also developing ADS-5102 that is in Phase III clinical study to treat walking impairment in patients with multiple sclerosis and other indications; and ADS-4101, which has completed two Phase I studies for treating partial onset seizures in patients with epilepsy. In addition, the company offers Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.",Mr. Neil McFarlane,Drug Manufacturers - Specialty & Generic,8.22,USD,0,https://images.financialmodelingprep.com/symbol/ADMS.png,1338689,0,0,3151400,-43313000,-57403000,"[{'period': '2020', 'revenue': 74.46, 'unit': 'M', 'net_profit': -57.4}, {'period': '2019', 'revenue': 54.64, 'unit': 'M', 'net_profit': -105.19}, {'period': '2018', 'revenue': 34.05, 'unit': 'M', 'net_profit': -131.0}, {'period': '2017', 'revenue': 0.5710000000000001, 'unit': 'M', 'net_profit': -89.49}]","[{'period': ""Q3 '21"", 'revenue': 25.9, 'unit': 'M', 'net_profit': -19.52}, {'period': ""Q2 '21"", 'revenue': 21.97, 'unit': 'M', 'net_profit': -12.34}, {'period': ""Q1 '21"", 'revenue': 19.31, 'unit': 'M', 'net_profit': -12.57}, {'period': ""Q4 '20"", 'revenue': 21.01, 'unit': 'M', 'net_profit': -18.27}, {'period': ""Q3 '20"", 'revenue': 20.18, 'unit': 'M', 'net_profit': -11.92}, {'period': ""Q2 '20"", 'revenue': 18.79, 'unit': 'M', 'net_profit': -10.57}]",-1.63,-1.63,120029000,111736000,83365000,170005000,9294000,0,34867000,71660000,-50708000,0.5129430550557754,0.45427148099556974,0.5710526315789474,__nan__,__nan__,__nan__,1.416366044872489
78,ADN,Advent Technologies Holdings Inc. Class A Common Stock,"Advent Technologies Holdings, Inc., an advanced materials and technology development company, operates in the fuel cell and hydrogen technology markets. It develops, manufactures, and assembles fuel cell systems and critical components that determine the performance of hydrogen fuel cells and other energy systems. The company offers high-temperature proton exchange membrane (HT-PEM) fuel cells, HT-PEM based membrane electrode assemblies, membranes, and electrodes. It serves stationary and portable power, automotive, aviation, energy storage, and sensor markets. The company is headquartered in Boston, Massachusetts.",Mr. Gary L. Herman,Renewable Utilities,2.4,USD,6327624,https://images.financialmodelingprep.com/symbol/ADN.png,27148,-0.07,-0.06,13999,-53226000,-71397000,"[{'period': '2023', 'revenue': 4.86, 'unit': 'M', 'net_profit': -71.4}, {'period': '2022', 'revenue': 7.84, 'unit': 'M', 'net_profit': -74.34}, {'period': '2021', 'revenue': 7.07, 'unit': 'M', 'net_profit': -20.52}, {'period': '2020', 'revenue': 882.65, 'unit': 'K', 'net_profit': -993.85}]","[{'period': ""Q3 '24"", 'revenue': 0.128, 'unit': 'M', 'net_profit': -18.52}, {'period': ""Q2 '24"", 'revenue': 0.805, 'unit': 'M', 'net_profit': -11.27}, {'period': ""Q1 '24"", 'revenue': 3.45, 'unit': 'M', 'net_profit': -9.36}, {'period': ""Q4 '23"", 'revenue': 1.51, 'unit': 'M', 'net_profit': -25.73}, {'period': ""Q3 '23"", 'revenue': 1.26, 'unit': 'M', 'net_profit': -11.85}, {'period': ""Q2 '23"", 'revenue': 1.11, 'unit': 'M', 'net_profit': -21.83}]",-37.24,-37.24,34737000,8835000,3562000,21289000,292000,0,11913000,3562000,-36741000,-0.19292662154287507,0.03954961862867751,0.13955637707948243,__nan__,__nan__,__nan__,0.6128623657771253
79,ADNWW,Advent Technologies Holdings Inc. Warrant,"Advent Technologies Holdings, Inc., an advanced materials and technology development company, operates in the fuel cell and hydrogen technology markets in North America, Europe, and Asia. It develops, manufactures, and assembles fuel cell systems and critical components that determine the performance of hydrogen fuel cells and other energy systems. The company offers high-temperature proton exchange membrane (HT-PEM) fuel cells, including membrane electrode assemblies, bipolar plates, and reformers, as well as provides fuel-cell stack assembly and testing services. It serves stationary power, portable power, automotive, aviation, energy storage, and sensor markets. The company is headquartered in Boston, Massachusetts.",Mr. Gary L. Herman,Renewable Utilities,0.0083,USD,21883,https://images.financialmodelingprep.com/symbol/ADNWW.png,104546.32661,,0.0017,7200,-53226000,-71397000,"[{'period': '2023', 'revenue': 4.86, 'unit': 'M', 'net_profit': -71.4}, {'period': '2022', 'revenue': 7.84, 'unit': 'M', 'net_profit': -74.34}, {'period': '2021', 'revenue': 7.07, 'unit': 'M', 'net_profit': -20.52}, {'period': '2020', 'revenue': 882.65, 'unit': 'K', 'net_profit': -993.85}]","[{'period': ""Q3 '24"", 'revenue': 0.128, 'unit': 'M', 'net_profit': -18.52}, {'period': ""Q2 '24"", 'revenue': 0.805, 'unit': 'M', 'net_profit': -11.27}, {'period': ""Q1 '24"", 'revenue': 3.45, 'unit': 'M', 'net_profit': -9.36}, {'period': ""Q4 '23"", 'revenue': 1.51, 'unit': 'M', 'net_profit': -25.73}, {'period': ""Q3 '23"", 'revenue': 1.26, 'unit': 'M', 'net_profit': -11.85}, {'period': ""Q2 '23"", 'revenue': 1.11, 'unit': 'M', 'net_profit': -21.83}]",-37.24,-37.24,34737000,8835000,3562000,21289000,292000,0,11913000,3562000,-36741000,-0.19292662154287507,0.03954961862867751,0.13955637707948243,__nan__,__nan__,__nan__,0.6128623657771253
80,ADOC,Edoc Acquisition Corp. Class A Ordinary Share,"Edoc Acquisition Corp. does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses primarily in the health care and health care provider space in North America and the Asia-Pacific. The company was incorporated in 2020 and is based in Victor, New York.",Mr. Kevin  Chen,Shell Companies,2.85,USD,10317599,https://images.financialmodelingprep.com/symbol/ADOC.png,22081,-1.4766839378238341,-4.95,571568,-5141.406000000001,-7686.39,"[{'period': '2022', 'revenue': 0.0, 'unit': 'K', 'net_profit': -7.69}, {'period': '2021', 'revenue': 0.0, 'unit': '', 'net_profit': -899.88}, {'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -1.7}]","[{'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -252.47}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': '', 'net_profit': -275.24}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': '', 'net_profit': -431.05}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -1.04}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': '', 'net_profit': -230.12}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -1.85}]",-0.0013,-0.0013,21405267,86112,13726,4389775,0,21319155,4366518,13726,-1459672,-6.724006866929855,-7.541572209627951,-11.999999999999998,__nan__,__nan__,__nan__,0.2050791984982014
81,ADOCR,Edoc Acquisition Corp. Right,"Edoc Acquisition Corp. does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses primarily in the health care and health care provider space in North America and the Asia-Pacific. The company was incorporated in 2020 and is based in Victor, New York.",Mr. Kevin  Chen,Shell Companies,0.27,USD,1063080,https://images.financialmodelingprep.com/symbol/ADOCR.png,0,-0.4900181488203267,0.07,3483784,-5141.406000000001,-7686.39,"[{'period': '2022', 'revenue': 0.0, 'unit': 'K', 'net_profit': -7.69}, {'period': '2021', 'revenue': 0.0, 'unit': '', 'net_profit': -899.88}, {'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -1.7}]","[{'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -252.47}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': '', 'net_profit': -275.24}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': '', 'net_profit': -431.05}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -1.04}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': '', 'net_profit': -230.12}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -1.85}]",-0.0013,-0.0013,21405267,86112,13726,4389775,0,21319155,4366518,13726,-1459672,-6.724006866929855,-7.541572209627951,-11.999999999999998,"[0.285, 0.285]","['2022-03-15', '2022-03-15']",__nan__,0.2050791984982014
82,ADOCW,Edoc Acquisition Corp. Warrant,"Edoc Acquisition Corp. does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses primarily in the healthcare and healthcare provider space in North America and the Asia-Pacific. Edoc Acquisition Corp. was incorporated in 2020 and is based in Victor, New York.",Mr. Kevin  Chen,Shell Companies,0.045,USD,177180,https://images.financialmodelingprep.com/symbol/ADOCW.png,0,0,0.015,108311,-5141.406000000001,-7686.39,"[{'period': '2022', 'revenue': 0.0, 'unit': 'K', 'net_profit': -7.69}, {'period': '2021', 'revenue': 0.0, 'unit': '', 'net_profit': -899.88}, {'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -1.7}]","[{'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -252.47}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': '', 'net_profit': -275.24}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': '', 'net_profit': -431.05}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -1.04}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': '', 'net_profit': -230.12}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -1.85}]",-0.0013,-0.0013,21405267,86112,13726,4389775,0,21319155,4366518,13726,-1459672,-6.724006866929855,-7.541572209627951,-11.999999999999998,__nan__,__nan__,__nan__,0.2050791984982014
83,ADP,Automatic Data Processing Inc. Common Stock,"Automatic Data Processing, Inc. provides cloud-based human capital management solutions worldwide. It operates in two segments, Employer Services and Professional Employer Organization (PEO). The Employer Services segment offers strategic, cloud-based platforms, and human resources (HR) outsourcing solutions. Its offerings include payroll, benefits administration, talent management, HR management, workforce management, insurance, retirement, and compliance services, as well as integrated HCM solutions. The PEO Services segment provides HR outsourcing solutions to small and mid-sized businesses through a co-employment model. This segment offers benefits package, protection and compliance, talent engagement, expertise, comprehensive outsourcing, and recruitment process outsourcing services. The company was founded in 1949 and is headquartered in Roseland, New Jersey.",Ms. Maria  Black,Staffing & Employment Services,319.3,USD,129611213900,https://images.financialmodelingprep.com/symbol/ADP.png,1948124,33.33,3.45,1482350,5800000000,3752000000,"[{'period': '2024', 'revenue': 19.2, 'unit': 'B', 'net_profit': 3.75}, {'period': '2023', 'revenue': 18.01, 'unit': 'B', 'net_profit': 3.41}, {'period': '2022', 'revenue': 16.5, 'unit': 'B', 'net_profit': 2.95}, {'period': '2021', 'revenue': 15.01, 'unit': 'B', 'net_profit': 2.6}]","[{'period': ""Q3 '25"", 'revenue': 5.55, 'unit': 'B', 'net_profit': 1.25}, {'period': ""Q2 '25"", 'revenue': 5050.0, 'unit': 'M', 'net_profit': 963.2}, {'period': ""Q1 '25"", 'revenue': 4830.0, 'unit': 'M', 'net_profit': 956.3}, {'period': ""Q4 '24"", 'revenue': 4770.0, 'unit': 'M', 'net_profit': 829.3}, {'period': ""Q3 '24"", 'revenue': 5.25, 'unit': 'B', 'net_profit': 1.18}, {'period': ""Q2 '24"", 'revenue': 4670.0, 'unit': 'M', 'net_profit': 878.4}]",9.14,9.1,54362700000,45542500000,2913400000,49815100000,3428200000,0,45080000000,2913400000,3594200000,0.10589940128894482,0.09964830011723329,0.10787878787878795,"[1.54, 0.14]","['2025-06-13', '1983-06-14']",__nan__,0.9163470541382235
84,ADPT,Adaptive Biotechnologies Corporation Common Stock,"Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.",Mr. Chad M. Robins M.B.A.,Biotechnology,9.05,USD,1374848850,https://images.financialmodelingprep.com/symbol/ADPT.png,2386769,-9.53,0.14,961224,-128759000,-159492000,"[{'period': '2024', 'revenue': 178.96, 'unit': 'M', 'net_profit': -159.49}, {'period': '2023', 'revenue': 170.28, 'unit': 'M', 'net_profit': -225.25}, {'period': '2022', 'revenue': 185.31, 'unit': 'M', 'net_profit': -142.46}, {'period': '2021', 'revenue': 154.34, 'unit': 'M', 'net_profit': -205.61}]","[{'period': ""Q1 '25"", 'revenue': 52.44, 'unit': 'M', 'net_profit': -29.85}, {'period': ""Q4 '24"", 'revenue': 47.46, 'unit': 'M', 'net_profit': -33.69}, {'period': ""Q3 '24"", 'revenue': 46.44, 'unit': 'M', 'net_profit': -32.07}, {'period': ""Q2 '24"", 'revenue': 43.19, 'unit': 'M', 'net_profit': -46.22}, {'period': ""Q1 '24"", 'revenue': 41.87, 'unit': 'M', 'net_profit': -47.51}, {'period': ""Q4 '23"", 'revenue': 45.78, 'unit': 'M', 'net_profit': -69.44}]",-1.08,-1.08,539376000,283752000,222294000,336891000,41731000,33660000,98053000,47920000,-98876000,0.319718079176639,0.29193340732519424,0.30769230769230765,__nan__,__nan__,__nan__,0.6245939752603008
85,ADSK,Autodesk Inc. Common Stock,"Autodesk, Inc. provides 3D design, engineering, and entertainment software and services worldwide. The company offers AutoCAD Civil 3D, a surveying, design, analysis, and documentation solution for civil engineering, including land development, transportation, and environmental projects; BIM 360, a construction management cloud-based software; AutoCAD, a software for professional design, drafting, detailing, and visualization; AutoCAD LT, a drafting and detailing software; computer-aided manufacturing (CAM) software for computer numeric control machining, inspection, and modelling for manufacturing; Fusion 360, a 3D CAD, CAM, and computer-aided engineering tool; and Industry Collections tools for professionals in architecture, engineering and construction, product design and manufacturing, and media and entertainment collection industries. It also provides Inventor tools for 3D mechanical design, simulation, analysis, tooling, visualization, and documentation; Vault, a data management software to manage data in one central location, accelerate design processes, and streamline internal/external collaboration; Maya and 3ds Max software products that offer 3D modeling, animation, effects, rendering, and compositing solutions; and ShotGrid, a cloud-based software for review and production tracking in the media and entertainment industry. It sells its products and services to customers directly, as well as through a network of resellers and distributors. Autodesk, Inc. was incorporated in 1982 and is headquartered in San Rafael, California.",Dr. Andrew  Anagnost Ph.D.,Software - Application,298.08,USD,63772725600,https://images.financialmodelingprep.com/symbol/ADSK.png,1706130,58.33,2.3,1897260,1534000000,1112000000,"[{'period': '2025', 'revenue': 6.13, 'unit': 'B', 'net_profit': 1.11}, {'period': '2024', 'revenue': 5440.0, 'unit': 'M', 'net_profit': 906.0}, {'period': '2023', 'revenue': 5000.0, 'unit': 'M', 'net_profit': 823.0}, {'period': '2022', 'revenue': 4390.0, 'unit': 'M', 'net_profit': 497.0}]","[{'period': ""Q4 '25"", 'revenue': 1640.0, 'unit': 'M', 'net_profit': 303.0}, {'period': ""Q3 '25"", 'revenue': 1570.0, 'unit': 'M', 'net_profit': 275.0}, {'period': ""Q2 '25"", 'revenue': 1500.0, 'unit': 'M', 'net_profit': 282.0}, {'period': ""Q1 '25"", 'revenue': 1420.0, 'unit': 'M', 'net_profit': 252.0}, {'period': ""Q4 '24"", 'revenue': 1470.0, 'unit': 'M', 'net_profit': 282.0}, {'period': ""Q3 '24"", 'revenue': 1410.0, 'unit': 'M', 'net_profit': 241.0}]",5.17,5.12,10833000000,3482000000,1886000000,8212000000,1008000000,267000000,5151000000,1599000000,1567000000,0.258408531583265,0.22737306843267108,0.2338902147971359,"[0.015, 0.1]","['2005-03-22', '1989-07-14']",__nan__,0.7580540939721222
86,ADTN,ADTRAN Inc. Common Stock,"ADTRAN Holdings, Inc., through its subsidiaries, provides end-to-end fiber networking solutions for communications service provider, enterprises, and government customers in the United States, Germany, the United Kingdom, Mexico, and internationally. It operates through two segments, Network Solutions, and Services & Support. The company offers fiber access and fiber to the node platforms; transceivers, cables, and other miscellaneous materials; passive optical network optical line terminals; fiber to the distribution point Gfast distribution point units; cabinet and outside plant enclosures and services; packet optical transports; fixed wireless access platforms; and network management and subscriber services, and control and orchestration software. It also provides broadband customer premises solutions, ethernet switches and routers, residential gateways, cloud-based software-as-a-service management platforms, virtual wireless local area networks, Internet of Things gateways, pre-sale and post-sale technical support, and multi-gigabit mesh Wi-Fi gateways. In addition, the company offers time division multiplexed and asynchronous transfer mode-based aggregation systems and customer devices; and high-bit-rate and asymmetric digital subscriber line, and other technologies. Further, it provides other access and aggregation, subscriber and experience, and traditional and other products, software, and services. Additionally, the company engages in the provision of planning, engineering, program management, maintenance, installation, and commissioning services to implement customer network solutions; and customer devices solutions into consumer, small business, and enterprise locations. ADTRAN Holdings, Inc. is headquartered in Huntsville, Alabama.",Mr. Thomas R. Stanton,Communication Equipment,8.13,USD,650091060,https://images.financialmodelingprep.com/symbol/ADTN.png,1128212,-4.84,-0.06,530245,-319125000,-450872000,"[{'period': '2024', 'revenue': 922.72, 'unit': 'M', 'net_profit': -450.87}, {'period': '2023', 'revenue': 1150.0, 'unit': 'M', 'net_profit': -267.69}, {'period': '2022', 'revenue': 1030.0, 'unit': 'M', 'net_profit': -8.89}, {'period': '2021', 'revenue': 563.0, 'unit': 'M', 'net_profit': -8.63}]","[{'period': ""Q1 '25"", 'revenue': 247.74, 'unit': 'M', 'net_profit': -10.63}, {'period': ""Q4 '24"", 'revenue': 242.85, 'unit': 'M', 'net_profit': -45.92}, {'period': ""Q3 '24"", 'revenue': 227.7, 'unit': 'M', 'net_profit': -31.24}, {'period': ""Q2 '24"", 'revenue': 225.99, 'unit': 'M', 'net_profit': -49.87}, {'period': ""Q1 '24"", 'revenue': 226.17, 'unit': 'M', 'net_profit': -324.55}, {'period': ""Q4 '23"", 'revenue': 225.48, 'unit': 'M', 'net_profit': -109.94}]",-5.71,-5.71,1179372000,608405000,77567000,622015000,193266000,32060000,293645000,77567000,70616000,-2.3220732443630157,-0.68431905800783,-0.6744868035190615,"[0.09, 2]","['2023-08-18', '2003-07-29']",__nan__,0.5274120464111408
87,ADTX,ADiTx Therapeutics Inc. Common Stock,"Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.",Mr. Amro A. Albanna,Biotechnology,1.66,USD,188170960,https://images.financialmodelingprep.com/symbol/ADTX.png,3048649,-0.01,0.05,66411,-27039162,-34446486,"[{'period': '2024', 'revenue': 0.13399000000000003, 'unit': 'M', 'net_profit': -34.45}, {'period': '2023', 'revenue': 0.64518, 'unit': 'M', 'net_profit': -32.38}, {'period': '2022', 'revenue': 0.93372, 'unit': 'M', 'net_profit': -28.19}, {'period': '2021', 'revenue': 0.10503, 'unit': 'M', 'net_profit': -48.31}]","[{'period': ""Q1 '25"", 'revenue': 0.00102, 'unit': 'M', 'net_profit': -5.71}, {'period': ""Q4 '24"", 'revenue': 0.00317, 'unit': 'M', 'net_profit': -5.23}, {'period': ""Q3 '24"", 'revenue': 0.00685, 'unit': 'M', 'net_profit': -6.94}, {'period': ""Q2 '24"", 'revenue': 0.04428, 'unit': 'M', 'net_profit': -7.55}, {'period': ""Q1 '24"", 'revenue': 0.07968000000000001, 'unit': 'M', 'net_profit': -14.73}, {'period': ""Q4 '23"", 'revenue': 0.0813, 'unit': 'M', 'net_profit': -10.97}]",-216.59,-216.59,32144390,1999841000,833031000,23857994,1152186,27277211,23407123,833031,-16762121,-0.06211015146380127,-0.06379226307261526,-1.002681460933888,__nan__,__nan__,__nan__,0.7422133068942979
88,ADUS,Addus HomeCare Corporation Common Stock,"Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. It operates through three segments: Personal Care, Hospice, and Home Health. The Personal Care segment provides non-medical assistance with activities of daily living. This segment offers services that include assistance with bathing, grooming, oral care, feeding and dressing, medication reminders, meal planning and preparation, housekeeping, and transportation services. The Hospice segment provides palliative nursing care, social work, spiritual counseling, homemaker, and bereavement counseling services for people who are terminally ill, as well as related services for their families. The Home Health segment offers skilled nursing and physical, occupational, and speech therapy for the individuals who requires assistance during an illness or after hospitalization. The company's payor clients include federal, state, and local governmental agencies; managed care organizations; commercial insurers; and private individuals. As of December 31, 2021, the company served consumers through 206 offices located in 22 states. Addus HomeCare Corporation was founded in 1979 and is based in Frisco, Texas.",Mr. R. Dirk Allison CPA,Medical - Care Facilities,111.63,USD,2053891533,https://images.financialmodelingprep.com/symbol/ADUS.png,232975,25.26,1.73,154431,120615000,73598000,"[{'period': '2024', 'revenue': 1150.0, 'unit': 'M', 'net_profit': 73.6}, {'period': '2023', 'revenue': 1060.0, 'unit': 'M', 'net_profit': 62.52}, {'period': '2022', 'revenue': 951.12, 'unit': 'M', 'net_profit': 46.02}, {'period': '2021', 'revenue': 864.5, 'unit': 'M', 'net_profit': 45.13}]","[{'period': ""Q1 '25"", 'revenue': 337.71, 'unit': 'M', 'net_profit': 21.23}, {'period': ""Q4 '24"", 'revenue': 297.14, 'unit': 'M', 'net_profit': 19.53}, {'period': ""Q3 '24"", 'revenue': 289.79, 'unit': 'M', 'net_profit': 20.16}, {'period': ""Q2 '24"", 'revenue': 286.92, 'unit': 'M', 'net_profit': 18.08}, {'period': ""Q1 '24"", 'revenue': 280.75, 'unit': 'M', 'net_profit': 15.83}, {'period': ""Q4 '23"", 'revenue': 276.35, 'unit': 'M', 'net_profit': 19.58}]",4.33,4.23,1464422000,260382000,0,442142000,135258000,0,155871000,0,110384000,0.13191876724412996,0.1772666197453452,0.12467532467532466,__nan__,__nan__,__nan__,0.3019225332588557
89,ADV,Advantage Solutions Inc. Class A Common Stock,"Advantage Solutions Inc. provides outsourced solutions to consumer goods companies and retailers in North America and internationally. It operates in two segments, Sales and Marketing. The Sales segment offers brand-centric services, such as headquarter relationship management; analytics, insights, and intelligence; administration; and brand-centric merchandising services. This segment also provides retailer-centric services comprising retailer-centric merchandising, in-store media, and digital commerce. The Marketing segment offers brand-centric services, including shopper and consumer marketing, and brand experiential services; and retailer-centric services, such as retail experiential, private label, digital marketing, and digital media and advertising. The company was formerly known as Karman Holding Corp. and changed its name to Advantage Solutions Inc. in March 2016. Advantage Solutions Inc. was founded in 1987 and is headquartered in Irvine, California.",Mr. David A. Peacock,Advertising Agencies,1.26,USD,408633120,https://images.financialmodelingprep.com/symbol/ADV.png,605746,-1.06,0.17,1389321,-82755000,-326962000,"[{'period': '2024', 'revenue': 3570.0, 'unit': 'M', 'net_profit': -326.96}, {'period': '2023', 'revenue': 4220.0, 'unit': 'M', 'net_profit': -63.26}, {'period': '2022', 'revenue': 4.05, 'unit': 'B', 'net_profit': -1.38}, {'period': '2021', 'revenue': 3600.0, 'unit': 'M', 'net_profit': 54.49}]","[{'period': ""Q1 '25"", 'revenue': 821.79, 'unit': 'M', 'net_profit': -56.13}, {'period': ""Q4 '24"", 'revenue': 892.28, 'unit': 'M', 'net_profit': -177.88}, {'period': ""Q3 '24"", 'revenue': 939.27, 'unit': 'M', 'net_profit': -42.78}, {'period': ""Q2 '24"", 'revenue': 873.36, 'unit': 'M', 'net_profit': -114.01}, {'period': ""Q1 '24"", 'revenue': 879.0, 'unit': 'M', 'net_profit': -62.32}, {'period': ""Q4 '23"", 'revenue': 1080.0, 'unit': 'M', 'net_profit': 17.43}]",-1.02,-1.02,3106517000,910738000,205233000,2357782000,637225000,226510000,460062000,205233000,85257000,-1.2747756272972677,-4.168705934427266,-4.1,__nan__,__nan__,__nan__,0.758979268421837
90,ADVM,Adverum Biotechnologies Inc. Common Stock,"Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.",Dr. Laurent  Fischer,Biotechnology,2.115,USD,44183831,https://images.financialmodelingprep.com/symbol/ADVM.png,331893,-0.32,0.065,391729,-127274000,-130927000,"[{'period': '2024', 'revenue': 1.0, 'unit': 'M', 'net_profit': -130.93}, {'period': '2023', 'revenue': 3.6, 'unit': 'M', 'net_profit': -117.17}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -154.54}, {'period': '2021', 'revenue': 7.5, 'unit': 'M', 'net_profit': -145.54}]","[{'period': ""Q1 '25"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -47.02}, {'period': ""Q4 '24"", 'revenue': -3.6, 'unit': 'M', 'net_profit': -32.88}, {'period': ""Q3 '24"", 'revenue': 1.0, 'unit': 'M', 'net_profit': -27.13}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -18.48}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -24.79}, {'period': ""Q4 '23"", 'revenue': -3.6, 'unit': 'M', 'net_profit': -23.71}]",-6.62,-6.62,179841000,131300000,125691000,109127000,0,0,22898000,60652000,-92850000,-0.0322470761893948,-0.11745828532411556,0.4533443435177539,__nan__,__nan__,__nan__,0.6067971152295639
91,ADVWW,Advantage Solutions Inc. Warrant,"Advantage Solutions Inc. provides business solutions to consumer goods manufacturers and retailers in North America and internationally. It operates in two segments, Sales and Marketing. The Sales segment offers brand-centric services, such as headquarter relationship management; analytics, insights, and intelligence; and brand-centric merchandising services. This segment also provides retailer-centric services comprising retailer-centric merchandising and in-store media services. The Marketing segment offers brand-centric services, including shopper and consumer marketing, and brand experiential services; retailer-centric services, such as retail experiential and private label services; and digital marketing, and digital media and advertising services. The company was formerly known as Karman Holding Corp. and changed its name to Advantage Solutions Inc. in March 2016. The company was founded in 1987 and is headquartered in Irvine, California.",Mr. David A. Peacock,Advertising Agencies,0.0129,USD,4183625,https://images.financialmodelingprep.com/symbol/ADVWW.png,46433.50481,,0.0028,13,-82755000,-326962000,"[{'period': '2024', 'revenue': 3570.0, 'unit': 'M', 'net_profit': -326.96}, {'period': '2023', 'revenue': 4220.0, 'unit': 'M', 'net_profit': -63.26}, {'period': '2022', 'revenue': 4.05, 'unit': 'B', 'net_profit': -1.38}, {'period': '2021', 'revenue': 3600.0, 'unit': 'M', 'net_profit': 54.49}]","[{'period': ""Q1 '25"", 'revenue': 821.79, 'unit': 'M', 'net_profit': -56.13}, {'period': ""Q4 '24"", 'revenue': 892.28, 'unit': 'M', 'net_profit': -177.88}, {'period': ""Q3 '24"", 'revenue': 939.27, 'unit': 'M', 'net_profit': -42.78}, {'period': ""Q2 '24"", 'revenue': 873.36, 'unit': 'M', 'net_profit': -114.01}, {'period': ""Q1 '24"", 'revenue': 879.0, 'unit': 'M', 'net_profit': -62.32}, {'period': ""Q4 '23"", 'revenue': 1080.0, 'unit': 'M', 'net_profit': 17.43}]",-1.02,-1.02,3106517000,910738000,205233000,2357782000,637225000,226510000,460062000,205233000,85257000,-1.2747756272972677,-4.168705934427266,-4.1,__nan__,__nan__,__nan__,0.758979268421837
92,ADXN,Addex Therapeutics Ltd American Depositary Shares,"Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.",Mr. Timothy Mark Dyer,Biotechnology,8.5,USD,6965903,https://images.financialmodelingprep.com/symbol/ADXN.png,7222,-0.37,0.38,674,-10228668,-10556227,"[{'period': '2023', 'revenue': 1.61, 'unit': 'M', 'net_profit': -10.56}, {'period': '2022', 'revenue': 1.42, 'unit': 'M', 'net_profit': -20.8}, {'period': '2021', 'revenue': 2.92, 'unit': 'M', 'net_profit': -15.35}, {'period': '2020', 'revenue': 3.61, 'unit': 'M', 'net_profit': -12.86}]","[{'period': ""Q3 '24"", 'revenue': 0.053840000000000006, 'unit': 'M', 'net_profit': -1.53}, {'period': ""Q2 '24"", 'revenue': 0.11528000000000001, 'unit': 'M', 'net_profit': 12.88}, {'period': ""Q1 '24"", 'revenue': 0.23491, 'unit': 'M', 'net_profit': -3.09}, {'period': ""Q4 '23"", 'revenue': 0.15345, 'unit': 'M', 'net_profit': -2.86}, {'period': ""Q3 '23"", 'revenue': 0.32773, 'unit': 'M', 'net_profit': -2.62}, {'period': ""Q2 '23"", 'revenue': 0.63088, 'unit': 'M', 'net_profit': -2.68}]",-16.8,-16.8,4641885,4234605,3866329,3496420,151268,0,2893284,3865481,-7999253,0.49434707257049587,0.49259186108121467,0.6956521739130435,__nan__,__nan__,__nan__,0.7532327922815839
93,ADXS,Advaxis Inc. Common Stock,"Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.",Mr. Kenneth A. Berlin J.D.,Biotechnology,0.03415,USD,1455931,https://images.financialmodelingprep.com/symbol/ADXS.png,4583,,0.00415,2906,-35869000,-48072000,"[{'period': '2023', 'revenue': 0.013000000000000001, 'unit': 'M', 'net_profit': -48.07}, {'period': '2022', 'revenue': 0.25, 'unit': 'M', 'net_profit': -14.36}, {'period': '2021', 'revenue': 3.24, 'unit': 'M', 'net_profit': -17.86}, {'period': '2020', 'revenue': 0.253, 'unit': 'M', 'net_profit': -26.47}]","[{'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -24.67}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -7.34}, {'period': ""Q2 '23"", 'revenue': 0.009000000000000001, 'unit': 'M', 'net_profit': -8.7}, {'period': ""Q1 '23"", 'revenue': 0.004, 'unit': 'M', 'net_profit': -7.36}, {'period': ""Q4 '22"", 'revenue': 0.105, 'unit': 'M', 'net_profit': -9.59}, {'period': ""Q3 '22"", 'revenue': 0.25, 'unit': 'M', 'net_profit': -4.96}]",-7.99,-7.99,16579000,7528000,4882000,40996000,0,0,25018000,4882000,-29485000,-1.2736435091277891,-2.3478654502402674,-0.01139240506329112,__nan__,__nan__,__nan__,2.4727667531214186
94,AEAC,Authentic Equity Acquisition Corp. Class A ordinary share,"Authentic Equity Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to identify business opportunities in the field of the consumer in North America. The company was incorporated in 2020 and is based in Rye, New York.",Mr. David M. Hooper,Shell Companies,10.13,USD,0,https://images.financialmodelingprep.com/symbol/AEAC.png,34356,0,-0.02,4203,6962388,15491848,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 15.49}, {'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -34.25}]","[{'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 4.14}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.34}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 8.66}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 17.02}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 6.21}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.35}]",0.52,0.52,697.5339999999997,675.792,442.162,18737,0,230021,876.735,442.162,-1010801,204.28733685655055,453.32993664048587,473.7272727272727,__nan__,__nan__,__nan__,26.861773046188443
95,AEACU,Authentic Equity Acquisition Corp. Unit,"Authentic Equity Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to identify business opportunities in the field of the consumer in North America. The company was incorporated in 2020 and is based in Rye, New York.",Mr. David M. Hooper,Shell Companies,10.13,USD,0,https://images.financialmodelingprep.com/symbol/AEACU.png,4936,0,-0.0048,1300,6962388,15491848,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 15.49}, {'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -34.25}]","[{'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 4.14}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.34}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 8.66}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 17.02}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 6.21}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.35}]",0.52,0.52,697.5339999999997,675.792,442.162,18737,0,230021,876.735,442.162,-1010801,204.28733685655055,453.32993664048587,473.7272727272727,__nan__,__nan__,__nan__,26.861773046188443
96,AEACW,Authentic Equity Acquisition Corp. Warrant,"Authentic Equity Acquisition Corp. focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded in 2020 and is based in Rye, New York.",Mr. David M. Hooper,Shell Companies,0.0009,USD,0,https://images.financialmodelingprep.com/symbol/AEACW.png,0,0,0,65887,6962388,15491848,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 15.49}, {'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -34.25}]","[{'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 4.14}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.34}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 8.66}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 17.02}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 6.21}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.35}]",0.52,0.52,697.5339999999997,675.792,442.162,18737,0,230021,876.735,442.162,-1010801,204.28733685655055,453.32993664048587,473.7272727272727,__nan__,__nan__,__nan__,26.861773046188443
97,AEHL,Antelope Enterprise Holdings Limited Common Stock (0.024 par),"Antelope Enterprise Holdings Limited, through its subsidiaries, manufactures and sells ceramic tiles for exterior siding and interior flooring, and design in residential and commercial buildings in the People's Republic of China. The company provides porcelain tiles, glazed tiles, glazed porcelain tiles, rustic tiles, and polished glazed tiles. It sells its products under the HD or Hengda brands through a network of distributors, as well as directly to property developers. The company was formerly known as China Ceramics Co., Ltd. and changed its name to Antelope Enterprise Holdings Limited in October 2020. Antelope Enterprise Holdings Limited was founded in 1993 and is headquartered in Jinjiang, the People's Republic of China.",Ms. Tingting  Zhang,Construction,2.82,USD,9640982,https://images.financialmodelingprep.com/symbol/AEHL.png,1019194,,0.13,143790,-9158000,-10544000,"[{'period': '2024', 'revenue': 98.77, 'unit': 'M', 'net_profit': -10.54}, {'period': '2023', 'revenue': 510.55, 'unit': 'M', 'net_profit': -14.34}, {'period': '2022', 'revenue': 286.35, 'unit': 'M', 'net_profit': -5.65}, {'period': '2021', 'revenue': 71.53, 'unit': 'M', 'net_profit': -90.06}]","[{'period': ""Q2 '24"", 'revenue': 315.86, 'unit': 'M', 'net_profit': -48.22}, {'period': ""Q4 '23"", 'revenue': 201.3, 'unit': 'M', 'net_profit': -48.95}, {'period': ""Q2 '23"", 'revenue': 309.25, 'unit': 'M', 'net_profit': -37.85}, {'period': ""Q4 '22"", 'revenue': 168.1, 'unit': 'M', 'net_profit': -6.83}, {'period': ""Q2 '22"", 'revenue': 118.25, 'unit': 'M', 'net_profit': -3.09}, {'period': ""Q2 '21"", 'revenue': 50.11, 'unit': 'M', 'net_profit': -70.77}]",0,0,38006000,26909000,1047000,11765000,20185000,0,10693000,1047000,-19685000,0.897365206379092,0.26471408647140865,1,"[0.0033, 0.025]","['2014-12-10', '2013-06-11']",__nan__,0.30955638583381573
98,AEHR,Aehr Test Systems Common Stock,"Aehr Test Systems provides test systems for burning-in and testing logic, optical, and memory integrated circuits worldwide. It offers products, such as the ABTS and FOX-P families of test and burn-in systems and FOX WaferPak Aligner, FOX-XP WaferPak Contactor, FOX DiePak Carrier, and FOX DiePak Loader. The ABTS system is used in production and qualification testing of packaged parts for lower power and higher power logic devices, as well as various common types of memory devices. The FOX-XP and FOX-NP systems are wafer contact and singulated die/module test and burn-in systems used for burn-in and functional test of complex devices, such as memories, digital signal processors, microprocessors, microcontrollers, systems-on-a-chip, and integrated optical devices. The FOX-CP system is a single-wafer compact test and reliability verification solution for logic, memory, and photonic devices. The WaferPak Contactor contains a unique full wafer probe card capable of testing wafers up to 300mm that enables IC manufacturers to perform test and burn-in of full wafers on Aehr Test FOX systems. The DiePak Carrier is a reusable, temporary package that enables IC manufacturers to perform final test and burn-in of bare die and modules. Aehr Test Systems was incorporated in 1977 and is headquartered in Fremont, California.",Mr. Gayn  Erickson,Semiconductors,9.29,USD,276576306,https://images.financialmodelingprep.com/symbol/AEHR.png,781848,12.06,0.01,476065,11441000,33156000,"[{'period': '2024', 'revenue': 66.22, 'unit': 'M', 'net_profit': 33.16}, {'period': '2023', 'revenue': 64.96, 'unit': 'M', 'net_profit': 14.56}, {'period': '2022', 'revenue': 50.83, 'unit': 'M', 'net_profit': 9.45}, {'period': '2021', 'revenue': 16.6, 'unit': 'M', 'net_profit': -2.03}]","[{'period': ""Q3 '25"", 'revenue': 18310.0, 'unit': 'K', 'net_profit': -643.0}, {'period': ""Q2 '25"", 'revenue': 13.45, 'unit': 'M', 'net_profit': -1.03}, {'period': ""Q1 '25"", 'revenue': 13120.0, 'unit': 'K', 'net_profit': 660.0}, {'period': ""Q4 '24"", 'revenue': 16.6, 'unit': 'M', 'net_profit': 23.86}, {'period': ""Q3 '24"", 'revenue': 7.56, 'unit': 'M', 'net_profit': -1.47}, {'period': ""Q2 '24"", 'revenue': 21.43, 'unit': 'M', 'net_profit': 6.09}]",1.15,1.12,127912000,97848000,49159000,16319000,9996000,0,10508000,49159000,1007000,-0.17244122965641953,1.2776671017379955,1.2115384615384612,__nan__,__nan__,__nan__,0.12757989868034272
99,AEI,Alset EHome International Inc. Common Stock,"Alset EHome International Inc., through its subsidiaries, engages in the real estate development, financial services, digital transformation technologies, biohealth, and consumer products businesses in the United States, Singapore, Hong Kong, Australia, and South Korea. It operates through four segments: Real Estate, Digital Transformation Technology, Biohealth, and Other Business Activities segments. The Real Estate segment develops property projects and participates in third-party property development projects; and owns, operates, and manages real estate development projects with a focus on land subdivision developments and house rental projects. The Digital Transformation Technology segment provides consulting, implementation, and development services with various technologies, including blockchain, e-commerce, social media, and payment solutions. Its technology platform focuses on business-to-business solutions, such as communications and workflow, instant messaging, international calling, social media, e-commerce and payment systems, and direct marketing solutions. The Biohealth segment engages in developing, researching, testing, manufacturing, licensing, and distributing biohealth products and services. The Other Business Activities segment offers corporate strategy and business development, asset management, corporate restructuring, and leveraged buy-out expertise services. The company was formerly known as HF Enterprises Inc. and changed its name to Alset EHome International Inc. in February 2021. Alset EHome International Inc. was incorporated in 2018 and is based in Bethesda, Maryland.",Mr. Heng Fai  Chan,Real Estate - Development,0.9482,USD,10179022,https://images.financialmodelingprep.com/symbol/AEI.png,49596,-2.21,-0.0118,28451,-2674819,-3965884,"[{'period': '2024', 'revenue': 21.12, 'unit': 'M', 'net_profit': -3.97}, {'period': '2023', 'revenue': 22.09, 'unit': 'M', 'net_profit': -58.95}, {'period': '2022', 'revenue': 4.48, 'unit': 'M', 'net_profit': -40.49}, {'period': '2021', 'revenue': 19.8, 'unit': 'M', 'net_profit': -119.02}]","[{'period': ""Q1 '25"", 'revenue': 1.07, 'unit': 'M', 'net_profit': -9.5}, {'period': ""Q4 '24"", 'revenue': 8.94, 'unit': 'M', 'net_profit': 2.33}, {'period': ""Q3 '24"", 'revenue': 4.96, 'unit': 'M', 'net_profit': 1.72}, {'period': ""Q2 '24"", 'revenue': 1.13, 'unit': 'M', 'net_profit': -1.24}, {'period': ""Q1 '24"", 'revenue': 6.09, 'unit': 'M', 'net_profit': -6.77}, {'period': ""Q4 '23"", 'revenue': 1.02, 'unit': 'M', 'net_profit': -33.27}]",-0.43,-0.43,96761977,59760342,27243787,6563126,75646,0,5476601,27243787,5053298,-2.344422563563958,0.9327204837223171,0.9340490797546013,__nan__,__nan__,__nan__,0.06782753105592293
100,AEIS,Advanced Energy Industries Inc. Common Stock,"Advanced Energy Industries, Inc. designs, manufactures, sells, and supports precision power conversion, measurement, and control solutions worldwide. It offers plasma power solutions, including direct current (DC), pulsed DC, low frequency alternating current, high voltage, and radio frequency (RF) power supplies, as well as RF power supplies, RF matching networks, and RF instrumentation products; and remote plasma sources for reactive gas applications. The company also provides power control modules and thermal instrumentation products for rapid thermal processing, chemical vapor deposition, epitaxy, crystal growing, and chemical processing, as well as metal, carbon fiber, and glass manufacturing and other industrial power applications; high voltage DC-DC products for semiconductor wafer processing and metrology, electrostatic clamping of substrates, scientific instrumentation, mass spectrometry, and X-ray systems for industrial and analytical applications; and low voltage DC-DC board mounted solutions for use in healthcare, telecommunications, test and measurement, instrumentation, and industrial equipment applications, as well as distributed power in server and storage systems. In addition, it offers gas sensing and monitoring products for the energy market, air quality monitoring, and automobile emission monitoring and testing; and embedded power products for medical equipment or IEC 60950-1 for information technology equipment. Further, it offers conversions, upgrades, and refurbishments and used equipment to companies, as well as repair services. The company provides its products through a direct sales force, independent sales representatives, channel partners, and distributors. Advanced Energy Industries, Inc. was incorporated in 1981 and is headquartered in Denver, Colorado.",Mr. Stephen D. Kelley J.D.,Electrical Equipment & Parts,118.15,USD,4448985510,https://images.financialmodelingprep.com/symbol/AEIS.png,394225,59.67,-0.61,199813,138219000,54214000,"[{'period': '2024', 'revenue': 1480.0, 'unit': 'M', 'net_profit': 54.21}, {'period': '2023', 'revenue': 1660.0, 'unit': 'M', 'net_profit': 128.28}, {'period': '2022', 'revenue': 1850.0, 'unit': 'M', 'net_profit': 199.66}, {'period': '2021', 'revenue': 1460.0, 'unit': 'M', 'net_profit': 134.74}]","[{'period': ""Q1 '25"", 'revenue': 404.6, 'unit': 'M', 'net_profit': 24.7}, {'period': ""Q4 '24"", 'revenue': 415.4, 'unit': 'M', 'net_profit': 48.87}, {'period': ""Q3 '24"", 'revenue': 374.22, 'unit': 'M', 'net_profit': -14.9}, {'period': ""Q2 '24"", 'revenue': 364.95, 'unit': 'M', 'net_profit': 15.03}, {'period': ""Q1 '24"", 'revenue': 327.48, 'unit': 'M', 'net_profit': 5.22}, {'period': ""Q4 '23"", 'revenue': 405.27, 'unit': 'M', 'net_profit': 37.5}]",1.45,1.43,2261894000,1389323000,722086000,1058723000,265315000,0,314222000,722086000,73959000,-0.32759778166958553,-0.5773907891864924,-0.5747800586510264,"[0.1, 0.1]","['2025-05-23', '2021-02-19']",__nan__,0.46806923755047763
101,AEMD,Aethlon Medical Inc. Common Stock,"Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.",Mr. James B. Frakes M.B.A.,Medical - Devices,0.4027,USD,6477751,https://images.financialmodelingprep.com/symbol/AEMD.png,166703,-0.26,0.0027,149931,-11849117,-12208174,"[{'period': '2024', 'revenue': 0.0, 'unit': 'M', 'net_profit': -12.21}, {'period': '2023', 'revenue': 0.57425, 'unit': 'M', 'net_profit': -12.03}, {'period': '2022', 'revenue': 0.29417000000000004, 'unit': 'M', 'net_profit': -10.42}, {'period': '2021', 'revenue': 0.6591, 'unit': 'M', 'net_profit': -7.89}]","[{'period': ""Q3 '25"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.75}, {'period': ""Q2 '25"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.81}, {'period': ""Q1 '25"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.57}, {'period': ""Q4 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.43}, {'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.47}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.03}]",-4.86,-4.86,8245982,6225788,5441978,2479650,0,0,1829899,5441978,-10380677,-0.01641578054625654,-0.014828858967233498,0.1706484641638225,__nan__,__nan__,__nan__,0.30071009129052184
102,AEP,American Electric Power Company Inc. Common Stock,"American Electric Power Company, Inc., an electric public utility holding company, engages in the generation, transmission, and distribution of electricity for sale to retail and wholesale customers in the United States. It operates through Vertically Integrated Utilities, Transmission and Distribution Utilities, AEP Transmission Holdco, and Generation & Marketing segments. The company generates electricity using coal and lignite, natural gas, nuclear, hydro, solar, wind, and other energy sources. It also supplies and markets electric power at wholesale to other electric utility companies, rural electric cooperatives, municipalities, and other market participants. American Electric Power Company, Inc. was incorporated in 1906 and is headquartered in Columbus, Ohio.",Mr. William J. Fehrman,Regulated Electric,103.04,USD,55043452800,https://images.financialmodelingprep.com/symbol/AEP.png,4342019,19.89,1.43,2845123,8098500000,2967100000,"[{'period': '2024', 'revenue': 19.72, 'unit': 'B', 'net_profit': 2.97}, {'period': '2023', 'revenue': 18.98, 'unit': 'B', 'net_profit': 2.21}, {'period': '2022', 'revenue': 19.64, 'unit': 'B', 'net_profit': 2.31}, {'period': '2021', 'revenue': 16.79, 'unit': 'B', 'net_profit': 2.49}]","[{'period': ""Q1 '25"", 'revenue': 5460.0, 'unit': 'M', 'net_profit': 800.2}, {'period': ""Q4 '24"", 'revenue': 4700.0, 'unit': 'M', 'net_profit': 664.1}, {'period': ""Q3 '24"", 'revenue': 5420.0, 'unit': 'M', 'net_profit': 959.6}, {'period': ""Q2 '24"", 'revenue': 4580.0, 'unit': 'M', 'net_profit': 340.3}, {'period': ""Q1 '24"", 'revenue': 5.03, 'unit': 'B', 'net_profit': 1.0}, {'period': ""Q4 '23"", 'revenue': 4580.0, 'unit': 'M', 'net_profit': 336.2}]",5.6,5.58,105729900000,5788800000,418300000,76091900000,2631900000,4949400000,13009300000,202900000,6664400000,0.12438563851942354,0.34373443231737694,0.3145539906103286,"[0.93, 0.41]","['2025-05-09', '1970-02-04']",__nan__,0.7196819442749874
103,AEPPL,American Electric Power Company Inc. Corporate Unit,,,,,,,,,,,,6849100000,2396400000,"[{'period': '2021', 'revenue': 16.79, 'unit': 'B', 'net_profit': 2.4}, {'period': '2020', 'revenue': 14.92, 'unit': 'B', 'net_profit': 2.2}, {'period': '2019', 'revenue': 15.56, 'unit': 'B', 'net_profit': 1.92}, {'period': '2018', 'revenue': 16.2, 'unit': 'B', 'net_profit': 1.92}]","[{'period': ""Q1 '22"", 'revenue': 4590.0, 'unit': 'M', 'net_profit': 702.4}, {'period': ""Q4 '21"", 'revenue': 4059.9999999999995, 'unit': 'M', 'net_profit': 522.8}, {'period': ""Q3 '21"", 'revenue': 4620.0, 'unit': 'M', 'net_profit': 796.0}, {'period': ""Q2 '21"", 'revenue': 3830.0, 'unit': 'M', 'net_profit': 578.2}, {'period': ""Q1 '21"", 'revenue': 4280.0, 'unit': 'M', 'net_profit': 575.0}, {'period': ""Q4 '20"", 'revenue': 3610.0, 'unit': 'M', 'net_profit': 435.5}]",0,0,87668700000,7809200000,623800000,64988500000,2063100000,4419800000,12426700000,403400000,-1924200000,0.08490282111799274,0.08922321712649425,0,__nan__,__nan__,__nan__,0.7412964946440406
104,AEPPZ,American Electric Power Company Inc. Corporate Units,"American Electric Power Company, Inc., an electric public utility holding company, engages in the generation, transmission, and distribution of electricity for sale to retail and wholesale customers in the United States. It operates through Vertically Integrated Utilities, Transmission and Distribution Utilities, AEP Transmission Holdco, and Generation & Marketing segments. The company generates electricity using coal and lignite, natural gas, nuclear, hydro, solar, wind, and other energy sources. It also supplies and markets electric power at wholesale to other electric utility companies, rural electric cooperatives, municipalities, and other market participants. American Electric Power Company, Inc. was incorporated in 1906 and is headquartered in Columbus, Ohio.",Ms. Julia A. Sloat,Regulated Electric,47.12,USD,0,https://images.financialmodelingprep.com/symbol/AEPPZ.png,363570,9.026819923371647,-0.52,2100159,8098500000,2967100000,"[{'period': '2024', 'revenue': 19.72, 'unit': 'B', 'net_profit': 2.97}, {'period': '2023', 'revenue': 18.98, 'unit': 'B', 'net_profit': 2.21}, {'period': '2022', 'revenue': 19.64, 'unit': 'B', 'net_profit': 2.31}, {'period': '2021', 'revenue': 16.79, 'unit': 'B', 'net_profit': 2.49}]","[{'period': ""Q1 '25"", 'revenue': 5460.0, 'unit': 'M', 'net_profit': 800.2}, {'period': ""Q4 '24"", 'revenue': 4700.0, 'unit': 'M', 'net_profit': 664.1}, {'period': ""Q3 '24"", 'revenue': 5420.0, 'unit': 'M', 'net_profit': 959.6}, {'period': ""Q2 '24"", 'revenue': 4580.0, 'unit': 'M', 'net_profit': 340.3}, {'period': ""Q1 '24"", 'revenue': 5.03, 'unit': 'B', 'net_profit': 1.0}, {'period': ""Q4 '23"", 'revenue': 4580.0, 'unit': 'M', 'net_profit': 336.2}]",5.6,5.58,105729900000,5788800000,418300000,76091900000,2631900000,4949400000,13009300000,202900000,6664400000,0.12438563851942354,0.34373443231737694,0.3145539906103286,"[0.76563, 0.774]","['2023-08-11', '2020-11-12']",__nan__,0.7196819442749874
105,AERI,Aerie Pharmaceuticals Inc. Common Stock,"Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.",Dr. Vicente Anido,Drug Manufacturers - Specialty & Generic,15.25,USD,0,https://images.financialmodelingprep.com/symbol/AERI.png,786842,0,0,1215184,-7813000,-74810000,"[{'period': '2021', 'revenue': 194.13, 'unit': 'M', 'net_profit': -74.81}, {'period': '2020', 'revenue': 83.14, 'unit': 'M', 'net_profit': -183.1}, {'period': '2019', 'revenue': 69.89, 'unit': 'M', 'net_profit': -199.58}, {'period': '2018', 'revenue': 24.18, 'unit': 'M', 'net_profit': -232.57}]","[{'period': ""Q3 '22"", 'revenue': 36.13, 'unit': 'M', 'net_profit': -26.83}, {'period': ""Q2 '22"", 'revenue': 33.31, 'unit': 'M', 'net_profit': -19.37}, {'period': ""Q1 '22"", 'revenue': 29.84, 'unit': 'M', 'net_profit': -35.89}, {'period': ""Q4 '21"", 'revenue': 114.67, 'unit': 'M', 'net_profit': 45.53}, {'period': ""Q3 '21"", 'revenue': 29.31, 'unit': 'M', 'net_profit': -39.69}, {'period': ""Q2 '21"", 'revenue': 27.18, 'unit': 'M', 'net_profit': -38.69}]",-1.61,-1.61,431391000,355650000,139801000,448724000,158828000,0,124991000,37187000,-102445000,0.9333486888126802,0.5914276819897215,0.5964912280701754,__nan__,__nan__,__nan__,1.0401793268751551
106,AESE,Allied Esports Entertainment Inc. Common Stock,"Allied Esports Entertainment Inc., a premier public esports and entertainment company, engages in the Allied Esports businesses worldwide. It operates esports properties to connect players and fans through a network of connected arenas; a flagship gaming arena located at the Luxor Hotel in Las Vegas, Nevada; a mobile esports truck that serves as a battleground and content generation hub; and a studio for recording and streaming gaming events. Allied Esports Entertainment Inc. was founded in 2018 and is based in Irvine, California.",Mr. Kenneth DeCubellis,Entertainment,1.3899,USD,0,https://images.financialmodelingprep.com/symbol/AESE.png,73781,0.864365671641791,0.0299,37968,-6771586000,-9092272000,"[{'period': '2022', 'revenue': 6.35, 'unit': 'B', 'net_profit': -9.09}, {'period': '2021', 'revenue': 4.96, 'unit': 'M', 'net_profit': -15.33}, {'period': '2020', 'revenue': 3.21, 'unit': 'M', 'net_profit': -45.06}, {'period': '2019', 'revenue': 26.07, 'unit': 'M', 'net_profit': -16.74}]","[{'period': ""Q3 '24"", 'revenue': 2.16, 'unit': 'B', 'net_profit': -4.03}, {'period': ""Q2 '24"", 'revenue': 2.64, 'unit': 'B', 'net_profit': -3.8}, {'period': ""Q3 '23"", 'revenue': 1120.0, 'unit': 'M', 'net_profit': 75.25}, {'period': ""Q2 '23"", 'revenue': 3270.0, 'unit': 'M', 'net_profit': -691.22}, {'period': ""Q1 '23"", 'revenue': 1.19, 'unit': 'B', 'net_profit': -1.13}, {'period': ""Q4 '22"", 'revenue': 6.35, 'unit': 'B', 'net_profit': -10.81}]",-232.71,-232.71,97729675000,82376852000,81167442000,9825607000,72739000,0,3298532000,11167442000,-10978860000,-102.91973922845533,-592.1574820578818,-595.6923076923077,__nan__,__nan__,__nan__,0.10053862350406875
107,AEY,ADDvantage Technologies Group Inc. Common Stock,"ADDvantage Technologies Group, Inc., through its subsidiaries, distributes and services electronics and hardware for the telecommunications industry in the United States and internationally. It operates through two segments, Wireless Infrastructure Services and Telecommunications. The Wireless Infrastructure Services segment provides turn-key wireless infrastructure services for U.S. wireless carriers, communication tower companies, national integrators, and original equipment manufacturers. This segment also offers installation and upgradation of technology on cell sites; and construction of new small cells for 5G. The Telecommunications segment provides central office equipment that include optical transport, switching, and data center equipment for communication networks; customer premise equipment, such as integrated access devices, channel banks, Internet protocol private branch exchange phones, and routers; and decommissioning services for surplus and obsolete telecom equipment. The company was formerly known as ADDvantage Media Group, Inc. and changed its name to ADDvantage Technologies Group, Inc. in December 1999. ADDvantage Technologies Group, Inc. was incorporated in 1989 and is headquartered in Carrollton, Texas.",Mr. Joseph E. Hart,Technology Distributors,0.36,USD,538096,https://images.financialmodelingprep.com/symbol/AEY.png,876776,-0.05625,-0.24,881062,1551000,471000,"[{'period': '2022', 'revenue': 97030.0, 'unit': 'K', 'net_profit': 471.0}, {'period': '2021', 'revenue': 62.16, 'unit': 'M', 'net_profit': -6.5}, {'period': '2020', 'revenue': 50.18, 'unit': 'M', 'net_profit': -17.33}, {'period': '2019', 'revenue': 55.12, 'unit': 'M', 'net_profit': -4.04}]","[{'period': ""Q3 '23"", 'revenue': 10.34, 'unit': 'M', 'net_profit': -2.73}, {'period': ""Q2 '23"", 'revenue': 12.09, 'unit': 'M', 'net_profit': -2.83}, {'period': ""Q1 '23"", 'revenue': 14.72, 'unit': 'M', 'net_profit': -2.99}, {'period': ""Q4 '22"", 'revenue': 19550.0, 'unit': 'K', 'net_profit': -493.0}, {'period': ""Q3 '22"", 'revenue': 25.93, 'unit': 'M', 'net_profit': 1.48}, {'period': ""Q2 '22"", 'revenue': 27790.0, 'unit': 'K', 'net_profit': 693.0}]",0.3,0.3,25426000,18130000,1837000,16111000,8688000,0,12788000,1837000,1944000,1.1922647824470063,1.072439249461704,1.0572519083969465,__nan__,__nan__,__nan__,0.6336427279163062
108,AEYE,AudioEye Inc. Common Stock,"AudioEye, Inc. provides patented, internet content publication, distribution software, and related services to Internet, print, broadcast, and other media to people regardless of their network connection, device, location, or disabilities in the United States. Its software and services enable conversion of digital content into accessible formats and allows for real time distribution to end users on any Internet connected device. The company offers AudioEye, an always-on testing, remediation, and monitoring solution that improves conformance with web content accessibility guidelines; identifies and fixes the common accessibility errors and addresses a range of disabilities including dyslexia, color blindness, epilepsy, and others; and provides additional solutions to provide for enhanced compliance and accessibility, including periodic manual auditing, manual remediations, and legal support services, as well as PDF remediation services and audit reports to help customers with their digital accessibility needs. The company serves small- and medium-sized businesses, corporate enterprises, non-profit organizations, and federal government agencies, as well as federal, state, and local governments and agencies through content management system partners, platform and agency partners, authorized resellers, and the marketplace. AudioEye, Inc. was incorporated in 2005 and is based in Tucson, Arizona.",Mr. David D. Moradi,Software - Application,13.59,USD,169308297,https://images.financialmodelingprep.com/symbol/AEYE.png,157819,-34.85,0.58,80138,-635000,-4254000,"[{'period': '2024', 'revenue': 35.2, 'unit': 'M', 'net_profit': -4.25}, {'period': '2023', 'revenue': 31.32, 'unit': 'M', 'net_profit': -5.87}, {'period': '2022', 'revenue': 29.91, 'unit': 'M', 'net_profit': -10.44}, {'period': '2021', 'revenue': 24.5, 'unit': 'M', 'net_profit': -12.63}]","[{'period': ""Q1 '25"", 'revenue': 9.73, 'unit': 'M', 'net_profit': -1.47}, {'period': ""Q4 '24"", 'revenue': 9.72, 'unit': 'M', 'net_profit': -1.49}, {'period': ""Q3 '24"", 'revenue': 8.93, 'unit': 'M', 'net_profit': -1.2}, {'period': ""Q2 '24"", 'revenue': 8470.0, 'unit': 'K', 'net_profit': -735.0}, {'period': ""Q1 '24"", 'revenue': 8080.0, 'unit': 'K', 'net_profit': -829.0}, {'period': ""Q4 '23"", 'revenue': 7870.0, 'unit': 'K', 'net_profit': -533.0}]",-0.36,-0.36,29766000,12120000,5651000,20330000,5932000,0,11571000,5651000,790000,0.8043746149106593,0.27554495912806537,0.28,__nan__,__nan__,__nan__,0.6829940200228448
109,AEZS,Aeterna Zentaris Inc. Common Stock,"Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.","Mr. Gilles R. Gagnon ICD.D, M.B.A., M.Sc.",Biotechnology,5.72,USD,17512867,https://images.financialmodelingprep.com/symbol/AEZS.png,6037,-2.4761904761904763,0.12,7508,-2886878.486356,-3550349.012513,"[{'period': '2023', 'revenue': 4.58, 'unit': 'M', 'net_profit': -3.55}, {'period': '2022', 'revenue': 5.64, 'unit': 'M', 'net_profit': -37.67}, {'period': '2021', 'revenue': 5.26, 'unit': 'M', 'net_profit': -8.37}, {'period': '2020', 'revenue': 3.65, 'unit': 'M', 'net_profit': -5.12}]","[{'period': ""Q2 '24"", 'revenue': 2.34, 'unit': 'M', 'net_profit': -1.42}, {'period': ""Q1 '24"", 'revenue': 0.00398, 'unit': 'M', 'net_profit': -1.4}, {'period': ""Q4 '23"", 'revenue': 0.12434, 'unit': 'M', 'net_profit': -5.79}, {'period': ""Q3 '23"", 'revenue': 0.003, 'unit': 'M', 'net_profit': -4.14}, {'period': ""Q2 '23"", 'revenue': 2.25, 'unit': 'M', 'net_profit': -2.52}, {'period': ""Q1 '23"", 'revenue': 2.13, 'unit': 'M', 'net_profit': -4.36}]",-0.06,-0.06,36826615,36180935,33841963,18723711,289505,0,4516771,6666472,-17451271,0.6224822170320388,0.9057487851412833,0.9922680412371134,__nan__,__nan__,__nan__,0.5084287817384248
110,AFAQU,AF Acquisition Corp. Units,"AF Acquisition Corp. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. AF Acquisition Corp. was incorporated in 2021 and is based in Palm Beach, Florida.",Mr. Andrew Z. Scharf,Shell Companies,9.9,USD,0,https://images.financialmodelingprep.com/symbol/AFAQU.png,4280,0,-0.14,1900,9764932,20368433,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 20.37}]","[{'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.75}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.04}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.57}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 19.81}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 6.07}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 18.79}]",0.73,0.73,225075028,991302,781302,15118434,0,224039393,225967,781302,-866877,0,0,0,__nan__,__nan__,__nan__,0.06717064142717778
111,AFAQW,AF Acquisition Corp. Warrants,"AF Acquisition Corp. is a blank check company that engages in effecting a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization. AF Acquisition Corp. was incorporated in 2021 and is based in Palm Beach, Florida.",Mr. Andrew Z. Scharf,Shell Companies,0.0053,USD,0,https://images.financialmodelingprep.com/symbol/AFAQW.png,0,0,0,101900,9764932,20368433,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 20.37}]","[{'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.75}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.04}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.57}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 19.81}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 6.07}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 18.79}]",0.73,0.73,225075028,991302,781302,15118434,0,224039393,225967,781302,-866877,0,0,0,__nan__,__nan__,__nan__,0.06717064142717778
112,AFBI,Affinity Bancshares Inc. Common Stock (MD),"Affinity Bancshares, Inc. operates as the holding company for Affinity Bank that provides various banking products and services. The company accepts various deposit accounts, including savings accounts, checking accounts, certificates of deposit, and individual retirement accounts. It also offers commercial and industrial, commercial real estate, one- to four-family residential real estate, construction and land, and consumer loans. In addition, the company invests in U.S. treasury securities; securities issued by the U.S. government and its agencies, or government sponsored enterprises, including mortgage-backed securities and collateralized mortgage obligations; corporate and municipal bonds; certificates of deposit in other financial institutions; and federal and money market funds. It operates a main and a branch office in Covington, Georgia; a branch office in Atlanta, Georgia; and a commercial loan production office in Alpharetta, Georgia; out of an office in Monroe, Georgia. The company was founded in 1928 and is headquartered in Covington, Georgia.","Mr. Edward J. Cooney CPA, CPA",Banks - Regional,18.52,USD,116973987,https://images.financialmodelingprep.com/symbol/AFBI.png,15835,20.35,0.02,4312,0,5441000,"[{'period': '2024', 'revenue': 30.61, 'unit': 'M', 'net_profit': 5.44}, {'period': '2023', 'revenue': 29.66, 'unit': 'M', 'net_profit': 6.45}, {'period': '2022', 'revenue': 32.16, 'unit': 'M', 'net_profit': 7.13}, {'period': '2021', 'revenue': 32.08, 'unit': 'M', 'net_profit': 7.57}]","[{'period': ""Q1 '25"", 'revenue': 12.11, 'unit': 'M', 'net_profit': 1.83}, {'period': ""Q4 '24"", 'revenue': 7.59, 'unit': 'M', 'net_profit': 1.34}, {'period': ""Q3 '24"", 'revenue': 7.98, 'unit': 'M', 'net_profit': 1.73}, {'period': ""Q2 '24"", 'revenue': 12.93, 'unit': 'M', 'net_profit': 1.03}, {'period': ""Q1 '24"", 'revenue': 11.8, 'unit': 'M', 'net_profit': 1.33}, {'period': ""Q4 '23"", 'revenue': 11.69, 'unit': 'M', 'net_profit': 1.51}]",0.85,0.83,866817000,41425000,41425000,737702000,0,0,5406000,41425000,6369000,0,-0.15617245657568238,-0.15000000000000002,"[1.5, 1.5]","['2025-03-13', '2025-03-13']",__nan__,0.851046991464173
113,AFCG,AFC Gamma Inc. Common Stock,"AFC Gamma, Inc. originates, structures, underwrites, and invests in senior secured loans, and other types of loans and debt securities for established companies operating in the cannabis industry in states that have legalized medicinal and/or adult use cannabis. It primarily originates loans structured as senior loans secured by real estate, equipment, and licenses and/or other assets of the loan parties to the extent permitted by applicable laws and the regulations governing such loan parties. AFC Gamma, Inc. has elected and qualified to be taxed as a real estate investment trust for the United States federal income tax purposes under the Internal Revenue Code of 1986. The company was incorporated in 2020 and is based in West Palm Beach, Florida.",Mr. Daniel  Neville,REIT - Specialty,5.27,USD,119080920,https://images.financialmodelingprep.com/symbol/AFCG.png,231774,8.23,0.01,185312,20646032,16784205,"[{'period': '2024', 'revenue': 35.76, 'unit': 'M', 'net_profit': 16.78}, {'period': '2023', 'revenue': 66.11, 'unit': 'M', 'net_profit': 20.95}, {'period': '2022', 'revenue': 71.54, 'unit': 'M', 'net_profit': 35.93}, {'period': '2021', 'revenue': 38.08, 'unit': 'M', 'net_profit': 21.0}]","[{'period': ""Q1 '25"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 4.07}, {'period': ""Q4 '24"", 'revenue': 9220.0, 'unit': 'K', 'net_profit': -991.53}, {'period': ""Q3 '24"", 'revenue': 8.7, 'unit': 'M', 'net_profit': 1.38}, {'period': ""Q2 '24"", 'revenue': 16.96, 'unit': 'M', 'net_profit': 16.45}, {'period': ""Q1 '24"", 'revenue': 16270.0, 'unit': 'K', 'net_profit': -54.12}, {'period': ""Q4 '23"", 'revenue': 17.45, 'unit': 'M', 'net_profit': -9.19}]",0.78,0.8,402057313,372227330,103610460,200681175,1982897,0,96883381,103610460,21557675,-0.2348337131610028,-0.19892110538373425,-0.23529411764705882,"[0.23, 0.38]","['2025-03-31', '2021-06-14']",__nan__,0.499135741376255
114,AFIB,Acutus Medical Inc. Common Stock,"Acutus Medical, Inc., an arrhythmia management company, designs, manufactures, and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. The company's product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact force ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. Acutus Medical, Inc. was incorporated in 2011 and is headquartered in Carlsbad, California.",Mr. Takeo  Mukai,Medical - Devices,0.031,USD,927281,https://images.financialmodelingprep.com/symbol/AFIB.png,28133,-0.21,0,2000,2249000,-9547000,"[{'period': '2024', 'revenue': 20.16, 'unit': 'M', 'net_profit': -9.55}, {'period': '2023', 'revenue': 7.16, 'unit': 'M', 'net_profit': -81.66}, {'period': '2022', 'revenue': 16.36, 'unit': 'M', 'net_profit': -39.62}, {'period': '2021', 'revenue': 17.26, 'unit': 'M', 'net_profit': -123.36}]","[{'period': ""Q4 '24"", 'revenue': 7.14, 'unit': 'M', 'net_profit': -1.41}, {'period': ""Q3 '24"", 'revenue': 5.27, 'unit': 'M', 'net_profit': -5.61}, {'period': ""Q2 '24"", 'revenue': 4130.0, 'unit': 'K', 'net_profit': -914.0}, {'period': ""Q1 '24"", 'revenue': 3.62, 'unit': 'M', 'net_profit': -1.62}, {'period': ""Q4 '23"", 'revenue': -7.53, 'unit': 'M', 'net_profit': -33.77}, {'period': ""Q3 '23"", 'revenue': 5.24, 'unit': 'M', 'net_profit': -13.24}]",-0.32,-0.32,28648000,25578000,14019000,40240000,7878000,0,12438000,14019000,-31772000,1.422030399699756,0.8830927102849516,0.8859871022909467,__nan__,__nan__,__nan__,1.4046355766545657
115,AFIN,American Finance Trust Inc. Class A Common Stock,"American Finance Trust, Inc. (Nasdaq: AFIN) is a publicly traded real estate investment trust listed on the Nasdaq focused on acquiring and managing a diversified portfolio of primarily service-oriented and traditional retail and distribution related commercial real estate properties in the U.S.",Mr. Edward Weil,REIT - Diversified,8.23,USD,1176280980,https://images.financialmodelingprep.com/symbol/AFIN.png,1005844,-28.87719298245614,-0.03000069,629237,169805000,-121972000,"[{'period': '2021', 'revenue': 335.16, 'unit': 'M', 'net_profit': -121.97}, {'period': '2020', 'revenue': 305.22, 'unit': 'M', 'net_profit': -31.86}, {'period': '2019', 'revenue': 299.74, 'unit': 'M', 'net_profit': 4.15}, {'period': '2018', 'revenue': 291.21, 'unit': 'M', 'net_profit': -37.41}]","[{'period': ""Q4 '21"", 'revenue': 82.48, 'unit': 'M', 'net_profit': -57.24}, {'period': ""Q3 '21"", 'revenue': 91920.0, 'unit': 'K', 'net_profit': -569.0}, {'period': ""Q2 '21"", 'revenue': 81.58, 'unit': 'M', 'net_profit': -1.48}, {'period': ""Q1 '21"", 'revenue': 79.19, 'unit': 'M', 'net_profit': -3.75}, {'period': ""Q4 '20"", 'revenue': 77.24, 'unit': 'M', 'net_profit': -4.67}, {'period': ""Q3 '20"", 'revenue': 78.49, 'unit': 'M', 'net_profit': -3.47}]",-1.13,-1.13,3803786000,521728000,214853000,2103932000,70789000,0,48469000,214853000,131820000,-0.03371649689865134,-2.828133827129496,-2.8965517241379306,"[0.2125, 0.0916667]","['2022-04-08', '2018-10-10']",__nan__,0.5531152383441129
116,AFINO,American Finance Trust Inc. 7.375% Series C Cumulative Redeemable Preferred Stock,"American Finance Trust, Inc. (Nasdaq: AFIN) is a publicly traded real estate investment trust listed on the Nasdaq focused on acquiring and managing a diversified portfolio of primarily service-oriented and traditional retail and distribution related commercial real estate properties in the U.S.",,REIT - Diversified,25.66,USD,3407887382,https://images.financialmodelingprep.com/symbol/AFINO.png,13989,-90.03508771929825,0.02000046,11543,169805000,-121972000,"[{'period': '2021', 'revenue': 335.16, 'unit': 'M', 'net_profit': -121.97}, {'period': '2020', 'revenue': 305.22, 'unit': 'M', 'net_profit': -31.86}, {'period': '2019', 'revenue': 299.74, 'unit': 'M', 'net_profit': 4.15}, {'period': '2018', 'revenue': 291.21, 'unit': 'M', 'net_profit': -37.41}]","[{'period': ""Q4 '21"", 'revenue': 82.48, 'unit': 'M', 'net_profit': -57.24}, {'period': ""Q3 '21"", 'revenue': 91920.0, 'unit': 'K', 'net_profit': -569.0}, {'period': ""Q2 '21"", 'revenue': 81.58, 'unit': 'M', 'net_profit': -1.48}, {'period': ""Q1 '21"", 'revenue': 79.19, 'unit': 'M', 'net_profit': -3.75}, {'period': ""Q4 '20"", 'revenue': 77.24, 'unit': 'M', 'net_profit': -4.67}, {'period': ""Q3 '20"", 'revenue': 78.49, 'unit': 'M', 'net_profit': -3.47}]",-1.13,-1.13,3803786000,521728000,214853000,2103932000,70789000,0,48469000,214853000,131820000,-0.03371649689865134,-2.828133827129496,-2.8965517241379306,"[0.46875, 0.53]","['2022-04-07', '2021-04-01']",__nan__,0.5531152383441129
117,AFINP,American Finance Trust Inc. 7.50% Series A Cumulative Redeemable Perpetual Preferred Stock,"American Finance Trust, Inc. (Nasdaq: AFIN) is a publicly traded real estate investment trust listed on the Nasdaq focused on acquiring and managing a diversified portfolio of primarily service-oriented and traditional retail and distribution related commercial real estate properties in the U.S.",Mr. Edward Michael Weil Jr.,REIT - Diversified,25.91,USD,3441089714,https://images.financialmodelingprep.com/symbol/AFINP.png,15846,-90.91228070175438,-0.4699993,12257,169805000,-121972000,"[{'period': '2021', 'revenue': 335.16, 'unit': 'M', 'net_profit': -121.97}, {'period': '2020', 'revenue': 305.22, 'unit': 'M', 'net_profit': -31.86}, {'period': '2019', 'revenue': 299.74, 'unit': 'M', 'net_profit': 4.15}, {'period': '2018', 'revenue': 291.21, 'unit': 'M', 'net_profit': -37.41}]","[{'period': ""Q4 '21"", 'revenue': 82.48, 'unit': 'M', 'net_profit': -57.24}, {'period': ""Q3 '21"", 'revenue': 91920.0, 'unit': 'K', 'net_profit': -569.0}, {'period': ""Q2 '21"", 'revenue': 81.58, 'unit': 'M', 'net_profit': -1.48}, {'period': ""Q1 '21"", 'revenue': 79.19, 'unit': 'M', 'net_profit': -3.75}, {'period': ""Q4 '20"", 'revenue': 77.24, 'unit': 'M', 'net_profit': -4.67}, {'period': ""Q3 '20"", 'revenue': 78.49, 'unit': 'M', 'net_profit': -3.47}]",-1.13,-1.13,3803786000,521728000,214853000,2103932000,70789000,0,48469000,214853000,131820000,-0.03371649689865134,-2.828133827129496,-2.8965517241379306,"[0.46875, 0.5]","['2022-04-07', '2019-07-02']",__nan__,0.5531152383441129
118,AFMD,Affimed N.V.,"Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.","Dr. Shawn M. Leland Pharm.D., R.Ph.",Biotechnology,0.279,USD,4248473,https://images.financialmodelingprep.com/symbol/AFMD.png,542038,-0.05,0.1939,907201410,-102380000,-105938000,"[{'period': '2023', 'revenue': 8.28, 'unit': 'M', 'net_profit': -105.94}, {'period': '2022', 'revenue': 41.35, 'unit': 'M', 'net_profit': -86.0}, {'period': '2021', 'revenue': 40.37, 'unit': 'M', 'net_profit': -57.52}, {'period': '2020', 'revenue': 28.36, 'unit': 'M', 'net_profit': -41.37}]","[{'period': ""Q3 '24"", 'revenue': 0.155, 'unit': 'M', 'net_profit': -15.14}, {'period': ""Q2 '24"", 'revenue': 0.154, 'unit': 'M', 'net_profit': -15.45}, {'period': ""Q1 '24"", 'revenue': 0.155, 'unit': 'M', 'net_profit': -19.18}, {'period': ""Q4 '23"", 'revenue': 0.41300000000000003, 'unit': 'M', 'net_profit': -20.2}, {'period': ""Q3 '23"", 'revenue': 1.96, 'unit': 'M', 'net_profit': -24.36}, {'period': ""Q2 '23"", 'revenue': 1.39, 'unit': 'M', 'net_profit': -29.39}]",-7.09,-7.09,97157000,84188000,72898000,39350000,5327000,0,25907000,38529000,-113998000,-0.2566126201318228,-0.2317799172131529,-0.17384105960264898,__nan__,__nan__,__nan__,0.40501456405611536
119,AFRM,Affirm Holdings Inc. Class A Common Stock,"Affirm Holdings, Inc. operates a platform for digital and mobile-first commerce in the United States and Canada. The company's platform includes point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. Its payments network and partnership with an originating bank, enables consumers to pay for a purchase over time with terms ranging from one to forty-eight months. As of June 30, 2021, the company had approximately 29,000 merchants integrated on its platform covering small businesses, large enterprises, direct-to-consumer brands, brick-and-mortar stores, and companies. Its merchants represent a range of industries, including sporting goods and outdoors, furniture and homewares, travel, apparel, accessories, consumer electronics, and jewelry. The company was founded in 2012 and is headquartered in San Francisco, California.",Mr. Max Roth Levchin,Software - Infrastructure,52.57,USD,16959080107,https://images.financialmodelingprep.com/symbol/AFRM.png,8878337,-276.68,0.82,5864826,0,-517757000,"[{'period': '2024', 'revenue': 2320.0, 'unit': 'M', 'net_profit': -517.76}, {'period': '2023', 'revenue': 1590.0, 'unit': 'M', 'net_profit': -985.35}, {'period': '2022', 'revenue': 1350.0, 'unit': 'M', 'net_profit': -707.42}, {'period': '2021', 'revenue': 870.46, 'unit': 'M', 'net_profit': -430.92}]","[{'period': ""Q3 '25"", 'revenue': 783.13, 'unit': 'M', 'net_profit': 2.8}, {'period': ""Q2 '25"", 'revenue': 866.38, 'unit': 'M', 'net_profit': 80.36}, {'period': ""Q1 '25"", 'revenue': 698.48, 'unit': 'M', 'net_profit': -100.22}, {'period': ""Q4 '24"", 'revenue': 659.18, 'unit': 'M', 'net_profit': -45.14}, {'period': ""Q3 '24"", 'revenue': 576.16, 'unit': 'M', 'net_profit': -133.94}, {'period': ""Q2 '24"", 'revenue': 591.11, 'unit': 'M', 'net_profit': -166.9}]",-1.67,-1.67,9519619000,2514229000,2144734000,6787630000,353028000,5503322000,159344000,1013106000,290842000,1,0.4745424191526826,0.5,__nan__,__nan__,__nan__,0.7130148801123238
120,AFYA,Afya Limited Class A Common Shares,"Afya Limited, through its subsidiaries, operates as a medical education group in Brazil. It offers educational products and services, including medical schools, medical residency preparatory courses, graduate courses, and other programs to lifelong medical learners enrolled across its distribution network, as well as to third-party medical schools. The company also provides digital health services, such as subscription-based mobile app and website portal that focuses on assisting health professionals and students with clinical decision-making through tools, such as medical calculators, charts, and updated content, as well as prescriptions, clinical scores, medical procedures and laboratory exams, and others. It offers health sciences courses, which comprise medicine, dentistry, nursing, radiology, psychology, pharmacy, physical education, physiotherapy, nutrition, and biomedicine; and degree programs and courses in other subjects and disciplines, including undergraduate and post graduate courses in business administration, accounting, law, civil engineering, industrial engineering, and pedagogy. In addition, the company provides medical postgraduate specialization programs; printed and digital content; and an online medical education platform and practical medical training services. As of December 31, 2021, it operated a network of 46 undergraduate and graduate medical school campuses consisted of 30 undergrad operating units and five approved units; and a network of 2,731 medical school seats that consisted of 2,481 operating seats and 278 approved seats. The company was founded in 1999 and is headquartered in Nova Lima, Brazil.",Mr. Virgilio Deloy Capobianco Gibbon,Education & Training Services,19.49,USD,1761678102,https://images.financialmodelingprep.com/symbol/AFYA.png,118966,14.65,0.14,72543,1218023000,631510000,"[{'period': '2024', 'revenue': 3300.0, 'unit': 'M', 'net_profit': 631.51}, {'period': '2023', 'revenue': 2880.0, 'unit': 'M', 'net_profit': 386.32}, {'period': '2022', 'revenue': 2330.0, 'unit': 'M', 'net_profit': 373.57}, {'period': '2021', 'revenue': 1720.0, 'unit': 'M', 'net_profit': 223.33}]","[{'period': ""Q1 '25"", 'revenue': 936.36, 'unit': 'M', 'net_profit': 252.0}, {'period': ""Q4 '24"", 'revenue': 849.01, 'unit': 'M', 'net_profit': 149.93}, {'period': ""Q3 '24"", 'revenue': 841.18, 'unit': 'M', 'net_profit': 119.98}, {'period': ""Q2 '24"", 'revenue': 809.89, 'unit': 'M', 'net_profit': 158.21}, {'period': ""Q1 '24"", 'revenue': 804.24, 'unit': 'M', 'net_profit': 203.39}, {'period': ""Q4 '23"", 'revenue': 729.87, 'unit': 'M', 'net_profit': 98.06}]",6.93,6.93,8829539000,1589784000,911015000,4518956000,621624000,54442000,1140195000,911015000,1295735000,0.10189535086743219,0.6346641679005187,0.6229508196721313,"[0.23205, 0.23205]","['2025-03-26', '2025-03-26']",__nan__,0.5117997666695849
121,AGBA,AGBA Acquisition Limited Ordinary Share,"AGBA Acquisition Limited does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the healthcare, education, entertainment, and financial services sectors in China. The company was incorporated in 2018 and is based in Tsim Sha Tsui, Hong Kong.",Mr. Wing Fai  Ng,Shell Companies,1.4,USD,66243100,https://images.financialmodelingprep.com/symbol/AGBA.png,376417,-1.044776119402985,0.18,4139318,-47873679,-49206019,"[{'period': '2023', 'revenue': 55.73, 'unit': 'M', 'net_profit': -49.21}, {'period': '2022', 'revenue': 31.08, 'unit': 'M', 'net_profit': -44.52}, {'period': '2021', 'revenue': 11.47, 'unit': 'M', 'net_profit': 96.46}, {'period': '2020', 'revenue': 14.05, 'unit': 'M', 'net_profit': -16.14}]","[{'period': ""Q3 '24"", 'revenue': 5.38, 'unit': 'B', 'net_profit': -9.42}, {'period': ""Q2 '24"", 'revenue': 4.92, 'unit': 'M', 'net_profit': -11.37}, {'period': ""Q1 '24"", 'revenue': 7.66, 'unit': 'M', 'net_profit': -8.06}, {'period': ""Q4 '23"", 'revenue': 12.54, 'unit': 'M', 'net_profit': -13.63}, {'period': ""Q3 '23"", 'revenue': 13.44, 'unit': 'M', 'net_profit': -12.92}, {'period': ""Q2 '23"", 'revenue': 17.93, 'unit': 'M', 'net_profit': -10.59}]",-0.75,-0.75,66588967,25618972,2571925,58486196,6940907,25724464,47840143,18678065,-42387005,-0.10580387854406641,-0.10524072713697817,0.050632911392405104,__nan__,__nan__,__nan__,0.8783166136215929
122,AGBAR,AGBA Acquisition Limited Right,,None,Shell Companies,0.551,USD,0,https://images.financialmodelingprep.com/symbol/AGBAR.png,0,0,0,244091,-47873679,-49206019,"[{'period': '2023', 'revenue': 55.73, 'unit': 'M', 'net_profit': -49.21}, {'period': '2022', 'revenue': 31.08, 'unit': 'M', 'net_profit': -44.52}, {'period': '2021', 'revenue': 11.47, 'unit': 'M', 'net_profit': 96.46}, {'period': '2020', 'revenue': 14.05, 'unit': 'M', 'net_profit': -16.14}]","[{'period': ""Q3 '24"", 'revenue': 5.38, 'unit': 'B', 'net_profit': -9.42}, {'period': ""Q2 '24"", 'revenue': 4.92, 'unit': 'M', 'net_profit': -11.37}, {'period': ""Q1 '24"", 'revenue': 7.66, 'unit': 'M', 'net_profit': -8.06}, {'period': ""Q4 '23"", 'revenue': 12.54, 'unit': 'M', 'net_profit': -13.63}, {'period': ""Q3 '23"", 'revenue': 13.44, 'unit': 'M', 'net_profit': -12.92}, {'period': ""Q2 '23"", 'revenue': 17.93, 'unit': 'M', 'net_profit': -10.59}]",-0.75,-0.75,66588967,25618972,2571925,58486196,6940907,25724464,47840143,18678065,-42387005,-0.10580387854406641,-0.10524072713697817,0.050632911392405104,"[0.285, 0.285]","['2022-03-15', '2022-03-15']",__nan__,0.8783166136215929
123,AGBAW,AGBA Acquisition Limited Warrant,"AGBA Group Holding Ltd. operates a wealth and health platform. Its group activities span a business-to-business platform, healthcare and wellness services, fintech businesses, as well as financial advisory services. It operates the TAG Business and OnePlatform brand, which offers a full-service platform to banks, other financial institutions, brokers, and individual financial advisors to advise and serve its retail clients. The company is headquartered in Hong Kong.",Mr. Wing Fai  Ng,Shell Companies,0.2001,USD,11596489,https://images.financialmodelingprep.com/symbol/AGBAW.png,0,0,-0.0147,79573,-47873679,-49206019,"[{'period': '2023', 'revenue': 55.73, 'unit': 'M', 'net_profit': -49.21}, {'period': '2022', 'revenue': 31.08, 'unit': 'M', 'net_profit': -44.52}, {'period': '2021', 'revenue': 11.47, 'unit': 'M', 'net_profit': 96.46}, {'period': '2020', 'revenue': 14.05, 'unit': 'M', 'net_profit': -16.14}]","[{'period': ""Q3 '24"", 'revenue': 5.38, 'unit': 'B', 'net_profit': -9.42}, {'period': ""Q2 '24"", 'revenue': 4.92, 'unit': 'M', 'net_profit': -11.37}, {'period': ""Q1 '24"", 'revenue': 7.66, 'unit': 'M', 'net_profit': -8.06}, {'period': ""Q4 '23"", 'revenue': 12.54, 'unit': 'M', 'net_profit': -13.63}, {'period': ""Q3 '23"", 'revenue': 13.44, 'unit': 'M', 'net_profit': -12.92}, {'period': ""Q2 '23"", 'revenue': 17.93, 'unit': 'M', 'net_profit': -10.59}]",-0.75,-0.75,66588967,25618972,2571925,58486196,6940907,25724464,47840143,18678065,-42387005,-0.10580387854406641,-0.10524072713697817,0.050632911392405104,__nan__,__nan__,__nan__,0.8783166136215929
124,AGC,Altimeter Growth Corp. Class A Ordinary Shares,"Altimeter Growth Corp. is a blank check company. The company was founded in in 2020 and is based in Menlo Park, California.",Mr. Bradley Thomas Gerstner J.D.,Shell Companies,11.01,USD,0,https://images.financialmodelingprep.com/symbol/AGC.png,4057663,0,-1.71,8848771,-212799,-212799,"[{'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -212.8}]","[{'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 49.39}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.87}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -212.8}]",-0.0034,-0.0034,501131563,1131563,855972,17564100,0,0,0,855972,,0,0,0,"[0.047, 0.047]","['2018-08-14', '2014-01-13']",__nan__,0.035048879968472474
125,AGCUU,Altimeter Growth Corp. Unit,"Altimeter Growth Corp. is a blank check company. The company was founded in in 2020 and is based in Menlo Park, California.",Mr. Bradley Thomas Gerstner,Shell Companies,11.87,USD,0,https://images.financialmodelingprep.com/symbol/AGCUU.png,137908,0,-1.6999998,150787,-212799,-212799,"[{'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -212.8}]","[{'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 49.39}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.87}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -212.8}]",-0.0034,-0.0034,501131563,1131563,855972,17564100,0,0,0,855972,,0,0,0,__nan__,__nan__,__nan__,0.035048879968472474
126,AGCWW,Altimeter Growth Corp. Warrant,,,,,,,,,,,,-212799,-212799,"[{'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -212.8}]","[{'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 49.39}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.87}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -212.8}]",50,50,501131563,1131563,855972,17564100,0,0,0,855972,,0,0,0,__nan__,__nan__,__nan__,0.035048879968472474
127,AGEN,Agenus Inc. Common Stock,"Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGF TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.",Dr. Garo H. Armen Ph.D.,Biotechnology,3.48,USD,95410464,https://images.financialmodelingprep.com/symbol/AGEN.png,625682,-0.33,0.1,806545,-101302000,-227212000,"[{'period': '2024', 'revenue': 103.46, 'unit': 'M', 'net_profit': -227.21}, {'period': '2023', 'revenue': 156.31, 'unit': 'M', 'net_profit': -245.76}, {'period': '2022', 'revenue': 98.02, 'unit': 'M', 'net_profit': -271.51}, {'period': '2021', 'revenue': 295.67, 'unit': 'M', 'net_profit': -94.7}]","[{'period': ""Q1 '25"", 'revenue': 24.07, 'unit': 'M', 'net_profit': -25.32}, {'period': ""Q4 '24"", 'revenue': 26.84, 'unit': 'M', 'net_profit': -45.86}, {'period': ""Q3 '24"", 'revenue': 25.11, 'unit': 'M', 'net_profit': -66.39}, {'period': ""Q2 '24"", 'revenue': 23.51, 'unit': 'M', 'net_profit': -53.08}, {'period': ""Q1 '24"", 'revenue': 28.0, 'unit': 'M', 'net_profit': -61.89}, {'period': ""Q4 '23"", 'revenue': 83.8, 'unit': 'M', 'net_profit': -46.29}]",-10.59,-10.59,226271000,45574000,40437000,532695000,407000,0,221401000,40437000,-158891000,0.3057893149858831,0.07547576710706744,0.22981818181818184,__nan__,__nan__,__nan__,2.3542345240883717
128,AGFS,AgroFresh Solutions Inc. Common Stock,"AgroFresh Solutions, Inc. provides science-based solutions, data-driven technologies, and high-touch customer services. The company's flagship product is the SmartFresh system that regulates the post-harvest ripening effects of ethylene to preserve the texture, firmness, taste, and appearance of produce during storage, transportation, and retail display. It also provides Harvista technology for use in near-harvest management of apples, pears, cherries, and blueberries; FreshCloud, a digital technology service platform of produce monitoring and screening solutions; and LandSpring, a 1- methlycycloproprene technology targeted to transplanted vegetable seedlings. In addition, the company offers fungicides, disinfectants, coatings, and packinghouse equipment for the citrus market under the Actiseal, FreshStart, VitaFresh Botanicals, Teycer Originals, and Control-Tec brands. It supports growers, packers, and retailers with solutions across the food supply chain to enhance the shelf life of fresh produce. The company primarily operates in the United States, Canada, Argentina, Brazil, Chile, Columbia, Costa Rica, the Dominican Republic, Ecuador, Guatemala, Mexico, Peru, Uruguay, Europe, the Middle East, Africa, Australia, China, India, Japan, New Zealand, South Korea, and the Philippines. AgroFresh Solutions, Inc. was founded in 1994 and is headquartered in Philadelphia, Pennsylvania.","Mr. Clinton A. Lewis Jr., B.S.",Agricultural Farm Products,3,USD,161152800,https://images.financialmodelingprep.com/symbol/AGFS.png,157171,-2.608695652173913,0,0,42761000,-33804000,"[{'period': '2022', 'revenue': 161.94, 'unit': 'M', 'net_profit': -33.8}, {'period': '2021', 'revenue': 165.99, 'unit': 'M', 'net_profit': -6.08}, {'period': '2020', 'revenue': 157.64, 'unit': 'M', 'net_profit': -52.97}, {'period': '2019', 'revenue': 170.06, 'unit': 'M', 'net_profit': -61.51}]","[{'period': ""Q4 '22"", 'revenue': 48.53, 'unit': 'M', 'net_profit': -7.65}, {'period': ""Q3 '22"", 'revenue': 47.76, 'unit': 'M', 'net_profit': -4.61}, {'period': ""Q2 '22"", 'revenue': 25.75, 'unit': 'M', 'net_profit': -18.37}, {'period': ""Q1 '22"", 'revenue': 39.89, 'unit': 'M', 'net_profit': -3.17}, {'period': ""Q4 '21"", 'revenue': 55.9, 'unit': 'M', 'net_profit': 2.42}, {'period': ""Q3 '21"", 'revenue': 49180.0, 'unit': 'K', 'net_profit': 994.0}]",-0.65,-0.65,697710000,158730000,54355000,354544000,71187000,0,66435000,54355000,12137000,-0.3475487877447016,-4.558040118382111,-4.416666666666667,__nan__,__nan__,__nan__,0.5081538174886414
129,AGFY,Agrify Corporation Common Stock,"Agrify Corporation develops precision hardware and software cultivation and extraction solutions for the cannabis and hemp industry in the United States. The company offers vertical farming units and Agrify Insights Software-as-a-Service software; integrated grow racks and LED grow lights; and non-proprietary products designed, engineered, and manufactured by third parties, such as air cleaning systems and pesticide-free surface protection products. It also provides associated services comprising consulting, engineering, and construction. The company was formerly known as Agrinamics, Inc. and changed its name to Agrify Corporation in September 2019. Agrify Corporation was incorporated in 2016 and is headquartered in Billerica, Massachusetts.",Mr. Benjamin  Kovler,Engineering & Construction,29.15,USD,56901092,https://images.financialmodelingprep.com/symbol/AGFY.png,30558,-1.05,2.13,9018,-27750000,-41746000,"[{'period': '2024', 'revenue': 9.68, 'unit': 'M', 'net_profit': -41.75}, {'period': '2023', 'revenue': 16.87, 'unit': 'M', 'net_profit': -18.65}, {'period': '2022', 'revenue': 58.26, 'unit': 'M', 'net_profit': -188.17}, {'period': '2021', 'revenue': 59.86, 'unit': 'M', 'net_profit': -32.33}]","[{'period': ""Q1 '25"", 'revenue': 0.538, 'unit': 'M', 'net_profit': -1.63}, {'period': ""Q4 '24"", 'revenue': 2.15, 'unit': 'M', 'net_profit': -24.36}, {'period': ""Q3 '24"", 'revenue': 1.93, 'unit': 'M', 'net_profit': -18.65}, {'period': ""Q2 '24"", 'revenue': 2.99, 'unit': 'M', 'net_profit': -2.97}, {'period': ""Q1 '24"", 'revenue': 2600.0, 'unit': 'K', 'net_profit': -38.0}, {'period': ""Q4 '23"", 'revenue': 2860.0, 'unit': 'K', 'net_profit': 575.0}]",-40.92,-40.92,54022000,34694000,31170000,25933000,585000,0,24679000,31170000,-11587000,-0.5197152245345017,-1.2385114483350315,0.7819112082289612,__nan__,__nan__,__nan__,0.48004516678390285
130,AGGR,Agile Growth Corp. Class A Ordinary Share,"Agile Growth Corp. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The company intends to acquire businesses in the technology industry, including infrastructure, and horizontal and vertical enterprise application software; healthcare IT; financial technology; robotics/automation; and education technology, as well as additional software and technology segments. Agile Growth Corp. was incorporated in 2021 and is based in Newton, Massachusetts.",Mr. Jay H. Bhatt,Shell Companies,10.21,USD,395637500,https://images.financialmodelingprep.com/symbol/AGGR.png,116575,340.3333333333333,0.02,2318,,,[],[],,,,,,,,,,,,,,,__nan__,__nan__,__nan__,__nan__
131,AGGRU,Agile Growth Corp. Units,"Agile Growth Corp. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The company intends to acquire businesses in the technology industry, including infrastructure, and horizontal and vertical enterprise application software; healthcare IT; financial technology; robotics/automation; and education technology, as well as additional software and technology segments. Agile Growth Corp. was incorporated in 2021 and is based in Newton, Massachusetts.",Mr. Jay H. Bhatt,Shell Companies,10.2,USD,420063193,https://images.financialmodelingprep.com/symbol/AGGRU.png,427,0,0,500,,,[],[],,,,,,,,,,,,,,,__nan__,__nan__,__nan__,__nan__
132,AGGRW,Agile Growth Corp. Warrant.,"Agile Growth Corp. is a blank check company. The company was incorporated in 2021 and is based in Newton, Massachusetts.",Mr. Jay H. Bhatt,Shell Companies,0.003,USD,395637500,https://images.financialmodelingprep.com/symbol/AGGRW.png,0,0,0,13436,,,[],[],,,,,,,,,,,,,,,__nan__,__nan__,__nan__,__nan__
133,AGIO,Agios Pharmaceuticals Inc. Common Stock,"Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.",Mr. Brian M. Goff M.B.A.,Biotechnology,29.18,USD,1689965536,https://images.financialmodelingprep.com/symbol/AGIO.png,651930,2.53,0.92,757870,-425737000,673725000,"[{'period': '2024', 'revenue': 36.5, 'unit': 'M', 'net_profit': 673.73}, {'period': '2023', 'revenue': 26.82, 'unit': 'M', 'net_profit': -352.09}, {'period': '2022', 'revenue': 14.24, 'unit': 'M', 'net_profit': -74.56}, {'period': '2021', 'revenue': 0.0, 'unit': 'B', 'net_profit': 1.6}]","[{'period': ""Q1 '25"", 'revenue': 8.73, 'unit': 'M', 'net_profit': -89.29}, {'period': ""Q4 '24"", 'revenue': 10.73, 'unit': 'M', 'net_profit': -96.52}, {'period': ""Q3 '24"", 'revenue': 8.96, 'unit': 'M', 'net_profit': 947.91}, {'period': ""Q2 '24"", 'revenue': 8.62, 'unit': 'M', 'net_profit': -96.12}, {'period': ""Q1 '24"", 'revenue': 8.19, 'unit': 'M', 'net_profit': -81.55}, {'period': ""Q4 '23"", 'revenue': 7.1, 'unit': 'M', 'net_profit': -95.94}]",11.86,11.64,1663199000,965600000,893710000,122243000,4109000,638321000,81156000,76247000,-391526000,-0.10620115157562152,2.913513098997978,2.8736176935229065,__nan__,__nan__,__nan__,0.0734987214398277
134,AGLE,Aeglea BioTherapeutics Inc. Common Stock,"Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.",Mr. Jonathan D. Alspaugh M.B.A.,Biotechnology,12.01,USD,48627649,https://images.financialmodelingprep.com/symbol/AGLE.png,59537,-0.1619689817936615,0.75,43238,-208566000,-208018000,"[{'period': '2024', 'revenue': 0.0, 'unit': 'M', 'net_profit': -208.02}, {'period': '2022', 'revenue': 2.33, 'unit': 'M', 'net_profit': -83.81}, {'period': '2021', 'revenue': 18.74, 'unit': 'M', 'net_profit': -65.8}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -80.3}]","[{'period': ""Q1 '25"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -44.77}, {'period': ""Q4 '24"", 'revenue': -0.886, 'unit': 'M', 'net_profit': 67.59}, {'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -69.03}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -38.84}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -40.11}, {'period': ""Q2 '23"", 'revenue': 0.6880000000000001, 'unit': 'M', 'net_profit': -217.08}]",-3.18,-3.18,608484000,608474000,603088000,90680000,0,0,54060000,89423000,-157410000,0,0,0,__nan__,__nan__,__nan__,0.14902610421966725
135,AGMH,AGM Group Holdings Inc. Class A Ordinary Shares,"AGM Group Holdings Inc. operates as a technology company. The company offers MetaTrader 5, a futures trading solution; FXSC, a retail-orientated online trading education website; and foreign exchange trading system that provides services to financial institutions. It also engages in the research and development, manufacture, and sales of technology hardware. In addition, the company sells cryptocurrency mining machine and standardized computing equipment, and technical support plans, as well as delivers software customization services. It has a strategic partnership with HighSharp (Shenzhen Gaorui) Electronic Technology Co., Ltd. The company was incorporated in 2015 and is based in Wan Chai, Hong Kong.",Dr. Bo  Zhu,Software - Application,0.067,USD,1765774,https://images.financialmodelingprep.com/symbol/AGMH.png,93156359,-0.05,0.007,152563548,-8767881,-7439280,"[{'period': '2023', 'revenue': 92.91, 'unit': 'M', 'net_profit': -7.44}, {'period': '2022', 'revenue': 242.4, 'unit': 'M', 'net_profit': 11.48}, {'period': '2021', 'revenue': 36.71, 'unit': 'M', 'net_profit': 3.55}, {'period': '2020', 'revenue': 0.0533, 'unit': 'M', 'net_profit': -1.1}]","[{'period': ""Q2 '24"", 'revenue': 1.91, 'unit': 'M', 'net_profit': -7.46}, {'period': ""Q1 '24"", 'revenue': 1.91, 'unit': 'M', 'net_profit': -7.46}, {'period': ""Q4 '23"", 'revenue': 28.16, 'unit': 'M', 'net_profit': -11.78}, {'period': ""Q3 '23"", 'revenue': 28.16, 'unit': 'M', 'net_profit': -11.78}, {'period': ""Q2 '23"", 'revenue': 36.59, 'unit': 'M', 'net_profit': 16.11}, {'period': ""Q1 '23"", 'revenue': 18.29, 'unit': 'M', 'net_profit': 8.06}]",-0.31,-0.31,97547345,87119145,2815995,78114845,8637179,1573,77981722,1599906,-1702426,-1.5302909533300735,-1.6482671683903616,-1.6595744680851066,__nan__,__nan__,__nan__,0.8007890424900852
136,AGNC,AGNC Investment Corp. Common Stock,"AGNC Investment Corp. operates as a real estate investment trust (REIT) in the United States. The company invests in residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by the United States government-sponsored enterprise or by the United States government agency. It funds its investments primarily through collateralized borrowings structured as repurchase agreements. The company has elected to be taxed as a REIT under the Internal Revenue Code of 1986 and would not be subject to federal corporate income taxes, if it distributes at least 90% of its taxable income to its stockholders. The company was formerly known as American Capital Agency Corp. and changed its name to AGNC Investment Corp. in September 2016. AGNC Investment Corp. was incorporated in 2008 and is headquartered in Bethesda, Maryland.",Mr. Peter J. Federico,REIT - Mortgage,9.18,USD,9367088400,https://images.financialmodelingprep.com/symbol/AGNC.png,31127648,25.5,0.1,13621558,3917000000,863000000,"[{'period': '2024', 'revenue': 3900.0, 'unit': 'M', 'net_profit': 863.0}, {'period': '2023', 'revenue': 251.0, 'unit': 'M', 'net_profit': 155.0}, {'period': '2022', 'revenue': 2.55, 'unit': 'B', 'net_profit': -1.19}, {'period': '2021', 'revenue': 837.0, 'unit': 'M', 'net_profit': 749.0}]","[{'period': ""Q1 '25"", 'revenue': -418.0, 'unit': 'M', 'net_profit': 50.0}, {'period': ""Q4 '24"", 'revenue': 154.0, 'unit': 'M', 'net_profit': 122.0}, {'period': ""Q3 '24"", 'revenue': 376.0, 'unit': 'M', 'net_profit': 346.0}, {'period': ""Q2 '24"", 'revenue': 967.0, 'unit': 'M', 'net_profit': -48.0}, {'period': ""Q1 '24"", 'revenue': 1650.0, 'unit': 'M', 'net_profit': 443.0}, {'period': ""Q4 '23"", 'revenue': 440.0, 'unit': 'M', 'net_profit': 412.0}]",0.93,0.93,88015000000,505000000,505000000,78253000000,0,74000000,217000000,505000000,86000000,0.5135239567233385,4.567741935483871,16.988394584139265,"[0.12, 0.31]","['2025-05-30', '2008-06-30']",__nan__,0.8890870874282792
137,AGNCM,AGNC Investment Corp. Depositary Shares rep 6.875% Series D Fixed-to-Floating Cumulative Redeemable Preferred Stock,"AGNC Investment Corp. operates as a real estate investment trust (REIT) in the United States. The company invests in residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by the United States government-sponsored enterprise or by the United States government agency. It funds its investments primarily through collateralized borrowings structured as repurchase agreements. The company has elected to be taxed as a REIT under the Internal Revenue Code of 1986 and would not be subject to federal corporate income taxes, if it distributes at least 90% of its taxable income to its stockholders. The company was formerly known as American Capital Agency Corp. and changed its name to AGNC Investment Corp. in September 2016. AGNC Investment Corp. was incorporated in 2008 and is headquartered in Bethesda, Maryland.",Mr. Peter J. Federico,REIT - Mortgage,24.5,USD,9161259765,https://images.financialmodelingprep.com/symbol/AGNCM.png,22614,-13.17,0.05,13007,3917000000,863000000,"[{'period': '2024', 'revenue': 3900.0, 'unit': 'M', 'net_profit': 863.0}, {'period': '2023', 'revenue': 251.0, 'unit': 'M', 'net_profit': 155.0}, {'period': '2022', 'revenue': 2.55, 'unit': 'B', 'net_profit': -1.19}, {'period': '2021', 'revenue': 837.0, 'unit': 'M', 'net_profit': 749.0}]","[{'period': ""Q1 '25"", 'revenue': -418.0, 'unit': 'M', 'net_profit': 50.0}, {'period': ""Q4 '24"", 'revenue': 154.0, 'unit': 'M', 'net_profit': 122.0}, {'period': ""Q3 '24"", 'revenue': 376.0, 'unit': 'M', 'net_profit': 346.0}, {'period': ""Q2 '24"", 'revenue': 967.0, 'unit': 'M', 'net_profit': -48.0}, {'period': ""Q1 '24"", 'revenue': 1650.0, 'unit': 'M', 'net_profit': 443.0}, {'period': ""Q4 '23"", 'revenue': 440.0, 'unit': 'M', 'net_profit': 412.0}]",0.93,0.93,88015000000,505000000,505000000,78253000000,0,74000000,217000000,505000000,86000000,0.5135239567233385,4.567741935483871,16.988394584139265,"[0.55632, 0.186]","['2025-04-01', '2019-03-29']",__nan__,0.8890870874282792
138,AGNCN,AGNC Investment Corp. Depositary Shares Each Representing a 1/1000th Interest in a Share of 7.00% Series C Fixed-To-Floating Rate Cumulative Redeemable Preferred Stock,"AGNC Investment Corp. operates as a real estate investment trust (REIT) in the United States. The company invests in residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by the United States government-sponsored enterprise or by the United States government agency. It funds its investments primarily through collateralized borrowings structured as repurchase agreements. The company has elected to be taxed as a REIT under the Internal Revenue Code of 1986 and would not be subject to federal corporate income taxes, if it distributes at least 90% of its taxable income to its stockholders. The company was formerly known as American Capital Agency Corp. and changed its name to AGNC Investment Corp. in September 2016. AGNC Investment Corp. was incorporated in 2008 and is headquartered in Bethesda, Maryland.",Mr. Peter J. Federico,REIT - Mortgage,25.67,USD,9160405934,https://images.financialmodelingprep.com/symbol/AGNCN.png,33550,-13.8,0.05,7204,3917000000,863000000,"[{'period': '2024', 'revenue': 3900.0, 'unit': 'M', 'net_profit': 863.0}, {'period': '2023', 'revenue': 251.0, 'unit': 'M', 'net_profit': 155.0}, {'period': '2022', 'revenue': 2.55, 'unit': 'B', 'net_profit': -1.19}, {'period': '2021', 'revenue': 837.0, 'unit': 'M', 'net_profit': 749.0}]","[{'period': ""Q1 '25"", 'revenue': -418.0, 'unit': 'M', 'net_profit': 50.0}, {'period': ""Q4 '24"", 'revenue': 154.0, 'unit': 'M', 'net_profit': 122.0}, {'period': ""Q3 '24"", 'revenue': 376.0, 'unit': 'M', 'net_profit': 346.0}, {'period': ""Q2 '24"", 'revenue': 967.0, 'unit': 'M', 'net_profit': -48.0}, {'period': ""Q1 '24"", 'revenue': 1650.0, 'unit': 'M', 'net_profit': 443.0}, {'period': ""Q4 '23"", 'revenue': 440.0, 'unit': 'M', 'net_profit': 412.0}]",0.93,0.93,88015000000,505000000,505000000,78253000000,0,74000000,217000000,505000000,86000000,0.5135239567233385,4.567741935483871,16.988394584139265,"[0.60501, 0.258]","['2025-04-01', '2017-09-28']",__nan__,0.8890870874282792
139,AGNCO,AGNC Investment Corp. Depositary Shares each representing a 1/1000th interest in a share of 6.50% Series E Fixed-to-Floating Cumulative Redeemable Preferred Stock,"AGNC Investment Corp. operates as a real estate investment trust (REIT) in the United States. The company invests in residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by the United States government-sponsored enterprise or by the United States government agency. It funds its investments primarily through collateralized borrowings structured as repurchase agreements. The company has elected to be taxed as a REIT under the Internal Revenue Code of 1986 and would not be subject to federal corporate income taxes, if it distributes at least 90% of its taxable income to its stockholders. The company was formerly known as American Capital Agency Corp. and changed its name to AGNC Investment Corp. in September 2016. AGNC Investment Corp. was incorporated in 2008 and is headquartered in Bethesda, Maryland.",Mr. Peter J. Federico,REIT - Mortgage,25.47,USD,9164151413,https://images.financialmodelingprep.com/symbol/AGNCO.png,41358,-13.69,0.06,10466,3917000000,863000000,"[{'period': '2024', 'revenue': 3900.0, 'unit': 'M', 'net_profit': 863.0}, {'period': '2023', 'revenue': 251.0, 'unit': 'M', 'net_profit': 155.0}, {'period': '2022', 'revenue': 2.55, 'unit': 'B', 'net_profit': -1.19}, {'period': '2021', 'revenue': 837.0, 'unit': 'M', 'net_profit': 749.0}]","[{'period': ""Q1 '25"", 'revenue': -418.0, 'unit': 'M', 'net_profit': 50.0}, {'period': ""Q4 '24"", 'revenue': 154.0, 'unit': 'M', 'net_profit': 122.0}, {'period': ""Q3 '24"", 'revenue': 376.0, 'unit': 'M', 'net_profit': 346.0}, {'period': ""Q2 '24"", 'revenue': 967.0, 'unit': 'M', 'net_profit': -48.0}, {'period': ""Q1 '24"", 'revenue': 1650.0, 'unit': 'M', 'net_profit': 443.0}, {'period': ""Q4 '23"", 'revenue': 440.0, 'unit': 'M', 'net_profit': 412.0}]",0.93,0.93,88015000000,505000000,505000000,78253000000,0,74000000,217000000,505000000,86000000,0.5135239567233385,4.567741935483871,16.988394584139265,"[0.59764, 0.46]","['2025-04-01', '2019-12-30']",__nan__,0.8890870874282792
140,AGNCP,AGNC Investment Corp. Depositary Shares Each Representing a 1/1000th Interest in a Share of 6.125% Series F Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock,"AGNC Investment Corp. operates as a real estate investment trust (REIT) in the United States. The company invests in residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by the United States government-sponsored enterprise or by the United States government agency. It funds its investments primarily through collateralized borrowings structured as repurchase agreements. The company has elected to be taxed as a REIT under the Internal Revenue Code of 1986 and would not be subject to federal corporate income taxes, if it distributes at least 90% of its taxable income to its stockholders. The company was formerly known as American Capital Agency Corp. and changed its name to AGNC Investment Corp. in September 2016. AGNC Investment Corp. was incorporated in 2008 and is headquartered in Bethesda, Maryland.",Mr. Peter J. Federico,REIT - Mortgage,25.02,USD,9157203132,https://images.financialmodelingprep.com/symbol/AGNCP.png,45880,-13.45,0.04,14373,3917000000,863000000,"[{'period': '2024', 'revenue': 3900.0, 'unit': 'M', 'net_profit': 863.0}, {'period': '2023', 'revenue': 251.0, 'unit': 'M', 'net_profit': 155.0}, {'period': '2022', 'revenue': 2.55, 'unit': 'B', 'net_profit': -1.19}, {'period': '2021', 'revenue': 837.0, 'unit': 'M', 'net_profit': 749.0}]","[{'period': ""Q1 '25"", 'revenue': -418.0, 'unit': 'M', 'net_profit': 50.0}, {'period': ""Q4 '24"", 'revenue': 154.0, 'unit': 'M', 'net_profit': 122.0}, {'period': ""Q3 '24"", 'revenue': 376.0, 'unit': 'M', 'net_profit': 346.0}, {'period': ""Q2 '24"", 'revenue': 967.0, 'unit': 'M', 'net_profit': -48.0}, {'period': ""Q1 '24"", 'revenue': 1650.0, 'unit': 'M', 'net_profit': 443.0}, {'period': ""Q4 '23"", 'revenue': 440.0, 'unit': 'M', 'net_profit': 412.0}]",0.93,0.93,88015000000,505000000,505000000,78253000000,0,74000000,217000000,505000000,86000000,0.5135239567233385,4.567741935483871,16.988394584139265,"[0.38281, 0.27222]","['2025-04-01', '2020-03-31']",__nan__,0.8890870874282792
141,AGRX,Agile Therapeutics Inc. Common Stock,"Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.",Mr. Alfred F. Altomari,Drug Manufacturers - Specialty & Generic,1.51,USD,10425795,https://images.financialmodelingprep.com/symbol/AGRX.png,143293,-0.888235294117647,0.05,119291,-19884000,-14465000,"[{'period': '2023', 'revenue': 19.59, 'unit': 'M', 'net_profit': -14.46}, {'period': '2022', 'revenue': 10.88, 'unit': 'M', 'net_profit': -25.41}, {'period': '2021', 'revenue': 4.1, 'unit': 'M', 'net_profit': -76.58}, {'period': '2020', 'revenue': 0.749, 'unit': 'M', 'net_profit': -54.69}]","[{'period': ""Q2 '24"", 'revenue': 5.58, 'unit': 'M', 'net_profit': -11.87}, {'period': ""Q1 '24"", 'revenue': 5.72, 'unit': 'M', 'net_profit': 1.28}, {'period': ""Q4 '23"", 'revenue': 3.61, 'unit': 'M', 'net_profit': -4.47}, {'period': ""Q3 '23"", 'revenue': 6660.0, 'unit': 'K', 'net_profit': -799.0}, {'period': ""Q2 '23"", 'revenue': 5.5, 'unit': 'M', 'net_profit': -3.81}, {'period': ""Q1 '23"", 'revenue': 3.81, 'unit': 'M', 'net_profit': -3.61}]",-6.71,-6.71,10255000,9530000,2557000,26573000,3392000,0,20777000,2557000,-9577000,0.5016541353383459,0.43078073351172674,0.88586494301752,__nan__,__nan__,__nan__,2.591223793271575
142,AGTC,Applied Genetic Technologies Corporation Common Stock,"Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.",Ms. Susan Washer,Biotechnology,0.3936,USD,0,https://images.financialmodelingprep.com/symbol/AGTC.png,1315880,-0.26958904109589044,0,764531,-64757000,-71424000,"[{'period': '2022', 'revenue': 0.325, 'unit': 'M', 'net_profit': -71.42}, {'period': '2021', 'revenue': 0.5, 'unit': 'M', 'net_profit': -57.83}, {'period': '2020', 'revenue': 2.45, 'unit': 'M', 'net_profit': -45.89}, {'period': '2019', 'revenue': 41.69, 'unit': 'M', 'net_profit': -2.01}]","[{'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 17.07}, {'period': ""Q4 '22"", 'revenue': 0.325, 'unit': 'M', 'net_profit': -18.97}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -14.91}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -18.44}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -17.12}, {'period': ""Q4 '21"", 'revenue': 0.5, 'unit': 'M', 'net_profit': -12.14}]",-1.59,-1.59,66684000,49561000,46366000,37207000,0,7807000,25207000,46366000,-67762000,-0.1366660230643661,-0.2350896608967819,0.10169491525423725,__nan__,__nan__,__nan__,0.5579599304180913
143,AGYS,Agilysys Inc. Common Stock,"Agilysys, Inc., together with its subsidiaries, operates as a developer and marketer of hardware and software products and services to the hospitality industry in North America, Europe, the Asia-Pacific, and India. It offers point of sale, property management systems, inventory and procurement, payments, reservations management, and seat solutions to enhance guest experience. The company also provides technical software support, maintenance, and subscription services; and professional services. It offers its solutions for gaming, hotels, resorts and cruise, corporate foodservice management, restaurants, universities, stadium, and healthcare. The company was formerly known as Pioneer-Standard Electronics, Inc. and changed its name to Agilysys, Inc. in 2003. Agilysys, Inc. was founded in 1932 and is headquartered in Alpharetta, Georgia.",Mr. Ramesh  Srinivasan,Software - Application,86,USD,2404904000,https://images.financialmodelingprep.com/symbol/AGYS.png,281396,114.67,3.28,299893,25946000,86195000,"[{'period': '2023', 'revenue': 237.46, 'unit': 'M', 'net_profit': 86.19}, {'period': '2022', 'revenue': 198.06, 'unit': 'M', 'net_profit': 14.58}, {'period': '2021', 'revenue': 162.64, 'unit': 'M', 'net_profit': 6.48}, {'period': '2020', 'revenue': 137.18, 'unit': 'M', 'net_profit': -21.0}]","[{'period': ""Q3 '24"", 'revenue': 69.56, 'unit': 'M', 'net_profit': 3.83}, {'period': ""Q2 '24"", 'revenue': 68.28, 'unit': 'M', 'net_profit': 1.36}, {'period': ""Q1 '24"", 'revenue': 63.51, 'unit': 'M', 'net_profit': 14.11}, {'period': ""Q4 '23"", 'revenue': 62.22, 'unit': 'M', 'net_profit': 2.96}, {'period': ""Q3 '23"", 'revenue': 60.57, 'unit': 'M', 'net_profit': 77.14}, {'period': ""Q2 '23"", 'revenue': 58.62, 'unit': 'M', 'net_profit': 4.54}]",3.31,3.17,350430000,188937000,144891000,113953000,31728000,0,89371000,144891000,40059000,0.34602614650342395,4.911054725003429,5.365384615384615,"[0.03, 0.0451]","['2009-07-16', '1985-01-10']",__nan__,0.32518049253773934
144,AHAC,Alpha Healthcare Acquisition Corp. Class A Common Stock,"Alpha Healthcare Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.",Mr. Rajiv Sarman Shukla,Shell Companies,10.96,USD,1130173280,https://images.financialmodelingprep.com/symbol/AHAC.png,222649,-72.10526315789474,0.8100004,295507,-132234000,-148701000,"[{'period': '2024', 'revenue': 0.0, 'unit': 'M', 'net_profit': -148.7}, {'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -110.78}, {'period': '2022', 'revenue': 1.56, 'unit': 'M', 'net_profit': 64.22}, {'period': '2021', 'revenue': 1.26, 'unit': 'M', 'net_profit': 37.54}]","[{'period': ""Q1 '25"", 'revenue': 0.517, 'unit': 'M', 'net_profit': 39.14}, {'period': ""Q4 '24"", 'revenue': 7.23, 'unit': 'M', 'net_profit': -20.94}, {'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -39.2}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -56.66}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -31.9}, {'period': ""Q4 '23"", 'revenue': 10.79, 'unit': 'M', 'net_profit': -25.11}]",-1.26,-1.26,137872000,47859000,44937000,190541000,0,0,19954000,44937000,-99694000,-0.3708971780464036,-0.3423575503719217,-0.17757009345794386,__nan__,__nan__,__nan__,1.382013751885807
145,AHACU,Alpha Healthcare Acquisition Corp. Unit,"Alpha Healthcare Acquisition Corp. is a blank check company. The company was incorporated in 2020 and is based in New York, New York.",Mr. Rajiv Sarman Shukla,Shell Companies,12.077,USD,0,https://images.financialmodelingprep.com/symbol/AHACU.png,1445,-79.45394736842105,0.877,2922,-132234000,-148701000,"[{'period': '2024', 'revenue': 0.0, 'unit': 'M', 'net_profit': -148.7}, {'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -110.78}, {'period': '2022', 'revenue': 1.56, 'unit': 'M', 'net_profit': 64.22}, {'period': '2021', 'revenue': 1.26, 'unit': 'M', 'net_profit': 37.54}]","[{'period': ""Q1 '25"", 'revenue': 0.517, 'unit': 'M', 'net_profit': 39.14}, {'period': ""Q4 '24"", 'revenue': 7.23, 'unit': 'M', 'net_profit': -20.94}, {'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -39.2}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -56.66}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -31.9}, {'period': ""Q4 '23"", 'revenue': 10.79, 'unit': 'M', 'net_profit': -25.11}]",-1.26,-1.26,137872000,47859000,44937000,190541000,0,0,19954000,44937000,-99694000,-0.3708971780464036,-0.3423575503719217,-0.17757009345794386,__nan__,__nan__,__nan__,1.382013751885807
146,AHACW,Alpha Healthcare Acquisition Corp. Warrant,,,,,,,,,,,,,,[],[],,,,,,,,,,,,,,,__nan__,__nan__,__nan__,__nan__
147,AHCO,AdaptHealth Corp. Class A Common Stock,"AdaptHealth Corp., together with its subsidiaries, provides home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps to patients for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs. It serves beneficiaries of Medicare, Medicaid, and commercial insurance payors. AdaptHealth Corp. is headquartered in Plymouth Meeting, Pennsylvania.",Ms. Suzanne M. Foster M.P.H.,Medical - Devices,9.02,USD,1217230960,https://images.financialmodelingprep.com/symbol/AHCO.png,1899832,15.55,-0.02,889628,303374000,90422000,"[{'period': '2024', 'revenue': 3260.0, 'unit': 'M', 'net_profit': 90.42}, {'period': '2023', 'revenue': 3200.0, 'unit': 'M', 'net_profit': -678.89}, {'period': '2022', 'revenue': 2970.0, 'unit': 'M', 'net_profit': 69.32}, {'period': '2021', 'revenue': 2450.0, 'unit': 'M', 'net_profit': 156.18}]","[{'period': ""Q1 '25"", 'revenue': 580.47, 'unit': 'M', 'net_profit': -7.21}, {'period': ""Q4 '24"", 'revenue': 856.64, 'unit': 'M', 'net_profit': 50.26}, {'period': ""Q3 '24"", 'revenue': 805.86, 'unit': 'M', 'net_profit': 22.86}, {'period': ""Q2 '24"", 'revenue': 805.98, 'unit': 'M', 'net_profit': 19.43}, {'period': ""Q1 '24"", 'revenue': 792.5, 'unit': 'M', 'net_profit': -2.13}, {'period': ""Q4 '23"", 'revenue': 858.23, 'unit': 'M', 'net_profit': -254.5}]",0.62,0.61,4486947000,755788000,109747000,2908829000,408019000,132000,566987000,109747000,235784000,2.773173340503007,1.1331899631018052,1.1165413533834587,__nan__,__nan__,__nan__,0.6482869086708624
148,AHPI,Allied Healthcare Products Inc. Common Stock,"Allied Healthcare Products, Inc. manufactures and markets respiratory products for use in the health care industry in a range of hospitals and alternate site settings worldwide. The company offers respiratory care/anesthesia products, including air compressors, calibration equipment, humidifiers, croup tents, and equipment dryers, as well as respiratory disposable products, such as oxygen tubing products, facemasks, cannulas, and ventilator circuits; and home respiratory care products comprising aluminum oxygen cylinders, oxygen regulators, pneumatic nebulizers, portable suction equipment, and a line of respiratory disposable products. It also provides medical gas equipment, which include construction products consisting of in-wall medical system components, central station pumps and compressors, and headwalls; regulation devices and suction equipment comprising flowmeters, vacuum regulators, and pressure regulators, as well as related adapters, fittings, and hoses that measure, regulate, monitor, and transfer medical gases from walled piping or equipment to patients; and disposable oxygen cylinders to provide oxygen for short periods. In addition, the company offers emergency medical products that include respiratory/resuscitation products, such as demand resuscitation valves, portable resuscitation systems, bag masks and related products, emergency transport ventilators, precision oxygen regulators, minilators, multilators, and humidifiers; and trauma and patient handling products that include spine immobilization products, pneumatic anti-shock garments, and trauma burn kits. It serves hospitals, hospital equipment dealers, hospital construction contractors, home health care dealers, emergency medical products dealers, and others. The company was incorporated in 1979 and is headquartered in St. Louis, Missouri.",Mr. Daniel C. Dunn,Medical - Devices,0.004,USD,0,https://images.financialmodelingprep.com/symbol/AHPI.png,3110,-0.0029850746268656717,0,3311,-4119041,-5361428,"[{'period': '2022', 'revenue': 27.05, 'unit': 'M', 'net_profit': -5.36}, {'period': '2021', 'revenue': 36.28, 'unit': 'M', 'net_profit': 1.69}, {'period': '2020', 'revenue': 31.89, 'unit': 'M', 'net_profit': -3.01}, {'period': '2019', 'revenue': 31.38, 'unit': 'M', 'net_profit': -2.11}]","[{'period': ""Q4 '22"", 'revenue': 6.01, 'unit': 'M', 'net_profit': -1.94}, {'period': ""Q3 '22"", 'revenue': 6.87, 'unit': 'M', 'net_profit': -1.33}, {'period': ""Q2 '22"", 'revenue': 6.81, 'unit': 'M', 'net_profit': -1.2}, {'period': ""Q1 '22"", 'revenue': 7360.0, 'unit': 'K', 'net_profit': -984.01}, {'period': ""Q4 '21"", 'revenue': 7.02, 'unit': 'M', 'net_profit': 1.55}, {'period': ""Q3 '21"", 'revenue': 7970.0, 'unit': 'K', 'net_profit': -413.44}]",-1.34,-1.34,19670586,16081530,3317047,14436506,2369956,0,5982199,3317047,-4171392,-78.8896999035607,-4.177730045495819,-4.190476190476191,"[0.07, 0.06]","['1996-06-26', '1993-03-25']",__nan__,0.7339133668920692
149,AIH,Aesthetic Medical International Holdings Group Ltd. American Depositary Shares,"Aesthetic Medical International Holdings Group Limited provides aesthetic medical services. It offers surgical aesthetic treatments, such as eye surgery, rhinoplasty, breast augmentation, and liposuction; and non-surgical aesthetic treatments comprising minimally invasive and energy-based treatments, including laser, ultrasound, and ultraviolet light treatments. The company also provides general healthcare and other aesthetic medical services, such as internal medicine, urology, gynecology, and obstetrics treatment services, as well as dentistry, dermatology, and hair loss treatment services. It operates 15 treatment centers in China, Hong Kong, and Singapore. Aesthetic Medical International Holdings Group Limited was founded in 1997 and is headquartered in Shenzhen, the People's Republic of China.",Dr. Pengwu  Zhou,Medical - Care Facilities,0.3334,USD,15932519,https://images.financialmodelingprep.com/symbol/AIH.png,261827,-2.7783333333333333,-0.1656,178322,25467000,-37432000,"[{'period': '2023', 'revenue': 682.59, 'unit': 'M', 'net_profit': -37.43}, {'period': '2022', 'revenue': 670.09, 'unit': 'M', 'net_profit': -76.11}, {'period': '2021', 'revenue': 645.59, 'unit': 'M', 'net_profit': -669.52}, {'period': '2020', 'revenue': 901.57, 'unit': 'M', 'net_profit': -246.91}]","[{'period': ""Q4 '23"", 'revenue': 181.64, 'unit': 'M', 'net_profit': -13.68}, {'period': ""Q3 '23"", 'revenue': 181.64, 'unit': 'M', 'net_profit': -13.68}, {'period': ""Q2 '23"", 'revenue': 170.42, 'unit': 'M', 'net_profit': -10.56}, {'period': ""Q1 '23"", 'revenue': 148880.0, 'unit': 'K', 'net_profit': 182.0}, {'period': ""Q4 '22"", 'revenue': 503.04, 'unit': 'M', 'net_profit': -23.7}, {'period': ""Q3 '22"", 'revenue': -171.55, 'unit': 'M', 'net_profit': -48.66}]",-0.85,-0.85,560664000,111569000,62336000,527035000,12920000,-76938000,411380000,62336000,18827000,1.634153909805544,0.5081596720363704,0.6953405017921147,__nan__,__nan__,__nan__,0.9400193342179987
150,AIHS,Senmiao Technology Limited Common Stock,"Senmiao Technology Limited engages in the automobile transaction and related services business in the People's Republic of China. The company offers car rental services to individual customers; and auto finance solutions through financing leases. It also engages in automobile sales; the facilitation of automobile transaction and financing; and the provision of supporting services provided to online ride-hailing drivers, as well as management and guarantee services. The company was founded in 2014 and is headquartered in Chengdu, the People's Republic of China.",Mr. Xi  Wen,Financial - Credit Services,0.9375,USD,9860625,https://images.financialmodelingprep.com/symbol/AIHS.png,15159,-2.68,-0.0025,3277,-3008405,-3668974,"[{'period': '2023', 'revenue': 6.81, 'unit': 'M', 'net_profit': -3.67}, {'period': '2022', 'revenue': 8.08, 'unit': 'M', 'net_profit': -3.11}, {'period': '2021', 'revenue': 4.91, 'unit': 'M', 'net_profit': -5.61}, {'period': '2020', 'revenue': 6.16, 'unit': 'M', 'net_profit': -12.6}]","[{'period': ""Q3 '24"", 'revenue': 919.84, 'unit': 'K', 'net_profit': -565.32}, {'period': ""Q2 '24"", 'revenue': 745.88, 'unit': 'K', 'net_profit': -711.45}, {'period': ""Q1 '24"", 'revenue': 1120.0, 'unit': 'K', 'net_profit': -673.42}, {'period': ""Q4 '23"", 'revenue': 1.27, 'unit': 'M', 'net_profit': -1.38}, {'period': ""Q3 '23"", 'revenue': 1620.0, 'unit': 'K', 'net_profit': -934.0}, {'period': ""Q2 '23"", 'revenue': 1830.0, 'unit': 'K', 'net_profit': -925.96}]",-0.41,-0.41,9861484,2651160,792299,5573116,989064,0,5343210,792299,-664438,-0.23413845103656955,-0.1783139874151706,0.046511627906976785,__nan__,__nan__,__nan__,0.5651396889149747
151,AIKI,AIkido Pharma Inc. Common Stock,"AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.",Mr. Anthony C. Hayes Esq.,Biotechnology,3.56,USD,19526956,https://images.financialmodelingprep.com/symbol/AIKI.png,35256,0,0.03,31931,-11527000,-14703000,"[{'period': '2024', 'revenue': 18.15, 'unit': 'M', 'net_profit': -14.7}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -29.87}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.9}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -12.34}]","[{'period': ""Q1 '25"", 'revenue': 8.11, 'unit': 'M', 'net_profit': -32.49}, {'period': ""Q4 '24"", 'revenue': 17.11, 'unit': 'M', 'net_profit': 1.19}, {'period': ""Q3 '24"", 'revenue': 4.04, 'unit': 'M', 'net_profit': -4.21}, {'period': ""Q2 '24"", 'revenue': 6.17, 'unit': 'M', 'net_profit': -6.12}, {'period': ""Q3 '23"", 'revenue': 0.963, 'unit': 'M', 'net_profit': -3.54}, {'period': ""Q2 '23"", 'revenue': 0.07100000000000001, 'unit': 'M', 'net_profit': -8.66}]",-2.38,-2.38,47125000,28150000,9852000,7272000,902000,12282000,3783000,4079000,-15118000,0,0,0,"[0.0389, 0.0667]","['1980-05-12', '1978-05-15']",__nan__,0.1543129973474801
152,AIMC,Altra Industrial Motion Corp. Common Stock,"Altra Industrial Motion Corp. designs, produces, and markets a range of electromechanical power transmission motion control products for use in various motion-related applications, and high-volume manufacturing and non-manufacturing processes. The company operates in two segments, Power Transmission Technologies (PTT) and Automation & Specialty (A&S). The PTT segment offers couplings, such as gear couplings, diaphragm and disc couplings, elastomeric couplings, miniature and precision couplings, universal joints, mill spindles, and shaft locking devices under the Ameridrives, Bibby, Guardian, Huco, Lamiflex, Stromag, and TB Wood's brands; clutches and brakes under the Industrial Clutch, Formsprag, Stieber, Stromag, Svendborg, Twiflex, and Wichita brands; electromagnetic clutches and brakes under the Inertia Dynamics, Matrix, Stromag, and Warner Electric brands; and gears under the Bauer Gear Motor, Boston Gear, Delroyd, and Nuttall brands. The A&S segment provides rotary precision motion solutions, including servo and stepper motors, precision linear actuators, and electronic drives and motion controllers, as well as related software under the Kollmorgen brand; and miniature motors, and motion control products, such as brush and brushless DC, can stack, and disc magnet motors under the Portescap brand. This segment also offers linear bearings, guides, glides, lead and ball screws, industrial linear actuators, resolvers, and inductors for the transition of rotary motion to linear motion under the Thomson and Nook brands. It serves in North America, the rest of Europe, Germany, China, the rest of Asia, and internationally. The company was formerly known as Altra Holdings, Inc. and changed its name to Altra Industrial Motion Corp. in November 2013. Altra Industrial Motion Corp. was incorporated in 2004 and is headquartered in Braintree, Massachusetts. As of March 27, 2023, Altra Industrial Motion Corp. operates as a subsidiary of Regal Rexnord Corporation.",Mr. Carl R. Christenson,Industrial - Machinery,61.98,USD,4050845454,https://images.financialmodelingprep.com/symbol/AIMC.png,1348099,31.948453608247423,0,1844123,353400000,127000000,"[{'period': '2022', 'revenue': 1950.0, 'unit': 'M', 'net_profit': 127.0}, {'period': '2021', 'revenue': 1900.0, 'unit': 'M', 'net_profit': 27.7}, {'period': '2020', 'revenue': 1730.0, 'unit': 'M', 'net_profit': -25.5}, {'period': '2019', 'revenue': 1830.0, 'unit': 'M', 'net_profit': 127.2}]","[{'period': ""Q4 '22"", 'revenue': 469.4, 'unit': 'M', 'net_profit': 22.3}, {'period': ""Q3 '22"", 'revenue': 466.3, 'unit': 'M', 'net_profit': 33.6}, {'period': ""Q2 '22"", 'revenue': 498.1, 'unit': 'M', 'net_profit': 26.3}, {'period': ""Q1 '22"", 'revenue': 511.7, 'unit': 'M', 'net_profit': 44.8}, {'period': ""Q4 '21"", 'revenue': 469.8, 'unit': 'M', 'net_profit': -87.7}, {'period': ""Q3 '21"", 'revenue': 469.3, 'unit': 'M', 'net_profit': 35.4}]",1.95,1.94,3676600000,836400000,208900000,1674200000,253500000,0,377300000,208900000,69100000,-0.044864864864864865,3.5848375451263537,3.5348837209302326,"[0.09, 0.05]","['2023-03-15', '2012-06-14']",__nan__,0.4553663711037371
153,AINV,Apollo Investment Corporation Common Stock,"Apollo Investment Corporation is business development company and a closed-end, externally managed, non-diversified management investment company. It is elected to be treated as a business development company (""BDC"") under the Investment Company Act of 1940 (the ""1940 Act"") specializing in private equity investments in leveraged buyouts, acquisitions, recapitalizations, growth capital, refinancing and private middle market companies. It provides direct equity capital, mezzanine, first lien secured loans, stretch senior loans, unitranche loans, second lien secured loans and senior secured loans, unsecured debt, and subordinated debt and loans. It also seeks to invest in PIPES transactions. The fund may also invest in securities of public companies that are thinly traded and may acquire investments in the secondary market and structured products. It prefers to invest in preferred equity, common equity / interests and warrants and makes equity co-investments. It may invest in cash equivalents, U.S. government securities, high-quality debt investments that mature in one year or less, high-yield bonds, distressed debt, non-U.S. investments, or securities of public companies that are not thinly traded. It also focuses on other investments such as collateralized loan obligations (""CLOs"") and credit-linked notes (""CLNs""). The fund typically invests in construction and building materials, business services, plastics & rubber, advertising, capital equipment, education, cable television, chemicals, consumer products/goods durable and non-durable and customer services, direct marketing, energy  oil & gas, electricity and utilities. The fund also invest in aerospace & defense, wholesale, telecommunications, financial services, hotel, gaming, leisure, restaurants; environmental industries, healthcare and pharmaceuticals, high tech industries, beverages, food and tobacco, manufacturing, media  diversified & production, printing and publishing, retail, automation, aviation and consumer transport, transportation, cargo and distribution. It primarily invests in United States. It primarily invests between $20 million and $250 million in its portfolio companies. The fund seeks to make investments with stated maturities of five to 10 years.",Mr. Howard Widra,Asset Management,13.65,USD,893411610,https://images.financialmodelingprep.com/symbol/AINV.png,0,15.511363636363637,0.07999992,224490,0,0,"[{'period': '2024', 'revenue': 301800.0, 'unit': '', 'net_profit': 0.0}, {'period': '2022', 'revenue': 96.72, 'unit': 'M', 'net_profit': 82.36}, {'period': '2021', 'revenue': 126.73, 'unit': 'M', 'net_profit': 111.86}, {'period': '2020', 'revenue': 276.92, 'unit': 'M', 'net_profit': -116.06}]","[{'period': ""Q4 '24"", 'revenue': 78700.0, 'unit': '', 'net_profit': 0.0}, {'period': ""Q3 '24"", 'revenue': -40660.0, 'unit': 'K', 'net_profit': 71.0}, {'period': ""Q2 '24"", 'revenue': 82100.0, 'unit': '', 'net_profit': 0.0}, {'period': ""Q1 '24"", 'revenue': 69200.0, 'unit': '', 'net_profit': 0.0}, {'period': ""Q1 '23"", 'revenue': 8.85, 'unit': 'M', 'net_profit': -10.72}, {'period': ""Q4 '22"", 'revenue': 7.83, 'unit': 'M', 'net_profit': 4.24}]",0,0,616483000,88232000,0,588271000,0,0,190643000,0,-9532000,0,0,0,"[0.32, 0.045]","['2022-09-19', '2004-09-21']",__nan__,0.9542371809117202
154,AIRG,Airgain Inc. Common Stock,"Airgain, Inc. designs, develops, and engineers antenna products for original equipment and design manufacturers, vertical markets, chipset vendors, service providers, value-added resellers and software developers worldwide. The company's products include MaxBeam embedded antennas; profile embedded antennas; profile contour embedded antennas; ultra-embedded antennas; SmartMax embedded antennas; and MaxBeam carrier class antennas, as well as automotive, fleet, public safety, and machine-to-machine antennas under the Antenna Plus brand. It provides embedded antenna technologies to enable high performance wireless networking in a range of devices and markets, including consumer, enterprise, and automotive. The company was formerly known as AM Group and changed its name to Airgain, Inc. in 2004. Airgain, Inc. was incorporated in 1995 and is headquartered in San Diego, California.",Mr. Jacob  Suen,Communication Equipment,4.19,USD,49417279,https://images.financialmodelingprep.com/symbol/AIRG.png,22369,-6.07,0.21,15872,-5219000,-8688000,"[{'period': '2024', 'revenue': 60.6, 'unit': 'M', 'net_profit': -8.69}, {'period': '2023', 'revenue': 56.04, 'unit': 'M', 'net_profit': -12.43}, {'period': '2022', 'revenue': 75.89, 'unit': 'M', 'net_profit': -8.66}, {'period': '2021', 'revenue': 64.27, 'unit': 'M', 'net_profit': -10.09}]","[{'period': ""Q1 '25"", 'revenue': 12.01, 'unit': 'M', 'net_profit': -1.55}, {'period': ""Q4 '24"", 'revenue': 15.08, 'unit': 'M', 'net_profit': -1.96}, {'period': ""Q3 '24"", 'revenue': 16.1, 'unit': 'M', 'net_profit': -1.76}, {'period': ""Q2 '24"", 'revenue': 15.18, 'unit': 'M', 'net_profit': -2.51}, {'period': ""Q1 '24"", 'revenue': 14.23, 'unit': 'M', 'net_profit': -2.46}, {'period': ""Q4 '23"", 'revenue': 10.07, 'unit': 'M', 'net_profit': -5.48}]",-0.79,-0.79,48443000,25831000,8510000,17474000,11671000,0,13501000,8510000,-3705000,0.404903078677309,0.3009333762471838,0.3416666666666666,__nan__,__nan__,__nan__,0.3607125900542906
155,AIRT,Air T Inc. Common Stock,"Air T, Inc., through its subsidiaries, provides overnight air cargo, ground equipment sale, and commercial jet engines and parts, and printing equipment and maintenance services in the United States and internationally. The company's Overnight Air Cargo segment offers air express delivery services. As of March 31, 2022, this segment had 72 aircraft under the dry-lease agreements with FedEx. Its Ground Equipment Sales segment manufactures, sells, and services aircraft deicers, scissor-type lifts, military and civilian decontamination units, flight-line tow tractors, glycol recovery vehicles, and other specialized equipment. This segment sells its products to passenger and cargo airlines, ground handling companies, the United States Air Force, airports, and industrial customers. Its Commercial Aircraft, Engines and Parts segment offers commercial aircraft trading, leasing, and parts solutions; commercial aircraft storage, storage maintenance, and aircraft disassembly/part-out services; commercial aircraft parts sales, exchanges, procurement services, consignment programs, and overhaul and repair services; and aircraft instrumentation, avionics, and a range of electrical accessories for civilian, military transport, regional/commuter and business/commercial jet, and turboprop aircraft. This segment also provides composite aircraft structures, and repair and support services. Air T, Inc. was incorporated in 1980 and is based in Denver, North Carolina.",Mr. Nicholas John Swenson,Integrated Freight & Logistics,18.26,USD,49775299,https://images.financialmodelingprep.com/symbol/AIRT.png,4040,-65.21,0.21,2747,5851000,-6819000,"[{'period': '2024', 'revenue': 286.83, 'unit': 'M', 'net_profit': -6.82}, {'period': '2023', 'revenue': 247.32, 'unit': 'M', 'net_profit': -11.79}, {'period': '2022', 'revenue': 177.08, 'unit': 'M', 'net_profit': 10.93}, {'period': '2021', 'revenue': 175.12, 'unit': 'M', 'net_profit': -8.39}]","[{'period': ""Q3 '25"", 'revenue': 77.88, 'unit': 'M', 'net_profit': -1.3}, {'period': ""Q2 '25"", 'revenue': 17.13, 'unit': 'M', 'net_profit': 2.52}, {'period': ""Q1 '25"", 'revenue': 66410.0, 'unit': 'K', 'net_profit': -335.0}, {'period': ""Q4 '24"", 'revenue': 72.68, 'unit': 'M', 'net_profit': -1.7}, {'period': ""Q3 '24"", 'revenue': 63.76, 'unit': 'M', 'net_profit': -2.98}, {'period': ""Q2 '24"", 'revenue': 78.97, 'unit': 'M', 'net_profit': -1.61}]",-2.42,-2.42,177167000,102877000,7100000,158371000,26004000,16653000,46841000,7100000,16102000,4.458022388059701,0.42138311412812895,0.4154589371980676,"[0.3, 0.01]","['2013-06-05', '1991-12-30']",__nan__,0.8939080076989507
156,AIRTP,Air T Inc. Air T Funding Alpha Income Trust Preferred Securities,"Air T, Inc., through its subsidiaries, provides overnight air cargo, ground equipment sale, and commercial jet engines and parts, and printing equipment and maintenance services in the United States and internationally. The company's Overnight Air Cargo segment offers air express delivery services. As of March 31, 2022, this segment had 72 aircraft under the dry-lease agreements with FedEx. Its Ground Equipment Sales segment manufactures, sells, and services aircraft deicers, scissor-type lifts, military and civilian decontamination units, flight-line tow tractors, glycol recovery vehicles, and other specialized equipment. This segment sells its products to passenger and cargo airlines, ground handling companies, the United States Air Force, airports, and industrial customers. Its Commercial Aircraft, Engines and Parts segment offers commercial aircraft trading, leasing, and parts solutions; commercial aircraft storage, storage maintenance, and aircraft disassembly/part-out services; commercial aircraft parts sales, exchanges, procurement services, consignment programs, and overhaul and repair services; and aircraft instrumentation, avionics, and a range of electrical accessories for civilian, military transport, regional/commuter and business/commercial jet, and turboprop aircraft. This segment also provides composite aircraft structures, and repair and support services. Air T, Inc. was incorporated in 1980 and is based in Denver, North Carolina.",Mr. Nicholas John Swenson,Integrated Freight & Logistics,17.09,USD,411682719,https://images.financialmodelingprep.com/symbol/AIRTP.png,4132,50.86,-0.0742,1487,5851000,-6819000,"[{'period': '2024', 'revenue': 286.83, 'unit': 'M', 'net_profit': -6.82}, {'period': '2023', 'revenue': 247.32, 'unit': 'M', 'net_profit': -11.79}, {'period': '2022', 'revenue': 177.08, 'unit': 'M', 'net_profit': 10.93}, {'period': '2021', 'revenue': 175.12, 'unit': 'M', 'net_profit': -8.39}]","[{'period': ""Q3 '25"", 'revenue': 77.88, 'unit': 'M', 'net_profit': -1.3}, {'period': ""Q2 '25"", 'revenue': 17.13, 'unit': 'M', 'net_profit': 2.52}, {'period': ""Q1 '25"", 'revenue': 66410.0, 'unit': 'K', 'net_profit': -335.0}, {'period': ""Q4 '24"", 'revenue': 72.68, 'unit': 'M', 'net_profit': -1.7}, {'period': ""Q3 '24"", 'revenue': 63.76, 'unit': 'M', 'net_profit': -2.98}, {'period': ""Q2 '24"", 'revenue': 78.97, 'unit': 'M', 'net_profit': -1.61}]",-2.42,-2.42,177167000,102877000,7100000,158371000,26004000,16653000,46841000,7100000,16102000,4.458022388059701,0.42138311412812895,0.4154589371980676,"[0.5, 0.0433]","['2025-11-14', '2019-08-23']",__nan__,0.8939080076989507
157,AIRTW,Air T Inc. Air T Funding Warrants to Purchase Alpha Income Trust Preferred Expiring 08/30/2021,,None,Integrated Freight & Logistics,0.01,USD,0,https://images.financialmodelingprep.com/symbol/AIRTW.png,0,0.022779043280182234,-0.03,459631,5851000,-6819000,"[{'period': '2024', 'revenue': 286.83, 'unit': 'M', 'net_profit': -6.82}, {'period': '2023', 'revenue': 247.32, 'unit': 'M', 'net_profit': -11.79}, {'period': '2022', 'revenue': 177.08, 'unit': 'M', 'net_profit': 10.93}, {'period': '2021', 'revenue': 175.12, 'unit': 'M', 'net_profit': -8.39}]","[{'period': ""Q3 '25"", 'revenue': 77.88, 'unit': 'M', 'net_profit': -1.3}, {'period': ""Q2 '25"", 'revenue': 17.13, 'unit': 'M', 'net_profit': 2.52}, {'period': ""Q1 '25"", 'revenue': 66410.0, 'unit': 'K', 'net_profit': -335.0}, {'period': ""Q4 '24"", 'revenue': 72.68, 'unit': 'M', 'net_profit': -1.7}, {'period': ""Q3 '24"", 'revenue': 63.76, 'unit': 'M', 'net_profit': -2.98}, {'period': ""Q2 '24"", 'revenue': 78.97, 'unit': 'M', 'net_profit': -1.61}]",-2.42,-2.42,177167000,102877000,7100000,158371000,26004000,16653000,46841000,7100000,16102000,4.458022388059701,0.42138311412812895,0.4154589371980676,__nan__,__nan__,__nan__,0.8939080076989507
158,AKAM,Akamai Technologies Inc. Common Stock,"Akamai Technologies, Inc. provides cloud services for securing, delivering, and optimizing content and business applications over the internet in the United States and internationally. The company offers cloud solutions to keep infrastructure, websites, applications, application programming interfaces, and users safe from various cyberattacks and online threats while enhancing performance. It also provides web and mobile performance solutions to enable dynamic websites and applications; media delivery solutions, including video streaming and video player services, game and software delivery, broadcast operations, authoritative domain name system, resolution, and data and analytics; and edge compute solutions to enable developers to deploy and distribute code at the edge. In addition, the company offers carrier offerings, including cybersecurity protection, parental controls, DNS infrastructure and content delivery solutions; and an array of service and support to assist customers with integrating, configuring, optimizing, and managing its offerings. It sells its solutions through direct sales and service organizations, as well as through various channel partners. Akamai Technologies, Inc. was incorporated in 1998 and is headquartered in Cambridge, Massachusetts.",Dr. F. Thomson Leighton,Software - Infrastructure,78.03,USD,11408454180,https://images.financialmodelingprep.com/symbol/AKAM.png,3060579,26.18,1.52,3368910,1262540000,504918000,"[{'period': '2024', 'revenue': 3990.0, 'unit': 'M', 'net_profit': 504.92}, {'period': '2023', 'revenue': 3810.0, 'unit': 'M', 'net_profit': 547.63}, {'period': '2022', 'revenue': 3620.0, 'unit': 'M', 'net_profit': 523.67}, {'period': '2021', 'revenue': 3460.0, 'unit': 'M', 'net_profit': 651.64}]","[{'period': ""Q1 '25"", 'revenue': 1020.0, 'unit': 'M', 'net_profit': 123.17}, {'period': ""Q4 '24"", 'revenue': 1020.0, 'unit': 'M', 'net_profit': 139.91}, {'period': ""Q3 '24"", 'revenue': 1000.0, 'unit': 'M', 'net_profit': 57.91}, {'period': ""Q2 '24"", 'revenue': 979.58, 'unit': 'M', 'net_profit': 131.69}, {'period': ""Q1 '24"", 'revenue': 986.97, 'unit': 'M', 'net_profit': 175.42}, {'period': ""Q4 '23"", 'revenue': 995.02, 'unit': 'M', 'net_profit': 161.16}]",3.34,3.27,10368785000,2578097000,1596583000,5490428000,727687000,275592000,2091323000,517707000,833904000,0.017347132823856658,-0.07799258256958634,-0.06963788300835655,__nan__,__nan__,__nan__,0.5295150781890067
159,AKBA,Akebia Therapeutics Inc. Common Stock,"Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.",Mr. John P. Butler MBA,Biotechnology,2.61,USD,685479960,https://images.financialmodelingprep.com/symbol/AKBA.png,4498459,-12.43,0.07,3533445,-13721000,-69410000,"[{'period': '2024', 'revenue': 160.18, 'unit': 'M', 'net_profit': -69.41}, {'period': '2023', 'revenue': 194.62, 'unit': 'M', 'net_profit': -51.92}, {'period': '2022', 'revenue': 292.6, 'unit': 'M', 'net_profit': -106.01}, {'period': '2021', 'revenue': 213.58, 'unit': 'M', 'net_profit': -244.87}]","[{'period': ""Q1 '25"", 'revenue': 57.34, 'unit': 'M', 'net_profit': 6.11}, {'period': ""Q4 '24"", 'revenue': 46.5, 'unit': 'M', 'net_profit': -22.8}, {'period': ""Q3 '24"", 'revenue': 37.43, 'unit': 'M', 'net_profit': -20.04}, {'period': ""Q2 '24"", 'revenue': 43.65, 'unit': 'M', 'net_profit': -8.58}, {'period': ""Q1 '24"", 'revenue': 32.61, 'unit': 'M', 'net_profit': -17.98}, {'period': ""Q4 '23"", 'revenue': 56200.0, 'unit': 'K', 'net_profit': 614.0}]",-0.33,-0.33,220670000,113831000,51870000,269855000,34368000,0,80914000,51870000,-40692000,-0.9978159580663949,-0.33673567645642755,-0.17857142857142852,__nan__,__nan__,__nan__,1.2228893823356142
160,AKIC,Sports Ventures Acquisition Corp. Class A Ordinary Shares,"Sports Ventures Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on businesses operating in the sports, media, and entertainment sectors, including traditional and emerging sports, as well as film and television production and infrastructure. The company was incorporated in 2020 and is based in Bal Harbour, Florida.",Mr. Alan  Kestenbaum,Shell Companies,10.1085,USD,0,https://images.financialmodelingprep.com/symbol/AKIC.png,81373,0,0.0085,166542,4935531,11403000,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 11.4}, {'period': '2020', 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]","[{'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.81}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 17.28}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.52}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 10.76}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 6.08}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.52}]",0.39,0.39,230.849726,0.81696,0.440475,13.632732,0,230026577,0.7712910000000001,0.440475,-1221369,0,0,0,__nan__,__nan__,__nan__,0.059054573016907114
161,AKICU,Sports Ventures Acquisition Corp. Unit,"Sports Ventures Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on businesses operating in the sports, media, and entertainment sectors, including traditional and emerging sports, as well as film and television production and infrastructure. The company was incorporated in 2020 and is based in Bal Harbour, Florida.",,Shell Companies,10.1,USD,0,https://images.financialmodelingprep.com/symbol/AKICU.png,448,0,-0.01,295,4935531,11403000,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 11.4}, {'period': '2020', 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]","[{'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.81}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 17.28}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.52}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 10.76}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 6.08}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.52}]",0.39,0.39,230.849726,0.81696,0.440475,13.632732,0,230026577,0.7712910000000001,0.440475,-1221369,0,0,0,__nan__,__nan__,__nan__,0.059054573016907114
162,AKICW,Sports Ventures Acquisition Corp. Warrant,"Sports Ventures Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on businesses operating in the sports, media, and entertainment sectors, including traditional and emerging sports, as well as film and television production and infrastructure. The company was incorporated in 2020 and is based in Bal Harbour, Florida.",Mr. Alan  Kestenbaum,Shell Companies,0.0003,USD,0,https://images.financialmodelingprep.com/symbol/AKICW.png,0,0,0,6807,4935531,11403000,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 11.4}, {'period': '2020', 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]","[{'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.81}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 17.28}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.52}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 10.76}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 6.08}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.52}]",0.39,0.39,230.849726,0.81696,0.440475,13.632732,0,230026577,0.7712910000000001,0.440475,-1221369,0,0,0,__nan__,__nan__,__nan__,0.059054573016907114
163,AKRO,Akero Therapeutics Inc. Common Stock,"Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.","Dr. Andrew  Cheng M.D., Ph.D.",Biotechnology,38.87,USD,3098623112,https://images.financialmodelingprep.com/symbol/AKRO.png,1134358,-9.82,-1.09,1275508,-285423000,-252060000,"[{'period': '2024', 'revenue': 0.0, 'unit': 'M', 'net_profit': -252.06}, {'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -151.76}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -108.91}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -100.74}]","[{'period': ""Q1 '25"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -70.72}, {'period': ""Q4 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -70.02}, {'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -72.7}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -55.99}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -53.34}, {'period': ""Q4 '23"", 'revenue': 0.28400000000000003, 'unit': 'M', 'net_profit': -55.19}]",-3.75,-3.75,825886000,770380000,743078000,75774000,0,54751000,39754000,340238000,-230107000,-0.9203463611225114,-0.6609229106675716,-0.29757785467128023,__nan__,__nan__,__nan__,0.09174874014089111
164,AKTS,Akoustis Technologies Inc. Common Stock,"Akoustis Technologies, Inc., through its subsidiary, Akoustis, Inc., develops, designs, manufactures, and sells radio frequency (RF) filter products for the mobile wireless device industry in the United States. It operates through two segments, Foundry Fabrication Services and RF Filters. The Foundry Fabrication Services segment provides engineering review services; and semiconductor wafer-manufacturing and microelectromechanical systems foundry services. The RF Filters segment consists of amplifier and filter products. It offers RF filters for mobile wireless devices, such as smartphones and tablets, cellular infrastructure equipment, Wi-Fi customer premise equipment, and military and defense applications. The company was incorporated in 2013 and is headquartered in Huntersville, North Carolina.",Mr. Kamran  Cheema,Communication Equipment,0.0372,USD,5750785,https://images.financialmodelingprep.com/symbol/AKTS.png,22564085,-0.022545454545454546,0,74784722,-152076000,-167950000,"[{'period': '2024', 'revenue': 27.38, 'unit': 'M', 'net_profit': -167.95}, {'period': '2023', 'revenue': 27.12, 'unit': 'M', 'net_profit': -63.56}, {'period': '2022', 'revenue': 15.35, 'unit': 'M', 'net_profit': -59.19}, {'period': '2021', 'revenue': 6.62, 'unit': 'M', 'net_profit': -46.92}]","[{'period': ""Q1 '25"", 'revenue': 9.03, 'unit': 'M', 'net_profit': -6.42}, {'period': ""Q4 '24"", 'revenue': 5.86, 'unit': 'M', 'net_profit': -108.8}, {'period': ""Q3 '24"", 'revenue': 7.51, 'unit': 'M', 'net_profit': -23.31}, {'period': ""Q2 '24"", 'revenue': 7.02, 'unit': 'M', 'net_profit': -15.71}, {'period': ""Q1 '24"", 'revenue': 7.0, 'unit': 'M', 'net_profit': -20.13}, {'period': ""Q4 '23"", 'revenue': 8.33, 'unit': 'M', 'net_profit': -17.77}]",-1.89,-1.89,69741000,36769000,24447000,126835000,5295000,0,84369000,24447000,-46338000,-1.922739852398524,-1.6425098730273613,-0.8899999999999999,__nan__,__nan__,__nan__,1.8186576045654637
165,AKTX,Akari Therapeutics plc ADR (0.01 USD),"Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barr syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.",Mr. Abizer  Gaslightwala,Biotechnology,1.27,USD,18336,https://images.financialmodelingprep.com/symbol/AKTX.png,28212,-0.49,-0.05,4473,-21643000,-19791000,"[{'period': '2024', 'revenue': 0.0, 'unit': 'M', 'net_profit': -19.79}, {'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -10.01}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -6.97}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -17.61}]","[{'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.77}, {'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.9}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -7.56}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.57}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.5}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.5}]",-1.6,-1.6,50562000,2952000,2599000,28333000,0,0,19910000,2599000,-12552000,-0.2881204618497798,-0.9775179856115108,0.19999999999999998,__nan__,__nan__,__nan__,0.5603615363316324
166,AKU,Akumin Inc. Common Shares,"Akumin Inc. provides outpatient diagnostic imaging services in the United States. It operates in two segments, Radiology and Oncology. The company offers various medical imaging services, including magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, digital radiography, fluoroscopy, and other diagnostic or interventional radiology procedures through a network of approximately 200 owned and/or operated imaging locations. It provides outpatient radiology, and oncology services and solutions to approximately 1,000 hospitals and health systems across 46 states. Akumin Inc. was founded in 2015 and is headquartered in Plantation, Florida.",Mr. Riadh  Zine-El-Abidine,Medical - Diagnostics & Research,0.2887,USD,26271266,https://images.financialmodelingprep.com/symbol/AKU.png,3626464,-0.13182648401826483,-0.0628,7893176,139864000,-151587000,"[{'period': '2022', 'revenue': 749.63, 'unit': 'M', 'net_profit': -151.59}, {'period': '2021', 'revenue': 421.08, 'unit': 'M', 'net_profit': -34.81}, {'period': '2020', 'revenue': 251.28, 'unit': 'M', 'net_profit': -17.67}, {'period': '2019', 'revenue': 247.44, 'unit': 'M', 'net_profit': 8.65}]","[{'period': ""Q2 '23"", 'revenue': 184.84, 'unit': 'M', 'net_profit': -96.65}, {'period': ""Q1 '23"", 'revenue': 187.59, 'unit': 'M', 'net_profit': -29.19}, {'period': ""Q4 '22"", 'revenue': 184.63, 'unit': 'M', 'net_profit': -49.33}, {'period': ""Q3 '22"", 'revenue': 186.6, 'unit': 'M', 'net_profit': -49.74}, {'period': ""Q2 '22"", 'revenue': 192.13, 'unit': 'M', 'net_profit': -26.08}, {'period': ""Q1 '22"", 'revenue': 186.26, 'unit': 'M', 'net_profit': -26.43}]",-1.69,-1.69,1765115000,191945000,59424000,1623824000,114166000,0,168518000,59424000,20605000,1.3355041245032229,-3.3541965875797093,-2.7555555555555555,__nan__,__nan__,__nan__,0.9199536574104237
167,AKUS,Akouos Inc. Common Stock,"Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.","Dr. Emmanuel  Simons M.B.A., Ph.D.",Biotechnology,13.29,USD,0,https://images.financialmodelingprep.com/symbol/AKUS.png,725973,-4.692796610169491,0,1790496,-82924000,-86671000,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -86.67}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -48.6}, {'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': -25.74}, {'period': '2018', 'revenue': 0.0, 'unit': 'M', 'net_profit': -6.01}]","[{'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -20.36}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -20.83}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -27.24}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -24.94}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -22.91}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -22.74}]",-4.94,-4.94,278755000,236163000,232452000,45105000,0,0,16801000,121907000,-72752000,-0.696481178396072,-0.7833539094650206,-0.7833935018050543,__nan__,__nan__,__nan__,0.16180875679360013
168,AKYA,Akoya BioSciences Inc. Common Stock,"Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.",Mr. Brian  McKelligon,Medical - Instruments & Supplies,1.03,USD,51371662,https://images.financialmodelingprep.com/symbol/AKYA.png,231995,-0.87,0.0301,218780,-37136000,-55365000,"[{'period': '2024', 'revenue': 81.67, 'unit': 'M', 'net_profit': -55.37}, {'period': '2023', 'revenue': 96.63, 'unit': 'M', 'net_profit': -63.32}, {'period': '2022', 'revenue': 74.86, 'unit': 'M', 'net_profit': -70.64}, {'period': '2021', 'revenue': 54.92, 'unit': 'M', 'net_profit': -42.94}]","[{'period': ""Q1 '25"", 'revenue': 16.64, 'unit': 'M', 'net_profit': -15.65}, {'period': ""Q4 '24"", 'revenue': 21.34, 'unit': 'M', 'net_profit': -8.2}, {'period': ""Q3 '24"", 'revenue': 18.81, 'unit': 'M', 'net_profit': -10.53}, {'period': ""Q2 '24"", 'revenue': 23.16, 'unit': 'M', 'net_profit': -13.15}, {'period': ""Q1 '24"", 'revenue': 18.35, 'unit': 'M', 'net_profit': -23.48}, {'period': ""Q4 '23"", 'revenue': 26.49, 'unit': 'M', 'net_profit': -10.8}]",-1.12,-1.12,125005000,76732000,35040000,117410000,13779000,0,29444000,11779000,-46559000,0.18618513323983168,0.12567313614326547,0.2167832167832167,__nan__,__nan__,__nan__,0.9392424303027879
169,ALAC,Alberton Acquisition Corporation Ordinary Shares,"Alberton Acquisition Corporation does not have significant operations. It focuses on the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more target businesses. The company was formerly known as Wisdom Resources Group Limited and changed its name to Alberton Acquisition Corporation in July 2018. Alberton Acquisition Corporation was founded in 2005 and is based in Wan Chai, Hong Kong.",Ms. Guan  Wang,Shell Companies,12.02,USD,0,https://images.financialmodelingprep.com/symbol/ALAC.png,0,-24.136546184738958,0.01000023,77891,-615039,-502026,"[{'period': '2021', 'revenue': 0.0, 'unit': 'K', 'net_profit': -502.03}, {'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': 14.56}, {'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.09}, {'period': '2018', 'revenue': 0.0, 'unit': 'K', 'net_profit': 341.71}]","[{'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -175.36}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -152.59}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -111.08}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -170.16}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -149.84}, {'period': ""Q3 '20"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]",-0.12,-0.12,14870460,1276,1276,9831761,0,0,5399926,1276,-115916,-43.23588792748249,-35.47507210548002,-36.294117647058826,__nan__,__nan__,__nan__,0.661160515545585
170,ALACR,Alberton Acquisition Corporation Rights exp April 26 2021,,None,,0.035,USD,0,https://images.financialmodelingprep.com/symbol/ALACR.png,0,0,-0.035,5158411,-615039,-502026,"[{'period': '2021', 'revenue': 0.0, 'unit': 'K', 'net_profit': -502.03}, {'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': 14.56}, {'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.09}, {'period': '2018', 'revenue': 0.0, 'unit': 'K', 'net_profit': 341.71}]","[{'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -175.36}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -152.59}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -111.08}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -170.16}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -149.84}, {'period': ""Q3 '20"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]",-0.12,-0.12,14870460,1276,1276,9831761,0,0,5399926,1276,-115916,-43.23588792748249,-35.47507210548002,-36.294117647058826,"[0.285, 0.285]","['2022-03-15', '2022-03-15']",__nan__,0.661160515545585
171,ALACU,Alberton Acquisition Corporation Unit,"Alberton Acquisition Corporation does not have significant operations. It focuses on the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more target businesses. The company was formerly known as Wisdom Resources Group Limited and changed its name to Alberton Acquisition Corporation in July 2018. Alberton Acquisition Corporation was founded in 2005 and is based in Wan Chai, Hong Kong.",Ms. Guan Wang,Shell Companies,11.8,USD,0,https://images.financialmodelingprep.com/symbol/ALACU.png,0,-23.694779116465863,0,0,-615039,-502026,"[{'period': '2021', 'revenue': 0.0, 'unit': 'K', 'net_profit': -502.03}, {'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': 14.56}, {'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.09}, {'period': '2018', 'revenue': 0.0, 'unit': 'K', 'net_profit': 341.71}]","[{'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -175.36}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -152.59}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -111.08}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -170.16}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -149.84}, {'period': ""Q3 '20"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]",-0.12,-0.12,14870460,1276,1276,9831761,0,0,5399926,1276,-115916,-43.23588792748249,-35.47507210548002,-36.294117647058826,__nan__,__nan__,__nan__,0.661160515545585
172,ALACW,Alberton Acquisition Corporation Warrant,"Alberton Acquisition Corporation does not have significant operations. It focuses on the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more target businesses. The company was formerly known as Wisdom Resources Group Limited and changed its name to Alberton Acquisition Corporation in July 2018. Alberton Acquisition Corporation was founded in 2005 and is based in Wan Chai, Hong Kong.",Ms. Guan Wang,Shell Companies,0.01,USD,0,https://images.financialmodelingprep.com/symbol/ALACW.png,0,-0.020080321285140562,-0.0125,3069456,-615039,-502026,"[{'period': '2021', 'revenue': 0.0, 'unit': 'K', 'net_profit': -502.03}, {'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': 14.56}, {'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.09}, {'period': '2018', 'revenue': 0.0, 'unit': 'K', 'net_profit': 341.71}]","[{'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -175.36}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -152.59}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -111.08}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -170.16}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -149.84}, {'period': ""Q3 '20"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]",-0.12,-0.12,14870460,1276,1276,9831761,0,0,5399926,1276,-115916,-43.23588792748249,-35.47507210548002,-36.294117647058826,__nan__,__nan__,__nan__,0.661160515545585
173,ALBO,Albireo Pharma Inc. Common Stock,"Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.",Mr. Ronald H. W. Cooper,Biotechnology,44.15,USD,915887335,https://images.financialmodelingprep.com/symbol/ALBO.png,566901,-6.629129129129129,0,1236106,-122129000,-151349000,"[{'period': '2021', 'revenue': 40.58, 'unit': 'M', 'net_profit': -151.35}, {'period': '2020', 'revenue': 8.31, 'unit': 'M', 'net_profit': -119.0}, {'period': '2019', 'revenue': 9.64, 'unit': 'M', 'net_profit': -71.7}, {'period': '2018', 'revenue': 12.74, 'unit': 'M', 'net_profit': -46.11}]","[{'period': ""Q3 '22"", 'revenue': 9.83, 'unit': 'M', 'net_profit': -38.41}, {'period': ""Q2 '22"", 'revenue': 8.21, 'unit': 'M', 'net_profit': -42.7}, {'period': ""Q1 '22"", 'revenue': 6.83, 'unit': 'M', 'net_profit': -45.31}, {'period': ""Q4 '21"", 'revenue': 32.52, 'unit': 'M', 'net_profit': -10.96}, {'period': ""Q3 '21"", 'revenue': 3.66, 'unit': 'M', 'net_profit': 57.09}, {'period': ""Q2 '21"", 'revenue': 2.43, 'unit': 'M', 'net_profit': -36.42}]",-7.87,-7.87,302051000,268930000,248107000,126443000,3272000,0,45347000,248107000,-108024000,0,-0.2718937770494559,-0.05637583892617449,__nan__,__nan__,__nan__,0.41861473724635906
174,ALCO,Alico Inc. Common Stock,"Alico, Inc., together with its subsidiaries, operates as an agribusiness and land management company in the United States. The company operates in two segments, Alico Citrus, and Land Management and Other Operations. The Alico Citrus segment cultivates citrus trees to produce citrus for delivery to the processed and fresh citrus markets. The Land Management and Other Operations segment owns and manages land in Collier, Glades, and Hendry Counties; and leasing of land for recreational and grazing purposes, conservation, and mining activities. As of September 30, 2021, it had 83,000 acres of land situated in eight counties in Florida, which include the Charlotte, Collier, DeSoto, Glades, Hardee, Hendry, Highlands, and Polk. The company was founded in 1960 and is headquartered in Fort Myers, Florida.",Mr. John E. Kiernan Esq.,Agricultural Farm Products,31.11,USD,237745420,https://images.financialmodelingprep.com/symbol/ALCO.png,45561,-5.25,0.26,42348,29500000,6973000,"[{'period': '2024', 'revenue': 46.64, 'unit': 'M', 'net_profit': 6.97}, {'period': '2023', 'revenue': 39.85, 'unit': 'M', 'net_profit': 1.83}, {'period': '2022', 'revenue': 91.95, 'unit': 'M', 'net_profit': 12.46}, {'period': '2021', 'revenue': 108.56, 'unit': 'M', 'net_profit': 34.86}]","[{'period': ""Q2 '25"", 'revenue': 17.98, 'unit': 'M', 'net_profit': -111.39}, {'period': ""Q1 '25"", 'revenue': 16.89, 'unit': 'M', 'net_profit': -9.17}, {'period': ""Q4 '24"", 'revenue': 0.935, 'unit': 'M', 'net_profit': -18.12}, {'period': ""Q3 '24"", 'revenue': 13.61, 'unit': 'M', 'net_profit': -2.04}, {'period': ""Q2 '24"", 'revenue': 18.11, 'unit': 'M', 'net_profit': -15.8}, {'period': ""Q1 '24"", 'revenue': 13.98, 'unit': 'M', 'net_profit': 42.95}]",0.91,0.91,398719000,40627000,3150000,142424000,771000,0,10651000,3150000,-48368000,0.29063306645666537,2.8,2.791666666666667,"[0.05, 1.2]","['2025-03-28', '1982-10-29']",__nan__,0.35720394563589897
175,ALDX,Aldeyra Therapeutics Inc. Common Stock,"Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.","Dr. Todd C. Brady M.D., Ph.D.",Biotechnology,2.16,USD,129374496,https://images.financialmodelingprep.com/symbol/ALDX.png,1794011,-2.3,0.01,808741,-60117032,-55851444,"[{'period': '2024', 'revenue': 0.0, 'unit': 'M', 'net_profit': -55.85}, {'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -37.54}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -61.37}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -59.25}]","[{'period': ""Q1 '25"", 'revenue': 0.0, 'unit': 'T', 'net_profit': -9.93}, {'period': ""Q4 '24"", 'revenue': 0.24453, 'unit': 'M', 'net_profit': -15.81}, {'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -15.11}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -16.85}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.08}, {'period': ""Q4 '23"", 'revenue': 0.39262, 'unit': 'M', 'net_profit': -4.75}]",-0.94,-0.94,104606694,101860515,101151272,33601823,0,0,18601823,54527092,-43208747,-0.7074678566513942,-0.4876853998307519,-0.4687499999999999,__nan__,__nan__,__nan__,0.3212205807785112
176,ALEC,Alector Inc. Common Stock,"Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.",Dr. Arnon  Rosenthal Ph.D.,Biotechnology,1.22,USD,121990972,https://images.financialmodelingprep.com/symbol/ALEC.png,857111,-0.97,0.115,1794524,-136156000,-119049000,"[{'period': '2024', 'revenue': 100.56, 'unit': 'M', 'net_profit': -119.05}, {'period': '2023', 'revenue': 97.06, 'unit': 'M', 'net_profit': -130.39}, {'period': '2022', 'revenue': 133.62, 'unit': 'M', 'net_profit': -133.31}, {'period': '2021', 'revenue': 207.09, 'unit': 'M', 'net_profit': -28.01}]","[{'period': ""Q1 '25"", 'revenue': 3.67, 'unit': 'M', 'net_profit': -40.47}, {'period': ""Q4 '24"", 'revenue': 54.24, 'unit': 'M', 'net_profit': -2.07}, {'period': ""Q3 '24"", 'revenue': 15.34, 'unit': 'M', 'net_profit': -42.22}, {'period': ""Q2 '24"", 'revenue': 15.08, 'unit': 'M', 'net_profit': -38.68}, {'period': ""Q1 '24"", 'revenue': 15.89, 'unit': 'M', 'net_profit': -36.08}, {'period': ""Q4 '23"", 'revenue': 15.19, 'unit': 'M', 'net_profit': -41.43}]",-1.23,-1.23,468303000,424817000,413397000,341503000,0,0,125059000,33021000,-231160000,0.04714049771855667,0.08698453114095298,0.21153846153846156,__nan__,__nan__,__nan__,0.7292351319551658
177,ALF,ALFI Inc. Common Stock,"Centurion Acquisition Corp. operates as a blank check company. The Company aims to acquire one and more businesses and assets, via a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization.",Mr. Mark  Gerhard,Shell Companies,10.43,USD,374470345,https://images.financialmodelingprep.com/symbol/ALF.png,120866,31.61,-0.06,224553,-467492,5573892,"[{'period': '2024', 'revenue': 0.0, 'unit': 'M', 'net_profit': 5.57}, {'period': '2021', 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.56}, {'period': '2019', 'revenue': 0.0, 'unit': 'K', 'net_profit': 66.73}]","[{'period': ""Q1 '25"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.32}, {'period': ""Q4 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.22}, {'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 4.05}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 612.18}, {'period': ""Q2 '22"", 'revenue': 0.12930000000000003, 'unit': 'M', 'net_profit': -11.1}, {'period': ""Q1 '22"", 'revenue': 0.0633, 'unit': 'T', 'net_profit': -5.29}]",0.33,0.33,296657187,798845,665430,13812496,0,0,124996,665430,-165249,0,0,0,"[0.015, 0.015]","['2019-12-19', '2019-12-19']",__nan__,0.046560463070796934
178,ALFIW,ALFI Inc. Warrant,"Alfi, Inc. provides interactive intelligent artificial intelligence and machine learning software solutions. Alfi, Inc. was formerly known as Lectrefy, Inc. and changed its name to Alfi, Inc. in January 2020. The company was founded in 2018 and is based in Miami Beach, Florida.",Dr. Paul Antonio Pereira,Software - Infrastructure,0.22,USD,0,https://images.financialmodelingprep.com/symbol/ALFIW.png,0,0,0.11,500,-428391000000,0,"[{'period': '2021', 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.56}, {'period': '2019', 'revenue': 0.0, 'unit': 'K', 'net_profit': 66.73}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 4.05}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 612.18}, {'period': ""Q2 '22"", 'revenue': 0.12930000000000003, 'unit': 'M', 'net_profit': -11.1}, {'period': ""Q1 '22"", 'revenue': 0.0633, 'unit': 'T', 'net_profit': -5.29}, {'period': ""Q4 '21"", 'revenue': -0.01839, 'unit': 'M', 'net_profit': 7.87}, {'period': ""Q3 '21"", 'revenue': 0.000112, 'unit': 'M', 'net_profit': -5.08}]",0,0,11373005,5323564,4391816,2362757,5578,0,2362757,4391816,-20566553,-143436.64031418995,1,1,__nan__,__nan__,__nan__,0.20775133748732194
179,ALGM,Allegro MicroSystems Inc. Common Stock,"Allegro MicroSystems, Inc. designs, develops, manufactures, and markets sensor integrated circuits (ICs) and application-specific analog power ICs for motion control and energy-efficient systems. Its products include magnetic sensor ICs, such as position, speed, and current sensor ICs; power ICs comprising motor driver ICs, and regulator and LED driver ICs; and photonic and 3D sensing components, including photodiodes, eye-safe lasers, and readout ICs for LiDAR applications. The company sells its products to original equipment manufacturers and suppliers primarily in the automotive and industrial markets through its direct sales force, third party distributors, independent sales representatives, and consignment. It operates in the United States, rest of the Americas, Europe, Japan, Greater China, South Korea, and other Asian markets. The company was founded in 1990 and is headquartered in Manchester, New Hampshire. Allegro MicroSystems, Inc. is a subsidiary of Sanken Electric Co., Ltd.",Mr. Michael C. Doogue,Semiconductors,27.51,USD,5065278750,https://images.financialmodelingprep.com/symbol/ALGM.png,3823200,-70.54,0.49,2174107,276942000,152697000,"[{'period': '2024', 'revenue': 1050.0, 'unit': 'M', 'net_profit': 152.7}, {'period': '2023', 'revenue': 973.65, 'unit': 'M', 'net_profit': 187.36}, {'period': '2022', 'revenue': 768.67, 'unit': 'M', 'net_profit': 119.41}, {'period': '2021', 'revenue': 591.21, 'unit': 'M', 'net_profit': 17.95}]","[{'period': ""Q4 '25"", 'revenue': 192.82, 'unit': 'M', 'net_profit': -14.8}, {'period': ""Q3 '25"", 'revenue': 177.87, 'unit': 'M', 'net_profit': -6.86}, {'period': ""Q2 '25"", 'revenue': 187.39, 'unit': 'M', 'net_profit': -33.67}, {'period': ""Q1 '25"", 'revenue': 166.92, 'unit': 'M', 'net_profit': -17.68}, {'period': ""Q4 '24"", 'revenue': 240.58, 'unit': 'M', 'net_profit': -7.12}, {'period': ""Q3 '24"", 'revenue': 254.98, 'unit': 'M', 'net_profit': 33.34}]",0.79,0.78,1530603000,572213000,212143000,398887000,125168000,26727000,117908000,212143000,56943000,0.04707928466104579,-0.18499442241282685,-0.1938775510204081,__nan__,__nan__,__nan__,0.2606077474041277
180,ALGN,Align Technology Inc. Common Stock,"Align Technology, Inc., a medical device company, designs, manufactures, and markets Invisalign clear aligners and iTero intraoral scanners and services for orthodontists and general practitioner dentists, and restorative and aesthetic dentistry. It operates in two segments, Clear Aligner; and Scanners and Services. The Clear Aligner segment consists of comprehensive products, including Invisalign comprehensive treatment that addresses the orthodontic needs of teenage patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of seven and ten years, which is a mixture of primary/baby and permanent teeth. This segment's non-comprehensive products comprise Invisalign moderate, lite and express packages, and Invisalign go; and non-case products include retention products, Invisalign training fees, and sales of ancillary products, such as cleaning material, and adjusting tools used by dental professionals during the course of treatment. The Scanners and Services segment offers iTero scanner, a single hardware platform with software options for restorative or orthodontic procedures; restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons; and software for orthodontists for digital records storage, orthodontic diagnosis, and for the fabrication of printed models and retainers. This segment also provides computer-aided design and computer-aided manufacturing services; ancillary products, such as disposable sleeves for the wand; iTero model and dies; third party scanners and digital scans; Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner; Invisalign progress assessment tool; and TimeLapse technology, which allows doctors or practitioners to compare a patient's historic 3D scans to the present-day scan. The company sells its products in the United States, Switzerland, China, and internationally. Align Technology, Inc. was incorporated in 1997 and is headquartered in Tempe, Arizona.",Mr. Joseph M. Hogan,Medical - Devices,188.29,USD,13648162992,https://images.financialmodelingprep.com/symbol/ALGN.png,1291904,34.17,1.57,684640,816798000,421362000,"[{'period': '2024', 'revenue': 4000.0, 'unit': 'M', 'net_profit': 421.36}, {'period': '2023', 'revenue': 3860.0, 'unit': 'M', 'net_profit': 445.05}, {'period': '2022', 'revenue': 3730.0, 'unit': 'M', 'net_profit': 361.57}, {'period': '2021', 'revenue': 3950.0, 'unit': 'M', 'net_profit': 772.02}]","[{'period': ""Q1 '25"", 'revenue': 979.26, 'unit': 'M', 'net_profit': 93.23}, {'period': ""Q4 '24"", 'revenue': 995.22, 'unit': 'M', 'net_profit': 103.81}, {'period': ""Q3 '24"", 'revenue': 977.87, 'unit': 'M', 'net_profit': 115.96}, {'period': ""Q2 '24"", 'revenue': 1030.0, 'unit': 'M', 'net_profit': 96.56}, {'period': ""Q1 '24"", 'revenue': 997.43, 'unit': 'M', 'net_profit': 105.03}, {'period': ""Q4 '23"", 'revenue': 956.73, 'unit': 'M', 'net_profit': 124.01}]",5.63,5.62,6214600000,2492441000,1043887000,2362615000,1029713000,0,2038027000,1043887000,622651000,0.02222544831979415,-0.053231862272583266,-0.0326460481099657,__nan__,__nan__,__nan__,0.38017169246612814
181,ALGS,Aligos Therapeutics Inc. Common Stock,"Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR- agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.","Dr. Lawrence M. Blatt MBA, Ph.D.",Biotechnology,5.84,USD,35710432,https://images.financialmodelingprep.com/symbol/ALGS.png,177235,-0.33,0.04,155913,-89154000,-131211000,"[{'period': '2024', 'revenue': 3.94, 'unit': 'M', 'net_profit': -131.21}, {'period': '2023', 'revenue': 15.53, 'unit': 'M', 'net_profit': -87.68}, {'period': '2022', 'revenue': 13.91, 'unit': 'M', 'net_profit': -96.05}, {'period': '2021', 'revenue': 4.36, 'unit': 'M', 'net_profit': -128.33}]","[{'period': ""Q1 '25"", 'revenue': 0.311, 'unit': 'M', 'net_profit': 43.09}, {'period': ""Q4 '24"", 'revenue': 0.629, 'unit': 'M', 'net_profit': -82.15}, {'period': ""Q3 '24"", 'revenue': 1.27, 'unit': 'M', 'net_profit': -19.26}, {'period': ""Q2 '24"", 'revenue': 1.06, 'unit': 'M', 'net_profit': 5.06}, {'period': ""Q1 '24"", 'revenue': 0.986, 'unit': 'M', 'net_profit': -34.86}, {'period': ""Q4 '23"", 'revenue': 2.68, 'unit': 'M', 'net_profit': -27.89}]",-20.94,-20.94,70094000,62141000,56939000,99067000,0,0,21737000,36997000,-80873000,-0.04815537633144443,-0.4964928888331299,-4.948863636363637,__nan__,__nan__,__nan__,1.4133449367991555
182,ALGT,Allegiant Travel Company Common Stock,"Allegiant Travel Company, a leisure travel company, provides travel services and products to residents of under-served cities in the United States. The company offers scheduled air transportation on limited-frequency, nonstop flights between under-served cities and leisure destinations. As of February 14, 2022, it operated a fleet of 110 Airbus A320 series aircraft. The company also provides air-related services and products in conjunction with air transportation, including baggage fees, advance seat assignments, travel protection products, priority boarding, a customer convenience fee, food and beverage purchases on board, and other air-related services, as well as use of its call center for purchases. In addition, it offers third party travel products, such as hotel rooms and ground transportation, such as rental cars and hotel shuttle products; and air transportation services through fixed fee agreements and charter service on a year-round and ad-hoc basis. Further, the company operates a golf course. Allegiant Travel Company was founded in 1997 and is based in Las Vegas, Nevada.",Mr. Gregory Clark Anderson CPA,"Airlines, Airports & Air Services",56.13,USD,1024636311,https://images.financialmodelingprep.com/symbol/ALGT.png,575715.4,-4.8,0.87,353256,60859000,-240238000,"[{'period': '2024', 'revenue': 2510.0, 'unit': 'M', 'net_profit': -240.24}, {'period': '2023', 'revenue': 2510.0, 'unit': 'M', 'net_profit': 117.6}, {'period': '2022', 'revenue': 2300.0, 'unit': 'M', 'net_profit': 2.49}, {'period': '2021', 'revenue': 1710.0, 'unit': 'M', 'net_profit': 151.85}]","[{'period': ""Q1 '25"", 'revenue': 699.07, 'unit': 'M', 'net_profit': 32.1}, {'period': ""Q4 '24"", 'revenue': 627.71, 'unit': 'M', 'net_profit': -216.23}, {'period': ""Q3 '24"", 'revenue': 562.2, 'unit': 'M', 'net_profit': -36.79}, {'period': ""Q2 '24"", 'revenue': 666.28, 'unit': 'M', 'net_profit': 13.7}, {'period': ""Q1 '24"", 'revenue': 656.41, 'unit': 'M', 'net_profit': -1.27}, {'period': ""Q4 '23"", 'revenue': 611.0, 'unit': 'M', 'net_profit': -2.3}]",-13.49,-13.49,4429853000,991605000,781126000,3340461000,90407000,51725000,1277404000,285892000,38302000,-0.875857496914745,-3.042909622776285,-3.134493670886076,"[0.6, 0.75]","['2024-05-14', '2010-05-12']",__nan__,0.7540794243059533
183,ALHC,Alignment Healthcare Inc. Common Stock,"Alignment Healthcare, Inc., a tech-enabled Medicare advantage company, operates consumer-centric health care platform. It provides customized health care in the United States to seniors and those who need it through its Medicare advantage plans. The company owns Medicare advantage plans in the states of California, North Carolina, and Nevada. It also coordinates and provides covered health care services, including professional, institutional, and ancillary services to members enrolled in certain benefit plans of unaffiliated Medicare Advantage Health Maintenance Organizations. The company was founded in 2013 and is based in Orange, California.",Mr. John E. Kao,Medical - Healthcare Plans,15.78,USD,3121962540,https://images.financialmodelingprep.com/symbol/ALHC.png,3215775,-33.57,0.88,2568814,-77595000,-128035000,"[{'period': '2024', 'revenue': 2700.0, 'unit': 'M', 'net_profit': -128.03}, {'period': '2023', 'revenue': 1820.0, 'unit': 'M', 'net_profit': -148.02}, {'period': '2022', 'revenue': 1430.0, 'unit': 'M', 'net_profit': -149.64}, {'period': '2021', 'revenue': 1170.0, 'unit': 'M', 'net_profit': -212.96}]","[{'period': ""Q1 '25"", 'revenue': 926.93, 'unit': 'M', 'net_profit': -9.11}, {'period': ""Q4 '24"", 'revenue': 701.24, 'unit': 'M', 'net_profit': -31.09}, {'period': ""Q3 '24"", 'revenue': 692.43, 'unit': 'M', 'net_profit': -26.41}, {'period': ""Q2 '24"", 'revenue': 681.29, 'unit': 'M', 'net_profit': -24.01}, {'period': ""Q1 '24"", 'revenue': 628.6, 'unit': 'M', 'net_profit': -46.52}, {'period': ""Q4 '23"", 'revenue': 465.39, 'unit': 'M', 'net_profit': -47.21}]",-0.67,-0.67,782063000,661638000,470650000,681108000,153904000,0,351845000,432859000,-6648000,0.2630774198450084,0.13499800698568407,0.15189873417721517,__nan__,__nan__,__nan__,0.8709119342047891
184,ALIM,Alimera Sciences Inc. Common Stock,"Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.",Mr. Richard S. Eiswirth Jr.,Drug Manufacturers - Specialty & Generic,5.54,USD,301288468,https://images.financialmodelingprep.com/symbol/ALIM.png,866825,5.276190476190476,-0.01,2677974,7276000,-20132000,"[{'period': '2023', 'revenue': 80.75, 'unit': 'M', 'net_profit': -20.13}, {'period': '2022', 'revenue': 54.13, 'unit': 'M', 'net_profit': -18.11}, {'period': '2021', 'revenue': 59.03, 'unit': 'M', 'net_profit': -4.37}, {'period': '2020', 'revenue': 50.82, 'unit': 'M', 'net_profit': -5.34}]","[{'period': ""Q2 '24"", 'revenue': 27.0, 'unit': 'M', 'net_profit': -3.31}, {'period': ""Q1 '24"", 'revenue': 23.01, 'unit': 'M', 'net_profit': -6.25}, {'period': ""Q4 '23"", 'revenue': 26.31, 'unit': 'M', 'net_profit': -3.78}, {'period': ""Q3 '23"", 'revenue': 23.36, 'unit': 'M', 'net_profit': -1.35}, {'period': ""Q2 '23"", 'revenue': 17.54, 'unit': 'M', 'net_profit': -10.03}, {'period': ""Q1 '23"", 'revenue': 13.55, 'unit': 'M', 'net_profit': -8.3}]",-0.79,-0.79,153524000,52423000,12090000,107354000,34545000,0,21913000,12090000,-89793000,1.8144168345645848,-0.11183520185563595,0.6949806949806949,__nan__,__nan__,__nan__,0.699265261457492
185,ALJJ,ALJ Regional Holdings Inc. Common Stock,"ALJ Regional Holdings, Inc. provides call center, back-office, staffing, and toll collection services to government and commercial clients in the healthcare, utility, toll, transportation, and toll revenue collection industries in the United States. It operates through two segments, Faneuil and Phoenix. The Faneuil segment offers customer contact centers, fulfillment operations, and information technology services, as well as manual and electronic toll collection, violation processing, and medical device tracking services. This segment also provides customer relationship management; billing, payment, and claims processing; data entry; document management; operational expertise; workforce and support analytics; quality assurance; staffing; and system support and maintenance services. The Phoenix segment manufactures book components; educational materials and related products; heavily illustrated books; and specialty commercial products. This segment also provides label, printing, and packaging solutions. The company was formerly known as YouthStream Media Networks, Inc. and changed its name to ALJ Regional Holdings, Inc. in October 2006. ALJ Regional Holdings, Inc. was incorporated in 1999 and is based in New York, New York.",Mr. Jess Marshall Ravich J.D.,Specialty Business Services,1.92,USD,0,https://images.financialmodelingprep.com/symbol/ALJJ.png,28910,1.0607734806629834,0,184093,8920000,-3580000,"[{'period': '2021', 'revenue': 440.85, 'unit': 'M', 'net_profit': -3.58}, {'period': '2020', 'revenue': 389.15, 'unit': 'M', 'net_profit': -67.67}, {'period': '2019', 'revenue': 355.0, 'unit': 'M', 'net_profit': -15.98}, {'period': '2018', 'revenue': 369.78, 'unit': 'M', 'net_profit': -7.33}]","[{'period': ""Q3 '22"", 'revenue': 57.62, 'unit': 'M', 'net_profit': 105.87}, {'period': ""Q2 '22"", 'revenue': 68.51, 'unit': 'M', 'net_profit': -8.48}, {'period': ""Q1 '22"", 'revenue': 103.08, 'unit': 'M', 'net_profit': -9.39}, {'period': ""Q4 '21"", 'revenue': 111.67, 'unit': 'M', 'net_profit': 1.06}, {'period': ""Q3 '21"", 'revenue': 103.46, 'unit': 'M', 'net_profit': -3.5}, {'period': ""Q2 '21"", 'revenue': 114590.0, 'unit': 'K', 'net_profit': -115.0}]",-0.0846,-0.0846,214653000,89396000,2276000,202077000,68572000,0,58928000,2276000,3574000,20.349240780911064,0.9470993291367438,0.947125,__nan__,__nan__,__nan__,0.9414124191136393
186,ALKS,Alkermes plc Ordinary Shares,"Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.",Mr. Richard F. Pops,Biotechnology,31.42,USD,5181189420,https://images.financialmodelingprep.com/symbol/ALKS.png,1771787,14.28,0.21,957411,494861000,367070000,"[{'period': '2024', 'revenue': 1560.0, 'unit': 'M', 'net_profit': 367.07}, {'period': '2023', 'revenue': 1660.0, 'unit': 'M', 'net_profit': 355.76}, {'period': '2022', 'revenue': 1110.0, 'unit': 'M', 'net_profit': -158.27}, {'period': '2021', 'revenue': 1170.0, 'unit': 'M', 'net_profit': -48.17}]","[{'period': ""Q1 '25"", 'revenue': 306.51, 'unit': 'M', 'net_profit': 22.46}, {'period': ""Q4 '24"", 'revenue': 429.99, 'unit': 'M', 'net_profit': 146.5}, {'period': ""Q3 '24"", 'revenue': 378.14, 'unit': 'M', 'net_profit': 92.38}, {'period': ""Q2 '24"", 'revenue': 399.13, 'unit': 'M', 'net_profit': 91.36}, {'period': ""Q1 '24"", 'revenue': 350.37, 'unit': 'M', 'net_profit': 36.83}, {'period': ""Q4 '23"", 'revenue': 377.48, 'unit': 'M', 'net_profit': 112.78}]",2.22,2.17,2055567000,1415355000,751668000,590590000,389518000,73148000,465199000,291146000,405640000,-0.04738795483158093,0.031799795928119476,0.03738317757009349,__nan__,__nan__,__nan__,0.28731245442255104
187,ALKT,Alkami Technology Inc. Common Stock,"Alkami Technology, Inc. offers a cloud-based digital banking platform in the United States. The company's platform allows financial institutions to onboard and engage new users, accelerate revenues, and enhance operational efficiency, with the support of a proprietary, cloud-based, multi-tenant architecture. It offers an end- to- end set of software products, which include Alkami Platform, Retail Banking Solutions, Business Banking Solutions, and The Alkami Difference. It serves community, regional, credit unions, and retail and business banking. Alkami Technology, Inc. was founded in 2009 and is headquartered in Plano, Texas.",Mr. Alex P. Shootman,Software - Application,30.89,USD,3182287800,https://images.financialmodelingprep.com/symbol/ALKT.png,1468700,-83.49,0.4,763807,-29558000,-40835000,"[{'period': '2024', 'revenue': 333.85, 'unit': 'M', 'net_profit': -40.84}, {'period': '2023', 'revenue': 264.83, 'unit': 'M', 'net_profit': -62.91}, {'period': '2022', 'revenue': 204.27, 'unit': 'M', 'net_profit': -58.6}, {'period': '2021', 'revenue': 152.16, 'unit': 'M', 'net_profit': -46.82}]","[{'period': ""Q1 '25"", 'revenue': 97.83, 'unit': 'M', 'net_profit': -7.82}, {'period': ""Q4 '24"", 'revenue': 89.66, 'unit': 'M', 'net_profit': -7.64}, {'period': ""Q3 '24"", 'revenue': 85.91, 'unit': 'M', 'net_profit': -9.44}, {'period': ""Q2 '24"", 'revenue': 82.16, 'unit': 'M', 'net_profit': -12.32}, {'period': ""Q1 '24"", 'revenue': 76.13, 'unit': 'M', 'net_profit': -11.43}, {'period': ""Q4 '23"", 'revenue': 71.37, 'unit': 'M', 'net_profit': -12.71}]",-0.41,-0.41,437277000,181377000,115734000,80247000,38739000,0,45570000,94359000,17402000,0.3410175235207562,0.35092906076645525,0.3880597014925374,__nan__,__nan__,__nan__,0.18351525463264703
188,ALLK,Allakos Inc. Common Stock,"Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.",Dr. Robert  Alexander Ph.D.,Biotechnology,0.3291,USD,29743071,https://images.financialmodelingprep.com/symbol/ALLK.png,1158693,-0.42,0,724800,-108094000,-115818000,"[{'period': '2024', 'revenue': 0.0, 'unit': 'M', 'net_profit': -115.82}, {'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -185.7}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -317.48}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -267.17}]","[{'period': ""Q1 '25"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -26.18}, {'period': ""Q4 '24"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 376.0}, {'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -18.37}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -26.68}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -71.15}, {'period': ""Q4 '23"", 'revenue': 10.76, 'unit': 'M', 'net_profit': -62.55}]",-1.3,-1.3,96601000,85586000,80820000,17784000,0,0,17784000,17753000,-93743000,0.4308295816549509,0.3763199982767998,0.3925233644859813,__nan__,__nan__,__nan__,0.1840974731110444
189,ALLO,Allogene Therapeutics Inc. Common Stock,"Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.","Dr. David D. Chang M.D., Ph.D.",Biotechnology,1.11,USD,242791410,https://images.financialmodelingprep.com/symbol/ALLO.png,5227217,-0.91,0.02,3139772,-243327000,-257590000,"[{'period': '2024', 'revenue': 0.022, 'unit': 'M', 'net_profit': -257.59}, {'period': '2023', 'revenue': 0.095, 'unit': 'M', 'net_profit': -327.26}, {'period': '2022', 'revenue': 0.156, 'unit': 'M', 'net_profit': -340.41}, {'period': '2021', 'revenue': 114.09, 'unit': 'M', 'net_profit': -182.05}]","[{'period': ""Q1 '25"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -59.73}, {'period': ""Q4 '24"", 'revenue': -0.022, 'unit': 'M', 'net_profit': -59.94}, {'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -66.29}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -66.36}, {'period': ""Q1 '24"", 'revenue': 0.022, 'unit': 'M', 'net_profit': -65.0}, {'period': ""Q4 '23"", 'revenue': -0.044, 'unit': 'M', 'net_profit': -89.26}]",-1.32,-1.32,548710000,303386000,292476000,126531000,0,80673000,35523000,75218000,-200994000,0.22276133467064452,0.2129008601591982,0.36842105263157887,__nan__,__nan__,__nan__,0.23059721893167612
190,ALLT,Allot Ltd. Ordinary Shares,"Allot Ltd. provides network intelligence and security solutions to protect and personalize the digital experience in Europe, Asia, Oceania, the Middle East, Africa, and the Americas. The company offers Allot Secure Management platform that includes Allot NetworkSecure, Allot HomeSecure, Allot DNSecure, EndPoint Secure, Allot BusinessSecure, Allot IoTSecure, and Allot Secure Cloud. It also provides Allot DDoS Secure/5G Protect, a solution that offers attack detection and mitigation services; integrated network intelligence solutions; and centralized management solutions, such as Allot NetXplorer for providing a central access point for network-wide monitoring, reporting, analytics, troubleshooting, accounting, and quality of service policy provisioning. The company markets its products through direct sales, distributors, resellers, original equipment manufacturers, and system integrators to carriers, mobile and fixed service providers, cable operators, satellite service providers, private networks, data centers, financial and educational institutions, and governments. Allot Ltd. was formerly known as Allot Communications Ltd. and changed its name to Allot Ltd. in October 2018. The company was incorporated in 1996 and is based in Hod Hasharon, Israel.",Mr. Eyal David Harari,Software - Infrastructure,8.26,USD,327862528,https://images.financialmodelingprep.com/symbol/ALLT.png,541520,-91.78,0.2,517416,2120000,-5869000,"[{'period': '2024', 'revenue': 92.19, 'unit': 'M', 'net_profit': -5.87}, {'period': '2023', 'revenue': 93.15, 'unit': 'M', 'net_profit': -62.8}, {'period': '2022', 'revenue': 122.74, 'unit': 'M', 'net_profit': -32.03}, {'period': '2021', 'revenue': 145.6, 'unit': 'M', 'net_profit': -15.04}]","[{'period': ""Q4 '24"", 'revenue': 24910.0, 'unit': 'K', 'net_profit': 241.0}, {'period': ""Q3 '24"", 'revenue': 23230.0, 'unit': 'K', 'net_profit': -244.0}, {'period': ""Q2 '24"", 'revenue': 22.16, 'unit': 'M', 'net_profit': -3.36}, {'period': ""Q1 '24"", 'revenue': 21.89, 'unit': 'M', 'net_profit': -2.51}, {'period': ""Q4 '23"", 'revenue': 24.34, 'unit': 'M', 'net_profit': -18.35}, {'period': ""Q3 '23"", 'revenue': 22.64, 'unit': 'M', 'net_profit': -12.36}]",-0.15,-0.15,139641000,90176000,57862000,89832000,17756000,0,35970000,16142000,2709000,1.038454561944495,0.9065505381822814,0.9096385542168676,__nan__,__nan__,__nan__,0.6433067652050616
191,ALNA,Allena Pharmaceuticals Inc. Common Stock,"Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.",Dr. Louis Brenner,Biotechnology,0.075,USD,0,https://images.financialmodelingprep.com/symbol/ALNA.png,0,-0.11755485893416928,0.0023000017,252311606,-31972000,-33355000,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -33.35}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -32.84}, {'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': -47.34}, {'period': '2018', 'revenue': 0.0, 'unit': 'M', 'net_profit': -35.65}]","[{'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.55}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -12.06}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 5.68}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -12.69}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -13.97}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -11.64}]",-1.03,-1.03,34757000,33006000,29988000,15889000,0,0,15679000,29988000,-46345000,0.021634688943970134,-0.015527477546049627,-0.01980198019801982,__nan__,__nan__,__nan__,0.45714532324423857
192,ALNY,Alnylam Pharmaceuticals Inc. Common Stock,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.","Dr. Yvonne L. Greenstreet M.B.A., M.D.",Biotechnology,285.31,USD,37201000280,https://images.financialmodelingprep.com/symbol/ALNY.png,1059177.2,-135.86,1.91,1138120,-178847000,-278157000,"[{'period': '2024', 'revenue': 2250.0, 'unit': 'M', 'net_profit': -278.16}, {'period': '2023', 'revenue': 1830.0, 'unit': 'M', 'net_profit': -440.24}, {'period': '2022', 'revenue': 1.04, 'unit': 'B', 'net_profit': -1.13}, {'period': '2021', 'revenue': 844.29, 'unit': 'M', 'net_profit': -852.82}]","[{'period': ""Q1 '25"", 'revenue': 594.19, 'unit': 'M', 'net_profit': -57.48}, {'period': ""Q4 '24"", 'revenue': 593.17, 'unit': 'M', 'net_profit': -83.76}, {'period': ""Q3 '24"", 'revenue': 500.92, 'unit': 'M', 'net_profit': -111.57}, {'period': ""Q2 '24"", 'revenue': 659.83, 'unit': 'M', 'net_profit': -16.89}, {'period': ""Q1 '24"", 'revenue': 494.33, 'unit': 'M', 'net_profit': -65.94}, {'period': ""Q4 '23"", 'revenue': 439.72, 'unit': 'M', 'net_profit': -137.87}]",-2.16,-2.16,4301817000,3295285000,2694504000,4172895000,405308000,0,1186272000,966428000,-42589000,0.30744418026502274,0.3681725051221828,0.38636363636363635,__nan__,__nan__,__nan__,0.9700308032629003
193,ALOT,AstroNova Inc. Common Stock,"AstroNova, Inc. designs, develops, manufactures, and distributes specialty printers, and data acquisition and analysis systems in the United States, Europe, Asia, Canada, Central and South America, and internationally. The company operates in two segments, Product Identification (PI) and Test & Measurement (T&M). The PI segment offers tabletop and production-ready digital color label printers, and OEM printing systems under the QuickLabel brand; digital color label mini-presses and inline printing systems under the TrojanLabel brand; and label materials, tags, inks, toners, and thermal transfer ribbons under the GetLabels brand. This segment also develops and licenses various specialized software programs to design and manage labels and print images; and provides training and support. This segment serves chemicals, cosmetics, food and beverage, medical products, pharmaceuticals, and other industries; and brand owners, label converters, commercial printers, and packaging manufacturers. The T&M segment offers airborne printing solutions, such as ToughWriter used to print hard copies of navigation maps, arrival and departure procedures, flight itineraries, weather maps, performance data, passenger data, and various air traffic control data; ToughSwitch, an ethernet switches used to connect multiple computers or Ethernet devices; TMX data acquisition systems; Daxus DXS-100 distributed data acquisition platform; SmartCorder DDX100 portable data acquisition systems for facility maintenance and field testing; and Everest EV-500, a digital strip chart recording system used primarily in telemetry applications. This segment serves aerospace and defense, automotive, commercial airline, energy, manufacturing, and transportation industries. The company was formerly known as Astro-Med, Inc. and changed its name to AstroNova, Inc. in May 2016. AstroNova, Inc. was incorporated in 1969 and is headquartered in West Warwick, Rhode Island.",Mr. Gregory A. Woods,Computer Hardware,9,USD,68366160,https://images.financialmodelingprep.com/symbol/ALOT.png,13633,-4.66,0.29,18326,-4297000,-14489000,"[{'period': '2025', 'revenue': 151.28, 'unit': 'M', 'net_profit': -14.49}, {'period': '2024', 'revenue': 148.09, 'unit': 'M', 'net_profit': 4.69}, {'period': '2023', 'revenue': 142.53, 'unit': 'M', 'net_profit': 2.66}, {'period': '2022', 'revenue': 117.48, 'unit': 'M', 'net_profit': 6.43}]","[{'period': ""Q4 '25"", 'revenue': 37.36, 'unit': 'M', 'net_profit': -15.6}, {'period': ""Q3 '25"", 'revenue': 40420.0, 'unit': 'K', 'net_profit': 240.0}, {'period': ""Q2 '25"", 'revenue': 40540.0, 'unit': 'K', 'net_profit': -311.0}, {'period': ""Q1 '25"", 'revenue': 32.96, 'unit': 'M', 'net_profit': 1.18}, {'period': ""Q4 '24"", 'revenue': 39.59, 'unit': 'M', 'net_profit': 2.71}, {'period': ""Q3 '24"", 'revenue': 37.55, 'unit': 'M', 'net_profit': 2.75}]",-1.93,-1.93,145595000,77917000,5050000,69845000,21218000,0,46346000,0,3683000,-1.3296256520405032,-4.086706433745206,-4.063492063492063,"[0.07, 0.03]","['2020-03-25', '1991-05-10']",__nan__,0.47972114427006424
194,ALPN,Alpine Immune Sciences Inc. Common Stock,"Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.",Dr. Mitchell H. Gold M.D.,Biotechnology,64.97,USD,4456779835,https://images.financialmodelingprep.com/symbol/ALPN.png,2371991,-101.515625,0.01,4288333,-43674000,-32184000,"[{'period': '2023', 'revenue': 58.88, 'unit': 'M', 'net_profit': -32.18}, {'period': '2022', 'revenue': 30.06, 'unit': 'M', 'net_profit': -57.76}, {'period': '2021', 'revenue': 23.44, 'unit': 'M', 'net_profit': -50.33}, {'period': '2020', 'revenue': 9.34, 'unit': 'M', 'net_profit': -27.94}]","[{'period': ""Q1 '24"", 'revenue': 7.03, 'unit': 'M', 'net_profit': -17.92}, {'period': ""Q4 '23"", 'revenue': 30.85, 'unit': 'M', 'net_profit': 5.96}, {'period': ""Q3 '23"", 'revenue': 10.04, 'unit': 'M', 'net_profit': -11.72}, {'period': ""Q2 '23"", 'revenue': 8.59, 'unit': 'M', 'net_profit': -13.16}, {'period': ""Q1 '23"", 'revenue': 9.39, 'unit': 'M', 'net_profit': -11.01}, {'period': ""Q4 '22"", 'revenue': 2.78, 'unit': 'M', 'net_profit': -18.86}]",-0.64,-0.64,379852000,330034000,327412000,51911000,749000,40556000,41980000,43921000,-79499000,0.20529150593201834,0.44281709428343896,0.630057803468208,__nan__,__nan__,__nan__,0.13666112064698882
195,ALRM,Alarm.com Holdings Inc. Common Stock,"Alarm.com Holdings, Inc. provides cloud-based solutions for smart residential and commercial properties in the United States and internationally. It operates in two segments, Alarm.com and Other. The company provides interactive security solutions to control and monitor their security systems, as well as connected security devices, including door locks, motion sensors, door locks, garage doors, Internet of Things, thermostats, and video cameras; and video monitoring solutions, such as video analytics, live streaming, video doorbell, video clips, video alerts, continuous high definition recording, and commercial video surveillance solutions. It also offers intelligent automation and energy management solutions comprising scenes button; smart thermostat schedules; responsive savings; precision comfort; energy usage monitoring; heating, ventilation, and air conditioning monitoring services; whole home water safety solutions; geo-services; and demand response programs. In addition, the company provides commercial solutions, such as daily safeguards, commercial grade video, energy savings, protection for valuables and inventory, temperature monitoring, multi-site management and access control, early identification, simple to use, professionally supported, and easy to maintain. Further, it offers service provider solutions, including a permission-based online portal that offers account management, sales, marketing, training, and support tools; sales, marketing, and training services; and home builder programs, as well as wellness solutions. The company serves residential and commercial subscribers. Alarm.com Holdings, Inc. was founded in 2000 and is based in Tysons, Virginia.",Mr. Stephen S. Trundle,Software - Application,59.64,USD,2966612880,https://images.financialmodelingprep.com/symbol/ALRM.png,410996,25.16,0.93,524091,196295000,124116000,"[{'period': '2024', 'revenue': 939.83, 'unit': 'M', 'net_profit': 124.12}, {'period': '2023', 'revenue': 881.68, 'unit': 'M', 'net_profit': 81.04}, {'period': '2022', 'revenue': 842.56, 'unit': 'M', 'net_profit': 56.34}, {'period': '2021', 'revenue': 748.97, 'unit': 'M', 'net_profit': 52.26}]","[{'period': ""Q1 '25"", 'revenue': 238.82, 'unit': 'M', 'net_profit': 27.95}, {'period': ""Q4 '24"", 'revenue': 242.24, 'unit': 'M', 'net_profit': 30.33}, {'period': ""Q3 '24"", 'revenue': 240.5, 'unit': 'M', 'net_profit': 36.68}, {'period': ""Q2 '24"", 'revenue': 233.81, 'unit': 'M', 'net_profit': 33.51}, {'period': ""Q1 '24"", 'revenue': 223.28, 'unit': 'M', 'net_profit': 23.59}, {'period': ""Q4 '23"", 'revenue': 226.24, 'unit': 'M', 'net_profit': 31.3}]",2.33,1.99,2038208000,1481592000,1220701000,1266915000,126082000,0,188806000,1220701000,196280000,0.3502665520206363,0.5314832866502968,0.4294478527607363,__nan__,__nan__,__nan__,0.6215827825226866
196,ALRN,Aileron Therapeutics Inc. Common Stock,"Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.",Dr. James Brian Windsor Ph.D.,Biotechnology,2.11,USD,45715049,https://images.financialmodelingprep.com/symbol/ALRN.png,101120,-0.7326388888888888,0.18,63394,-65112000,-62883000,"[{'period': '2024', 'revenue': 0.0, 'unit': 'M', 'net_profit': -62.88}, {'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -15.73}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -27.01}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -25.76}]","[{'period': ""Q1 '25"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.5}, {'period': ""Q4 '24"", 'revenue': 0.126, 'unit': 'M', 'net_profit': -40.98}, {'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.85}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.94}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -7.11}, {'period': ""Q4 '23"", 'revenue': 0.134, 'unit': 'M', 'net_profit': -7.34}]",-3.51,-3.51,62190000,13657000,12865000,7798000,0,0,5749000,12865000,-22291000,-3.1703708448088133,-2.9971395881006866,-0.02631578947368417,__nan__,__nan__,__nan__,0.12538993407300209
197,ALRS,Alerus Financial Corporation Common Stock,"Alerus Financial Corporation, through its subsidiary, Alerus Financial, National Association, provides various financial services to businesses and consumers. The company operates in four segments: Banking, Retirement and Benefit Services, Wealth Management, and Mortgage. It offers various deposit products, including demand deposits, interest-bearing transaction accounts, money market accounts, time and savings deposits, checking accounts, and certificates of deposit; and treasury management products, including electronic receivables management, remote deposit capture, cash vault services, merchant services, and other cash management services. The company also provides commercial loans, business term loans, lines of credit, and commercial real estate loans, as well as construction and land development loans; consumer lending products, including residential first mortgage loans; installment loans and lines of credit; and second mortgage loans. In addition, it offers retirement plan administration and investment advisory services, employee stock ownership plan, fiduciary services, payroll, health savings accounts, and other benefit services, as well as individual retirement accounts; and financial planning, investment management, personal and corporate trust, estate administration, and custody services. Further, the company provides debit and credit cards, online banking, mobile banking/wallet, payment, private banking, payroll accounts, flex spending accounts, administration, and government health insurance program services. It offers banking services through fourteen offices in North Dakota, Minnesota, and Arizona; and retirement and benefit plans in 50 states through offices located in Michigan, Minnesota, and Colorado. The company was formerly known as First National Bank North Dakota and changed its name to Alerus Financial Corporation in 2000. Alerus Financial Corporation was founded in 1879 and is headquartered in Grand Forks, North Dakota.",Ms. Katie A. Lorenson C.P.A.,Banks - Regional,22,USD,558045400,https://images.financialmodelingprep.com/symbol/ALRS.png,77554,21.36,-0.25,85313,38039000,17780000,"[{'period': '2024', 'revenue': 215.87, 'unit': 'M', 'net_profit': 17.78}, {'period': '2023', 'revenue': 166.01, 'unit': 'M', 'net_profit': 11.7}, {'period': '2022', 'revenue': 208.77, 'unit': 'M', 'net_profit': 40.01}, {'period': '2021', 'revenue': 230.24, 'unit': 'M', 'net_profit': 52.68}]","[{'period': ""Q1 '25"", 'revenue': 19.74, 'unit': 'M', 'net_profit': 13.31}, {'period': ""Q4 '24"", 'revenue': 67650.0, 'unit': 'K', 'net_profit': -66.0}, {'period': ""Q3 '24"", 'revenue': 50.22, 'unit': 'M', 'net_profit': 5.18}, {'period': ""Q2 '24"", 'revenue': 80.07, 'unit': 'M', 'net_profit': 6.21}, {'period': ""Q1 '24"", 'revenue': 74.15, 'unit': 'M', 'net_profit': 6.43}, {'period': ""Q4 '23"", 'revenue': 45.49, 'unit': 'M', 'net_profit': -14.75}]",0.85,0.84,5261673000,81314000,61239000,4766263000,56311000,0,238960000,61239000,16590000,0,0.5201778385772914,0.44067796610169496,"[0.2, 0.23]","['2025-03-14', '2003-06-18']",__nan__,0.9058455362011284
198,ALSK,Alaska Communications Systems Group Inc. Common Stock,"Alaska Communications Systems Group, Inc., through its subsidiaries, provides broadband telecommunication and managed information technology services to business, wholesale, and consumer customers in the United States. Its services include voice and broadband services; and managed IT services comprising remote network monitoring and support service, managed IT security and IT professional services, and long distance services primarily over its own terrestrial network to business and wholesale customers. The company's business customers comprise enterprises; federal, state, and local governments; and small and medium business. It also provides voice and broadband services to residential customers in residential homes and multi-dwelling units; voice and broadband origination and termination services to inter and intrastate carriers; and access and support services. The company markets and sells its products through direct sales channels. Alaska Communications Systems Group, Inc. was incorporated in 1998 and is based in Anchorage, Alaska.",Mr. William Bishop,Telecommunications Services,3.4,USD,0,https://images.financialmodelingprep.com/symbol/ALSK.png,476388,0,0.00999999,878092,56156000,-1073000,"[{'period': '2020', 'revenue': 240.57, 'unit': 'M', 'net_profit': -1.07}, {'period': '2019', 'revenue': 231.69, 'unit': 'M', 'net_profit': 4.93}, {'period': '2018', 'revenue': 232.47, 'unit': 'M', 'net_profit': 9.08}, {'period': '2017', 'revenue': 226.91, 'unit': 'M', 'net_profit': -6.1}]","[{'period': ""Q1 '21"", 'revenue': 60670.0, 'unit': 'K', 'net_profit': 606.0}, {'period': ""Q4 '20"", 'revenue': 62.33, 'unit': 'M', 'net_profit': -8.2}, {'period': ""Q3 '20"", 'revenue': 60.51, 'unit': 'M', 'net_profit': 2.3}, {'period': ""Q2 '20"", 'revenue': 59.46, 'unit': 'M', 'net_profit': 2.44}, {'period': ""Q1 '20"", 'revenue': 58.27, 'unit': 'M', 'net_profit': 2.39}, {'period': ""Q4 '19"", 'revenue': 58.26, 'unit': 'M', 'net_profit': 2.64}]",-0.0199,-0.0199,569432000,77325000,20078000,403513000,42246000,0,62159000,19644000,8297000,-0.015290734376095953,-1.2177353896103895,-1.2191629955947136,"[0.09, 0.185]","['2020-04-17', '2004-12-29']",__nan__,0.7086236811419099
199,ALT,Altimmune Inc. Common Stock,"Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.",Dr. Vipin K. Garg Ph.D.,Biotechnology,5.58,USD,452577060,https://images.financialmodelingprep.com/symbol/ALT.png,2626177,-4.1,-0.2,2082868,-94812000,-95059000,"[{'period': '2024', 'revenue': 0.02, 'unit': 'M', 'net_profit': -95.06}, {'period': '2023', 'revenue': 0.426, 'unit': 'M', 'net_profit': -88.45}, {'period': '2022', 'revenue': -0.068, 'unit': 'M', 'net_profit': -84.71}, {'period': '2021', 'revenue': 4.41, 'unit': 'M', 'net_profit': -96.17}]","[{'period': ""Q1 '25"", 'revenue': 0.005, 'unit': 'M', 'net_profit': -19.57}, {'period': ""Q4 '24"", 'revenue': 0.005, 'unit': 'M', 'net_profit': -23.18}, {'period': ""Q3 '24"", 'revenue': 0.005, 'unit': 'M', 'net_profit': -22.84}, {'period': ""Q2 '24"", 'revenue': 0.005, 'unit': 'M', 'net_profit': -24.64}, {'period': ""Q1 '24"", 'revenue': 0.005, 'unit': 'M', 'net_profit': -24.39}, {'period': ""Q4 '23"", 'revenue': 0.037, 'unit': 'M', 'net_profit': -31.64}]",-1.34,-1.34,139306000,137254000,131891000,15798000,3117000,0,10468000,36926000,-79848000,-0.07820549269346677,-0.07475663391635669,0.19277108433734932,"[291, 291.0033]","['2017-02-06', '2017-01-20']",__nan__,0.11340502203781604
200,ALTA,Altabancorp Common Stock,"Altabancorp operates as the bank holding company for Altabank, a state-chartered bank that provides retail and commercial banking products and services. The company accepts various deposits, such as checking, rewards checking, savings, and money market deposit accounts, as well as individual retirement accounts and certificates of deposit. Its loan products include commercial and residential real estate lending comprising acquisition and development loans, construction loans, and mortgage financing; commercial and industrial loans; consumer loans consisting of home equity loans, home improvement loans, automobile loans, debt consolidation loans, and general consumer lending; and SBA loans. The company also offers credit and debit cards; investment securities, such as U.S. Agency issues, mortgage-backed securities, and municipal bonds; and mobile and Internet banking, automatic teller machine, treasury management, remote deposit capture, bill pay, cashier's checks, money orders, and safe deposit services. It serves real estate developers and contractors, small to medium sized businesses, individuals, and professionals and professional firms through 26 retail branches located in Utah and southern Idaho. The company was formerly known as People's Utah Bancorp and changed its name to Altabancorp in July 2020. Altabancorp was founded in 1905 and is headquartered in American Fork, Utah.",Mr. Len E. Williams,Banks - Regional,44.16,USD,0,https://images.financialmodelingprep.com/symbol/ALTA.png,80075,19.89189189189189,-0.5600014,410642,67922000,43502000,"[{'period': '2020', 'revenue': 126.14, 'unit': 'M', 'net_profit': 43.5}, {'period': '2019', 'revenue': 125.1, 'unit': 'M', 'net_profit': 44.32}, {'period': '2018', 'revenue': 123.31, 'unit': 'M', 'net_profit': 40.63}, {'period': '2017', 'revenue': 95.03, 'unit': 'M', 'net_profit': 19.85}]","[{'period': ""Q2 '21"", 'revenue': 30.59, 'unit': 'M', 'net_profit': 12.7}, {'period': ""Q1 '21"", 'revenue': 28.98, 'unit': 'M', 'net_profit': 9.44}, {'period': ""Q4 '20"", 'revenue': 31.37, 'unit': 'M', 'net_profit': 11.05}, {'period': ""Q3 '20"", 'revenue': 31.91, 'unit': 'M', 'net_profit': 11.34}, {'period': ""Q2 '20"", 'revenue': 31.91, 'unit': 'M', 'net_profit': 10.34}, {'period': ""Q1 '20"", 'revenue': 30.96, 'unit': 'M', 'net_profit': 10.77}]",2.31,2.31,3366228000,239.874,1557474000,2995090000,11336000,1323283000,71.943,237081000,49124000,-0.034568041618102736,-0.018545257648226694,-0.012820512820512739,"[0.17, 0.06]","['2021-09-24', '2015-07-30']",__nan__,0.889746624411656
201,ALTM,Altus Midstream Company Class A Common Stock,"Arcadium Lithium plc engages in the production of lithium chemicals products in the Asia Pacific, North America, Europe, the Middle East, Africa, and Latin America. The company offers battery-grade lithium hydroxide, lithium carbonate, butyllithium and high purity lithium metal for electric vehicles, greases, polymers, pharmaceutical, battery, and aerospace applications. It also owns 100% interest in the Sal de Vida property located in Argentina; the Cauchari property located in Argentina; the James Bay property located in northwestern Quebec, Canada; the Salar Del Hombre Muerto property located in Argentina; Mt Cattlin property located in Western Australia; owns 66.5% interest in the Salar de Olaroz property located in Jujuy Province, Argentina; and owns 50% interest in the Whabouchi Mine property located in Canada. The company was founded in 1944 and is based in Shannon, Ireland.",Mr. Paul W. Graves A.C.A.,Chemicals - Specialty,5.84,USD,6288862587,https://images.financialmodelingprep.com/symbol/ALTM.png,18726440,64.88888888888889,0,22394351,279400000,103200000,"[{'period': '2024', 'revenue': 1010.0, 'unit': 'M', 'net_profit': 103.2}, {'period': '2023', 'revenue': 882.5, 'unit': 'M', 'net_profit': 330.1}, {'period': '2022', 'revenue': 1210.0, 'unit': 'M', 'net_profit': 441.71}, {'period': '2021', 'revenue': 420400.0, 'unit': 'K', 'net_profit': 600.0}]","[{'period': ""Q4 '24"", 'revenue': 289.0, 'unit': 'M', 'net_profit': -14.2}, {'period': ""Q3 '24"", 'revenue': 203.1, 'unit': 'M', 'net_profit': 16.1}, {'period': ""Q2 '24"", 'revenue': 254.5, 'unit': 'M', 'net_profit': 85.7}, {'period': ""Q1 '24"", 'revenue': 283.49, 'unit': 'M', 'net_profit': 15.6}, {'period': ""Q4 '23"", 'revenue': 195.51, 'unit': 'M', 'net_profit': 37.7}, {'period': ""Q3 '23"", 'revenue': 211.4, 'unit': 'M', 'net_profit': 87.4}]",0.0965,0.0906,10190100000,859800000,93200000,3009300000,130300000,36900000,789000000,93200000,-176000000,-0.33381020505484027,-0.6873674644047258,-0.8537878787878788,"[3.609, 3.609]","['2021-05-27', '2021-02-25']",__nan__,0.2953160420408043
202,ALTO,Alto Ingredients Inc. Common Stock,"Alto Ingredients, Inc. produces and markets specialty alcohols and essential ingredients in the United States. The company operates in three segments: Marketing and Distribution, Pekin Production, and Other Production. It offers specialty alcohols used in mouthwash, cosmetics, pharmaceuticals, hand sanitizers, disinfectants, and cleaners for health, home, and beauty markets; grain neutral spirits used in alcoholic beverages, flavor extracts, and vinegar, as well as corn germ used in corn oils and carbon dioxide for food and beverage markets; and essential ingredients include dried yeast, corn gluten meal, corn gluten feed, distillers grains, and liquid feed for commercial animal feed and pet food applications. The company also provides fuel-grade ethanol used as transportation fuel and distillers corn oil used as a biodiesel feedstock, as well as fuel-grade ethanol produced by third parties. In addition, it offers transportation, storage, and delivery services through third-party service providers. The company sells ethanol to integrated oil companies and gasoline marketers; essential ingredient feed products to dairies and feedlots; and corn oil to poultry and biodiesel customers. It operates five alcohol production facilities, including three plants in the Midwestern states of Illinois; and two facilities located in the Western states of Oregon and Idaho. The company was formerly known as Pacific Ethanol, Inc. and changed its name to Alto Ingredients, Inc. in January 2021. Alto Ingredients, Inc. was founded in 2003 and is headquartered in Pekin, Illinois.",Mr. Bryon T. McGregor,Chemicals - Specialty,0.9104,USD,70292166,https://images.financialmodelingprep.com/symbol/ALTO.png,591877,-1.12,0.0435,465724,-26759000,-58984000,"[{'period': '2024', 'revenue': 965.26, 'unit': 'M', 'net_profit': -58.98}, {'period': '2023', 'revenue': 1220.0, 'unit': 'M', 'net_profit': -28.0}, {'period': '2022', 'revenue': 1340.0, 'unit': 'M', 'net_profit': -41.6}, {'period': '2021', 'revenue': 1210.0, 'unit': 'M', 'net_profit': 46.08}]","[{'period': ""Q1 '25"", 'revenue': 226.54, 'unit': 'M', 'net_profit': -11.99}, {'period': ""Q4 '24"", 'revenue': 236.35, 'unit': 'M', 'net_profit': -41.71}, {'period': ""Q3 '24"", 'revenue': 251.81, 'unit': 'M', 'net_profit': -2.44}, {'period': ""Q2 '24"", 'revenue': 236.47, 'unit': 'M', 'net_profit': -3.11}, {'period': ""Q1 '24"", 'revenue': 240.63, 'unit': 'M', 'net_profit': -11.72}, {'period': ""Q4 '23"", 'revenue': 273.62, 'unit': 'M', 'net_profit': -18.95}]",-0.82,-0.82,403054000,153118000,36211000,176375000,58217000,0,57804000,35469000,-14587000,-11.303812090874086,-1.1061953222638814,-1.0499999999999998,__nan__,__nan__,__nan__,0.4375964510958829
203,ALTR,Altair Engineering Inc. Class A Common Stock,"Altair Engineering Inc., together with its subsidiaries, provides software and cloud solutions in the areas of simulation, high-performance computing, data analytics, and artificial intelligence worldwide. The company operates in two segments, Software and Client Engineering Services. The Software segment includes solvers and optimization technology products, high-performance computing software applications and hardware products, modeling and visualization tools, data analytics and analysis products, and Internet of Things platform and analytics tools, as well as support and the complementary software products. This segment also offers software technologies in the areas of computational fluid dynamics and fatigue, manufacturing process simulation, and cost estimation for the applications in marine, motorcycle, aerospace, chemical, and architecture industries; and software-related services, such as consulting, implementation, and training services that focuses on the product design and development expertise and analysis from the component level up to complete product engineering at various stage of the lifecycle. The Client Engineering Services segment provides client engineering services. In addition, the company is involved in the development and sale of solid state lighting technology along with communication and control protocols based on its intellectual property for the direct replacement of fluorescent light tubes with LED lamps. Its integrated suite of software optimizes design performance across various disciplines, including structures, motion, fluids, thermal management, electromagnetics, system modeling, and embedded systems. The company's customers include universities, government agencies, manufacturers, pharmaceutical firms, banking, financial services, and insurance, weather prediction agencies, and electronics design companies. Altair Engineering Inc. was incorporated in 1985 and is headquartered in Troy, Michigan.",Mr. James R. Scapa,Software - Infrastructure,111.85,USD,9632991211,https://images.financialmodelingprep.com/symbol/ALTR.png,788509,699.06,0,888809,80630000,14175000,"[{'period': '2024', 'revenue': 665.79, 'unit': 'M', 'net_profit': 14.18}, {'period': '2023', 'revenue': 612.7, 'unit': 'M', 'net_profit': -8.93}, {'period': '2022', 'revenue': 572.22, 'unit': 'M', 'net_profit': -43.43}, {'period': '2021', 'revenue': 532.18, 'unit': 'M', 'net_profit': -8.79}]","[{'period': ""Q4 '24"", 'revenue': 192630.0, 'unit': 'K', 'net_profit': 996.0}, {'period': ""Q3 '24"", 'revenue': 151.45, 'unit': 'M', 'net_profit': 1.78}, {'period': ""Q2 '24"", 'revenue': 148.79, 'unit': 'M', 'net_profit': -5.15}, {'period': ""Q1 '24"", 'revenue': 172.91, 'unit': 'M', 'net_profit': 16.55}, {'period': ""Q4 '23"", 'revenue': 171.5, 'unit': 'M', 'net_profit': 19.68}, {'period': ""Q3 '23"", 'revenue': 134.0, 'unit': 'M', 'net_profit': -4.36}]",0.17,0.17,1445647000,784978000,561898000,588458000,195022000,0,487769000,561898000,139998000,0.3935602067094143,2.5880573605198296,2.545454545454546,"[0.18, 0.05]","['2015-11-06', '2009-08-06']",__nan__,0.40705511096415653
204,ALTU,Altitude Acquisition Corp. Class A Common Stock,"Altitude Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on travel, travel technology and travel-related businesses. The company was incorporated in 2020 and is based in Atlanta, Georgia.",Mr. Gary  Teplis,Shell Companies,10.12,USD,85771655,https://images.financialmodelingprep.com/symbol/ALTU.png,2354,56.22222222222222,-0.13,68972,-15405581,9342644,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 9.34}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 15.23}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -7.12}]","[{'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -664.63}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.66}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.28}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -198.27}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.16}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -234.91}]",0.77,0.77,16977371,1575,760,18830171,0,16975796,1594065,760,-375360,0.41596786378693007,-0.3863950527751231,0.878048780487805,__nan__,__nan__,__nan__,1.10913350482828
205,ALTUU,Altitude Acquisition Corp. Unit,"Altitude Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on travel, travel technology and travel-related businesses. The company was incorporated in 2020 and is based in Atlanta, Georgia.",Mr. Gary  Teplis,Shell Companies,10.1,USD,85771654,https://images.financialmodelingprep.com/symbol/ALTUU.png,120,12.5,-0.16,3300,-15405581,9342644,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 9.34}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 15.23}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -7.12}]","[{'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -664.63}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.66}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.28}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -198.27}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.16}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -234.91}]",0.77,0.77,16977371,1575,760,18830171,0,16975796,1594065,760,-375360,0.41596786378693007,-0.3863950527751231,0.878048780487805,__nan__,__nan__,__nan__,1.10913350482828
206,ALTUW,Altitude Acquisition Corp. Warrant,"Altitude Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. Altitude Acquisition Corp. was incorporated in 2020 and is based in Atlanta, Georgia. Altitude Acquisition Corp. operates as a subsidiary of Altitude Acquisition Holdco LLC.",Mr. Gary  Teplis,Shell Companies,0.0007,USD,85771655,https://images.financialmodelingprep.com/symbol/ALTUW.png,11998,0,-0.0217,2133842,-15405581,9342644,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 9.34}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 15.23}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -7.12}]","[{'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -664.63}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.66}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.28}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -198.27}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.16}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -234.91}]",0.77,0.77,16977371,1575,760,18830171,0,16975796,1594065,760,-375360,0.41596786378693007,-0.3863950527751231,0.878048780487805,__nan__,__nan__,__nan__,1.10913350482828
207,ALVR,AlloVir Inc. Common Stock,"Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.","Mr. Vikas  Sinha C.A., CPA, M.B.A.",Biotechnology,9.81,USD,49475362,https://images.financialmodelingprep.com/symbol/ALVR.png,22940,-0.8363171355498721,0.39,9402,-65441000,-58769000,"[{'period': '2024', 'revenue': 0.0, 'unit': 'M', 'net_profit': -58.77}, {'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -190.42}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -168.71}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -171.96}]","[{'period': ""Q1 '25"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': ""Q4 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -18.27}, {'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.13}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -6.08}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -30.3}, {'period': ""Q4 '23"", 'revenue': 8.38, 'unit': 'M', 'net_profit': -59.7}]",-0.51,-0.51,118546000,118546000,118289000,5239000,0,0,5239000,118289000,-67705000,0.6558381454250944,0.6913684630654665,0.7213114754098361,__nan__,__nan__,__nan__,0.04419381505913316
208,ALXN,Alexion Pharmaceuticals Inc. Common Stock,"Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG and NMOSD; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1810 (Subcutaneous) that is in Phase I clinical trial for renal diseases; and ALXN1720 (Subcutaneous), which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 and ABY-039, which are in Phase I clinical trials for neonatal Fc receptor. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; collaborations with Caelum Biosciences, Inc., Dicerna Pharmaceuticals, Inc. and Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc.; agreement with Stealth BioTherapeutics Corp.; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.",Dr. Ludwig Hantson,Biotechnology,182.5,USD,0,https://images.financialmodelingprep.com/symbol/ALXN.png,4222993,59.23401493021746,0,3,1003100000,603400000,"[{'period': '2020', 'revenue': 6070.0, 'unit': 'M', 'net_profit': 603.4}, {'period': '2019', 'revenue': 4.99, 'unit': 'B', 'net_profit': 2.4}, {'period': '2018', 'revenue': 4130.0, 'unit': 'M', 'net_profit': 77.6}, {'period': '2017', 'revenue': 3550.0, 'unit': 'M', 'net_profit': 443.3}]","[{'period': ""Q1 '21"", 'revenue': 1640.0, 'unit': 'M', 'net_profit': 636.0}, {'period': ""Q4 '20"", 'revenue': 1590.0, 'unit': 'M', 'net_profit': 535.8}, {'period': ""Q3 '20"", 'revenue': 1590.0, 'unit': 'M', 'net_profit': 578.1}, {'period': ""Q2 '20"", 'revenue': 1.44, 'unit': 'B', 'net_profit': -1.07}, {'period': ""Q1 '20"", 'revenue': 1440.0, 'unit': 'M', 'net_profit': 557.6}, {'period': ""Q4 '19"", 'revenue': 1380.0, 'unit': 'M', 'net_profit': 889.0}]",2.75,2.75,18103000000,5833000000,2999400000,6451800000,1409300000,0,1624700000,2964500000,2896200000,-0.6190855927698034,-0.7490329825728902,-0.7429906542056075,__nan__,__nan__,__nan__,0.3563939678506325
209,ALXO,ALX Oncology Holdings Inc. Common Stock,"ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.",Mr. Jason W. Lettmann,Biotechnology,0.4374,USD,23376406,https://images.financialmodelingprep.com/symbol/ALXO.png,790388,-0.18,0.0016,322851,-132249000,-134850000,"[{'period': '2024', 'revenue': 0.0, 'unit': 'M', 'net_profit': -134.85}, {'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -160.81}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -123.48}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -83.46}]","[{'period': ""Q1 '25"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -30.75}, {'period': ""Q4 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -29.16}, {'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -30.71}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -39.4}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -35.58}, {'period': ""Q4 '23"", 'revenue': 2.48, 'unit': 'M', 'net_profit': -45.47}]",-2.58,-2.58,147775000,134352000,127757000,34157000,0,3524000,18500000,17567000,-122359000,0.16511577990454787,0.16140667267808836,0.31016042780748665,__nan__,__nan__,__nan__,0.23114193875824735
210,ALYA,Alithya Group inc. Class A Subordinate Voting Shares,"Alithya Group Inc. provides strategy and digital technology services in Canada, the United States, and Europe. The company's business strategy services include strategic consulting, digital transformation, organizational performance, and enterprise architecture services. It also provides application services, such as digital applications DevOps, legacy systems modernization, control and software engineering, cloud infrastructure, quality assurance, and automated testing; enterprise solutions comprising enterprise resource planning, corporate performance management, customer relationship management, and human capital management; and data and analytics solutions, including business intelligence, data management, artificial intelligence (AI), and machine learning, as well as internet of things. In addition, the company provides AI-FI, an integrated artificial intelligence and fidelity solution; Alithya GoTest, solution allows clients to test the functionality of applications on various platforms; CASSI analytics for online weekly maintenance, outage management, petrochemical turnarounds, and maintenance and reliability; and SIDER, a secure solution that facilitates distribution of medical results to healthcare sectors and to centralized electronic medical records. It serves financial services, energy, manufacturing, telecommunications, transportation and logistics, professional services, healthcare, and government sectors. Alithya Group Inc. was founded in 1992 and is headquartered in Montreal, Canada.",Mr. Paul  Raymond,Information Technology Services,1.13,USD,110306527,https://images.financialmodelingprep.com/symbol/ALYA.png,42649,-3.4242424242424243,0.05,40583,17118000,-30097000,"[{'period': '2022', 'revenue': 522.7, 'unit': 'M', 'net_profit': -30.1}, {'period': '2021', 'revenue': 437.88, 'unit': 'M', 'net_profit': -15.55}, {'period': '2020', 'revenue': 287.64, 'unit': 'M', 'net_profit': -17.34}, {'period': '2019', 'revenue': 279.01, 'unit': 'M', 'net_profit': -39.67}]","[{'period': ""Q3 '23"", 'revenue': 120.5, 'unit': 'M', 'net_profit': -2.54}, {'period': ""Q2 '23"", 'revenue': 118.49, 'unit': 'M', 'net_profit': -9.18}, {'period': ""Q1 '23"", 'revenue': 131.59, 'unit': 'M', 'net_profit': -7.25}, {'period': ""Q4 '22"", 'revenue': 136.22, 'unit': 'M', 'net_profit': -19.99}, {'period': ""Q3 '22"", 'revenue': 130.78, 'unit': 'M', 'net_profit': -5.5}, {'period': ""Q2 '22"", 'revenue': 128930.0, 'unit': 'K', 'net_profit': -435.0}]",-0.32,-0.32,464101000,156080000,22583000,277033000,126654000,12108000,130219000,22583000,26297000,8.820998278829604,-0.935747363004888,-0.7777777777777779,"[1.15, 1.15]","['2018-11-02', '2018-11-02']",__nan__,0.5969239454342913
211,AMAL,Amalgamated Financial Corp. Common Stock (DE),"Amalgamated Financial Corp. operates as the bank holding company for Amalgamated Bank that provides commercial and retail banking, investment management, and trust and custody services for commercial and retail customers in the United States. The company accepts various deposit products, including non-interest bearing accounts, interest-bearing demand products, savings accounts, money market accounts, NOW accounts, and certificates of deposit. It also provides various commercial loans comprising commercial and industrial, multifamily mortgage, and commercial real estate loans; and retail loans, such as residential real estate, and consumer and other loans. In addition, the company offers online banking, bill payment, online cash management, and safe deposit box rental services; debit and ATM cards; and trust, custody, and investment management services comprising asset safekeeping, corporate actions, income collections, proxy, account transition, asset transfers, and conversion management services. Further, it provides investment products, such as equity, fixed-income, real estate, and alternative investment products; and brokerage, asset management, and insurance products. The company operates through its three branch offices across New York City, one branch office in Washington, D.C., one branch office in San Francisco, one commercial office in Boston, and digital banking platform. Amalgamated Financial Corp. was founded in 1923 and is headquartered in New York, New York.",Ms. Priscilla Sims Brown,Banks - Regional,30.62,USD,936656614,https://images.financialmodelingprep.com/symbol/AMAL.png,246516,9.11,-0.3,141668,0,106434000,"[{'period': '2024', 'revenue': 316.48, 'unit': 'M', 'net_profit': 106.43}, {'period': '2023', 'revenue': 274.58, 'unit': 'M', 'net_profit': 87.98}, {'period': '2022', 'revenue': 266.51, 'unit': 'M', 'net_profit': 81.48}, {'period': '2021', 'revenue': 202.54, 'unit': 'M', 'net_profit': 52.94}]","[{'period': ""Q1 '25"", 'revenue': 109.6, 'unit': 'M', 'net_profit': 25.03}, {'period': ""Q4 '24"", 'revenue': 78.41, 'unit': 'M', 'net_profit': 24.49}, {'period': ""Q3 '24"", 'revenue': 78.5, 'unit': 'M', 'net_profit': 27.94}, {'period': ""Q2 '24"", 'revenue': 109.77, 'unit': 'M', 'net_profit': 26.75}, {'period': ""Q1 '24"", 'revenue': 105.09, 'unit': 'M', 'net_profit': 27.25}, {'period': ""Q4 '23"", 'revenue': 101.72, 'unit': 'M', 'net_profit': 22.69}]",3.48,3.44,8256892000,4738138000,4042000,7549238000,4734096000,8482000,6840249000,60749000,122290000,0,0.2097797176566869,0.20833333333333337,"[0.14, 0.06]","['2025-05-06', '2018-11-15']",__nan__,0.9142953547170048
212,AMAO,American Acquisition Opportunity Inc. Class A Common Stock,"American Acquisition Opportunity Inc. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more target businesses in the land holdings and resources industry in the United States. The company was incorporated in 2021 and is based in Fishers, Indiana.",Mr. Mark C. Jensen,Shell Companies,7.35,USD,22598090,https://images.financialmodelingprep.com/symbol/AMAO.png,17245,91.875,0.89,69810,,,[],[],,,,,,,,,,,,,,,__nan__,__nan__,__nan__,__nan__
213,AMAOU,American Acquisition Opportunity Inc. Units,"American Acquisition Opportunity Inc. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more target businesses in the land holdings and resources industry in the United States. The company was incorporated in 2021 and is based in Fishers, Indiana.",Mr. Mark C. Jensen,Shell Companies,7.19,USD,23514895,https://images.financialmodelingprep.com/symbol/AMAOU.png,581,0,0.71,4964,,,[],[],,,,,,,,,,,,,,,__nan__,__nan__,__nan__,__nan__
214,AMAOW,American Acquisition Opportunity Inc. Warrant,"American Acquisition Opportunity Inc. intends to enter into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more target businesses. It intends to focus on companies in the land holdings and resources industry in the United States. The company was incorporated in 2021 and is based in Fishers, Indiana.",Mr. Mark C. Jensen,Shell Companies,0.0699,USD,244693,https://images.financialmodelingprep.com/symbol/AMAOW.png,0,0,0.0199,99089,,,[],[],,,,,,,,,,,,,,,__nan__,__nan__,__nan__,__nan__
215,AMAT,Applied Materials Inc. Common Stock,"Applied Materials, Inc. provides manufacturing equipment, services, and software to the semiconductor, display, and related industries. It operates through three segments: Semiconductor Systems, Applied Global Services, and Display and Adjacent Markets. The Semiconductor Systems segment develops, manufactures, and sells various manufacturing equipment that is used to fabricate semiconductor chips or integrated circuits. This segment also offers various technologies, including epitaxy, ion implantation, oxidation/nitridation, rapid thermal processing, physical vapor deposition, chemical vapor deposition, chemical mechanical planarization, electrochemical deposition, atomic layer deposition, etching, and selective deposition and removal, as well as metrology and inspection tools. The Applied Global Services segment provides integrated solutions to optimize equipment and fab performance and productivity comprising spares, upgrades, services, remanufactured earlier generation equipment, and factory automation software for semiconductor, display, and other products. The Display and Adjacent Markets segment offers products for manufacturing liquid crystal displays; organic light-emitting diodes; and other display technologies for TVs, monitors, laptops, personal computers, electronic tablets, smart phones, and other consumer-oriented devices. The company operates in the United States, China, Korea, Taiwan, Japan, Southeast Asia, and Europe. Applied Materials, Inc. was incorporated in 1967 and is headquartered in Santa Clara, California.",Mr. Gary E. Dickerson,Semiconductors,165.57,USD,134515856370,https://images.financialmodelingprep.com/symbol/AMAT.png,7935230,21.64,-9.18,16444639,8259000000,7177000000,"[{'period': '2024', 'revenue': 27.18, 'unit': 'B', 'net_profit': 7.18}, {'period': '2023', 'revenue': 26.52, 'unit': 'B', 'net_profit': 6.86}, {'period': '2022', 'revenue': 25.79, 'unit': 'B', 'net_profit': 6.53}, {'period': '2021', 'revenue': 23.06, 'unit': 'B', 'net_profit': 5.89}]","[{'period': ""Q2 '25"", 'revenue': 7.1, 'unit': 'B', 'net_profit': 2.14}, {'period': ""Q1 '25"", 'revenue': 7.17, 'unit': 'B', 'net_profit': 1.19}, {'period': ""Q4 '24"", 'revenue': 7.04, 'unit': 'B', 'net_profit': 1.73}, {'period': ""Q3 '24"", 'revenue': 6.78, 'unit': 'B', 'net_profit': 1.71}, {'period': ""Q2 '24"", 'revenue': 6.65, 'unit': 'B', 'net_profit': 1.72}, {'period': ""Q1 '24"", 'revenue': 6.71, 'unit': 'B', 'net_profit': 2.02}]",8.68,8.61,34409000000,21220000000,9471000000,15408000000,5234000000,2787000000,8468000000,8022000000,7487000000,0.011017260374586852,0.04682030338389732,0.06372549019607837,"[0.46, 0.03]","['2025-05-22', '2005-05-16']",__nan__,0.4477898224301782
216,AMBA,Ambarella Inc. Ordinary Shares,"Ambarella, Inc. develops semiconductor solutions for video that enable high-definition (HD) and ultra HD compression, image processing, and deep neural network processing worldwide. The company's system-on-a-chip designs integrated HD video processing, image processing, artificial intelligence computer vision algorithms, audio processing, and system functions onto a single chip for delivering video and image quality, differentiated functionality, and low power consumption. Its solutions are used in automotive cameras, such as automotive video recorders, electronic mirrors, front advanced driver assistance system camera, cabin monitoring system and driver monitoring system camera, and central domain controllers for autonomous vehicle; and professional and home internet protocol security camera; robotics and industrial application, including identification/authentication cameras, robotic products, and sensing cameras, as well as cameras for the home, public spaces, and consumer leisure comprising wearable body cameras, sports action cameras, social media cameras, drones for capturing aerial video or photographs, video conferencing, and virtual reality applications. The company sells its solutions to original design manufacturers and original equipment manufacturers through its direct sales force and distributors. Ambarella, Inc. was incorporated in 2004 and is headquartered in Santa Clara, California.",Dr. Feng-Ming  Wang Ph.D.,Semiconductors,63.51,USD,2693668683,https://images.financialmodelingprep.com/symbol/AMBA.png,882166,-22.36,0.89,627783,-100535000,-117126000,"[{'period': '2025', 'revenue': 284.87, 'unit': 'M', 'net_profit': -117.13}, {'period': '2024', 'revenue': 226.47, 'unit': 'M', 'net_profit': -169.42}, {'period': '2023', 'revenue': 337.61, 'unit': 'M', 'net_profit': -65.39}, {'period': '2022', 'revenue': 331.86, 'unit': 'M', 'net_profit': -26.41}]","[{'period': ""Q4 '25"", 'revenue': 84.02, 'unit': 'M', 'net_profit': -20.23}, {'period': ""Q3 '25"", 'revenue': 82.65, 'unit': 'M', 'net_profit': -24.07}, {'period': ""Q2 '25"", 'revenue': 63.72, 'unit': 'M', 'net_profit': -34.89}, {'period': ""Q1 '25"", 'revenue': 54.47, 'unit': 'M', 'net_profit': -37.93}, {'period': ""Q4 '24"", 'revenue': 51.62, 'unit': 'M', 'net_profit': -60.61}, {'period': ""Q3 '24"", 'revenue': 50.59, 'unit': 'M', 'net_profit': -41.71}]",-2.84,-2.84,688968000,320551000,250265000,127556000,29767000,0,120994000,144622000,23455000,0.22514586079061558,0.3086526145546197,0.33176470588235296,__nan__,__nan__,__nan__,0.18514067416774074
217,AMCX,AMC Networks Inc. Class A Common Stock,"AMC Networks Inc., an entertainment company, owns and operates a suite of video entertainment products that are delivered to audiences and a platform to distributors and advertisers in the United States and internationally. The company operates in two segments, Domestic Operations, and International and Other. The Domestic Operations segment operates various national programming networks, including the AMC, WE tv, BBC AMERICA, IFC, and SundanceTV; provides subscription streaming services comprising Acorn TV, Shudder, Sundance Now, ALLBLK, and HIDIVE, as well as AMC+ and other streaming initiatives; and engages in film distribution business under the IFC Films name. This segment also produces and licenses original programming for various programming networks, as well as services the national programming networks. The International and Other segment operates a portfolio of channels under the AMCNI name; and production and comedy venues activities under the Levity name. AMC Networks Inc. was founded in 1980 and is headquartered in New York, New York.",Ms. Kristin Aigner Dolan,Entertainment,6.23,USD,279896948,https://images.financialmodelingprep.com/symbol/AMCX.png,616893,-1.08,-0.19,791377,985145999,-226546000,"[{'period': '2024', 'revenue': 2420.0, 'unit': 'M', 'net_profit': -226.55}, {'period': '2023', 'revenue': 2710.0, 'unit': 'M', 'net_profit': 215.46}, {'period': '2022', 'revenue': 3100.0, 'unit': 'M', 'net_profit': 11.03}, {'period': '2021', 'revenue': 3080.0, 'unit': 'M', 'net_profit': 250.6}]","[{'period': ""Q1 '25"", 'revenue': 555.23, 'unit': 'M', 'net_profit': 52.06}, {'period': ""Q4 '24"", 'revenue': 599.3, 'unit': 'M', 'net_profit': -284.5}, {'period': ""Q3 '24"", 'revenue': 599.61, 'unit': 'M', 'net_profit': 41.38}, {'period': ""Q2 '24"", 'revenue': 625.93, 'unit': 'M', 'net_profit': -29.23}, {'period': ""Q1 '24"", 'revenue': 596.46, 'unit': 'M', 'net_profit': 45.8}, {'period': ""Q4 '23"", 'revenue': 678.85, 'unit': 'M', 'net_profit': -21.81}]",-5.1,-4.5,4362221000,1670804000,784649000,3422080000,623898000,0,702668000,784649000,330840000,-0.32628948640776767,-2.051433186054283,-2.0365853658536586,__nan__,__nan__,__nan__,0.7844811163854376
218,AMD,Advanced Micro Devices Inc. Common Stock,"Advanced Micro Devices, Inc. operates as a semiconductor company worldwide. The company operates in two segments, Computing and Graphics; and Enterprise, Embedded and Semi-Custom. Its products include x86 microprocessors as an accelerated processing unit, chipsets, discrete and integrated graphics processing units (GPUs), data center and professional GPUs, and development services; and server and embedded processors, and semi-custom System-on-Chip (SoC) products, development services, and technology for game consoles. The company provides processors for desktop and notebook personal computers under the AMD Ryzen, AMD Ryzen PRO, Ryzen Threadripper, Ryzen Threadripper PRO, AMD Athlon, AMD Athlon PRO, AMD FX, AMD A-Series, and AMD PRO A-Series processors brands; discrete GPUs for desktop and notebook PCs under the AMD Radeon graphics, AMD Embedded Radeon graphics brands; and professional graphics products under the AMD Radeon Pro and AMD FirePro graphics brands. It also offers Radeon Instinct, Radeon PRO V-series, and AMD Instinct accelerators for servers; chipsets under the AMD trademark; microprocessors for servers under the AMD EPYC; embedded processor solutions under the AMD Athlon, AMD Geode, AMD Ryzen, AMD EPYC, AMD R-Series, and G-Series processors brands; and customer-specific solutions based on AMD CPU, GPU, and multi-media technologies, as well as semi-custom SoC products. It serves original equipment manufacturers, public cloud service providers, original design manufacturers, system integrators, independent distributors, online retailers, and add-in-board manufacturers through its direct sales force, independent distributors, and sales representatives. The company was incorporated in 1969 and is headquartered in Santa Clara, California.",Dr. Lisa T. Su Ph.D.,Semiconductors,117.17,USD,189979438000,https://images.financialmodelingprep.com/symbol/AMD.png,40978785,85.53,2.18,41318255,1900000000,1641000000,"[{'period': '2024', 'revenue': 25.79, 'unit': 'B', 'net_profit': 1.64}, {'period': '2023', 'revenue': 22680.0, 'unit': 'M', 'net_profit': 854.0}, {'period': '2022', 'revenue': 23.6, 'unit': 'B', 'net_profit': 1.32}, {'period': '2021', 'revenue': 16.43, 'unit': 'B', 'net_profit': 3.16}]","[{'period': ""Q1 '25"", 'revenue': 7440.0, 'unit': 'M', 'net_profit': 709.0}, {'period': ""Q4 '24"", 'revenue': 7660.0, 'unit': 'M', 'net_profit': 482.0}, {'period': ""Q3 '24"", 'revenue': 6820.0, 'unit': 'M', 'net_profit': 771.0}, {'period': ""Q2 '24"", 'revenue': 5830.0, 'unit': 'M', 'net_profit': 265.0}, {'period': ""Q1 '24"", 'revenue': 5470.0, 'unit': 'M', 'net_profit': 123.0}, {'period': ""Q4 '23"", 'revenue': 6170.0, 'unit': 'M', 'net_profit': 667.0}]",1.01,1,69226000000,19049000000,5132000000,11658000000,6933000000,149000000,7281000000,3787000000,2405000000,-0.542058327307785,0.9215456674473068,0.9056603773584905,"[0.01, 0.01]","['1995-04-28', '1995-04-28']",__nan__,0.16840493456215871
219,AMED,Amedisys Inc Common Stock,"Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The Personal Care segment provides assistance for patients with the activities of daily living. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care and palliative care to patients in their homes. As of December 31, 2021, the company owned and operated 331 home health care centers, 175 hospice care centers, and 14 personal-care, and 8 high acuity care centers in 38 states within the United States and the District of Columbia. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.",Mr. Richard M. Ashworth,Medical - Care Facilities,94.62,USD,3105390552,https://images.financialmodelingprep.com/symbol/AMED.png,389962,34.92,0.9,421746,73449000,43231000,"[{'period': '2024', 'revenue': 2350.0, 'unit': 'M', 'net_profit': 43.23}, {'period': '2023', 'revenue': 2240.0, 'unit': 'M', 'net_profit': -9.75}, {'period': '2022', 'revenue': 2220.0, 'unit': 'M', 'net_profit': 118.61}, {'period': '2021', 'revenue': 2210.0, 'unit': 'M', 'net_profit': 209.07}]","[{'period': ""Q1 '25"", 'revenue': 594.78, 'unit': 'M', 'net_profit': 61.01}, {'period': ""Q4 '24"", 'revenue': 598.05, 'unit': 'M', 'net_profit': -20.38}, {'period': ""Q3 '24"", 'revenue': 587.67, 'unit': 'M', 'net_profit': 41.46}, {'period': ""Q2 '24"", 'revenue': 591.19, 'unit': 'M', 'net_profit': 32.3}, {'period': ""Q1 '24"", 'revenue': 571.41, 'unit': 'M', 'net_profit': 14.4}, {'period': ""Q4 '23"", 'revenue': 570.79, 'unit': 'M', 'net_profit': 39.38}]",1.32,1.31,2138714000,632083000,303242000,958749000,306275000,0,514392000,303242000,215115000,-0.6613895893745418,5.435313429773264,5.4,__nan__,__nan__,__nan__,0.4482829401219611
220,AMEH,Apollo Medical Holdings Inc. Common Stock,"Apollo Medical Holdings, Inc., a physician-centric technology-powered healthcare company, provides medical care services. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The company's physician network consists of primary care physicians, specialist physicians, and hospitalists. It serves patients, primarily covered by private or public insurance, such as Medicare, Medicaid, and health maintenance organization plans; and non-insured patients in California. The company was founded in 1994 and is headquartered in Alhambra, California.",Mr. Brandon  Sim,Medical - Care Facilities,40.82,USD,1830332062,https://images.financialmodelingprep.com/symbol/AMEH.png,208841,39.25,-0.88,313943,68865000,43149000,"[{'period': '2024', 'revenue': 2029.9999999999998, 'unit': 'M', 'net_profit': 43.15}, {'period': '2023', 'revenue': 1390.0, 'unit': 'M', 'net_profit': 60.72}, {'period': '2022', 'revenue': 1140.0, 'unit': 'M', 'net_profit': 45.17}, {'period': '2021', 'revenue': 773.91, 'unit': 'M', 'net_profit': 68.92}]","[{'period': ""Q1 '25"", 'revenue': 620.39, 'unit': 'M', 'net_profit': 6.69}, {'period': ""Q4 '24"", 'revenue': 1000.0, 'unit': 'M', 'net_profit': -5.21}, {'period': ""Q3 '24"", 'revenue': 478.71, 'unit': 'M', 'net_profit': 16.09}, {'period': ""Q2 '24"", 'revenue': 486.26, 'unit': 'M', 'net_profit': 19.17}, {'period': ""Q4 '23"", 'revenue': 353.04, 'unit': 'M', 'net_profit': 12.36}, {'period': ""Q3 '23"", 'revenue': 348.17, 'unit': 'M', 'net_profit': 22.06}]",0.91,0.9,937199000,318873000,161181000,256076000,115223000,15442000,222688000,158922000,44167000,-0.463120473380162,-0.2893423588121943,-0.3,__nan__,__nan__,__nan__,0.27323546013173294
221,AMGN,Amgen Inc. Common Stock,"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.",Mr. Robert A. Bradway,Drug Manufacturers - General,272.41,USD,146476491460,https://images.financialmodelingprep.com/symbol/AMGN.png,3469188,24.81,0.72,2586425,13356000000,4090000000,"[{'period': '2024', 'revenue': 33.42, 'unit': 'B', 'net_profit': 4.09}, {'period': '2023', 'revenue': 28.19, 'unit': 'B', 'net_profit': 6.72}, {'period': '2022', 'revenue': 26.32, 'unit': 'B', 'net_profit': 6.55}, {'period': '2021', 'revenue': 25.98, 'unit': 'B', 'net_profit': 5.89}]","[{'period': ""Q1 '25"", 'revenue': 8.15, 'unit': 'B', 'net_profit': 1.73}, {'period': ""Q4 '24"", 'revenue': 9090.0, 'unit': 'M', 'net_profit': 627.0}, {'period': ""Q3 '24"", 'revenue': 8.5, 'unit': 'B', 'net_profit': 2.83}, {'period': ""Q2 '24"", 'revenue': 8390.0, 'unit': 'M', 'net_profit': 746.0}, {'period': ""Q1 '24"", 'revenue': 7450.0, 'unit': 'M', 'net_profit': -113.0}, {'period': ""Q4 '23"", 'revenue': 8200.0, 'unit': 'M', 'net_profit': 767.0}]",7.56,7.56,91839000000,29030000000,11973000000,85962000000,7501000000,0,23099000000,11973000000,10394000000,-0.09155216977282002,-0.3910972160190561,-0.39808917197452237,"[2.38, 0.28]","['2025-05-16', '2011-08-16']",__nan__,0.9360075784797308
222,AMHC,Amplitude Healthcare Acquisition Corporation Class A Common Stock,"Amplitude Healthcare Acquisition Corporation does not have significant operations. It intends to acquire assets and businesses through a merger, share exchange, share purchase, reorganization, or similar business combination with one or more businesses in the healthcare or healthcare related industries. The company was founded in 2019 and is based in New York, New York.",Mr. Balaji Venkataraman,Shell Companies,10.23,USD,1118364060,https://images.financialmodelingprep.com/symbol/AMHC.png,263450,0,-0.42000008,245352,-552250,-590701,"[{'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -590.7}]","[{'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.57}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 5.5}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -513.8}, {'period': ""Q2 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -282.06}, {'period': ""Q1 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 38.86}]",-0.0473,-0.0473,101261021,921642,101109493,3769451,0,0,269451,770114,-640984,0,0,0,__nan__,__nan__,__nan__,0.03722509375053605
223,AMHCU,Amplitude Healthcare Acquisition Corporation Unit,"Amplitude Healthcare Acquisition Corporation does not have significant operations. It intends to acquire assets and businesses through a merger, share exchange, share purchase, reorganization, or similar business combination with one or more businesses in the healthcare or healthcare related industries. The company was founded in 2019 and is based in New York, New York.",Mr. Balaji Venkataraman,Shell Companies,10.96,USD,0,https://images.financialmodelingprep.com/symbol/AMHCU.png,1193,0,0.35999966,4228,-552250,-590701,"[{'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -590.7}]","[{'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.57}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 5.5}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -513.8}, {'period': ""Q2 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -282.06}, {'period': ""Q1 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 38.86}]",-0.0473,-0.0473,101261021,921642,101109493,3769451,0,0,269451,770114,-640984,0,0,0,__nan__,__nan__,__nan__,0.03722509375053605
224,AMHCW,Amplitude Healthcare Acquisition Corporation Warrants,,None,Shell Companies,1.57,USD,0,https://images.financialmodelingprep.com/symbol/AMHCW.png,0,0,0.05000007,92280,-552250,-590701,"[{'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -590.7}]","[{'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.57}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 5.5}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -513.8}, {'period': ""Q2 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -282.06}, {'period': ""Q1 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 38.86}]",-0.0473,-0.0473,101261021,921642,101109493,3769451,0,0,269451,770114,-640984,0,0,0,__nan__,__nan__,__nan__,0.03722509375053605
225,AMKR,Amkor Technology Inc. Common Stock,"Amkor Technology, Inc. provides outsourced semiconductor packaging and test services in the United States, Japan, Europe, the Middle East, Africa, and the rest of the Asia Pacific. It offers turnkey packaging and test services, including semiconductor wafer bump, wafer probe, wafer back-grind, package design, packaging, and test and drop shipment services. The company also provides flip chip-scale package products for use in smartphones, tablets, and other mobile consumer electronic devices; flip-chip stacked chip-scale packages that are used to stack memory on top of digital baseband, and as applications processors in mobile devices; and flip-chip ball grid array packages for various networking, storage, computing, and consumer applications. In addition, it offers wafer-level CSP packages that are used in power management, transceivers, sensors, wireless charging, codecs, radar, and specialty silicon; wafer-level fan-out packages for use in ICs; and silicon wafer integrated fan-out technology, which replaces a laminate substrate with a thinner structure. Further, the company provides lead frame packages that are used in electronic devices for low to medium pin count analog and mixed-signal applications; substrate-based wirebond packages, which are used to connect a die to a substrate; micro-electro-mechanical systems (MEMS) packages that are miniaturized mechanical and electromechanical devices; and advanced system-in-package modules, which are used in radio frequency and front end modules, basebands, connectivity, fingerprint sensors, display and touch screen drivers, sensors and MEMS, and NAND memory and solid-state drives. It primarily serves integrated device manufacturers, fabless semiconductor companies, original equipment manufacturers, and contract foundries. Amkor Technology, Inc. was founded in 1968 and is headquartered in Tempe, Arizona.",Mr. Guillaume Marie Jean Rutten,Semiconductors,19.73,USD,4874414880,https://images.financialmodelingprep.com/symbol/AMKR.png,2593393,15.54,-0.19,1750145,1090624000,354012000,"[{'period': '2024', 'revenue': 6320.0, 'unit': 'M', 'net_profit': 354.01}, {'period': '2023', 'revenue': 6500.0, 'unit': 'M', 'net_profit': 359.81}, {'period': '2022', 'revenue': 7090.0, 'unit': 'M', 'net_profit': 765.82}, {'period': '2021', 'revenue': 6140.0, 'unit': 'M', 'net_profit': 643.0}]","[{'period': ""Q1 '25"", 'revenue': 1320.0, 'unit': 'M', 'net_profit': 21.13}, {'period': ""Q4 '24"", 'revenue': 1630.0, 'unit': 'M', 'net_profit': 105.65}, {'period': ""Q3 '24"", 'revenue': 1860.0, 'unit': 'M', 'net_profit': 122.57}, {'period': ""Q2 '24"", 'revenue': 1460.0, 'unit': 'M', 'net_profit': 66.9}, {'period': ""Q1 '24"", 'revenue': 1370.0, 'unit': 'M', 'net_profit': 58.9}, {'period': ""Q4 '23"", 'revenue': 1750.0, 'unit': 'M', 'net_profit': 117.56}]",1.44,1.43,6944328000,3073472000,1646537000,2761163000,1055013000,0,1455275000,1133553000,345072000,-0.03854633803176977,-0.01612226350910056,-0.013698630136986314,"[0.08269, 0.04]","['2025-03-13', '2020-12-17']",__nan__,0.397614139193886
226,AMNB,American National Bankshares Inc. Common Stock,"American National Bankshares Inc. operates as the bank holding company for American National Bank and Trust Company that provides financial products and services. The company operates in two segments, Community Banking and Wealth Management. It accepts deposit products, including checking, money market, savings, and consumer and commercial time deposits. The company's loan products comprise commercial and residential real estate loans, commercial loans to small and medium-sized businesses, construction and land development loans, home equity loans, mortgage loans, and consumer loans. It also offers wealth management services, including estate planning, trust account administration, and retail brokerage services; investment management services, such as purchasing equity, fixed income, and mutual fund investments for customer accounts; online and telephone banking services; and insurance services, as well as operates 37 automated teller machines. As of December 31, 2021, the company operated 26 banking offices in south central Virginia and north central North Carolina; and one loan production office in Roanoke, Virginia. American National Bankshares Inc. was founded in 1909 and is based in Danville, Virginia.",Mr. Jeffrey Vernon Haley,Banks - Regional,47.76,USD,507722232,https://images.financialmodelingprep.com/symbol/AMNB.png,20507,19.414634146341463,-0.16,119440,0,26159000,"[{'period': '2023', 'revenue': 138.73, 'unit': 'M', 'net_profit': 26.16}, {'period': '2022', 'revenue': 109.27, 'unit': 'M', 'net_profit': 34.43}, {'period': '2021', 'revenue': 112.31, 'unit': 'M', 'net_profit': 43.53}, {'period': '2020', 'revenue': 100.77, 'unit': 'M', 'net_profit': 30.05}]","[{'period': ""Q4 '23"", 'revenue': 36.31, 'unit': 'M', 'net_profit': 4.08}, {'period': ""Q3 '23"", 'revenue': 25.44, 'unit': 'M', 'net_profit': 5.79}, {'period': ""Q2 '23"", 'revenue': 25.51, 'unit': 'M', 'net_profit': 7.14}, {'period': ""Q1 '23"", 'revenue': 27.7, 'unit': 'M', 'net_profit': 9.16}, {'period': ""Q4 '22"", 'revenue': 28.04, 'unit': 'M', 'net_profit': 8.03}, {'period': ""Q3 '22"", 'revenue': 28.77, 'unit': 'M', 'net_profit': 9.26}]",2.46,2.46,3090717000,76011000,-31500000,2747549000,0,47112000,903522000,66719000,16822000,0,-0.2401824096665505,-0.23839009287925697,"[0.3, 0.27]","['2024-02-16', '1995-06-06']",__nan__,0.8889681585211457
227,AMOT,Allied Motion Technologies Inc.,"Allied Motion Technologies Inc., together with its subsidiaries, designs, manufactures, and sells precision and specialty controlled motion components and systems that are used in a range of industries worldwide. The company offers brush and brushless DC motors, brushless servo and torque motors, coreless DC motors, integrated brushless motor-drives, gearmotors, gearing, modular digital servo drives, motion controllers, optical encoders, active, and passive filters. It also provides electronic power steering, drive-by-wire applications, drive systems and pumps, automated and remotely guided power steering, and HVAC systems, and construction and agricultural equipment. The company sells its products to end customers and original equipment manufacturers in vehicle, medical, aerospace and defense, and industrial markets through direct sales force, as well as authorized manufacturers' representatives, agents, and distributors. Allied Motion Technologies Inc. was incorporated in 1962 and is headquartered in Amherst, New York.",Mr. Richard S. Warzala,"Hardware, Equipment & Parts",34.08,USD,550906608,https://images.financialmodelingprep.com/symbol/AMOT.png,68443,23.50344827586207,0.69,84782,30038000,13166000,"[{'period': '2024', 'revenue': 529.97, 'unit': 'M', 'net_profit': 13.17}, {'period': '2023', 'revenue': 578.63, 'unit': 'M', 'net_profit': 24.1}, {'period': '2022', 'revenue': 502.99, 'unit': 'M', 'net_profit': 17.39}, {'period': '2021', 'revenue': 403.52, 'unit': 'M', 'net_profit': 24.09}]","[{'period': ""Q1 '25"", 'revenue': 132.8, 'unit': 'M', 'net_profit': 3.56}, {'period': ""Q4 '24"", 'revenue': 92.33, 'unit': 'M', 'net_profit': -6.58}, {'period': ""Q3 '24"", 'revenue': 125.21, 'unit': 'M', 'net_profit': 2.1}, {'period': ""Q2 '24"", 'revenue': 136.03, 'unit': 'M', 'net_profit': 1.15}, {'period': ""Q3 '23"", 'revenue': 145.32, 'unit': 'M', 'net_profit': 6.67}, {'period': ""Q2 '23"", 'revenue': 146.77, 'unit': 'M', 'net_profit': 6.77}]",0.8,0.79,575781000,237580000,36102000,310927000,78774000,0,57377000,36102000,32167000,-0.290116746230562,-0.4536249325642196,-0.45945945945945943,"[0.03, 0.1]","['2023-08-16', '1987-02-13']",__nan__,0.5400091354178064
228,AMPG,Amplitech Group Inc. Common Stock,"AmpliTech Group, Inc. designs, engineers, and assembles micro-wave component-based amplifiers. The company's products include radio frequency (RF) amplifiers and related subsystems, such as low noise amplifiers for use in receivers of various communication systems comprising Wi-Fi, radar, satellite, base station, cell phone, radio, etc.; and medium power amplifiers that provide enhanced output power and gain in transceiver chains. It also provides specialty microwave block downconverters used as a test device on satellite access point antennas; specialty microwave 1:2 Tx protection switch panels that is used in satellite communication earth stations; desktop/benchtop and compact wideband power amplifiers; and waveguide to coaxial adapters for SATCOM and satellite internet gateway systems. In addition, the company offers cryogenic amplifiers for quantum computing, medical, RF imaging, research and development, space communications, accelerators, radiometry, and telephony applications; and cryogenic and non-cryogenic 4g/5g small cell subsystems for high-speed networks and airline Wi-Fi systems. Further, it provides custom assembly designs and non-recurring engineering services on a project-by-project basis, as well as IC packaging and lids products. The company serves aerospace, government, defense, commercial satellite, and wireless industries through sales representatives and distributors in the United States, Europe, the Middle East, and South Asia. AmpliTech Group, Inc. was founded in 2002 and is based in Bohemia, New York.",Mr. Fawad A. Maqbool,Communication Equipment,2.06,USD,40497540,https://images.financialmodelingprep.com/symbol/AMPG.png,294841,-1.91,0.08,641334,-7423300,-11242404,"[{'period': '2024', 'revenue': 9.51, 'unit': 'M', 'net_profit': -11.24}, {'period': '2023', 'revenue': 15.58, 'unit': 'M', 'net_profit': -2.47}, {'period': '2022', 'revenue': 19.39, 'unit': 'M', 'net_profit': -1.49}, {'period': '2021', 'revenue': 5.28, 'unit': 'M', 'net_profit': -5.06}]","[{'period': ""Q1 '25"", 'revenue': 3.6, 'unit': 'M', 'net_profit': -1.84}, {'period': ""Q4 '24"", 'revenue': 1.85, 'unit': 'M', 'net_profit': -3.82}, {'period': ""Q3 '24"", 'revenue': 2.83, 'unit': 'M', 'net_profit': -1.19}, {'period': ""Q2 '24"", 'revenue': 2.53, 'unit': 'M', 'net_profit': -1.58}, {'period': ""Q1 '24"", 'revenue': 2.29, 'unit': 'M', 'net_profit': -4.66}, {'period': ""Q4 '23"", 'revenue': 4010.0, 'unit': 'K', 'net_profit': -523.0}]",-1.12,-1.12,43220482,28331386,19315984,5729681,1256725,348250,1535641,19315984,-5338634,-2.6275347248013072,-3.560000876111719,-3.307692307692308,__nan__,__nan__,__nan__,0.13256865113165558
229,AMPGW,Amplitech Group Inc. Warrants,"AmpliTech Group, Inc. designs, engineers, and assembles micro-wave component based amplifiers. The company's products include radio frequency amplifiers and related subsystems, such as low noise amplifiers for use in receivers of various communication systems comprise Wi-Fi, radar, satellite, base station, cell phone, radio, etc.; medium power amplifiers to provide increased output power and gain in transceiver chains; oscillators that consist of phase locked oscillators and dielectric resonator oscillators for transceiver applications; and filters that discriminate or block out frequencies in communication systems. It also provides custom assembly designs and non-recurring engineering services on a project-by-project basis. The company serves aerospace, government, defense, and commercial satellite industries. It sells its products through sales representatives or distributors in North America, Europe, and Asia. AmpliTech Group, Inc. was founded in 2002 and is based in Bohemia, New York.",Mr. Fawad A. Maqbool,Communication Equipment,0.4991,USD,36966326,https://images.financialmodelingprep.com/symbol/AMPGW.png,14090,,0.0301,10277,-7423300,-11242404,"[{'period': '2024', 'revenue': 9.51, 'unit': 'M', 'net_profit': -11.24}, {'period': '2023', 'revenue': 15.58, 'unit': 'M', 'net_profit': -2.47}, {'period': '2022', 'revenue': 19.39, 'unit': 'M', 'net_profit': -1.49}, {'period': '2021', 'revenue': 5.28, 'unit': 'M', 'net_profit': -5.06}]","[{'period': ""Q1 '25"", 'revenue': 3.6, 'unit': 'M', 'net_profit': -1.84}, {'period': ""Q4 '24"", 'revenue': 1.85, 'unit': 'M', 'net_profit': -3.82}, {'period': ""Q3 '24"", 'revenue': 2.83, 'unit': 'M', 'net_profit': -1.19}, {'period': ""Q2 '24"", 'revenue': 2.53, 'unit': 'M', 'net_profit': -1.58}, {'period': ""Q1 '24"", 'revenue': 2.29, 'unit': 'M', 'net_profit': -4.66}, {'period': ""Q4 '23"", 'revenue': 4010.0, 'unit': 'K', 'net_profit': -523.0}]",-1.12,-1.12,43220482,28331386,19315984,5729681,1256725,348250,1535641,19315984,-5338634,-2.6275347248013072,-3.560000876111719,-3.307692307692308,__nan__,__nan__,__nan__,0.13256865113165558
230,AMPH,Amphastar Pharmaceuticals Inc. Common Stock,"Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.",Dr. Yongfeng  Zhang Ph.D.,Drug Manufacturers - Specialty & Generic,24.86,USD,1171878026,https://images.financialmodelingprep.com/symbol/AMPH.png,653630,9.01,0.54,461513,277312000,159519000,"[{'period': '2024', 'revenue': 712.81, 'unit': 'M', 'net_profit': 159.52}, {'period': '2023', 'revenue': 644.39, 'unit': 'M', 'net_profit': 137.54}, {'period': '2022', 'revenue': 498.99, 'unit': 'M', 'net_profit': 91.39}, {'period': '2021', 'revenue': 437.77, 'unit': 'M', 'net_profit': 62.12}]","[{'period': ""Q1 '25"", 'revenue': 170.53, 'unit': 'M', 'net_profit': 25.29}, {'period': ""Q4 '24"", 'revenue': 186.52, 'unit': 'M', 'net_profit': 37.96}, {'period': ""Q3 '24"", 'revenue': 188.82, 'unit': 'M', 'net_profit': 40.43}, {'period': ""Q2 '24"", 'revenue': 182.39, 'unit': 'M', 'net_profit': 37.95}, {'period': ""Q1 '24"", 'revenue': 171.84, 'unit': 'M', 'net_profit': 43.18}, {'period': ""Q4 '23"", 'revenue': 178.1, 'unit': 'M', 'net_profit': 36.17}]",3.29,3.06,1577470000,534071000,221645000,845172000,138036000,10996000,173759000,151609000,172345000,0.1540529518007108,0.15975862445017994,0.15438596491228068,"[0.3, 0.3]","['2010-06-11', '2009-06-11']",__nan__,0.5357769085941413
231,AMRB,American River Bankshares Common Stock,"American River Bankshares operates as a bank holding company, which engages in financial services. The company is headquartered in Rancho Cordova, California and currently employs 104 full-time employees. The firm's banking subsidiary is American River Bank (the Bank). The Bank's primary business is serving the commercial banking needs of small to mid-sized businesses. The Bank accepts checking and savings deposits; offers money market deposit accounts and certificates of deposit; makes secured and unsecured commercial loans, secured real estate loans, and other installment and term loans, and offers other customary banking services. The Bank also conducts lease financing for various types of business equipment, from computer software to heavy earth-moving equipment. The company serves various communities located in Sacramento, Placer, Yolo, El Dorado, Sonoma and Amador counties. The company also serves Alameda, Contra Costa and Santa Clara Counties through loan production offices located in the Cities of San Jose and San Ramon. Its loans include real estate construction loans; lease financing receivable; agriculture loans, and consumer loans.",Mr. David Ritchie,Banks - Regional,20.91,USD,0,https://images.financialmodelingprep.com/symbol/AMRB.png,10735,13.930712858094603,0.40999985,115144,11580000,7055000,"[{'period': '2020', 'revenue': 27.84, 'unit': 'M', 'net_profit': 7.05}, {'period': '2019', 'revenue': 24.9, 'unit': 'M', 'net_profit': 5.5}, {'period': '2018', 'revenue': 22.16, 'unit': 'M', 'net_profit': 4.9}, {'period': '2017', 'revenue': 20.95, 'unit': 'M', 'net_profit': 3.2}]","[{'period': ""Q2 '21"", 'revenue': 7.66, 'unit': 'M', 'net_profit': 2.37}, {'period': ""Q1 '21"", 'revenue': 7.72, 'unit': 'M', 'net_profit': 2.65}, {'period': ""Q4 '20"", 'revenue': 7.25, 'unit': 'M', 'net_profit': 2.1}, {'period': ""Q3 '20"", 'revenue': 7.09, 'unit': 'M', 'net_profit': 1.78}, {'period': ""Q2 '20"", 'revenue': 6.86, 'unit': 'M', 'net_profit': 1.74}, {'period': ""Q1 '20"", 'revenue': 6.64, 'unit': 'M', 'net_profit': 1.43}]",1.2,1.2,30351000,14030000,349475000,775896000,9215000,306978000,7000000,42509000,6423000,0.14903750744195277,0.2827272727272727,0.2765957446808511,"[0.07, 0.125]","['2021-07-27', '1994-07-06']",__nan__,25.56410002965306
232,AMRK,A-Mark Precious Metals Inc. Common Stock,"A-Mark Precious Metals, Inc., together with its subsidiaries, operates as a precious metals trading company. It operates in three segments: Wholesale Sales & Ancillary Services, Direct-to-Consumer, and Secured Lending. The Wholesale Sales & Ancillary Services segment sells gold, silver, platinum, and palladium in the form of bars, plates, powders, wafers, grains, ingots, and coins. This segment also offers various ancillary services, including financing, storage, consignment, logistics, and various customized financial programs; and designs and produces minted silver products. The Direct-to-Consumer segment provides access to an array of gold, silver, copper, platinum, and palladium products through its websites and marketplaces. It operates five company-owned websites targeting specific niches within the precious metals retail market. This segment also operates as a direct retailer of precious metals to the investor community and markets its precious metal products on television, radio, and the internet, as well as through customer service outreach. The Secured Lending segment originates and acquires commercial loans secured by bullion and numismatic coins; and serves coin and precious metal dealers, investors, and collectors. The company serves customers, including financial institutions, bullion retailers, industrial manufacturers and fabricators, sovereign mints, refiners, coin and metal dealers, investors, collectors, and e-commerce and other retail customers. It has operations in the United States, rest of North America, Europe, the Asia Pacific, Africa, and Australia. A-Mark Precious Metals, Inc. was founded in 1965 and is headquartered in El Segundo, California.",Mr. Gregory N. Roberts,Financial - Capital Markets,21.43,USD,527707321,https://images.financialmodelingprep.com/symbol/AMRK.png,301824,13.65,0.25,202032,133706000,68546000,"[{'period': '2024', 'revenue': 9700.0, 'unit': 'M', 'net_profit': 68.55}, {'period': '2023', 'revenue': 9320.0, 'unit': 'M', 'net_profit': 156.36}, {'period': '2022', 'revenue': 8160.0, 'unit': 'M', 'net_profit': 132.54}, {'period': '2021', 'revenue': 7610.0, 'unit': 'M', 'net_profit': 159.64}]","[{'period': ""Q3 '25"", 'revenue': 3010.0, 'unit': 'M', 'net_profit': -8.55}, {'period': ""Q2 '25"", 'revenue': 2740.0, 'unit': 'M', 'net_profit': 6.56}, {'period': ""Q1 '25"", 'revenue': 2720.0, 'unit': 'M', 'net_profit': 8.98}, {'period': ""Q4 '24"", 'revenue': 2520.0, 'unit': 'M', 'net_profit': 30.94}, {'period': ""Q3 '24"", 'revenue': 2630.0, 'unit': 'M', 'net_profit': 5.01}, {'period': ""Q2 '24"", 'revenue': 2080.0, 'unit': 'M', 'net_profit': 13.77}]",2.97,2.84,1827820000,1442203000,48636000,1165964000,36596000,50458000,883770000,48636000,45163000,-0.3623087489030486,-0.5616142235865951,-0.5553892215568862,"[0.2, 0.05]","['2025-04-15', '2015-03-10']",__nan__,0.6378986989966189
233,AMRN,Amarin Corporation plc,"Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.",Mr. Aaron D. Berg,Biotechnology,10.58,USD,219080039,https://images.financialmodelingprep.com/symbol/AMRN.png,97913,-2.4,0.06,59937,-74218219,-82183000,"[{'period': '2024', 'revenue': 228.61, 'unit': 'M', 'net_profit': -82.18}, {'period': '2023', 'revenue': 306.91, 'unit': 'M', 'net_profit': -59.11}, {'period': '2022', 'revenue': 369.19, 'unit': 'M', 'net_profit': -105.8}, {'period': '2021', 'revenue': 583.19, 'unit': 'M', 'net_profit': 7.73}]","[{'period': ""Q1 '25"", 'revenue': 41.03, 'unit': 'M', 'net_profit': -15.7}, {'period': ""Q4 '24"", 'revenue': 62.31, 'unit': 'M', 'net_profit': -48.62}, {'period': ""Q3 '24"", 'revenue': 42.3, 'unit': 'M', 'net_profit': -25.13}, {'period': ""Q2 '24"", 'revenue': 67.57, 'unit': 'M', 'net_profit': 1.52}, {'period': ""Q1 '24"", 'revenue': 56.49, 'unit': 'M', 'net_profit': -9.95}, {'period': ""Q4 '23"", 'revenue': 75.36, 'unit': 'M', 'net_profit': -5.83}]",-0.2,-0.2,685349000,595399000,294220000,199173000,122279000,0,179949000,121038000,-31020000,-0.45807439465818817,-0.3902930031127351,-0.3333333333333335,__nan__,__nan__,__nan__,0.2906154382657595
234,AMRS,Amyris Inc. Common Stock,"Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. It offers its products under the Biossance, Pipette, Purecane, Terasana, Costa Brazil, OLIKA, Rose Inc., and JVN brand names. The company has a collaboration agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California.",Mr. Hermanus  Kieftenbeld,Chemicals - Specialty,0.05,USD,0,https://images.financialmodelingprep.com/symbol/AMRS.png,46746028,-0.04310344827586207,0,46746028,-514205000,-535928000,"[{'period': '2022', 'revenue': 269.85, 'unit': 'M', 'net_profit': -535.93}, {'period': '2021', 'revenue': 341.82, 'unit': 'M', 'net_profit': -264.2}, {'period': '2020', 'revenue': 173.14, 'unit': 'M', 'net_profit': -324.14}, {'period': '2019', 'revenue': 152.56, 'unit': 'M', 'net_profit': -242.77}]","[{'period': ""Q1 '23"", 'revenue': 56.08, 'unit': 'M', 'net_profit': -201.78}, {'period': ""Q4 '22"", 'revenue': 75.8, 'unit': 'M', 'net_profit': -150.66}, {'period': ""Q3 '22"", 'revenue': 71.13, 'unit': 'M', 'net_profit': -167.27}, {'period': ""Q2 '22"", 'revenue': 65.21, 'unit': 'M', 'net_profit': -108.55}, {'period': ""Q1 '22"", 'revenue': 57.71, 'unit': 'M', 'net_profit': -109.44}, {'period': ""Q4 '21"", 'revenue': 64.78, 'unit': 'M', 'net_profit': 37.84}]",-1.58,-1.58,824932000,306361000,64437000,1292642000,97568000,10892000,387147000,64437000,-631841000,-1.6950371337075532,-1.0285165993557837,-0.7555555555555555,__nan__,__nan__,__nan__,1.5669679440244773
235,AMSC,American Superconductor Corporation Common Stock,"American Superconductor Corporation, together with its subsidiaries, provides megawatt-scale power resiliency solutions worldwide. The company operates in two segments, Grid and Wind. The Grid segment offers products and services that enable electric utilities, industrial facilities, and renewable energy project developers to connect, transmit, and distribute power under the Gridtec Solutions brand; and engineering planning services. It provides transmission planning services, which identify power grid congestion, poor power quality, and other risks; grid interconnection solutions for wind farms and solar power plants, power quality systems, and transmission and distribution cable systems; resilient electric grid systems, resilient electric grid systems; D-VAR systems used for controlling power flow and voltage in the AC transmission system; actiVAR system, a fast-switching medium-voltage reactive compensation solution; armorVAR system installed for reactive compensation, power factor correction, loss reduction, utility bill savings, and mitigation of common power quality concerns related to power converter-based generation and load devices; and D-VAR volt var optimization (VVO) that serves the distribution power grid market. This segment also offers ship protection systems, which reduce a naval ship's magnetic signature; and in board power delivery systems, power generation systems, and propulsion systems; and transformers and rectifiers systems. The Wind segment designs wind turbine systems and licenses these designs to third parties under the Windtec Solutions brand. It supplies power electronics and software-based control systems, engineered designs, and support services; and provides customer support services to wind turbine manufacturers. This segment's design portfolio comprises a range of drivetrains and power ratings of 2 megawatts and higher. The company was incorporated in 1987 and is headquartered in Ayer, Massachusetts.",Mr. Daniel Patrick McGahn,Industrial - Machinery,24.02,USD,947821994,https://images.financialmodelingprep.com/symbol/AMSC.png,717911,266.89,0.5,381265,-1966000,-11111000,"[{'period': '2023', 'revenue': 145.64, 'unit': 'M', 'net_profit': -11.11}, {'period': '2022', 'revenue': 105.98, 'unit': 'M', 'net_profit': -35.04}, {'period': '2021', 'revenue': 108.44, 'unit': 'M', 'net_profit': -19.19}, {'period': '2020', 'revenue': 87.12, 'unit': 'M', 'net_profit': -22.68}]","[{'period': ""Q3 '24"", 'revenue': 61.4, 'unit': 'M', 'net_profit': 2.46}, {'period': ""Q2 '24"", 'revenue': 54.47, 'unit': 'M', 'net_profit': 4.89}, {'period': ""Q1 '24"", 'revenue': 40.29, 'unit': 'M', 'net_profit': -2.52}, {'period': ""Q4 '23"", 'revenue': 42.03, 'unit': 'M', 'net_profit': -1.58}, {'period': ""Q3 '23"", 'revenue': 39.35, 'unit': 'M', 'net_profit': -1.65}, {'period': ""Q2 '23"", 'revenue': 34.0, 'unit': 'M', 'net_profit': -2.48}]",-0.37,-0.37,232771000,166467000,90522000,88200000,26325000,0,78808000,90522000,1204000,0.925895212966453,0.6829143003909706,0.7063492063492064,__nan__,__nan__,__nan__,0.37891318076564523
236,AMSF,AMERISAFE Inc. Common Stock,"AMERISAFE, Inc., an insurance holding company, underwrites workers' compensation insurance in the United States. The company's workers' compensation insurance policies provide benefits to injured employees for temporary or permanent disability, death, and medical and hospital expenses. It serves small to mid-sized employers engaged in hazardous industries, including construction, trucking, logging and lumber, agriculture, manufacturing, telecommunications, and maritime. The company was incorporated in 1985 and is based in DeRidder, Louisiana.",Ms. Gerry Janelle Frost,Insurance - Specialty,47.95,USD,913461885,https://images.financialmodelingprep.com/symbol/AMSF.png,101574,18.73,0.43,99604,0,55436000,"[{'period': '2024', 'revenue': 309.04, 'unit': 'M', 'net_profit': 55.44}, {'period': '2023', 'revenue': 306.91, 'unit': 'M', 'net_profit': 62.11}, {'period': '2022', 'revenue': 294.69, 'unit': 'M', 'net_profit': 55.6}, {'period': '2021', 'revenue': 316.01, 'unit': 'M', 'net_profit': 65.76}]","[{'period': ""Q1 '25"", 'revenue': 72.6, 'unit': 'M', 'net_profit': 8.95}, {'period': ""Q4 '24"", 'revenue': 74.05, 'unit': 'M', 'net_profit': 13.19}, {'period': ""Q3 '24"", 'revenue': 78.71, 'unit': 'M', 'net_profit': 14.32}, {'period': ""Q2 '24"", 'revenue': 75.83, 'unit': 'M', 'net_profit': 10.99}, {'period': ""Q1 '24"", 'revenue': 80.49, 'unit': 'M', 'net_profit': 16.93}, {'period': ""Q4 '23"", 'revenue': 80.12, 'unit': 'M', 'net_profit': 19.18}]",2.91,2.89,1157791000,501781000,351795000,900450000,149986000,481028000,1430000,44045000,23350000,0,-0.10742577445739679,-0.10185185185185187,"[0.39, 0.08]","['2025-06-13', '2013-03-12']",__nan__,0.777731041267379
237,AMST,Amesite Inc. Common Stock,"Amesite Inc., an artificial intelligence driven platform and course designer, provides online products in the United States. The company uses machine learning to offer a mass customized experience to learners. Its customers include businesses, universities and colleges, K-12 schools, and non-profit organizations. The company was incorporated in 2017 and is headquartered in Detroit, Michigan.",Dr. Ann Marie Sastry Ph.D.,Software - Application,3.36,USD,13420210,https://images.financialmodelingprep.com/symbol/AMST.png,763212,-1.92,1.12,64462149,-3869515,-4403182,"[{'period': '2024', 'revenue': 0.16688, 'unit': 'M', 'net_profit': -4.4}, {'period': '2023', 'revenue': 0.84501, 'unit': 'M', 'net_profit': -4.15}, {'period': '2022', 'revenue': 0.6970000000000001, 'unit': 'M', 'net_profit': -9.07}, {'period': '2021', 'revenue': 0.6745800000000001, 'unit': 'M', 'net_profit': -15.2}]","[{'period': ""Q3 '25"", 'revenue': 30.69, 'unit': 'K', 'net_profit': -663.42}, {'period': ""Q2 '25"", 'revenue': 0.01276, 'unit': 'M', 'net_profit': -1.12}, {'period': ""Q1 '25"", 'revenue': 11.25, 'unit': 'K', 'net_profit': -908.04}, {'period': ""Q4 '24"", 'revenue': 0.02784, 'unit': 'M', 'net_profit': -1.18}, {'period': ""Q3 '24"", 'revenue': 0.03426, 'unit': 'M', 'net_profit': -1.43}, {'period': ""Q2 '24"", 'revenue': 41.44, 'unit': 'K', 'net_profit': -905.61}]",-1.73,-1.73,3314177,2604565,2071016,798465,30060,0,798465,2071016,-3189645,-0.09245841009027322,-0.060163922545501736,-0.029761904761904788,__nan__,__nan__,__nan__,0.24092406651787154
238,AMSWA,American Software Inc. Class A Common Stock,"American Software, Inc. develops, markets, and supports a range of computer business application software products in the United States and internationally. The company operates in three segments: Supply Chain Management (SCM), Information Technology Consulting (IT Consulting), and Other. The SCM segment offers Logility Digital Supply Chain Platform, a cloud-architected supply chain management platform that helps manage seven critical planning processes, such as product, demand, inventory, supply, deploy, integrated business planning, and supply chain data management. The IT Consulting segment provides IT staffing and consulting services, such as software enhancement, documentation, update, customer education, consulting, systems integration, maintenance, and support services. The Other segment offers American Software ERP, which provides purchasing and materials management, customer order processing, financial, e-commerce, and traditional manufacturing solutions. It also provides ongoing support and maintenance services; cloud hosting and managed services; and implementation and training services. The company markets its products through direct and indirect sales channels to the apparel and other soft goods, food and beverage, consumer packaged goods, consumer durable goods, wholesale distribution, specialty chemicals, and other process manufacturing industries. American Software, Inc. was incorporated in 1970 and is headquartered in Atlanta, Georgia.",Mr. H. Allan Dow,Software - Application,10.95,USD,388512570,https://images.financialmodelingprep.com/symbol/AMSWA.png,226237,40.55555555555556,-0.24,113503,8089000,11373000,"[{'period': '2024', 'revenue': 102.52, 'unit': 'M', 'net_profit': 11.37}, {'period': '2023', 'revenue': 123.66, 'unit': 'M', 'net_profit': 10.31}, {'period': '2022', 'revenue': 127.55, 'unit': 'M', 'net_profit': 12.8}, {'period': '2021', 'revenue': 111.41, 'unit': 'M', 'net_profit': 8.09}]","[{'period': ""Q3 '25"", 'revenue': 25.01, 'unit': 'M', 'net_profit': -2.76}, {'period': ""Q2 '25"", 'revenue': 25.29, 'unit': 'M', 'net_profit': -2.02}, {'period': ""Q1 '25"", 'revenue': 26.19, 'unit': 'M', 'net_profit': 2.05}, {'period': ""Q4 '24"", 'revenue': 25.39, 'unit': 'M', 'net_profit': 2.17}, {'period': ""Q3 '24"", 'revenue': 25.54, 'unit': 'M', 'net_profit': 4.09}, {'period': ""Q2 '24"", 'revenue': 25.69, 'unit': 'M', 'net_profit': 2.36}]",0.27,0.27,192444000,116196000,83773000,61963000,28339000,0,60343000,59512000,14283000,-0.35689298775640005,0.10288983708301008,-0.12903225806451607,"[0.11, 0.0237]","['2024-11-15', '1986-07-21']",__nan__,0.3219793810147368
239,AMTB,Amerant Bancorp Inc. Class A Common Stock,"Amerant Bancorp Inc. operates as the bank holding company for Amerant Bank, N.A. that provides banking products and services to individuals and businesses in the United States and internationally. The company offers checking, savings, and money market accounts; and certificates of deposits. It also provides variable and fixed rate commercial real estate loans; loans secured by owner-occupied properties; loans to domestic and foreign individuals primarily secured by personal residence; working capital loans, asset-based lending, participations in shared national credits, purchased receivables, and small business administration loans; loans to financial institutions and acceptances; and consumer loans and overdrafts, such as automobile, personal, or loans secured by cash or securities and revolving credit card agreements. In addition, the company offers trust and estate planning products and services to high-net-worth customers, brokerage and investment advisory services in global capital markets, and wealth management and fiduciary services. Further, it provides debit and credit cards, night depositories, direct deposits, cashier's checks, safe deposit boxes, letters of credit, and treasury management services, including wire transfer, remote deposit capture, and automated clearinghouse services; derivative instruments; and online and mobile banking, account balances, statements and other documents, online transfers and bill payment, and electronic delivery of customer statements services, as well as automated teller machines, and banking by mobile devices, telephone, and mail. As of December 31, 2021, the company operated 24 banking centers comprising 17 in Florida and 7 in Texas. It also operates loan production offices in Tampa, Florida. The company was formerly known as Mercantil Bank Holding Corporation and changed its name to Amerant Bancorp Inc. in June 2019. Amerant Bancorp Inc. was founded in 1979 and is headquartered in Coral Gables, Florida.","Mr. Gerald Paul Plush C.M.A., C.P.A.",Banks - Regional,18.09,USD,756684801,https://images.financialmodelingprep.com/symbol/AMTB.png,196475,-37.69,-0.17,115834,0,-15752000,"[{'period': '2024', 'revenue': 305.29, 'unit': 'M', 'net_profit': -15.75}, {'period': '2023', 'revenue': 328.91, 'unit': 'M', 'net_profit': 32.49}, {'period': '2022', 'revenue': 266.67, 'unit': 'M', 'net_profit': 63.31}, {'period': '2021', 'revenue': 205.14, 'unit': 'M', 'net_profit': 112.92}]","[{'period': ""Q1 '25"", 'revenue': 164.26, 'unit': 'M', 'net_profit': 15.43}, {'period': ""Q4 '24"", 'revenue': 84.58, 'unit': 'M', 'net_profit': 16.88}, {'period': ""Q3 '24"", 'revenue': 31.51, 'unit': 'M', 'net_profit': -48.16}, {'period': ""Q2 '24"", 'revenue': 96.75, 'unit': 'M', 'net_profit': 4.96}, {'period': ""Q1 '24"", 'revenue': 92.45, 'unit': 'M', 'net_profit': 10.57}, {'period': ""Q4 '23"", 'revenue': 57.15, 'unit': 'M', 'net_profit': -17.12}]",-0.44,-0.44,9901734000,1476367000,1476367000,9011267000,0,1439647000,59843000,565994000,74793000,0,-1.4848261003385657,-1.4536082474226804,"[0.09, 0.06]","['2025-05-15', '2021-12-21']",__nan__,0.9100695898314376
240,AMTBB,Amerant Bancorp Inc. Class B Common Stock,"Amerant Bancorp Inc. operates as the bank holding company for Amerant Bank, N.A. that provides banking products and services to individuals and businesses in the United States and internationally. It offers a range of checking and savings accounts, certificates of deposit, and money market accounts. The company also provides variable and fixed rate commercial real estate loans; loans secured by owner-occupied properties; loans to domestic and foreign individuals primarily secured by personal residence; working capital loans, asset-based lending, participations in shared national credits, purchased receivables, and small business administration loans; loans to financial institutions and acceptances; and consumer loans and overdrafts. In addition, it offers trust and estate planning products and services, brokerage and investment advisory services in global capital markets, and wealth management and fiduciary services. Further, the company provides debit and credit cards; remote deposit capture, online and mobile banking, night depository, direct deposit, and treasury management services; and cashier's checks, safe deposit boxes, and letters of credit, as well as automated teller machines. As of April 10, 2020, it operated 27 banking centers comprising 19 in South Florida and 8 in Houston, Texas, as well as loan production offices in Dallas, Texas, and New York. The company was formerly known as Mercantil Bank Holding Corporation and changed its name to Amerant Bancorp Inc. in June 2019. Amerant Bancorp Inc. was founded in 1979 and is headquartered in Coral Gables, Florida.",Mr. Millar Wilson,Banks - Regional,28.72,USD,0,https://images.financialmodelingprep.com/symbol/AMTBB.png,18790,19.847961299239806,-0.3600006,3933,0,-15752000,"[{'period': '2024', 'revenue': 305.29, 'unit': 'M', 'net_profit': -15.75}, {'period': '2023', 'revenue': 328.91, 'unit': 'M', 'net_profit': 32.49}, {'period': '2022', 'revenue': 266.67, 'unit': 'M', 'net_profit': 63.31}, {'period': '2021', 'revenue': 205.14, 'unit': 'M', 'net_profit': 112.92}]","[{'period': ""Q1 '25"", 'revenue': 164.26, 'unit': 'M', 'net_profit': 15.43}, {'period': ""Q4 '24"", 'revenue': 84.58, 'unit': 'M', 'net_profit': 16.88}, {'period': ""Q3 '24"", 'revenue': 31.51, 'unit': 'M', 'net_profit': -48.16}, {'period': ""Q2 '24"", 'revenue': 96.75, 'unit': 'M', 'net_profit': 4.96}, {'period': ""Q1 '24"", 'revenue': 92.45, 'unit': 'M', 'net_profit': 10.57}, {'period': ""Q4 '23"", 'revenue': 57.15, 'unit': 'M', 'net_profit': -17.12}]",-0.44,-0.44,9901734000,1476367000,1476367000,9011267000,0,1439647000,59843000,565994000,74793000,0,-1.4848261003385657,-1.4536082474226804,__nan__,__nan__,__nan__,0.9100695898314376
241,AMTI,Applied Molecular Transport Inc. Common Stock,"Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral and respiratory biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications. It develops AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California.",Mr. Shawn M. Cross,Biotechnology,0.263,USD,11006287,https://images.financialmodelingprep.com/symbol/AMTI.png,320195,-0.13915343915343914,-0.0085,235210,-127219000,-125431000,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -125.43}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -96.41}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -64.49}, {'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': -28.04}]","[{'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -6.94}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -17.33}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -26.77}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -22.1}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -24.89}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -35.87}]",-3.23,-3.23,107446000,64019000,61145000,46608000,0,0,15087000,61145000,-98052000,-0.2622309974302751,-0.3010164920651385,-0.26171874999999994,__nan__,__nan__,__nan__,0.4337806898348938
242,AMTX,Aemetis Inc. Common Stock,"Aemetis, Inc. operates as a renewable natural gas and renewable fuels company in North America and India. It operates through three segments: California Ethanol, Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the acquisition, development, and commercialization of negative carbon intensity products and technologies that replace traditional petroleum-based products. It sells biodiesel primarily to government oil marketing companies, transport companies, resellers, distributors, and private refiners through its own sales force and independent sales agents, as well as to brokers who resell the product to end-users. The company also produces and sells ethanol; and wet distillers grains, distillers corn oil, and condensed distillers solubles to dairies and feedlots as animal feed. In addition, it produces dairy biogas; produces and sells high-grade alcohol and various feed products, as well as hand sanitizers; and researches and develops conversion technologies using waste feedstocks to produce biofuels and biochemicals. The company was formerly known as AE Biofuels, Inc. and changed its name to Aemetis, Inc. in November 2011. Aemetis, Inc. was founded in 2005 and is headquartered in Cupertino, California.",Mr. Eric A. McAfee,Oil & Gas Refining & Marketing,1.7,USD,94127980,https://images.financialmodelingprep.com/symbol/AMTX.png,892383,-0.94,0.07,1715170,-37126000,-87537000,"[{'period': '2024', 'revenue': 267.64, 'unit': 'M', 'net_profit': -87.54}, {'period': '2023', 'revenue': 186.72, 'unit': 'M', 'net_profit': -46.42}, {'period': '2022', 'revenue': 256.51, 'unit': 'M', 'net_profit': -107.76}, {'period': '2021', 'revenue': 211.95, 'unit': 'M', 'net_profit': -47.15}]","[{'period': ""Q1 '25"", 'revenue': 42.89, 'unit': 'M', 'net_profit': -24.53}, {'period': ""Q4 '24"", 'revenue': 47.0, 'unit': 'M', 'net_profit': -16.2}, {'period': ""Q3 '24"", 'revenue': 81.44, 'unit': 'M', 'net_profit': -17.93}, {'period': ""Q2 '24"", 'revenue': 66.56, 'unit': 'M', 'net_profit': -29.17}, {'period': ""Q1 '24"", 'revenue': 72.63, 'unit': 'M', 'net_profit': -24.23}, {'period': ""Q4 '23"", 'revenue': 70.76, 'unit': 'M', 'net_profit': -25.44}]",-1.91,-1.91,259302000,44696000,898000,523230000,14105000,0,143968000,898000,-53183000,-0.06552248658267083,-0.8857604480827229,-0.5655737704918032,__nan__,__nan__,__nan__,2.017840201772451
243,AMWD,American Woodmark Corporation Common Stock,"American Woodmark Corporation manufactures and distributes kitchen, bath, office, home organization, and hardware products for the remodelling and new home construction markets in the United States. The company offers made-to-order and cash and carry products. It also provides turnkey installation services to its direct builder customers through a network of eight service centers. The company sells its products under the American Woodmark, Timberlake, Shenandoah Cabinetry, Waypoint Living Spaces, Estate, Stor-It-All, and Professional Cabinet Solutions brands, as well as Hampton Bay, Glacier Bay, Style Selections, Allen + Roth, Home Decorators Collection, and Project Source. It markets its products directly to home centers and builders, as well as through independent dealers and distributors. The company was incorporated in 1980 and is based in Winchester, Virginia.",Mr. M. Scott Culbreth,"Furnishings, Fixtures & Appliances",61.55,USD,913075785,https://images.financialmodelingprep.com/symbol/AMWD.png,169037,9.48,1.04,112910,238956000,116216000,"[{'period': '2024', 'revenue': 1850.0, 'unit': 'M', 'net_profit': 116.22}, {'period': '2023', 'revenue': 2070.0, 'unit': 'M', 'net_profit': 93.72}, {'period': '2022', 'revenue': 1860.0, 'unit': 'M', 'net_profit': -29.72}, {'period': '2021', 'revenue': 1740.0, 'unit': 'M', 'net_profit': 61.19}]","[{'period': ""Q3 '25"", 'revenue': 397.58, 'unit': 'M', 'net_profit': 16.57}, {'period': ""Q2 '25"", 'revenue': 452.48, 'unit': 'M', 'net_profit': 27.69}, {'period': ""Q1 '25"", 'revenue': 459.13, 'unit': 'M', 'net_profit': 29.63}, {'period': ""Q4 '24"", 'revenue': 453.28, 'unit': 'M', 'net_profit': 26.8}, {'period': ""Q3 '24"", 'revenue': 422.1, 'unit': 'M', 'net_profit': 21.23}, {'period': ""Q2 '24"", 'revenue': 473.87, 'unit': 'M', 'net_profit': 30.34}]",7.15,7.15,1593865000,402710000,87398000,683489000,132107000,0,195726000,87398000,139702000,0.045192105815662395,0.23999445173543313,0.26773049645390085,"[0.09, 0.005]","['2011-06-09', '1996-09-11']",__nan__,0.42882490047776944
244,AMYT,Amryt Pharma plc American Depositary Shares,"Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.",Dr. Joseph A. Wiley,Drug Manufacturers - Specialty & Generic,14.7,USD,0,https://images.financialmodelingprep.com/symbol/AMYT.png,2376385,39.729729729729726,0,2376385,29103000,-18171000,"[{'period': '2021', 'revenue': 222.54, 'unit': 'M', 'net_profit': -18.17}, {'period': '2020', 'revenue': 182.61, 'unit': 'M', 'net_profit': -104.53}, {'period': '2019', 'revenue': 58.12, 'unit': 'M', 'net_profit': -65.53}, {'period': '2018', 'revenue': 16.53, 'unit': 'M', 'net_profit': -29.49}]","[{'period': ""Q3 '22"", 'revenue': 61.13, 'unit': 'M', 'net_profit': -20.8}, {'period': ""Q2 '22"", 'revenue': 68.54, 'unit': 'M', 'net_profit': -7.05}, {'period': ""Q1 '22"", 'revenue': 59.13, 'unit': 'M', 'net_profit': -14.49}, {'period': ""Q4 '21"", 'revenue': 54.83, 'unit': 'M', 'net_profit': 22.37}, {'period': ""Q3 '21"", 'revenue': 56.52, 'unit': 'M', 'net_profit': -17.21}, {'period': ""Q2 '21"", 'revenue': 62.76, 'unit': 'M', 'net_profit': -6.8}]",-0.39,-0.37,783365000,282709000,112771000,445918000,53908000,0,157279000,112771000,13986000,30.788126919140225,0.8261597481990299,0.8664383561643835,__nan__,__nan__,__nan__,0.56923400968897
245,AMZN,Amazon.com Inc. Common Stock,"Amazon.com, Inc. engages in the retail sale of consumer products and subscriptions through online and physical stores in North America and internationally. The company operates through three segments: North America, International, and Amazon Web Services (AWS). Its products offered through its stores include merchandise and content purchased for resale; and products offered by third-party sellers The company also manufactures and sells electronic devices, including Kindle, Fire tablets, Fire TVs, Rings, Blink, eero, and Echo; and develops and produces media content. In addition, it offers programs that enable sellers to sell their products in its stores; and programs that allow authors, musicians, filmmakers, Twitch streamers, skill and app developers, and others to publish and sell content. Further, the company provides compute, storage, database, analytics, machine learning, and other services, as well as fulfillment, advertising, and digital content subscriptions. Additionally, it offers Amazon Prime, a membership program. The company serves consumers, sellers, developers, enterprises, content creators, and advertisers. Amazon.com, Inc. was incorporated in 1994 and is headquartered in Seattle, Washington.",Mr. Andrew R. Jassy,Specialty Retail,205.59,USD,2182625676000,https://images.financialmodelingprep.com/symbol/AMZN.png,52173369,33.54,0.42,41874015,123815000000,59248000000,"[{'period': '2024', 'revenue': 637.96, 'unit': 'B', 'net_profit': 59.25}, {'period': '2023', 'revenue': 574.78, 'unit': 'B', 'net_profit': 30.43}, {'period': '2022', 'revenue': 513.98, 'unit': 'B', 'net_profit': -2.72}, {'period': '2021', 'revenue': 469.82, 'unit': 'B', 'net_profit': 33.36}]","[{'period': ""Q1 '25"", 'revenue': 155.67, 'unit': 'B', 'net_profit': 17.13}, {'period': ""Q4 '24"", 'revenue': 187.79, 'unit': 'B', 'net_profit': 20.0}, {'period': ""Q3 '24"", 'revenue': 158.88, 'unit': 'B', 'net_profit': 15.33}, {'period': ""Q2 '24"", 'revenue': 147.98, 'unit': 'B', 'net_profit': 13.48}, {'period': ""Q1 '24"", 'revenue': 143.31, 'unit': 'B', 'net_profit': 10.43}, {'period': ""Q4 '23"", 'revenue': 169.96, 'unit': 'B', 'net_profit': 10.62}]",5.66,5.53,624894000000,190867000000,101202000000,338924000000,55451000000,0,179431000000,78779000000,32878000000,0.3849242746247288,0.9473459326211997,0.9186440677966101,__nan__,__nan__,__nan__,0.5423703860174686
246,ANAB,AnaptysBio Inc. Common Stock,"AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.",Mr. Daniel R. Faga,Biotechnology,20.22,USD,594073710,https://images.financialmodelingprep.com/symbol/ANAB.png,751077,-4.25,-0.18,349802,-92744000,-145231000,"[{'period': '2024', 'revenue': 91.28, 'unit': 'M', 'net_profit': -145.23}, {'period': '2023', 'revenue': 17.16, 'unit': 'M', 'net_profit': -163.62}, {'period': '2022', 'revenue': 10.29, 'unit': 'M', 'net_profit': -128.72}, {'period': '2021', 'revenue': 63.17, 'unit': 'M', 'net_profit': -57.19}]","[{'period': ""Q1 '25"", 'revenue': 27.77, 'unit': 'M', 'net_profit': -39.33}, {'period': ""Q4 '24"", 'revenue': 43.11, 'unit': 'M', 'net_profit': -21.78}, {'period': ""Q3 '24"", 'revenue': 30.02, 'unit': 'M', 'net_profit': -32.85}, {'period': ""Q2 '24"", 'revenue': 10.97, 'unit': 'M', 'net_profit': -46.66}, {'period': ""Q1 '24"", 'revenue': 7.18, 'unit': 'M', 'net_profit': -43.94}, {'period': ""Q4 '23"", 'revenue': 9.01, 'unit': 'M', 'net_profit': -42.21}]",-5.12,-5.12,483834000,431876000,385373000,412966000,40765000,35470000,45428000,123080000,-135695000,0.3521835098209047,0.11238303619995232,0.15789473684210525,__nan__,__nan__,__nan__,0.8535282762269704
247,ANAT,American National Group Inc. Common Stock,"American National Group, Inc., together with its subsidiaries, provides life insurance, annuities, property and casualty insurance, health insurance, credit insurance, and pension products in the United States, the District of Columbia, and Puerto Rico. It operates through five segments: Life, Annuity, Health, Property and Casualty, and Corporate and Other. The Life segment offers whole life, term life, universal life, variable universal life, and credit life insurance products. The Annuity segment provides deferred, single premium immediate, and variable annuity products. The Health segment offers medicare supplement, supplemental, stop-loss, credit disability, and medical expense insurance products. The Property and Casualty segment provides personal lines insurance, such as auto, homeowners, boats, motorcycles, recreational vehicles, and other exposures; commercial lines of insurance, including property and casualty coverage tailored for a farm, ranch, or other agricultural business, as well as business owners' property and liability, workers' compensation insurance, and other commercial insurance; and specialty markets products comprising collateral or creditor protection insurance, and guaranteed auto protection or guaranteed asset protection insurance. The Corporate and Other segment engages in the investment activities. The company distributes its products through career, multiple-line, and independent agents, as well as direct marketing channels; brokers and financial institutions; managing general underwriters; and multiple-line and managing general agents. American National Group, Inc. was incorporated in 1905 and is headquartered in Galveston, Texas.",Mr. James Pozzi,Insurance - Diversified,188.99,USD,0,https://images.financialmodelingprep.com/symbol/ANAT.png,108431,6.725383438311804,-0.06999207,72185,915893000,696408000,"[{'period': '2021', 'revenue': 4390.0, 'unit': 'M', 'net_profit': 696.41}, {'period': '2020', 'revenue': 3790.0, 'unit': 'M', 'net_profit': 467.5}, {'period': '2019', 'revenue': 4070.0000000000005, 'unit': 'M', 'net_profit': 620.36}, {'period': '2018', 'revenue': 3330.0, 'unit': 'M', 'net_profit': 159.0}]","[{'period': ""Q1 '22"", 'revenue': 946.13, 'unit': 'M', 'net_profit': 111.55}, {'period': ""Q4 '21"", 'revenue': 1210.0, 'unit': 'M', 'net_profit': 249.64}, {'period': ""Q3 '21"", 'revenue': 975.23, 'unit': 'M', 'net_profit': 51.05}, {'period': ""Q2 '21"", 'revenue': 1170.0, 'unit': 'M', 'net_profit': 227.98}, {'period': ""Q1 '21"", 'revenue': 1040.0, 'unit': 'M', 'net_profit': 170.17}, {'period': ""Q4 '20"", 'revenue': 1190.0, 'unit': 'M', 'net_profit': 306.35}]",25.9,25.9,31312630000,2892645000,12151862000,24318262000,842183000,17571189000,149248000,1930882000,313637000,0.4385836777070444,0.48962684891070685,0.48936170212765945,"[0.82, 0.47]","['2022-03-03', '1985-06-10']",__nan__,0.7766278974330805
248,ANDA,Andina Acquisition Corp. III Ordinary Shares,"Andina Acquisition Corp. III is a blank check company for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities. The company is headquartered in New York, New York. The firm's purpose is to enter into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities.",Mr. Julio A. Torres Garca,Shell Companies,9.2,USD,335919600,https://images.financialmodelingprep.com/symbol/ANDA.png,30343,0,0.3000002,314275,-1139861,0,"[{'period': '2020', 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.76}, {'period': '2018', 'revenue': 0.0, 'unit': 'K', 'net_profit': -14.77}, {'period': '2017', 'revenue': 0.0, 'unit': '', 'net_profit': -424.0}]","[{'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -790.13}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': ""Q2 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -781.0}, {'period': ""Q4 '19"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 390.43}, {'period': ""Q2 '19"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 585.8}, {'period': ""Q4 '18"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -7.49}]",0,0,13743695,198192,13743695,8743689,0,0,0,198192,-254332,-1.646749093731613,-1,-1,__nan__,__nan__,__nan__,0.6361963795034742
249,ANDAR,Andina Acquisition Corp. III Right,"Andina Acquisition Corp. III is a blank check company for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities. The company is headquartered in New York, New York. The firm's purpose is to enter into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities.",Mr. Julio A. Torres Garca,Shell Companies,0.905,USD,0,https://images.financialmodelingprep.com/symbol/ANDAR.png,0,0,0.09499997,512197,-1139861,0,"[{'period': '2020', 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.76}, {'period': '2018', 'revenue': 0.0, 'unit': 'K', 'net_profit': -14.77}, {'period': '2017', 'revenue': 0.0, 'unit': '', 'net_profit': -424.0}]","[{'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -790.13}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': ""Q2 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -781.0}, {'period': ""Q4 '19"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 390.43}, {'period': ""Q2 '19"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 585.8}, {'period': ""Q4 '18"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -7.49}]",0,0,13743695,198192,13743695,8743689,0,0,0,198192,-254332,-1.646749093731613,-1,-1,__nan__,__nan__,__nan__,0.6361963795034742
250,ANDAU,Andina Acquisition Corp. III Unit,"Andina Acquisition Corp. III does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities. The company was founded in 2016 and is based in Bogot, Colombia.",Mr. Julio A. Torres Garca,Shell Companies,11.1,USD,405294300,https://images.financialmodelingprep.com/symbol/ANDAU.png,409,-17.34375,0,1123,-1139861,0,"[{'period': '2020', 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.76}, {'period': '2018', 'revenue': 0.0, 'unit': 'K', 'net_profit': -14.77}, {'period': '2017', 'revenue': 0.0, 'unit': '', 'net_profit': -424.0}]","[{'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -790.13}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': ""Q2 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -781.0}, {'period': ""Q4 '19"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 390.43}, {'period': ""Q2 '19"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 585.8}, {'period': ""Q4 '18"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -7.49}]",0,0,13743695,198192,13743695,8743689,0,0,0,198192,-254332,-1.646749093731613,-1,-1,__nan__,__nan__,__nan__,0.6361963795034742
251,ANDAW,Andina Acquisition Corp. III Warrant,,None,Shell Companies,1.27,USD,0,https://images.financialmodelingprep.com/symbol/ANDAW.png,0,0,0.14999998,666563,-1139861,0,"[{'period': '2020', 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.76}, {'period': '2018', 'revenue': 0.0, 'unit': 'K', 'net_profit': -14.77}, {'period': '2017', 'revenue': 0.0, 'unit': '', 'net_profit': -424.0}]","[{'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -790.13}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': ""Q2 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -781.0}, {'period': ""Q4 '19"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 390.43}, {'period': ""Q2 '19"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 585.8}, {'period': ""Q4 '18"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -7.49}]",0,0,13743695,198192,13743695,8743689,0,0,0,198192,-254332,-1.646749093731613,-1,-1,__nan__,__nan__,__nan__,0.6361963795034742
252,ANDE,Andersons Inc. (The) Common Stock,"The Andersons, Inc., an agriculture company, operates in trade, renewables, and plant nutrient sectors in the United States and internationally. The company's Trade segment operates grain elevators; stores commodities; and provides grain marketing, risk management, and origination services to its customers and affiliated ethanol facilities. This segment also engages in the commodity merchandising business, as well as offers logistics for physical commodities, such as whole grains, grain products, feed ingredients, domestic fuel products, and other agricultural commodities. Its Renewables segment produces, purchases, and sells ethanol, and co-products, as well as offers facility operations, risk management, and ethanol and coproducts marketing services to the ethanol plants it invests in and operates. The company's Plant Nutrient segment manufactures, distributes, and retails agricultural and related plant nutrients, corncob-based products, and pelleted lime and gypsum products; and crop nutrients, crop protection chemicals, and seed products, as well as provides application and agronomic services to commercial and family farmers. It also offers warehousing, packaging, and manufacturing services to nutrient producers and other distributors; and manufactures and distributes various industrial products, such as nitrogen reagents for air pollution control systems that are used in coal-fired power plants, and water treatment and dust abatement products. In addition, this segment produces corncob-based products for laboratory animal bedding and private-label cat litter, as well as absorbents, blast cleaners, carriers, and polishers; professional lawn care products for golf course and turf care markets; fertilizer and weed and pest control products; pelleted lime, gypsum, and value add soil amendments; and specialty ag liquids, seed starters, zinc, and industrial liquids. The Andersons, Inc. was founded in 1947 and is based in Maumee, Ohio.",Mr. William E. Krueger,Food Distribution,36.07,USD,1233153946,https://images.financialmodelingprep.com/symbol/ANDE.png,384054,10.86,0.63,221639,359753000,114012000,"[{'period': '2024', 'revenue': 11260.0, 'unit': 'M', 'net_profit': 114.01}, {'period': '2023', 'revenue': 14750.0, 'unit': 'M', 'net_profit': 101.19}, {'period': '2022', 'revenue': 17330.0, 'unit': 'M', 'net_profit': 131.08}, {'period': '2021', 'revenue': 12610.0, 'unit': 'M', 'net_profit': 103.99}]","[{'period': ""Q1 '25"", 'revenue': 2660000.0, 'unit': 'K', 'net_profit': 284.0}, {'period': ""Q4 '24"", 'revenue': 3120.0, 'unit': 'M', 'net_profit': 45.09}, {'period': ""Q3 '24"", 'revenue': 2620.0, 'unit': 'M', 'net_profit': 27.36}, {'period': ""Q2 '24"", 'revenue': 2800.0, 'unit': 'M', 'net_profit': 35.98}, {'period': ""Q1 '24"", 'revenue': 2720.0, 'unit': 'M', 'net_profit': 5.58}, {'period': ""Q4 '23"", 'revenue': 3210.0, 'unit': 'M', 'net_profit': 51.19}]",3.35,3.32,4121314000,2850277000,561771000,2521478000,764550000,0,1731172000,561771000,182319000,0.053338447484306196,0.12671212570412096,0.1166666666666667,"[0.195, 0.03]","['2025-04-01', '1996-12-30']",__nan__,0.6118140961838869
253,ANEB,Anebulo Pharmaceuticals Inc. Common Stock,"Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.",Mr. Richard Anthony Cunningham,Biotechnology,1.02,USD,41906394,https://images.financialmodelingprep.com/symbol/ANEB.png,27883,-3.52,0.01,15969,-8050473,-8201703,"[{'period': '2024', 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.2}, {'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -11.73}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -6.81}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -30.26}]","[{'period': ""Q3 '25"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.68}, {'period': ""Q2 '25"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.46}, {'period': ""Q1 '25"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.2}, {'period': ""Q4 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.35}, {'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.65}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.72}]",-0.32,-0.32,4073114,3507990,3094200,260583,0,0,260583,3094200,-8090849,0.31680694497496054,0.3009319199634378,0.3191489361702127,__nan__,__nan__,__nan__,0.06397635813777862
254,ANGI,Angi Inc. Class A Common Stock,"Angi Inc. connects home service professionals with consumers in the United States and internationally. Its Angi Ads business, which connects consumers with service professionals for local services through the Angi nationwide online directory of service professionals in various service categories; provides consumers with valuable tools, services, and content, including verified reviews, to help them research, shop, and hire for local services; and sells term-based website, and mobile and digital magazine advertising to service professionals, as well as provides quoting, invoicing, and payment services. The company also owns and operates Angi Leads digital marketplace service that connects consumers with service professionals for home repair, maintenance, and improvement projects; offers consumers with tools and resources to find local, pre-screened, and customer-rated service professionals, as well as online appointment booking; and connects consumers with service professionals by telephone, and home services-related resources. In addition, it operates Handy, a platform for household services, primarily cleaning and handyman services; Angi Roofing, which provides roof replacement and repair services; and home services marketplaces under the Travaux, MyHammer, Werkspot, MyBuilder, and Instapro names. As of December 31, 2021, it had a network of approximately 206,000 transacting service professionals; and approximately 38,000 advertising service professionals. The company was formerly known as ANGI Homeservices Inc. and changed its name to Angi Inc. in March 2021. The company was incorporated in 2017 and is headquartered in Denver, Colorado. Angi Inc. is a subsidiary of IAC/InterActiveCorp.",Mr. Jeffrey W. Kip,Internet Content & Information,16.38,USD,786027060,https://images.financialmodelingprep.com/symbol/ANGI.png,1030552,15.9,0.03,922089,128898000,36004000,"[{'period': '2024', 'revenue': 1190.0, 'unit': 'M', 'net_profit': 36.0}, {'period': '2023', 'revenue': 1360.0, 'unit': 'M', 'net_profit': -40.94}, {'period': '2022', 'revenue': 1890.0, 'unit': 'M', 'net_profit': -127.98}, {'period': '2021', 'revenue': 1690.0, 'unit': 'M', 'net_profit': -70.49}]","[{'period': ""Q1 '25"", 'revenue': 245.91, 'unit': 'M', 'net_profit': 15.11}, {'period': ""Q4 '24"", 'revenue': 267.87, 'unit': 'M', 'net_profit': -1.29}, {'period': ""Q3 '24"", 'revenue': 296.72, 'unit': 'M', 'net_profit': 35.16}, {'period': ""Q2 '24"", 'revenue': 315.13, 'unit': 'M', 'net_profit': 3.76}, {'period': ""Q1 '24"", 'revenue': 305.39, 'unit': 'M', 'net_profit': -1.63}, {'period': ""Q4 '23"", 'revenue': 300.43, 'unit': 'M', 'net_profit': -5.56}]",0.072,0.0711,1830735000,495085000,416434000,767934000,36670000,0,231678000,416434000,105449000,0.37872094640125786,1.8794333170493405,1.8899876390605683,__nan__,__nan__,__nan__,0.4194675908856279
255,ANGN,Angion Biomedica Corp. Common Stock,"Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung. It also develops ANG-3777, a hepatocyte growth factor mimetic to treat acute organ injuries, such as delayed graft function; ROCK2 inhibitors programs for fibrotic diseases; and CYP11B2 inhibitor program. The company was incorporated in 1998 and is based in Uniondale, New York.","Dr. Jay R. Venkatesan M.B.A., M.D., Ph.D.",Biotechnology,1,USD,30113700,https://images.financialmodelingprep.com/symbol/ANGN.png,9772,-0.09891196834817013,0,224803,-44986000,-51898000,"[{'period': '2024', 'revenue': 0.0, 'unit': 'M', 'net_profit': -51.9}, {'period': '2022', 'revenue': 2.3, 'unit': 'M', 'net_profit': -55.7}, {'period': '2021', 'revenue': 28.31, 'unit': 'M', 'net_profit': -53.77}, {'period': '2020', 'revenue': 2.88, 'unit': 'M', 'net_profit': -79.48}]","[{'period': ""Q1 '25"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -11.21}, {'period': ""Q4 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -29.21}, {'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -18.84}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -7.23}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -10.66}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -7.56}]",-4.25,-4.25,28178000,20693000,17618000,39490000,0,0,11523000,17618000,-37155000,0,0,0,__nan__,__nan__,__nan__,1.4014479381077436
256,ANGO,AngioDynamics Inc. Common Stock,"AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.",Mr. James C. Clemmer,Medical - Instruments & Supplies,9.4,USD,381705800,https://images.financialmodelingprep.com/symbol/ANGO.png,506119,-9.31,0.23,207770,-14292000,-184349000,"[{'period': '2024', 'revenue': 303.91, 'unit': 'M', 'net_profit': -184.35}, {'period': '2023', 'revenue': 338.75, 'unit': 'M', 'net_profit': -52.44}, {'period': '2022', 'revenue': 316.22, 'unit': 'M', 'net_profit': -26.55}, {'period': '2021', 'revenue': 291.01, 'unit': 'M', 'net_profit': -31.55}]","[{'period': ""Q3 '25"", 'revenue': 72.0, 'unit': 'M', 'net_profit': -4.41}, {'period': ""Q2 '25"", 'revenue': 72.84, 'unit': 'M', 'net_profit': -10.74}, {'period': ""Q1 '25"", 'revenue': 67.49, 'unit': 'M', 'net_profit': -12.8}, {'period': ""Q4 '24"", 'revenue': 70.98, 'unit': 'M', 'net_profit': -13.45}, {'period': ""Q3 '24"", 'revenue': 75.18, 'unit': 'M', 'net_profit': -187.74}, {'period': ""Q2 '24"", 'revenue': 79.07, 'unit': 'M', 'net_profit': -29.05}]",-4.59,-4.59,317671000,193253000,76056000,112085000,43610000,0,91155000,76056000,-33926000,-2.1720518287682467,-2.515293085694672,-2.451127819548872,__nan__,__nan__,__nan__,0.352833591986678
257,ANIK,Anika Therapeutics Inc. Common Stock,"Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.",Dr. Cheryl Renee Blanchard Ph.D.,Medical - Devices,12.19,USD,174821666,https://images.financialmodelingprep.com/symbol/ANIK.png,86729.2,-16.25,-0.05,74541,3020000,-56385000,"[{'period': '2024', 'revenue': 119.91, 'unit': 'M', 'net_profit': -56.38}, {'period': '2023', 'revenue': 166.66, 'unit': 'M', 'net_profit': -82.67}, {'period': '2022', 'revenue': 156.24, 'unit': 'M', 'net_profit': -14.86}, {'period': '2021', 'revenue': 147.79, 'unit': 'M', 'net_profit': 4.13}]","[{'period': ""Q1 '25"", 'revenue': 26.17, 'unit': 'M', 'net_profit': -4.87}, {'period': ""Q4 '24"", 'revenue': -1.29, 'unit': 'M', 'net_profit': -21.86}, {'period': ""Q3 '24"", 'revenue': 38.75, 'unit': 'M', 'net_profit': -29.92}, {'period': ""Q2 '24"", 'revenue': 41920.0, 'unit': 'K', 'net_profit': -88.0}, {'period': ""Q1 '24"", 'revenue': 40.52, 'unit': 'M', 'net_profit': -4.51}, {'period': ""Q4 '23"", 'revenue': 42.97, 'unit': 'M', 'net_profit': -63.0}]",-3.83,-3.83,202740000,113652000,55629000,48751000,23594000,0,23306000,55629000,-2331000,1.2688746438746439,0.3179261373946073,0.3209219858156028,__nan__,__nan__,__nan__,0.24046068856663708
258,ANIP,ANI Pharmaceuticals Inc.,"ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.",Mr. Nikhil  Lalwani,Drug Manufacturers - Specialty & Generic,59.99,USD,1298849489,https://images.financialmodelingprep.com/symbol/ANIP.png,404622,-50.84,0.46,364642,79147000,-18522000,"[{'period': '2024', 'revenue': 614.38, 'unit': 'M', 'net_profit': -18.52}, {'period': '2023', 'revenue': 486.82, 'unit': 'M', 'net_profit': 18.78}, {'period': '2022', 'revenue': 316.38, 'unit': 'M', 'net_profit': -47.9}, {'period': '2021', 'revenue': 216.14, 'unit': 'M', 'net_profit': -42.6}]","[{'period': ""Q1 '25"", 'revenue': 197.12, 'unit': 'M', 'net_profit': 15.68}, {'period': ""Q4 '24"", 'revenue': 190.57, 'unit': 'M', 'net_profit': -10.28}, {'period': ""Q3 '24"", 'revenue': 148.33, 'unit': 'M', 'net_profit': -24.17}, {'period': ""Q2 '24"", 'revenue': 138.04, 'unit': 'M', 'net_profit': -2.29}, {'period': ""Q1 '24"", 'revenue': 137.43, 'unit': 'M', 'net_profit': 18.21}, {'period': ""Q4 '23"", 'revenue': 131.65, 'unit': 'M', 'net_profit': 1.16}]",-0.87,-0.87,1283697000,527684000,151168000,855167000,221726000,0,193680000,144861000,47064000,-0.257527957500659,-1.9863145002396294,-1.9157894736842105,__nan__,__nan__,__nan__,0.6661751176484794
259,ANIX,Anixa Biosciences Inc. Common Stock,"Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.",Dr. Amit  Kumar Ph.D.,Biotechnology,2.65,USD,85321785,https://images.financialmodelingprep.com/symbol/ANIX.png,65800,-6.79,0.13,58657,-12661000,-12554000,"[{'period': '2024', 'revenue': 0.0, 'unit': 'M', 'net_profit': -12.55}, {'period': '2023', 'revenue': 0.21, 'unit': 'M', 'net_profit': -9.81}, {'period': '2022', 'revenue': 2470.0, 'unit': 'M', 'net_profit': -13.49}, {'period': '2021', 'revenue': 0.5125, 'unit': 'M', 'net_profit': -12.95}]","[{'period': ""Q1 '25"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.18}, {'period': ""Q4 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.88}, {'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.28}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.14}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.25}, {'period': ""Q4 '23"", 'revenue': 0.156, 'unit': 'M', 'net_profit': -2.69}]",-0.39,-0.39,21591000,21362000,19924000,2703000,173000,0,2500000,1271000,-7335000,-0.15467396260829913,-0.27958414025073897,-0.21875000000000003,__nan__,__nan__,__nan__,0.1251910518271502
260,ANNX,Annexon Inc. Common Stock,"Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barr syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.","Mr. Douglas E. Love Esq., J.D.",Biotechnology,2.01,USD,220525140,https://images.financialmodelingprep.com/symbol/ANNX.png,1689385,-1.72,0.2,1755199,-134746000,-138200000,"[{'period': '2024', 'revenue': 0.0, 'unit': 'M', 'net_profit': -138.2}, {'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -134.24}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -138.29}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -127.79}]","[{'period': ""Q1 '25"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -54.36}, {'period': ""Q4 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -48.59}, {'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -34.82}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -29.61}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -25.18}, {'period': ""Q4 '23"", 'revenue': 4.87, 'unit': 'M', 'net_profit': -27.89}]",-1.01,-1.01,350071000,316461000,312017000,56966000,0,0,30512000,49498000,-118021000,0.04823591735829066,-0.029522411853661806,0.4293785310734463,__nan__,__nan__,__nan__,0.16272698966781024
261,ANPC,AnPac Bio-Medical Science Co. Ltd. American Depositary Shares,"AnPac Bio-Medical Science Co., Ltd., a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests using cancer differentiation analysis technology and device to corporations and life insurance companies in the People's Republic of China. It also offers physical checkup package services. The company was incorporated in 2010 and is headquartered in Lishui, the People's Republic of China.",Dr. Chris Chang  Yu,Biotechnology,4.3,USD,26974846,https://images.financialmodelingprep.com/symbol/ANPC.png,22069,-0.37554585152838427,-0.14,35704,-78401000,-103598000,"[{'period': '2022', 'revenue': 12.04, 'unit': 'M', 'net_profit': -103.6}, {'period': '2021', 'revenue': 17.99, 'unit': 'M', 'net_profit': -120.09}, {'period': '2020', 'revenue': 20.51, 'unit': 'M', 'net_profit': -80.56}, {'period': '2019', 'revenue': 10.85, 'unit': 'M', 'net_profit': -101.62}]","[{'period': ""Q4 '22"", 'revenue': 0.437, 'unit': 'M', 'net_profit': -32.31}, {'period': ""Q3 '22"", 'revenue': 6.39, 'unit': 'M', 'net_profit': -20.2}, {'period': ""Q2 '22"", 'revenue': 3.25, 'unit': 'M', 'net_profit': -33.91}, {'period': ""Q1 '22"", 'revenue': 1.97, 'unit': 'M', 'net_profit': -14.9}, {'period': ""Q4 '21"", 'revenue': 4.31, 'unit': 'M', 'net_profit': -31.14}, {'period': ""Q3 '21"", 'revenue': 4.42, 'unit': 'M', 'net_profit': -30.55}]",-54.18,-54.18,40469000,13699000,1870000,49873000,5541000,1079000,42278000,1870000,-56652000,0.3005968045531995,0.1373087844645965,0.6930833286127004,__nan__,__nan__,__nan__,1.232375398453137
262,ANSS,ANSYS Inc. Common Stock,"ANSYS, Inc. develops and markets engineering simulation software and services worldwide. It offers ANSYS Workbench, a framework upon which its multiphysics engineering simulation technologies are built and enables engineers to simulate the interactions between structures, heat transfer, fluids, electronics, and optical elements in a unified engineering simulation environment; high-performance computing product suite; power analysis and optimization software suite that manages the power budget, power delivery integrity, and power-induced noise in an electronic design; and structural analysis product suite that provides simulation tools for product design and optimization. The company also provides electronics product suite that offers field simulation software for designing electronic and electromechanical products; SCADE product suite, a solution for embedded software simulation, code production, and automated certification; fluids product suite that enables modeling of fluid flow and other related physical phenomena; Ansys Granta products to give access to material intelligence; photonic design and simulation tools; and optical sensor and closed-loop, and real-time simulation, as well as safety-certified embedded software solutions. In addition, the company provides Discovery product family for use in the simulation of product design; and academic product suite used in research and teaching settings, which allows students to become familiar with its simulation software. It serves engineers, designers, researchers, and students in the aerospace and defense, automotive transportation and mobility, construction, consumer products, energy, healthcare, high-tech, industrial equipment, materials and chemical processing, and sports industries. The company was founded in 1970 and is headquartered in Canonsburg, Pennsylvania.",Dr. Ajei S. Gopal Ph.D.,Software - Application,346.63,USD,30474357743,https://images.financialmodelingprep.com/symbol/ANSS.png,612754,51.51,3.11,660590,908559000,575692000,"[{'period': '2024', 'revenue': 2540.0, 'unit': 'M', 'net_profit': 575.69}, {'period': '2023', 'revenue': 2270.0, 'unit': 'M', 'net_profit': 500.41}, {'period': '2022', 'revenue': 2070.0, 'unit': 'M', 'net_profit': 523.71}, {'period': '2021', 'revenue': 1910.0, 'unit': 'M', 'net_profit': 454.63}]","[{'period': ""Q1 '25"", 'revenue': 504.89, 'unit': 'M', 'net_profit': 51.87}, {'period': ""Q4 '24"", 'revenue': 882.17, 'unit': 'M', 'net_profit': 282.69}, {'period': ""Q3 '24"", 'revenue': 601.89, 'unit': 'M', 'net_profit': 128.19}, {'period': ""Q2 '24"", 'revenue': 594.14, 'unit': 'M', 'net_profit': 130.03}, {'period': ""Q1 '24"", 'revenue': 466.61, 'unit': 'M', 'net_profit': 34.78}, {'period': ""Q4 '23"", 'revenue': 805.11, 'unit': 'M', 'net_profit': 274.76}]",6.59,6.55,8051431000,2831493000,1497517000,1964991000,1275210000,785000,941184000,1446743000,751695000,0.19761704842487665,0.15043604070246117,0.14409722222222224,__nan__,__nan__,__nan__,0.2440548767045262
263,ANTE,AirNet Technology Inc. American Depositary Shares,"AirNet Technology Inc. operates out-of-home advertising platforms in the People's Republic of China. It operates through two segments, Cryptocurrency Mining and Air Travel Media Network. The company provides in-flight solutions to connectivity, entertainment, and digital multimedia; and in-flight entertainment and advertising contents, such as sports, comedies, local attractions, reality shows, commentaries, documentaries. It also offers advertising time slots in the form of digital TV screens on airplanes; and media contents display in air travel. In addition, the company operates CIBN-AirNet channel to broadcast network TV programs to air travelers. Further, it engages in cryptocurrency mining business. The company was formerly known as AirMedia Group Inc. AirNet Technology Inc. was founded in 2005 and is headquartered in Beijing, the People's Republic of China.",Ms. Dan  Shao,Telecommunications Services,0.7496,USD,10743753,https://images.financialmodelingprep.com/symbol/ANTE.png,2680004,-0.79,-0.0703,32910,-10483000,-13651000,"[{'period': '2024', 'revenue': 0.343, 'unit': 'M', 'net_profit': -13.65}, {'period': '2023', 'revenue': 845.0, 'unit': 'K', 'net_profit': -574.0}, {'period': '2022', 'revenue': 2.87, 'unit': 'M', 'net_profit': -12.31}, {'period': '2021', 'revenue': 11.68, 'unit': 'M', 'net_profit': -17.79}]","[{'period': ""Q2 '24"", 'revenue': 0.193, 'unit': 'M', 'net_profit': 19.89}, {'period': ""Q4 '23"", 'revenue': 0.31362, 'unit': 'M', 'net_profit': 3.75}, {'period': ""Q2 '23"", 'revenue': 0.538, 'unit': 'M', 'net_profit': -3.92}, {'period': ""Q4 '22"", 'revenue': 0.39405, 'unit': 'M', 'net_profit': -12.0}, {'period': ""Q2 '22"", 'revenue': 2.49, 'unit': 'M', 'net_profit': -1.76}, {'period': ""Q4 '21"", 'revenue': 2.9, 'unit': 'M', 'net_profit': -10.84}]",-1.7,-1.7,60220000,25955000,356000,82226000,23011000,0,78595000,113000,-1557000,-8.377199155524279,-22.782229965156795,1,__nan__,__nan__,__nan__,1.3654267685154433
264,ANY,Sphere 3D Corp. Common Shares,"Sphere 3D Corp. focuses on operating as a carbon neutral bitcoin mining company. It also provides data management solutions through hybrid cloud, cloud, and on-premises implementations directly and through its reseller network and professional services organization. Its products portfolio includes HVE-STACK high density server, which provides computer and storage appliance for the data centers; HVE-VELOCITY, a high availability dual enclosure storage area network that offers reliability and integrity for optimal data storage, protection, and recovery; HVE 3DGFX, a virtual desktop infrastructure solution; HVE STAGE, a server virtualization platform; and HVE VAULT, an appliance designed to handle requirements for backup and replication storage. In addition, it offers self-service and support services. Sphere 3D Corp. is based in Toronto, Canada.",Mr. Kurt L. Kalbfleisch,Software - Application,0.838,USD,22171720,https://images.financialmodelingprep.com/symbol/ANY.png,348535,-1.75,0.0569,629197,-2207000,-9470000,"[{'period': '2024', 'revenue': 16.61, 'unit': 'M', 'net_profit': -9.47}, {'period': '2023', 'revenue': 21.91, 'unit': 'M', 'net_profit': -23.41}, {'period': '2022', 'revenue': 6.08, 'unit': 'M', 'net_profit': -192.91}, {'period': '2021', 'revenue': 3.72, 'unit': 'M', 'net_profit': -17.29}]","[{'period': ""Q1 '25"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.79}, {'period': ""Q4 '24"", 'revenue': 2.64, 'unit': 'M', 'net_profit': -7.22}, {'period': ""Q3 '24"", 'revenue': 2350.0, 'unit': 'K', 'net_profit': 104.0}, {'period': ""Q2 '24"", 'revenue': 4.67, 'unit': 'M', 'net_profit': 2.12}, {'period': ""Q1 '24"", 'revenue': 6.95, 'unit': 'M', 'net_profit': -4.48}, {'period': ""Q4 '23"", 'revenue': 7.69, 'unit': 'M', 'net_profit': -8.77}]",-0.48,-0.48,43228000,17787000,12955000,3913000,0,0,3895000,5425000,-13520000,0.8615780230807827,0.5954028881483381,0.7512953367875648,__nan__,__nan__,__nan__,0.0905200333117424
265,ANZU,Anzu Special Acquisition Corp I Class A Common Stock,"Anzu Special Acquisition Corp I does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. It intends to identify business opportunities in the field of industrial applications. The company was incorporated in 2020 and is based in Tampa, Florida.",Dr. Whitney Patrick Haring-Smith,Shell Companies,6.86,USD,102473308,https://images.financialmodelingprep.com/symbol/ANZU.png,35220,114.33333333333333,1.22,157285,-19806000,-20795000,"[{'period': '2024', 'revenue': 0.225, 'unit': 'M', 'net_profit': -20.8}, {'period': '2023', 'revenue': 0.316, 'unit': 'M', 'net_profit': -29.91}, {'period': '2022', 'revenue': 0.23700000000000002, 'unit': 'M', 'net_profit': -15.92}, {'period': '2021', 'revenue': 0.31, 'unit': 'M', 'net_profit': -8.68}]","[{'period': ""Q1 '25"", 'revenue': 0.046, 'unit': 'M', 'net_profit': -5.0}, {'period': ""Q4 '24"", 'revenue': 0.042, 'unit': 'M', 'net_profit': -4.62}, {'period': ""Q3 '24"", 'revenue': 0.056, 'unit': 'M', 'net_profit': -5.96}, {'period': ""Q2 '24"", 'revenue': 0.068, 'unit': 'M', 'net_profit': -3.95}, {'period': ""Q1 '24"", 'revenue': 0.059000000000000004, 'unit': 'M', 'net_profit': -6.27}, {'period': ""Q4 '23"", 'revenue': 0.095, 'unit': 'M', 'net_profit': -4.88}]",-1.49,-1.49,11538000,9384000,5483000,30380000,818000,0,7538000,5483000,-18929000,-0.08597433929158899,0.30470108332218804,0.3739495798319327,__nan__,__nan__,__nan__,2.6330386548795284
266,ANZUU,Anzu Special Acquisition Corp I Units,"Anzu Special Acquisition Corp I does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. It intends to identify business opportunities in the field of industrial applications. The company was incorporated in 2020 and is based in Tampa, Florida.",Dr. Whitney Patrick Haring-Smith,Shell Companies,7.09,USD,104595615,https://images.financialmodelingprep.com/symbol/ANZUU.png,741,27.587548638132297,0.49,3436,-19806000,-20795000,"[{'period': '2024', 'revenue': 0.225, 'unit': 'M', 'net_profit': -20.8}, {'period': '2023', 'revenue': 0.316, 'unit': 'M', 'net_profit': -29.91}, {'period': '2022', 'revenue': 0.23700000000000002, 'unit': 'M', 'net_profit': -15.92}, {'period': '2021', 'revenue': 0.31, 'unit': 'M', 'net_profit': -8.68}]","[{'period': ""Q1 '25"", 'revenue': 0.046, 'unit': 'M', 'net_profit': -5.0}, {'period': ""Q4 '24"", 'revenue': 0.042, 'unit': 'M', 'net_profit': -4.62}, {'period': ""Q3 '24"", 'revenue': 0.056, 'unit': 'M', 'net_profit': -5.96}, {'period': ""Q2 '24"", 'revenue': 0.068, 'unit': 'M', 'net_profit': -3.95}, {'period': ""Q1 '24"", 'revenue': 0.059000000000000004, 'unit': 'M', 'net_profit': -6.27}, {'period': ""Q4 '23"", 'revenue': 0.095, 'unit': 'M', 'net_profit': -4.88}]",-1.49,-1.49,11538000,9384000,5483000,30380000,818000,0,7538000,5483000,-18929000,-0.08597433929158899,0.30470108332218804,0.3739495798319327,__nan__,__nan__,__nan__,2.6330386548795284
267,ANZUW,Anzu Special Acquisition Corp I Warrant,"Anzu Special Acquisition Corp I is a blank check company. The company was incorporated in 2020 and is based in Tampa, Florida.",Dr. Whitney Patrick Haring-Smith,Shell Companies,0.085,USD,0,https://images.financialmodelingprep.com/symbol/ANZUW.png,0,0,-0.035,16473,-19806000,-20795000,"[{'period': '2024', 'revenue': 0.225, 'unit': 'M', 'net_profit': -20.8}, {'period': '2023', 'revenue': 0.316, 'unit': 'M', 'net_profit': -29.91}, {'period': '2022', 'revenue': 0.23700000000000002, 'unit': 'M', 'net_profit': -15.92}, {'period': '2021', 'revenue': 0.31, 'unit': 'M', 'net_profit': -8.68}]","[{'period': ""Q1 '25"", 'revenue': 0.046, 'unit': 'M', 'net_profit': -5.0}, {'period': ""Q4 '24"", 'revenue': 0.042, 'unit': 'M', 'net_profit': -4.62}, {'period': ""Q3 '24"", 'revenue': 0.056, 'unit': 'M', 'net_profit': -5.96}, {'period': ""Q2 '24"", 'revenue': 0.068, 'unit': 'M', 'net_profit': -3.95}, {'period': ""Q1 '24"", 'revenue': 0.059000000000000004, 'unit': 'M', 'net_profit': -6.27}, {'period': ""Q4 '23"", 'revenue': 0.095, 'unit': 'M', 'net_profit': -4.88}]",-1.49,-1.49,11538000,9384000,5483000,30380000,818000,0,7538000,5483000,-18929000,-0.08597433929158899,0.30470108332218804,0.3739495798319327,__nan__,__nan__,__nan__,2.6330386548795284
268,AOSL,Alpha and Omega Semiconductor Limited Common Shares,"Alpha and Omega Semiconductor Limited designs, develops, and supplies power semiconductor products for computing, consumer electronics, communication, and industrial applications in Hong Kong, China, South Korea, the United States, and internationally. It offers power discrete products, including metal-oxide-semiconductor field-effect transistors (MOSFET), SRFETs, XSFET, electrostatic discharge, protected MOSFETs, high and mid-voltage MOSFETs, and insulated gate bipolar transistors for use in smart phone chargers, battery packs, notebooks, desktop and servers, data centers, base stations, graphics card, game boxes, TVs, AC adapters, power supplies, motor control, power tools, e-vehicles, white goods and industrial motor drives, UPS systems, solar inverters, and industrial welding. The company also provides power ICs that deliver power, as well as control and regulate the power management variables, such as the flow of current and level of voltage. Its power ICs are used in flat panel displays, TVs, Notebooks, graphic cards, servers, DVD/Blu-Ray players, set-top boxes, and networking equipment. In addition, the company offers aMOS5 MOSFET for quick charger, adapter, PC power, server, industrial power, telecom, and datacenter applications; and Transient Voltage Suppressors for laptops, televisions, and other electronic devices. Further, it provides EZBuck regulators; SOA MOSFET for hot swap applications; RigidCSP for battery management; and Type-C power delivery protection switches. The company was incorporated in 2000 and is headquartered in Sunnyvale, California.",Mr. Stephen Chunping Chang,Semiconductors,23.14,USD,688646400,https://images.financialmodelingprep.com/symbol/AOSL.png,544538,-30.05,-0.32,259827,50001000,-11081000,"[{'period': '2024', 'revenue': 657.27, 'unit': 'M', 'net_profit': -11.08}, {'period': '2023', 'revenue': 691.32, 'unit': 'M', 'net_profit': 12.36}, {'period': '2022', 'revenue': 777.55, 'unit': 'M', 'net_profit': 453.16}, {'period': '2021', 'revenue': 656.9, 'unit': 'M', 'net_profit': 58.12}]","[{'period': ""Q3 '25"", 'revenue': 164.63, 'unit': 'M', 'net_profit': -10.81}, {'period': ""Q2 '25"", 'revenue': 173.16, 'unit': 'M', 'net_profit': -6.61}, {'period': ""Q1 '25"", 'revenue': 181.89, 'unit': 'M', 'net_profit': -2.5}, {'period': ""Q4 '24"", 'revenue': 161.3, 'unit': 'M', 'net_profit': -2.73}, {'period': ""Q3 '24"", 'revenue': 150.06, 'unit': 'M', 'net_profit': -11.21}, {'period': ""Q2 '24"", 'revenue': 165.28, 'unit': 'M', 'net_profit': -2.92}]",-0.39,-0.39,1145013000,398001000,175127000,253406000,15951000,356139000,154233000,175127000,-11378000,-0.23936655713764146,-1.8962309932060821,-1.8666666666666667,__nan__,__nan__,__nan__,0.2213127711213759
269,AOUT,American Outdoor Brands Inc. Common Stock ,"American Outdoor Brands, Inc. provides outdoor products and accessories for rugged outdoor enthusiasts in the United States and internationally. It offers hunting, fishing, camping, shooting, and personal security and defense products. The company also provides shooting sports accessories products include rests, vaults, and other related accessories; outdoor lifestyle products, such as premium sportsmen knives and tools for fishing and hunting; land management tools for hunting preparedness; harvesting products for post-hunt or post-fishing activities; outdoor cooking products; and camping, survival, and emergency preparedness products. In addition, it offers electro-optical devices, including hunting optics, firearm aiming devices, flashlights, and laser grips; and reloading, gunsmithing, and firearm cleaning supplies. The company sells its products through e-commerce and traditional distribution channels under the Adventurer, Harvester, Marksman, and Defender brand lanes. American Outdoor Brands, Inc. was incorporated in 2020 and is headquartered in Columbia, Missouri.",Mr. Brian Daniel Murphy,Leisure,12.66,USD,161222568,https://images.financialmodelingprep.com/symbol/AOUT.png,57462,-37.24,-0.05,24394,3604000,-12248000,"[{'period': '2024', 'revenue': 201.1, 'unit': 'M', 'net_profit': -12.25}, {'period': '2023', 'revenue': 191.21, 'unit': 'M', 'net_profit': -12.02}, {'period': '2022', 'revenue': 247.53, 'unit': 'M', 'net_profit': -64.88}, {'period': '2021', 'revenue': 276.69, 'unit': 'M', 'net_profit': 18.41}]","[{'period': ""Q3 '25"", 'revenue': 58510.0, 'unit': 'K', 'net_profit': 169.0}, {'period': ""Q2 '25"", 'revenue': 60.23, 'unit': 'M', 'net_profit': 3.11}, {'period': ""Q1 '25"", 'revenue': 41.64, 'unit': 'M', 'net_profit': -2.37}, {'period': ""Q4 '24"", 'revenue': 46.3, 'unit': 'M', 'net_profit': -5.3}, {'period': ""Q3 '24"", 'revenue': 53.42, 'unit': 'M', 'net_profit': -2.91}, {'period': ""Q2 '24"", 'revenue': 57930.0, 'unit': 'K', 'net_profit': 77.0}]",-0.94,-0.94,240597000,155374000,29698000,62672000,25951000,0,29383000,29698000,18384000,-0.27905581116223244,-0.018629407850964737,-0.04444444444444436,__nan__,__nan__,__nan__,0.26048537596063126
270,APA,APA Corporation Common Stock,"APA Corporation, through its subsidiaries, explores for, develops, and produces oil and gas properties. It has operations in the United States, Egypt, and the United Kingdom, as well as has exploration activities offshore Suriname. The company also operates gathering, processing, and transmission assets in West Texas, as well as holds ownership in four Permian-to-Gulf Coast pipelines. APA Corporation was founded in 1954 and is based in Houston, Texas.",Mr. John J. Christmann IV,Oil & Gas Exploration & Production,17.59,USD,6347263550,https://images.financialmodelingprep.com/symbol/APA.png,9657795,6.3,-0.17,5699095,4223000000,804000000,"[{'period': '2024', 'revenue': 9740.0, 'unit': 'M', 'net_profit': 804.0}, {'period': '2023', 'revenue': 8.28, 'unit': 'B', 'net_profit': 2.85}, {'period': '2022', 'revenue': 11.07, 'unit': 'B', 'net_profit': 3.67}, {'period': '2021', 'revenue': 7990.0, 'unit': 'M', 'net_profit': 973.0}]","[{'period': ""Q1 '25"", 'revenue': 2640.0, 'unit': 'M', 'net_profit': 347.0}, {'period': ""Q4 '24"", 'revenue': 2710.0, 'unit': 'M', 'net_profit': 354.0}, {'period': ""Q3 '24"", 'revenue': 2530.0, 'unit': 'M', 'net_profit': -223.0}, {'period': ""Q2 '24"", 'revenue': 2540.0, 'unit': 'M', 'net_profit': 541.0}, {'period': ""Q1 '24"", 'revenue': 1950.0, 'unit': 'M', 'net_profit': 132.0}, {'period': ""Q4 '23"", 'revenue': 2.17, 'unit': 'B', 'net_profit': 1.77}]",2.28,2.28,19390000000,3404000000,625000000,13028000000,1959000000,0,2955000000,625000000,769000000,-0.11094736842105263,-0.7183887915936953,-0.7540453074433657,"[0.25, 0.06]","['2025-04-22', '1982-03-25']",__nan__,0.6718927282104178
271,APDN,Applied DNA Sciences Inc. Common Stock,"Applied DNA Sciences, Inc. develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes. The company's supply chain security and product authentication solutions include SigNature molecular tags that provide forensic power and protection for various applications used to fortify brand protection efforts and strengthen supply chain security, as well as mark, track, and convict criminals; SigNify IF portable DNA readers and SigNify consumable reagent test kits that provide real-time authentication of molecular tags in the field; and CertainT, which indicates the use of tagging, testing, and tracking platforms and solutions enabling manufacturers, brands, and trade organizations to convey proof of their product claims. It also manufactures and sells COVID-19 PCR-based molecular diagnostic test kit under the LineaTM COVID-19 Assay Kit trademark; and COVID-19 diagnostic test kit to prevent virus spread within a community, school, or workplace under the safeCircle trademark. In addition, the company provides preclinical contract research and manufacturing services for the nucleic acid-based therapeutic markets; and contract research services to RNA based drug and biologic customers for preclinical studies. Further, it develops an invasive circulating tumor cell capture and identification technology that uses a patented functional assay to capture live invasive circulating tumor cell and associated lymphocytes. The company operates in the United States, Europe, Asia, and internationally. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.","Dr. James A. Hayward Ph.D., Sc.D.",Medical - Diagnostics & Research,0.67,USD,4353519,https://images.financialmodelingprep.com/symbol/APDN.png,1304961,-0.02,-0.14,1258590,-13328340,-6992521,"[{'period': '2024', 'revenue': 3.43, 'unit': 'M', 'net_profit': -6.99}, {'period': '2023', 'revenue': 13.37, 'unit': 'M', 'net_profit': -9.95}, {'period': '2022', 'revenue': 18.17, 'unit': 'M', 'net_profit': -8.38}, {'period': '2021', 'revenue': 9.03, 'unit': 'M', 'net_profit': -16.03}]","[{'period': ""Q2 '25"", 'revenue': 0.9833700000000001, 'unit': 'M', 'net_profit': -27.22}, {'period': ""Q1 '25"", 'revenue': 1.2, 'unit': 'M', 'net_profit': -2.64}, {'period': ""Q4 '24"", 'revenue': 0.81311, 'unit': 'M', 'net_profit': -3.3}, {'period': ""Q3 '24"", 'revenue': 0.79752, 'unit': 'M', 'net_profit': 1.88}, {'period': ""Q2 '24"", 'revenue': 0.9296300000000001, 'unit': 'M', 'net_profit': -4.47}, {'period': ""Q1 '24"", 'revenue': 0.89116, 'unit': 'M', 'net_profit': -1.18}]",-1.82,-1.82,12789040,8047670,6431095,3820955,362013,0,2398124,6431095,-14119301,-0.3896656264945588,0.29702628686529353,0.8803418803418803,__nan__,__nan__,__nan__,0.2987679294145612
272,APEI,American Public Education Inc. Common Stock,"American Public Education, Inc., together with its subsidiaries, provides online and campus-based postsecondary education. The company operates through three segments: American Public University System, Rasmussen University, and Hondros College of Nursing. It offers 130 degree programs and 111 certificate programs in various fields of study, including business administration, health science, technology, criminal justice, education, and liberal arts, as well as national security, military studies, intelligence, and homeland security. The company also provides nursing-and health sciences-focused postsecondary education, diploma in practical nursing, an associate degree in nursing, and an associate degree in medical laboratory technology. American Public Education, Inc. was incorporated in 1991 and is headquartered in Charles Town, West Virginia.",Ms. Angela K. Selden,Education & Training Services,27.85,USD,502405645,https://images.financialmodelingprep.com/symbol/APEI.png,143167,50.64,0.05,442341,52369000,16113000,"[{'period': '2024', 'revenue': 624.56, 'unit': 'M', 'net_profit': 16.11}, {'period': '2023', 'revenue': 600.54, 'unit': 'M', 'net_profit': -47.29}, {'period': '2022', 'revenue': 606.33, 'unit': 'M', 'net_profit': -114.97}, {'period': '2021', 'revenue': 418.8, 'unit': 'M', 'net_profit': 17.75}]","[{'period': ""Q1 '25"", 'revenue': 164.55, 'unit': 'M', 'net_profit': 8.89}, {'period': ""Q4 '24"", 'revenue': 164.11, 'unit': 'M', 'net_profit': 12.96}, {'period': ""Q3 '24"", 'revenue': 153.12, 'unit': 'M', 'net_profit': 2.26}, {'period': ""Q2 '24"", 'revenue': 152900.0, 'unit': 'K', 'net_profit': 371.0}, {'period': ""Q1 '24"", 'revenue': 154430.0, 'unit': 'K', 'net_profit': 516.0}, {'period': ""Q4 '23"", 'revenue': 152.8, 'unit': 'M', 'net_profit': 13.01}]",0.57,0.55,570103000,260572000,158941000,266224000,63414000,0,79155000,158941000,27790000,3.555832113225964,1.3407562492069534,1.193877551020408,__nan__,__nan__,__nan__,0.4669752658730089
273,APEN,Apollo Endosurgery Inc. Common Stock,"Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. The company offers OverStitch and OverStitch Sx Endoscopic Suturing Systems that enable advanced endoscopic procedures by allowing physicians to sutures and secure the approximation of tissue through a flexible endoscope. It also provides Orbera, an intragastric balloon system that reduces stomach capacity causing patients to consume less following the procedure, as well as delays gastric content emptying under the Orbera Intragastric Balloon System, BIB, and Orbera365 Managed Weight Loss System brands. Additionally, the company offers X-Tack Endoscopic HeliX Tacking System, a suture-based device for closing and healing defects in the lower and upper gastrointestinal tract. The company sells its products to medical services providers; and hospitals, outpatient surgical centers, clinics, and physicians in the United States, Australia, Costa Rica, and other European countries. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas.",Mr. Charles S. McKhann,Medical - Devices,10,USD,579718970,https://images.financialmodelingprep.com/symbol/APEN.png,1329953,-9.433962264150944,0,1639528,-31422000,-39839000,"[{'period': '2022', 'revenue': 76.86, 'unit': 'M', 'net_profit': -39.84}, {'period': '2021', 'revenue': 62.99, 'unit': 'M', 'net_profit': -24.68}, {'period': '2020', 'revenue': 42.05, 'unit': 'M', 'net_profit': -22.61}, {'period': '2019', 'revenue': 50.71, 'unit': 'M', 'net_profit': -27.43}]","[{'period': ""Q4 '22"", 'revenue': 21.31, 'unit': 'M', 'net_profit': -9.55}, {'period': ""Q3 '22"", 'revenue': 19.57, 'unit': 'M', 'net_profit': -11.45}, {'period': ""Q2 '22"", 'revenue': 19.31, 'unit': 'M', 'net_profit': -10.43}, {'period': ""Q1 '22"", 'revenue': 16.66, 'unit': 'M', 'net_profit': -8.41}, {'period': ""Q4 '21"", 'revenue': 16.17, 'unit': 'M', 'net_profit': -10.4}, {'period': ""Q3 '21"", 'revenue': 16.35, 'unit': 'M', 'net_profit': -6.66}]",-0.98,-0.98,110231000,92878000,57002000,77637000,14991000,0,39536000,57002000,-34007000,-0.8284550480069829,-0.6140912405801799,-0.19512195121951226,__nan__,__nan__,__nan__,0.7043118541970952
274,API,Agora Inc. American Depositary Shares,"Agora, Inc. provides Real-Time Engagement Platform-as-a-Service (RTE-PaaS) in the People's Republic of China, the United States, and internationally. The company RTE-PaaS offers developers with software tools to embed real-time video, voice, and messaging functionalities into applications. Its products include video calling, voice calling, interactive live streaming, chat, signaling. Acceleration products; and extensions, which comprise interactive whiteboard, recording, analytics, and extensions marketplace products to enable developers to launch RTE in specific use cases and verticals. The company also provides Flexible Classroom that offers a low-code application Platform as a Service; and App Builder, no-code application platform. Its real-time engagement products are delivered through its Software-Defined Real-Time Network, which is a virtual network overlay on top of the public internet. The company serves social, entertainment, gaming, education, enterprise solutions, e-commerce, financial services, healthcare, and IoT industries. Agora, Inc. was incorporated in 2013 and is headquartered in Shanghai, the People's Republic of China.",Mr. Bin  Zhao,Software - Application,3.5,USD,81821866,https://images.financialmodelingprep.com/symbol/API.png,885703,-7.95,0.04,475951,-31192000,-42727000,"[{'period': '2024', 'revenue': 133.26, 'unit': 'M', 'net_profit': -42.73}, {'period': '2023', 'revenue': 141.54, 'unit': 'M', 'net_profit': -87.22}, {'period': '2022', 'revenue': 160.67, 'unit': 'M', 'net_profit': -120.62}, {'period': '2021', 'revenue': 167.98, 'unit': 'M', 'net_profit': -72.69}]","[{'period': ""Q4 '24"", 'revenue': 34450.0, 'unit': 'K', 'net_profit': 158.0}, {'period': ""Q3 '24"", 'revenue': 31.57, 'unit': 'M', 'net_profit': -24.18}, {'period': ""Q2 '24"", 'revenue': 34.21, 'unit': 'M', 'net_profit': -9.24}, {'period': ""Q1 '24"", 'revenue': 33.02, 'unit': 'M', 'net_profit': -9.46}, {'period': ""Q4 '23"", 'revenue': 36.04, 'unit': 'M', 'net_profit': -2.61}, {'period': ""Q3 '23"", 'revenue': 35.02, 'unit': 'M', 'net_profit': -22.51}]",-1.76,-1.84,699654000,328050000,269661000,126993000,32051000,137610000,58335000,27083000,-49377000,0.601461681956405,0.5101182081885828,-1,__nan__,__nan__,__nan__,0.18150828838254338
275,APLS,Apellis Pharmaceuticals Inc. Common Stock,"Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.","Dr. Cedric  Francois M.D., Ph.D.",Biotechnology,17.45,USD,2193150900,https://images.financialmodelingprep.com/symbol/APLS.png,2408958,-9.69,1.09,5263711,-154528000,-197878000,"[{'period': '2024', 'revenue': 781.37, 'unit': 'M', 'net_profit': -197.88}, {'period': '2023', 'revenue': 396.59, 'unit': 'M', 'net_profit': -528.63}, {'period': '2022', 'revenue': 75.42, 'unit': 'M', 'net_profit': -652.17}, {'period': '2021', 'revenue': 66.56, 'unit': 'M', 'net_profit': -746.35}]","[{'period': ""Q1 '25"", 'revenue': 166.8, 'unit': 'M', 'net_profit': -92.22}, {'period': ""Q4 '24"", 'revenue': 212.53, 'unit': 'M', 'net_profit': -36.35}, {'period': ""Q3 '24"", 'revenue': 196.83, 'unit': 'M', 'net_profit': -57.45}, {'period': ""Q2 '24"", 'revenue': 199.69, 'unit': 'M', 'net_profit': -37.66}, {'period': ""Q1 '24"", 'revenue': 172.32, 'unit': 'M', 'net_profit': -66.42}, {'period': ""Q4 '23"", 'revenue': 146.38, 'unit': 'M', 'net_profit': -88.58}]",-1.6,-1.6,885051000,788954000,411290000,656512000,271723000,0,185509000,411290000,-88269000,0.6879552352431589,0.6256762789712236,0.6404494382022472,__nan__,__nan__,__nan__,0.7417787223561129
276,APLT,Applied Therapeutics Inc. Common Stock,"Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.",Mr. Les D. Funtleyder,Biotechnology,0.6029,USD,85356170,https://images.financialmodelingprep.com/symbol/APLT.png,2162693,-0.79,0.112,7586999,-103873000,-105624000,"[{'period': '2024', 'revenue': 0.455, 'unit': 'M', 'net_profit': -105.62}, {'period': '2023', 'revenue': 9.99, 'unit': 'M', 'net_profit': -119.76}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -81.69}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -104.61}]","[{'period': ""Q1 '25"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -21.82}, {'period': ""Q4 '24"", 'revenue': -0.001, 'unit': 'M', 'net_profit': 44.01}, {'period': ""Q3 '24"", 'revenue': 0.122, 'unit': 'M', 'net_profit': -68.59}, {'period': ""Q2 '24"", 'revenue': 0.14400000000000002, 'unit': 'M', 'net_profit': 2.9}, {'period': ""Q1 '24"", 'revenue': 0.19, 'unit': 'M', 'net_profit': -83.94}, {'period': ""Q4 '23"", 'revenue': -0.667, 'unit': 'M', 'net_profit': -37.68}]",-0.76,-0.76,86691000,83646000,79398000,29685000,0,0,27296000,79398000,-84305000,-0.609585644776397,0.11805816487562937,0.4647887323943662,__nan__,__nan__,__nan__,0.34242308890196216
277,APM,Aptorum Group Limited Class A Ordinary Shares,"Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.",Mr. Chung Yuen  Huen,Biotechnology,0.9521,USD,6801571,https://images.financialmodelingprep.com/symbol/APM.png,71170,-1.22,-0.0279,49014,-9598997,-2824647,"[{'period': '2023', 'revenue': 0.43138, 'unit': 'M', 'net_profit': -2.82}, {'period': '2022', 'revenue': 1.3, 'unit': 'M', 'net_profit': -5.31}, {'period': '2021', 'revenue': 1.54, 'unit': 'M', 'net_profit': -25.29}, {'period': '2020', 'revenue': 0.91151, 'unit': 'M', 'net_profit': 7.07}]","[{'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.64}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.66}, {'period': ""Q2 '23"", 'revenue': 0.43138, 'unit': 'M', 'net_profit': -5.49}, {'period': ""Q4 '22"", 'revenue': 0.76843, 'unit': 'M', 'net_profit': -7.91}, {'period': ""Q2 '22"", 'revenue': 0.52746, 'unit': 'M', 'net_profit': -1.89}, {'period': ""Q4 '21"", 'revenue': 0.9039900000000001, 'unit': 'M', 'net_profit': -8.97}]",-0.62,-0.62,20640091,2476092,2005351,5256738,70945,16098846,2098753,2005351,-7727379,0.4542668793277321,0.46849563396919863,0.9583613163196777,__nan__,__nan__,__nan__,0.25468579571669525
278,APOG,Apogee Enterprises Inc. Common Stock,"Apogee Enterprises, Inc. designs and develops glass and metal products and services in the United States, Canada, and Brazil. The company operates in four segments: Architectural Framing Systems, Architectural Glass, Architectural Services, and Large-Scale Optical Technologies (LSO). The Architectural Framing Systems segment designs, engineers, fabricates, and finishes the aluminum frames used in customized aluminum and glass window; curtain wall; storefront; and entrance systems, such as the outside skin and entrances of commercial, institutional, and multi-family residential buildings. The Architectural Glass segment fabricates coated and high-performance glass used in customized window and wall systems, including the outside skin of commercial, institutional, and multi-family residential buildings. The Architectural Services segment offers full-service installation of the walls of glass, windows, and other curtain wall products making up the outside skin of commercial and institutional buildings. The LSO segment manufactures value-added glass and acrylic products for framing and display applications. The company's products and services are primarily used in commercial buildings, such as office buildings, hotels, and retail centers; and institutional buildings comprising education facilities, health care facilities, and government buildings, as well as multi-family residential buildings. It markets its architectural products and services through direct sales force, independent sales representatives, and distributors to glazing subcontractors and general contractors; and value-added glass and acrylics through retail chains, picture-framing shops, and independent distributors to museums, galleries, and other customers. The company was incorporated in 1949 and is based in Minneapolis, Minnesota.",Mr. Ty R. Silberhorn,Construction,41.38,USD,892694878,https://images.financialmodelingprep.com/symbol/APOG.png,227391,9.26,0.41,132720,166800000,85052000,"[{'period': '2025', 'revenue': 1360.0, 'unit': 'M', 'net_profit': 85.05}, {'period': '2024', 'revenue': 1420.0, 'unit': 'M', 'net_profit': 99.61}, {'period': '2023', 'revenue': 1440.0, 'unit': 'M', 'net_profit': 104.11}, {'period': '2022', 'revenue': 1310.0, 'unit': 'M', 'net_profit': 3.49}]","[{'period': ""Q4 '25"", 'revenue': 345.69, 'unit': 'M', 'net_profit': 2.49}, {'period': ""Q3 '25"", 'revenue': 341.34, 'unit': 'M', 'net_profit': 20.99}, {'period': ""Q2 '25"", 'revenue': 342.44, 'unit': 'M', 'net_profit': 30.57}, {'period': ""Q1 '25"", 'revenue': 331.52, 'unit': 'M', 'net_profit': 31.01}, {'period': ""Q4 '24"", 'revenue': 361.84, 'unit': 'M', 'net_profit': 15.74}, {'period': ""Q3 '24"", 'revenue': 339.71, 'unit': 'M', 'net_profit': 26.97}]",3.91,3.89,1175269000,442104000,41448000,687371000,257432000,0,285456000,41448000,89569000,-0.06727059218251971,-0.14617569995884072,-0.1406593406593406,"[0.26, 0.0603]","['2025-05-13', '1985-02-04']",__nan__,0.5848626995181528
279,APOP,Cellect Biotechnology Ltd. American Depositary Shares,,Dr. Shai Yarkoni,Biotechnology,13.17,USD,129021222,https://images.financialmodelingprep.com/symbol/APOP.png,1950309,-15.421545667447306,0.05000019,17433,17241000,16808000,"[{'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': 16.81}, {'period': '2018', 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': '2017', 'revenue': 0.0, 'unit': 'M', 'net_profit': 28.22}, {'period': '2016', 'revenue': 0.0, 'unit': 'M', 'net_profit': 15.32}]",[],0.32,0.32,19394000,18106000,18106000,6483000,0,0,0,18106000,-20460000,36.56209150326797,0,0,__nan__,__nan__,__nan__,0.33427864287924103
280,APOPW,Cellect Biotechnology Ltd. Warrants to Purchase ADRs,,None,,0.0876,USD,0,https://images.financialmodelingprep.com/symbol/APOPW.png,0,0,-0.0005,51821,,,[],[],,,,,,,,,,,,,,,__nan__,__nan__,__nan__,__nan__
281,APP,Applovin Corporation Class A Common Stock,"AppLovin Corporation engages in building a software-based platform for mobile app developers to enhance the marketing and monetization of their apps in the United States and internationally. The company's software solutions include AppDiscovery, a marketing software solution, which matches advertiser demand with publisher supply through auctions; Adjust, an analytics platform that helps marketers grow their mobile apps with solutions for measuring, optimizing campaigns, and protecting user data; and MAX, an in-app bidding software that optimizes the value of an app's advertising inventory by running a real-time competitive auction. Its business clients include various advertisers, publishers, internet platforms, and others. The company was incorporated in 2011 and is headquartered in Palo Alto, California.",Mr. Adam Arash Foroughi,Software - Application,362.34,USD,122611083982,https://images.financialmodelingprep.com/symbol/APP.png,9659006,65.4,-4.27,4492879,2322139000,1579776000,"[{'period': '2024', 'revenue': 4.71, 'unit': 'B', 'net_profit': 1.58}, {'period': '2023', 'revenue': 3280.0, 'unit': 'M', 'net_profit': 356.71}, {'period': '2022', 'revenue': 2820.0, 'unit': 'M', 'net_profit': -217.41}, {'period': '2021', 'revenue': 2790.0, 'unit': 'M', 'net_profit': 35.45}]","[{'period': ""Q1 '25"", 'revenue': 1480.0, 'unit': 'M', 'net_profit': 576.42}, {'period': ""Q4 '24"", 'revenue': 1370.0, 'unit': 'M', 'net_profit': 599.2}, {'period': ""Q3 '24"", 'revenue': 1200.0, 'unit': 'M', 'net_profit': 434.42}, {'period': ""Q2 '24"", 'revenue': 1080.0, 'unit': 'M', 'net_profit': 309.97}, {'period': ""Q1 '24"", 'revenue': 1060.0, 'unit': 'M', 'net_profit': 236.18}, {'period': ""Q4 '23"", 'revenue': 953.26, 'unit': 'M', 'net_profit': 172.23}]",4.68,4.53,5869259000,2312190000,741411000,4779441000,1414246000,0,1057472000,741411000,2094235000,1.0276386758094134,3.428728017919268,3.633663366336634,__nan__,__nan__,__nan__,0.8143176165849897
282,APPF,AppFolio Inc. Class A Common Stock,"AppFolio, Inc., together with its subsidiaries, provides cloud business management solutions for the real estate industry. The company offers AppFolio Property Manager, a platform to leverage process automation, easy to use interface, and the optimization of common workflows for property management companies, as well as completes and records critical transactions in the system and give its customers access to the data they need to run their business; AppFolio Property Manager Plus, which offers customizable workflows that allow customers to digitize their existing processes, performance insights, intelligent revenue management, and integrations through selected partners and dedicated strategic account managers; and AppFolio Investment Management, a solution that is designed to enable real estate investment management organizations to manage investor relationships through enhancing transparency and streamlining certain business processes. It also provides value added services that are designed to enhance, automate, and streamline processes and workflows for property management businesses, such as electronic payment, tenant screening, and insurance services. AppFolio, Inc. was incorporated in 2006 and is headquartered in Santa Barbara, California.",Mr. Shane  Trigg,Software - Application,218.91,USD,7886959531,https://images.financialmodelingprep.com/symbol/APPF.png,342129,40.77,6.48,257132,169867000,204068000,"[{'period': '2024', 'revenue': 794.2, 'unit': 'M', 'net_profit': 204.07}, {'period': '2023', 'revenue': 620.45, 'unit': 'M', 'net_profit': 2.7}, {'period': '2022', 'revenue': 471.88, 'unit': 'M', 'net_profit': -68.12}, {'period': '2021', 'revenue': 359.37, 'unit': 'M', 'net_profit': 1.03}]","[{'period': ""Q1 '25"", 'revenue': 217.7, 'unit': 'M', 'net_profit': 31.38}, {'period': ""Q4 '24"", 'revenue': 203.66, 'unit': 'M', 'net_profit': 102.73}, {'period': ""Q3 '24"", 'revenue': 205.73, 'unit': 'M', 'net_profit': 33.01}, {'period': ""Q2 '24"", 'revenue': 197.38, 'unit': 'M', 'net_profit': 29.66}, {'period': ""Q1 '24"", 'revenue': 187.43, 'unit': 'M', 'net_profit': 38.66}, {'period': ""Q4 '23"", 'revenue': 171.83, 'unit': 'M', 'net_profit': 30.27}]",5.63,5.55,626678000,335402000,278249000,107388000,24346000,0,63280000,42504000,186143000,4.671496778070849,74.52479644707624,73.27440633245382,__nan__,__nan__,__nan__,0.17136073071018929
283,APPH,AppHarvest Inc. Common Stock,"AppHarvest, Inc., an applied agricultural technology company, develops and operates indoor farms to grow non-GMO produce free of chemical pesticide residues. Its products include tomatoes; and other fruits and vegetables, such as berries, peppers, cucumbers, and salad greens. The company was incorporated in 2018 and is based in Morehead, Kentucky.",Mr. Anthony  Martin,Agricultural Farm Products,0.0666,USD,10330259,https://images.financialmodelingprep.com/symbol/APPH.png,4291016,-0.14170212765957446,-0.0127,9356857,-107795000,-176646000,"[{'period': '2022', 'revenue': 14.59, 'unit': 'M', 'net_profit': -176.65}, {'period': '2021', 'revenue': 9.05, 'unit': 'M', 'net_profit': -166.19}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -17.45}]","[{'period': ""Q1 '23"", 'revenue': 13.01, 'unit': 'M', 'net_profit': -33.63}, {'period': ""Q4 '22"", 'revenue': 4.55, 'unit': 'M', 'net_profit': -93.32}, {'period': ""Q3 '22"", 'revenue': 0.524, 'unit': 'M', 'net_profit': -23.98}, {'period': ""Q2 '22"", 'revenue': 4.36, 'unit': 'M', 'net_profit': -28.7}, {'period': ""Q1 '22"", 'revenue': 5.16, 'unit': 'M', 'net_profit': -30.64}, {'period': ""Q4 '21"", 'revenue': 3.07, 'unit': 'M', 'net_profit': -88.39}]",-1.69,-1.69,595328000,114112000,54334000,335037000,2786000,5000000,42968000,54334000,-266870000,0.16367318121513527,-0.06294152335335107,0.028735632183908073,__nan__,__nan__,__nan__,0.5627771581380349
284,APPHW,AppHarvest Inc. Warrants,,,Agricultural Farm Products,0.0101,USD,10330259,https://images.financialmodelingprep.com/symbol/APPHW.png,0,0,-1.7999,3961,-107795000,-176646000,"[{'period': '2022', 'revenue': 14.59, 'unit': 'M', 'net_profit': -176.65}, {'period': '2021', 'revenue': 9.05, 'unit': 'M', 'net_profit': -166.19}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -17.45}]","[{'period': ""Q1 '23"", 'revenue': 13.01, 'unit': 'M', 'net_profit': -33.63}, {'period': ""Q4 '22"", 'revenue': 4.55, 'unit': 'M', 'net_profit': -93.32}, {'period': ""Q3 '22"", 'revenue': 0.524, 'unit': 'M', 'net_profit': -23.98}, {'period': ""Q2 '22"", 'revenue': 4.36, 'unit': 'M', 'net_profit': -28.7}, {'period': ""Q1 '22"", 'revenue': 5.16, 'unit': 'M', 'net_profit': -30.64}, {'period': ""Q4 '21"", 'revenue': 3.07, 'unit': 'M', 'net_profit': -88.39}]",-1.69,-1.69,595328000,114112000,54334000,335037000,2786000,5000000,42968000,54334000,-266870000,0.16367318121513527,-0.06294152335335107,0.028735632183908073,__nan__,__nan__,__nan__,0.5627771581380349
285,APPN,Appian Corporation Class A Common Stock,"Appian Corporation provides low-code automation platform in the United States and internationally. The company's platform automates the creation of forms, workflows, data structures, reports, user interfaces, and other software elements that are needed to be manually coded. The company also offers professional and customer support services. It serves to financial services, government, life sciences, insurance, manufacturing, energy, healthcare, telecommunications, and transportation industries. The company was incorporated in 1999 and is headquartered in McLean, Virginia.",Mr. Matthew W. Calkins,Software - Infrastructure,32.54,USD,2415384652,https://images.financialmodelingprep.com/symbol/APPN.png,664361,-25.83,-0.59,707552,-57596000,-92262000,"[{'period': '2024', 'revenue': 617.02, 'unit': 'M', 'net_profit': -92.26}, {'period': '2023', 'revenue': 545.36, 'unit': 'M', 'net_profit': -111.44}, {'period': '2022', 'revenue': 467.99, 'unit': 'M', 'net_profit': -150.92}, {'period': '2021', 'revenue': 369.26, 'unit': 'M', 'net_profit': -88.64}]","[{'period': ""Q1 '25"", 'revenue': 166.43, 'unit': 'M', 'net_profit': -1.18}, {'period': ""Q4 '24"", 'revenue': 166.69, 'unit': 'M', 'net_profit': -13.65}, {'period': ""Q3 '24"", 'revenue': 154.05, 'unit': 'M', 'net_profit': -2.1}, {'period': ""Q2 '24"", 'revenue': 146.45, 'unit': 'M', 'net_profit': -43.59}, {'period': ""Q1 '24"", 'revenue': 149.84, 'unit': 'M', 'net_profit': -32.92}, {'period': ""Q4 '23"", 'revenue': 145.32, 'unit': 'M', 'net_profit': -10.01}]",-1.26,-1.26,621039000,435543000,159860000,653679000,195069000,0,354756000,118552000,3080000,0.28803293076381076,0.17210003499609658,0.17105263157894737,__nan__,__nan__,__nan__,1.052557085786883
286,APPS,Digital Turbine Inc. Common Stock,"Digital Turbine, Inc., through its subsidiaries, operates a mobile growth platform for advertisers, publishers, carriers, and device original equipment manufacturers (OEMs). The company operates through three segments: On Device Media, In App Media  AdColony, and In App Media  Fyber. Its application media platform delivers mobile applications to various publishers, carriers, OEMs, and devices; and content media platform offers news, weather, sports, and other content, as well as programmatic advertising, and sponsored and editorial content media. The company also provides an end-to-end platform for brands, agencies, publishers, and application developers to deliver advertising to consumers on mobile devices; and a platform that allows mobile application developers and digital publishers to monetize their content through display, native, and video advertising. It operates in the United States, Canada, Europe, the Middle East, Africa, the Asia Pacific, China, Mexico, Central America, and South America. The company is headquartered in Austin, Texas.",Mr. William Gordon Stone III,Software - Application,4.62,USD,485132340,https://images.financialmodelingprep.com/symbol/APPS.png,3866814,-1.52,0.16,1790535,54566000,-420228000,"[{'period': '2024', 'revenue': 544.48, 'unit': 'M', 'net_profit': -420.23}, {'period': '2023', 'revenue': 665.92, 'unit': 'M', 'net_profit': 16.67}, {'period': '2022', 'revenue': 747.6, 'unit': 'M', 'net_profit': 35.55}, {'period': '2021', 'revenue': 313.58, 'unit': 'M', 'net_profit': 54.88}]","[{'period': ""Q3 '25"", 'revenue': 134.64, 'unit': 'M', 'net_profit': -23.13}, {'period': ""Q2 '25"", 'revenue': 118.73, 'unit': 'M', 'net_profit': -24.99}, {'period': ""Q1 '25"", 'revenue': 117.99, 'unit': 'M', 'net_profit': -25.16}, {'period': ""Q4 '24"", 'revenue': 112.22, 'unit': 'M', 'net_profit': -236.51}, {'period': ""Q3 '24"", 'revenue': 142.63, 'unit': 'M', 'net_profit': -14.06}, {'period': ""Q2 '24"", 'revenue': 143.26, 'unit': 'M', 'net_profit': -161.48}]",-4.16,-4.16,865540000,242341000,33605000,651608000,191015000,17637000,236024000,33605000,4398000,0.18197768872522474,-26.204102441072394,-25.470588235294116,__nan__,__nan__,__nan__,0.7528340689049611
287,APR,Apria Inc. Common Stock,"Apria, Inc. provides integrated home healthcare equipment and related services in the United States. The company offers home respiratory therapies, including the supply of stationary and portable home oxygen equipment, and non-invasive ventilators; obstructive sleep apnea therapy devices comprising continuous positive airway pressure and bi-level positive airway pressure devices, and patient support services; and negative pressure wound therapy products. It also provides a range of home medical equipment and other products, and services for patients with home care needs; and clinical and administrative support services, and related products and supplies to patients. Apria, Inc. was incorporated in 2018 and is headquartered in Indianapolis, Indiana. As of March 29, 2022, Apria, Inc. operates as a subsidiary of Byram Healthcare Centers, Inc.",Mr. Daniel J. Starck,Medical - Instruments & Supplies,37.5,USD,0,https://images.financialmodelingprep.com/symbol/APR.png,435036,22.59036144578313,0,436727,215859000,65668000,"[{'period': '2021', 'revenue': 1150.0, 'unit': 'M', 'net_profit': 65.67}, {'period': '2020', 'revenue': 1110.0, 'unit': 'M', 'net_profit': 46.14}, {'period': '2019', 'revenue': 1090.0, 'unit': 'M', 'net_profit': 15.62}, {'period': '2018', 'revenue': 1110.0, 'unit': 'M', 'net_profit': 13.13}]","[{'period': ""Q4 '21"", 'revenue': 296.52, 'unit': 'M', 'net_profit': 17.74}, {'period': ""Q3 '21"", 'revenue': 287.2, 'unit': 'M', 'net_profit': 22.81}, {'period': ""Q2 '21"", 'revenue': 286.28, 'unit': 'M', 'net_profit': 20.58}, {'period': ""Q1 '21"", 'revenue': 275.27, 'unit': 'M', 'net_profit': 4.54}, {'period': ""Q4 '20"", 'revenue': 293.79, 'unit': 'M', 'net_profit': 25.87}, {'period': ""Q3 '20"", 'revenue': 276.76, 'unit': 'M', 'net_profit': 5.7}]",1.86,1.86,775429000,333277000,219561000,735696000,81720000,2809000,306829000,219561000,92849000,0.15509214666409812,0.42326448340882983,0.41984732824427484,__nan__,__nan__,__nan__,0.9487599767354586
288,APRE,Aprea Therapeutics Inc. Common stock,"Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.",Dr. Oren  Gilad Ph.D.,Biotechnology,1.86,USD,10288348,https://images.financialmodelingprep.com/symbol/APRE.png,25796,-0.79,0.06,112960,-12936393,-12958711,"[{'period': '2024', 'revenue': 1.5, 'unit': 'M', 'net_profit': -12.96}, {'period': '2023', 'revenue': 0.58323, 'unit': 'M', 'net_profit': -14.29}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -224.88}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -36.54}]","[{'period': ""Q1 '25"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.93}, {'period': ""Q4 '24"", 'revenue': 0.20582, 'unit': 'M', 'net_profit': -2.89}, {'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.78}, {'period': ""Q2 '24"", 'revenue': 0.56157, 'unit': 'M', 'net_profit': -3.47}, {'period': ""Q1 '24"", 'revenue': 0.38057, 'unit': 'M', 'net_profit': -2.81}, {'period': ""Q4 '23"", 'revenue': 0.014070000000000001, 'unit': 'M', 'net_profit': -3.44}]",-2.35,-2.35,23979493,23576139,22849885,4672038,0,0,3360975,22849885,-13572196,0.09407160146411958,0.09295637162138137,0.4050632911392405,__nan__,__nan__,__nan__,0.19483472815709657
289,APTO,Aptose Biosciences Inc. Common Shares,"Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.",Dr. William G. Rice Ph.D.,Biotechnology,1.71,USD,4364655,https://images.financialmodelingprep.com/symbol/APTO.png,225970,-0.047003848268279275,0,648213,0,-25430000,"[{'period': '2024', 'revenue': 0.0, 'unit': 'M', 'net_profit': -25.43}, {'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -51.21}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -41.82}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -65.35}]","[{'period': ""Q1 '25"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.54}, {'period': ""Q4 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.58}, {'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -6.95}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -7.25}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -9.64}, {'period': ""Q4 '23"", 'revenue': 0.95527, 'unit': 'M', 'net_profit': -11.96}]",-5.73,-18.94,10127000,9530000,6152000,14670000,0,0,4459000,6152000,-35982000,1,0.5033882086433495,0.24406332453825852,__nan__,__nan__,__nan__,1.4486027451367631
290,APTX,Aptinyx Inc. Common Stock,"Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase II/b clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase II clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.",Mr. Craig R. Jalbert CIRA,Biotechnology,0.096,USD,0,https://images.financialmodelingprep.com/symbol/APTX.png,132918,-0.09795918367346938,0.003,231126,-61708000,-64112000,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -64.11}, {'period': '2021', 'revenue': 1.0, 'unit': 'M', 'net_profit': -74.36}, {'period': '2020', 'revenue': 1.56, 'unit': 'M', 'net_profit': -49.63}, {'period': '2019', 'revenue': 3.67, 'unit': 'M', 'net_profit': -56.95}]","[{'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -21.81}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 25.97}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -15.1}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -18.23}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -20.27}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -19.61}]",-0.95,-0.95,66684000,64030000,56205000,28399000,0,0,6291000,56205000,-59684000,0,0.13781603012372243,0.14414414414414425,__nan__,__nan__,__nan__,0.42587427268910083
291,APVO,Aptevo Therapeutics Inc. Common Stock,"Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.",Mr. Marvin L. White,Biotechnology,0.32,USD,2003219,https://images.financialmodelingprep.com/symbol/APVO.png,3061772,,-0.01,530571,-23778000,-24130000,"[{'period': '2024', 'revenue': 0.0, 'unit': 'M', 'net_profit': -24.13}, {'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -17.41}, {'period': '2022', 'revenue': 3.11, 'unit': 'M', 'net_profit': 8.03}, {'period': '2021', 'revenue': 12.29, 'unit': 'M', 'net_profit': -27.31}]","[{'period': ""Q1 '25"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -6.41}, {'period': ""Q4 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -6.31}, {'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.1}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.88}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -6.83}, {'period': ""Q4 '23"", 'revenue': 0.902, 'unit': 'M', 'net_profit': -5.9}]",-84.67,-84.67,15591000,10659000,8714000,10836000,0,0,6207000,8714000,-23785000,0.16011444314930592,-0.3859054620642123,-0.3521239220696264,__nan__,__nan__,__nan__,0.6950163555897634
292,APWC,Asia Pacific Wire & Cable Corporation Ltd. Ordinary Shares (Bermuda),"Asia Pacific Wire & Cable Corporation Limited, through its subsidiaries, manufactures and distributes enameled wire, power cable, and telecommunications products in Thailand, Singapore, Australia, the People's Republic of China, Hong Kong, and other markets in the Asia Pacific region. The company offers copper rods; and telecommunications cable products, including copper-based and fiber optic cables for telephone and data transmissions; and armored and unarmored low voltage power transmission cable, which is used to transmit electricity to and within commercial and residential buildings, as well as to outdoor installations, such as streetlights, traffic signals, and other signs. It also provides enameled wire for use in the assembly of a range of electrical products consisting of oil-filled transformers, refrigerator motors, telephones, radios, televisions, fan motors, air conditioner compressors, and other electric appliances. In addition, the company distributes wire and cable products; and offers project engineering services in the supply, delivery, and installation of power cables, as well as fabrication services for converting raw materials to wire and cable products. It serves government organizations, electric contracting firms, electrical dealers, and wire and cable factories. The company was incorporated in 1996 and is headquartered in Taipei, Taiwan. Asia Pacific Wire & Cable Corporation Limited is a subsidiary of Pacific Electric Wire & Cable Co., Ltd.",Mr. Chun-Tang  Yuan M.S.,Electrical Equipment & Parts,1.56,USD,32161272,https://images.financialmodelingprep.com/symbol/APWC.png,5458,9.18,0.01,7854,17631000,3486000,"[{'period': '2024', 'revenue': 472.67, 'unit': 'M', 'net_profit': 3.49}, {'period': '2023', 'revenue': 425.77, 'unit': 'M', 'net_profit': 3.87}, {'period': '2022', 'revenue': 433.89, 'unit': 'M', 'net_profit': 3.87}, {'period': '2021', 'revenue': 476.66, 'unit': 'M', 'net_profit': -8.51}]","[{'period': ""Q4 '24"", 'revenue': 136.11, 'unit': 'M', 'net_profit': 2.59}, {'period': ""Q3 '24"", 'revenue': 122.23, 'unit': 'M', 'net_profit': 1.41}, {'period': ""Q2 '24"", 'revenue': 107170.0, 'unit': 'K', 'net_profit': -255.0}, {'period': ""Q1 '24"", 'revenue': 107170.0, 'unit': 'K', 'net_profit': -255.0}, {'period': ""Q4 '23"", 'revenue': 131.56, 'unit': 'M', 'net_profit': 2.75}, {'period': ""Q3 '23"", 'revenue': 100.73, 'unit': 'M', 'net_profit': 1.1}]",0.17,0.17,339860000,271661000,34035000,124495000,105341000,3876000,108022000,34035000,20029000,1.0446480343268003,-0.09852598913886734,-0.1052631578947368,"[0.08, 0.1]","['2018-09-13', '2017-10-30']",__nan__,0.3663125993055964
293,APXT,Apex Technology Acquisition Corporation Class A Common Stock,"Apex Technology Acquisition Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The Company has not conducted any business operations. The Company has generated no revenues.",Mr. Jeff Epstein,Shell Companies,12.11,USD,2260585907,https://images.financialmodelingprep.com/symbol/APXT.png,745248,0,-0.14000034,747560,-3839770,-4251085,"[{'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.25}]","[{'period': ""Q2 '21"", 'revenue': 45.34, 'unit': 'M', 'net_profit': -11.06}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 58.52}, {'period': ""Q2 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -155.24}, {'period': ""Q1 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 815.68}, {'period': ""Q2 '19"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -1.0}]",-0.0954,-0.0954,352608027,749707,197628,17639744,0,0,4489744,197628,-2419063,0,0,0,__nan__,__nan__,__nan__,0.05002649585172376
294,APXTU,Apex Technology Acquisition Corporation Unit,"Apex Technology Acquisition Corporation does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the software and internet technology industries. The company was founded in 2019 and is based in Burlingame, California.",Mr. Jeffrey Emanuel Epstein,Shell Companies,13.61,USD,2540592419,https://images.financialmodelingprep.com/symbol/APXTU.png,573,0,0,1,-3839770,-4251085,"[{'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.25}]","[{'period': ""Q2 '21"", 'revenue': 45.34, 'unit': 'M', 'net_profit': -11.06}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 58.52}, {'period': ""Q2 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -155.24}, {'period': ""Q1 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 815.68}, {'period': ""Q2 '19"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -1.0}]",-0.0954,-0.0954,352608027,749707,197628,17639744,0,0,4489744,197628,-2419063,0,0,0,__nan__,__nan__,__nan__,0.05002649585172376
295,APXTW,Apex Technology Acquisition Corporation Warrant,,None,Shell Companies,3.39,USD,0,https://images.financialmodelingprep.com/symbol/APXTW.png,0,0,0.02000022,161823,-3839770,-4251085,"[{'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.25}]","[{'period': ""Q2 '21"", 'revenue': 45.34, 'unit': 'M', 'net_profit': -11.06}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 58.52}, {'period': ""Q2 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -155.24}, {'period': ""Q1 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 815.68}, {'period': ""Q2 '19"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -1.0}]",-0.0954,-0.0954,352608027,749707,197628,17639744,0,0,4489744,197628,-2419063,0,0,0,__nan__,__nan__,__nan__,0.05002649585172376
296,APYX,Apyx Medical Corporation Common Stock,"Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures. The company offers Renuvion branded products for the cosmetic surgery market that enable plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and J-Plasma branded products for the hospital surgical market. It also develops, manufactures, and sells disposable hand pieces, and OEM generators and accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.",Mr. Charles D. Goodwin II,Medical - Devices,1.43,USD,54045277,https://images.financialmodelingprep.com/symbol/APYX.png,183729,-2.65,-0.05,63629,-16801000,-23463000,"[{'period': '2024', 'revenue': 48.1, 'unit': 'M', 'net_profit': -23.46}, {'period': '2023', 'revenue': 52.35, 'unit': 'M', 'net_profit': -18.71}, {'period': '2022', 'revenue': 44.51, 'unit': 'M', 'net_profit': -23.28}, {'period': '2021', 'revenue': 48.52, 'unit': 'M', 'net_profit': -15.2}]","[{'period': ""Q1 '25"", 'revenue': 9.43, 'unit': 'M', 'net_profit': -4.15}, {'period': ""Q4 '24"", 'revenue': 14.22, 'unit': 'M', 'net_profit': -4.63}, {'period': ""Q3 '24"", 'revenue': 11.49, 'unit': 'M', 'net_profit': -4.7}, {'period': ""Q2 '24"", 'revenue': 12.15, 'unit': 'M', 'net_profit': -6.56}, {'period': ""Q1 '24"", 'revenue': 14.54, 'unit': 'M', 'net_profit': -7.58}, {'period': ""Q4 '23"", 'revenue': 14.66, 'unit': 'M', 'net_profit': -9.61}]",-0.66,-0.66,64842000,56440000,31741000,50507000,15480000,0,10721000,31741000,-18769000,0.07238295053003534,-0.2538342328862288,-0.2222222222222222,__nan__,__nan__,__nan__,0.7789241540976528
297,AQB,AquaBounty Technologies Inc. Common Stock,"AquaBounty Technologies, Inc., a biotechnology company, focuses on enhancing productivity in the commercial aquaculture industry in the United States and Canada. The company engages in genetic, genomic, and fish health and nutrition research activities. It offers AquAdvantage Salmon, a bioengineered Atlantic salmon for human consumption; and sells conventional Atlantic salmon, salmon eggs, fry, and byproducts. The company was formerly known as Aqua Bounty Farms, Inc. and changed its name to AquaBounty Technologies, Inc. in June 2004. AquaBounty Technologies, Inc. was incorporated in 1991 and is headquartered in Maynard, Massachusetts.",Mr. David A. Frank M.B.A.,Agricultural Farm Products,0.781,USD,3021970,https://images.financialmodelingprep.com/symbol/AQB.png,1215212,-0.03,0.015,42389,113752933,149192660,"[{'period': '2024', 'revenue': 0.0, 'unit': 'M', 'net_profit': 149.19}, {'period': '2023', 'revenue': 2.47, 'unit': 'M', 'net_profit': -27.56}, {'period': '2022', 'revenue': 3.14, 'unit': 'M', 'net_profit': -21.99}, {'period': '2021', 'revenue': 1.17, 'unit': 'M', 'net_profit': -22.75}]","[{'period': ""Q1 '25"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 401.13}, {'period': ""Q4 '24"", 'revenue': -0.70526, 'unit': 'M', 'net_profit': -84.12}, {'period': ""Q3 '24"", 'revenue': 0.047810000000000005, 'unit': 'M', 'net_profit': -3.4}, {'period': ""Q2 '24"", 'revenue': 0.18018, 'unit': 'M', 'net_profit': -50.51}, {'period': ""Q1 '24"", 'revenue': 0.47726999999999997, 'unit': 'M', 'net_profit': -11.16}, {'period': ""Q4 '23"", 'revenue': 0.55325, 'unit': 'M', 'net_profit': -8.42}]",38646,38646,34061798,11342289000,230362,18221088,0,0,16201548,230362,-16792884,5.5214750416243215,6.413788952939486,5390.958158995816,__nan__,__nan__,__nan__,0.5349420485671367
298,AQMS,Aqua Metals Inc. Common Stock,"Aqua Metals, Inc. engages in the recycling of lead primarily in the United States. It produces and sells hard lead, lead compounds, and plastics. Aqua Metals, Inc. was incorporated in 2014 and is headquartered in Reno, Nevada.",Mr. Stephen  Cotton,Waste Management,1.1,USD,9785985,https://images.financialmodelingprep.com/symbol/AQMS.png,102145,-0.29,-0.05,242972,-23847000,-24555000,"[{'period': '2024', 'revenue': 0.0, 'unit': 'M', 'net_profit': -24.55}, {'period': '2023', 'revenue': 0.025, 'unit': 'M', 'net_profit': -23.94}, {'period': '2022', 'revenue': 0.004, 'unit': 'M', 'net_profit': -15.43}, {'period': '2021', 'revenue': 0.17300000000000001, 'unit': 'M', 'net_profit': -18.19}]","[{'period': ""Q1 '25"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.31}, {'period': ""Q4 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -7.44}, {'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.21}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -6.15}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.75}, {'period': ""Q4 '23"", 'revenue': 0.024, 'unit': 'M', 'net_profit': -10.03}]",-3.83,-3.83,26365000,4644000,4079000,10121000,100000,0,8182000,4079000,-21553000,-0.08169282409507393,-0.025774918539560532,0.24901960784313718,__nan__,__nan__,__nan__,0.383880144130476
299,AQST,Aquestive Therapeutics Inc. Common Stock,"Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.",Mr. Daniel  Barber,Drug Manufacturers - Specialty & Generic,2.38,USD,236400402,https://images.financialmodelingprep.com/symbol/AQST.png,1490077,-4.1,0.005,2563729,-26616000,-44137000,"[{'period': '2024', 'revenue': 57.56, 'unit': 'M', 'net_profit': -44.14}, {'period': '2023', 'revenue': 50.58, 'unit': 'M', 'net_profit': -7.87}, {'period': '2022', 'revenue': 47.68, 'unit': 'M', 'net_profit': -60.2}, {'period': '2021', 'revenue': 50.83, 'unit': 'M', 'net_profit': -90.04}]","[{'period': ""Q1 '25"", 'revenue': 8.72, 'unit': 'M', 'net_profit': -22.93}, {'period': ""Q4 '24"", 'revenue': 11.87, 'unit': 'M', 'net_profit': -17.05}, {'period': ""Q3 '24"", 'revenue': 13.54, 'unit': 'M', 'net_profit': -11.51}, {'period': ""Q2 '24"", 'revenue': 20.1, 'unit': 'M', 'net_profit': -2.75}, {'period': ""Q1 '24"", 'revenue': 12.05, 'unit': 'M', 'net_profit': -12.83}, {'period': ""Q4 '23"", 'revenue': 13.21, 'unit': 'M', 'net_profit': -8.11}]",-0.51,-0.51,101424000,88220000,71546000,161580000,7344000,0,18865000,71546000,-35918000,-23.517766497461928,-4.608259212198221,-2.923076923076923,__nan__,__nan__,__nan__,1.5931140558447705
300,ARAV,Aravive Inc. Common Stock,"Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics (Hong Kong) Limited to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.",Dr. Fredric N. Eshelman Pharm.D.,Biotechnology,0.0401,USD,2949860,https://images.financialmodelingprep.com/symbol/ARAV.png,2242572,-0.052763157894736845,-0.0062,4040076,-70837000,-80921000,"[{'period': '2022', 'revenue': 9.14, 'unit': 'M', 'net_profit': -80.92}, {'period': '2021', 'revenue': 7.44, 'unit': 'M', 'net_profit': -38.14}, {'period': '2020', 'revenue': 5.68, 'unit': 'M', 'net_profit': -34.24}, {'period': '2019', 'revenue': 4.75, 'unit': 'M', 'net_profit': -20.25}]","[{'period': ""Q3 '23"", 'revenue': 2.76, 'unit': 'M', 'net_profit': 21.23}, {'period': ""Q2 '23"", 'revenue': 1.27, 'unit': 'M', 'net_profit': 18.01}, {'period': ""Q1 '23"", 'revenue': 1.49, 'unit': 'M', 'net_profit': -82.0}, {'period': ""Q4 '22"", 'revenue': 1.47, 'unit': 'M', 'net_profit': -38.38}, {'period': ""Q3 '22"", 'revenue': 4.96, 'unit': 'M', 'net_profit': -14.63}, {'period': ""Q2 '22"", 'revenue': 1.61, 'unit': 'M', 'net_profit': -17.28}]",-2.22,-2.22,62153000,56134000,53689000,51496000,85000,0,20538000,53689000,-65090000,-0.7426504957071515,-1.1216832721552177,-0.1684210526315791,__nan__,__nan__,__nan__,0.8285360320499413
301,ARAY,Accuray Incorporated Common Stock,"Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy System, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.",Ms. Suzanne  Winter M.B.A.,Medical - Specialties,1.62,USD,166881060,https://images.financialmodelingprep.com/symbol/ARAY.png,629235,-40.5,0.03,425831,5709000,-15545000,"[{'period': '2024', 'revenue': 446.55, 'unit': 'M', 'net_profit': -15.54}, {'period': '2023', 'revenue': 447.61, 'unit': 'M', 'net_profit': -9.28}, {'period': '2022', 'revenue': 429.91, 'unit': 'M', 'net_profit': -5.35}, {'period': '2021', 'revenue': 396.29, 'unit': 'M', 'net_profit': -6.31}]","[{'period': ""Q3 '25"", 'revenue': 113.24, 'unit': 'M', 'net_profit': -1.3}, {'period': ""Q2 '25"", 'revenue': 116.17, 'unit': 'M', 'net_profit': 2.54}, {'period': ""Q1 '25"", 'revenue': 101.55, 'unit': 'M', 'net_profit': -3.95}, {'period': ""Q4 '24"", 'revenue': 134.29, 'unit': 'M', 'net_profit': 3.39}, {'period': ""Q3 '24"", 'revenue': 101.13, 'unit': 'M', 'net_profit': -6.34}, {'period': ""Q2 '24"", 'revenue': 107.24, 'unit': 'M', 'net_profit': -9.62}]",-0.16,-0.16,468627000,323236000,68570000,423543000,92001000,9826000,195267000,68570000,-15505000,-0.4058694973462379,-0.6751077586206896,-0.6359918200408998,__nan__,__nan__,__nan__,0.9037955559538823
302,ARBG,Aequi Acquisition Corp. Class A Common Stock,"Aequi Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Greenwich, Connecticut.",Ms. Hope Schefler Taitz,Shell Companies,10.24,USD,95631759,https://images.financialmodelingprep.com/symbol/ARBG.png,1045,170.66666666666666,-0.01,2821,-7602071,6860102,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 6.86}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 6.35}, {'period': '2020', 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]","[{'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -596.51}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 342.88}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 826.43}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.56}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'T', 'net_profit': 4.31}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 434.55}]",1.19,0.26,36667491,213552,170652,9164506,0,36453939,776639,170652,-1103975,0.08013317978969103,0.08024137209400102,0.08181818181818168,__nan__,__nan__,__nan__,0.24993545372384493
303,ARBGU,Aequi Acquisition Corp. Unit,"Aequi Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Greenwich, Connecticut.",Ms. Hope Schefler Taitz,Shell Companies,10.26,USD,0,https://images.financialmodelingprep.com/symbol/ARBGU.png,19,35.25773195876289,0.01,600,-7602071,6860102,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 6.86}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 6.35}, {'period': '2020', 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]","[{'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -596.51}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 342.88}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 826.43}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.56}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'T', 'net_profit': 4.31}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 434.55}]",1.19,0.26,36667491,213552,170652,9164506,0,36453939,776639,170652,-1103975,0.08013317978969103,0.08024137209400102,0.08181818181818168,__nan__,__nan__,__nan__,0.24993545372384493
304,ARBGW,Aequi Acquisition Corp. warrants,,,Shell Companies,0.0007,USD,0,https://images.financialmodelingprep.com/symbol/ARBGW.png,0,0,0.0001,37830,-7602071,6860102,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 6.86}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 6.35}, {'period': '2020', 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]","[{'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -596.51}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 342.88}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 826.43}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.56}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'T', 'net_profit': 4.31}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 434.55}]",1.19,0.26,36667491,213552,170652,9164506,0,36453939,776639,170652,-1103975,0.08013317978969103,0.08024137209400102,0.08181818181818168,__nan__,__nan__,__nan__,0.24993545372384493
305,ARCB,ArcBest Corporation Common Stock,"ArcBest Corporation provides freight transportation and integrated logistics services. It operates through three segments: Asset-Based, ArcBest, and FleetNet. The Asset-Based segment transports general commodities, such as food, textiles, apparel, furniture, appliances, chemicals, nonbulk petroleum products, rubber, plastics, metal and metal products, wood, glass, automotive parts, machinery, and miscellaneous manufactured products through less-than-truckload services. It also offers motor carrier freight transportation services to customers in Mexico through arrangements with trucking companies. The ArcBest segment provides expedite freight transportation services to commercial and government customers; premium logistics services, such as deployment of specialized equipment to meet linehaul requirements; and international freight transportation with air, ocean, and ground services. It also offers third-party transportation brokerage services by sourcing various capacity solutions, including dry van over the road and intermodal, temperature-controlled and refrigerated, flatbed, intermodal or container shipping, and specialized equipment; full-container and less-than-container load ocean transportation services; warehousing and distribution services; managed transportation services; and moving services to 'do-it-yourself' consumer, as well as provides final mile, time critical, product launch, warehousing, retail logistics, supply chain optimization, and trade show shipping services. The FleetNet segment provides roadside repair solutions and vehicle maintenance management services for commercial and private fleets through a network of third-party service providers. The company was formerly known as Arkansas Best Corporation and changed its name to ArcBest Corporation in May 2014. ArcBest Corporation was founded in 1923 and is headquartered in Fort Smith, Arkansas.",Mr. Seth K. Runser,Trucking,66.93,USD,1533460002,https://images.financialmodelingprep.com/symbol/ARCB.png,420656,9.18,-0.86,315566,376781000,173961000,"[{'period': '2024', 'revenue': 4180.0, 'unit': 'M', 'net_profit': 173.96}, {'period': '2023', 'revenue': 4430.0, 'unit': 'M', 'net_profit': 142.16}, {'period': '2022', 'revenue': 5320.0, 'unit': 'M', 'net_profit': 298.21}, {'period': '2021', 'revenue': 3980.0, 'unit': 'M', 'net_profit': 213.52}]","[{'period': ""Q1 '25"", 'revenue': 967.08, 'unit': 'M', 'net_profit': 3.13}, {'period': ""Q4 '24"", 'revenue': 1000.0, 'unit': 'M', 'net_profit': 29.04}, {'period': ""Q3 '24"", 'revenue': 1060.0, 'unit': 'M', 'net_profit': 100.31}, {'period': ""Q2 '24"", 'revenue': 1080.0, 'unit': 'M', 'net_profit': 46.92}, {'period': ""Q1 '24"", 'revenue': 1040.0, 'unit': 'M', 'net_profit': -3.12}, {'period': ""Q4 '23"", 'revenue': 1090.0, 'unit': 'M', 'net_profit': 48.79}]",7.39,7.3,2429731000,675642000,157203000,1115369000,430893000,0,665985000,127444000,45846000,0.10377082124924566,0.22366421878956697,-0.09213759213759223,"[0.12, 0.01]","['2025-05-09', '1992-07-30']",__nan__,0.45905040516830875
306,ARCC,Ares Capital Corporation Common Stock,"Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.",Mr. Kort  Schnabel,Asset Management,21.91,USD,15109837120,https://images.financialmodelingprep.com/symbol/ARCC.png,5409153,10.74,0.24,2368059,2319000000,1522000000,"[{'period': '2024', 'revenue': 1.71, 'unit': 'B', 'net_profit': 1.52}, {'period': '2023', 'revenue': 1.64, 'unit': 'B', 'net_profit': 1.52}, {'period': '2022', 'revenue': 741.0, 'unit': 'M', 'net_profit': 600.0}, {'period': '2021', 'revenue': 1.68, 'unit': 'B', 'net_profit': 1.57}]","[{'period': ""Q1 '25"", 'revenue': 599.0, 'unit': 'M', 'net_profit': 365.0}, {'period': ""Q4 '24"", 'revenue': 393.0, 'unit': 'M', 'net_profit': 357.0}, {'period': ""Q3 '24"", 'revenue': 751.0, 'unit': 'M', 'net_profit': 394.0}, {'period': ""Q2 '24"", 'revenue': 388.0, 'unit': 'M', 'net_profit': 322.0}, {'period': ""Q1 '24"", 'revenue': 495.0, 'unit': 'M', 'net_profit': 449.0}, {'period': ""Q4 '23"", 'revenue': 444.0, 'unit': 'M', 'net_profit': 413.0}]",2.25,2.25,28254000000,927000000,635000000,14899000000,516000000,26720000000,865000000,635000000,-2128000000,0.09180790960451977,0,-0.18181818181818182,"[0.48, 0.3]","['2025-06-13', '2004-12-22']",__nan__,0.5273235648049833
307,ARCE,Arco Platform Limited Class A Common Shares,"Arco Platform Limited, a technology company in the education sector, provides a pedagogical system with technology-enabled features to deliver educational content to private schools in Brazil. The company's curriculum solutions provide educational content from basic to secondary education K-12 curriculum in printed and digital formats delivered through its platform. As of March 31, 2022, it had a network consisted of 8,056 partner schools and 1,614,648 enrolled students. The company's activities also comprise editing, publishing, advertising, and sale of educational content for private schools. It serves students, teachers, administrators, and parents. Arco Platform Limited was founded in 1941 and is headquartered in Sao Paulo, Brazil.",Mr. Ari  de Sa Cavalcante Neto,Education & Training Services,13.98,USD,927434556,https://images.financialmodelingprep.com/symbol/ARCE.png,237541,-73.57894736842105,-0.01,470862,983859000,39489000,"[{'period': '2022', 'revenue': 1780.0, 'unit': 'M', 'net_profit': 39.49}, {'period': '2021', 'revenue': 1230.0, 'unit': 'M', 'net_profit': -158.08}, {'period': '2020', 'revenue': 1000.0, 'unit': 'M', 'net_profit': 16.78}, {'period': '2019', 'revenue': 572.84, 'unit': 'M', 'net_profit': -9.43}]","[{'period': ""Q2 '23"", 'revenue': 470.96, 'unit': 'M', 'net_profit': -74.04}, {'period': ""Q1 '23"", 'revenue': 534.91, 'unit': 'M', 'net_profit': 90.62}, {'period': ""Q4 '22"", 'revenue': 679.33, 'unit': 'M', 'net_profit': 22.64}, {'period': ""Q3 '22"", 'revenue': 253.92, 'unit': 'M', 'net_profit': -72.46}, {'period': ""Q2 '22"", 'revenue': 412.14, 'unit': 'M', 'net_profit': -13.34}, {'period': ""Q1 '22"", 'revenue': 430.04, 'unit': 'M', 'net_profit': 102.66}]",0.71,-1.49,5753408000,1872729000,608145000,3855978000,928009000,142492000,1533589000,216360000,-280297000,3.9582419908380326,1.2497991561394963,1.22397476340694,__nan__,__nan__,__nan__,0.6702076404106923
308,ARCT,Arcturus Therapeutics Holdings Inc. Common Stock,"Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.",Mr. Joseph E. Payne M.Sc.,Biotechnology,11.65,USD,315954990,https://images.financialmodelingprep.com/symbol/ARCT.png,434270,-4.3,0.01,335676,-77401000,-80941000,"[{'period': '2024', 'revenue': 138.39, 'unit': 'M', 'net_profit': -80.94}, {'period': '2023', 'revenue': 157.75, 'unit': 'M', 'net_profit': -29.73}, {'period': '2022', 'revenue': 205.75, 'unit': 'M', 'net_profit': 9.35}, {'period': '2021', 'revenue': 12.36, 'unit': 'M', 'net_profit': -206.86}]","[{'period': ""Q1 '25"", 'revenue': 29.38, 'unit': 'M', 'net_profit': 2.77}, {'period': ""Q4 '24"", 'revenue': 21.0, 'unit': 'M', 'net_profit': -30.0}, {'period': ""Q3 '24"", 'revenue': 38.81, 'unit': 'M', 'net_profit': -6.9}, {'period': ""Q2 '24"", 'revenue': 45.98, 'unit': 'M', 'net_profit': -17.22}, {'period': ""Q1 '24"", 'revenue': 32.6, 'unit': 'M', 'net_profit': -26.82}, {'period': ""Q4 '23"", 'revenue': 28.21, 'unit': 'M', 'net_profit': -8.57}]",-3,-3,344069000,305979000,237028000,103091000,3974000,0,65489000,237028000,-60395000,-2.2028883555408427,-1.7229941126997477,-1.6785714285714284,"[0.0085, 0.0029]","['2013-01-08', '2012-03-06']",__nan__,0.29962304072729595
309,ARDS,Aridis Pharmaceuticals Inc. Common Stock,"Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.",Dr. Vu L. Truong Ph.D.,Biotechnology,0.0001,USD,4457,https://images.financialmodelingprep.com/symbol/ARDS.png,4648,,0,12500,-29506000,-30749000,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -30.75}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -42.28}, {'period': '2020', 'revenue': 1.0, 'unit': 'M', 'net_profit': -21.92}, {'period': '2019', 'revenue': 1.02, 'unit': 'M', 'net_profit': -28.99}]","[{'period': ""Q3 '23"", 'revenue': 417.0, 'unit': 'K', 'net_profit': -83.0}, {'period': ""Q2 '23"", 'revenue': 19.65, 'unit': 'M', 'net_profit': 12.14}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -6.82}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -6.39}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -9.07}, {'period': ""Q2 '22"", 'revenue': 0.292, 'unit': 'M', 'net_profit': -8.22}]",-1.64,-1.64,14695000,11626000,4876000,38927000,1240000,0,36898000,4876000,-29209000,0.3359440055814372,0.2727466237790024,0.5232558139534884,__nan__,__nan__,__nan__,2.6489962572303503
310,ARDX,Ardelyx Inc. Common Stock,"Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.",Mr. Michael G. Raab,Biotechnology,3.88,USD,928309400,https://images.financialmodelingprep.com/symbol/ARDX.png,5226716,-16.87,0.5,10681680,-16713000,-39136000,"[{'period': '2024', 'revenue': 333.62, 'unit': 'M', 'net_profit': -39.14}, {'period': '2023', 'revenue': 124.46, 'unit': 'M', 'net_profit': -66.07}, {'period': '2022', 'revenue': 52.16, 'unit': 'M', 'net_profit': -67.21}, {'period': '2021', 'revenue': 10.1, 'unit': 'M', 'net_profit': -158.16}]","[{'period': ""Q1 '25"", 'revenue': 74.11, 'unit': 'M', 'net_profit': -41.14}, {'period': ""Q4 '24"", 'revenue': 116.13, 'unit': 'M', 'net_profit': 4.64}, {'period': ""Q3 '24"", 'revenue': 98240.0, 'unit': 'K', 'net_profit': -809.0}, {'period': ""Q2 '24"", 'revenue': 73.22, 'unit': 'M', 'net_profit': -16.45}, {'period': ""Q1 '24"", 'revenue': 46.02, 'unit': 'M', 'net_profit': -26.52}, {'period': ""Q4 '23"", 'revenue': 34.36, 'unit': 'M', 'net_profit': -28.8}]",-0.17,-0.17,435754000,356452000,250100000,262465000,57705000,0,77830000,64932000,-45820000,0.6980706001372982,0.4076316466617222,0.4333333333333333,__nan__,__nan__,__nan__,0.6023237881924205
311,AREC,American Resources Corporation Class A Common Stock,"American Resources Corporation engages in the extraction, processing, transportation, distribution, and sale of metallurgical coal to the steel industries. The company supplies raw materials; and sells coal used in pulverized coal injections. It has a portfolio of operations located in the Pike, Knott, and Letcher Counties in Kentucky; and Wyoming County, West Virginia. American Resources Corporation was founded in 2006 and is headquartered in Fishers, Indiana.",Mr. Mark C. Jensen,Coal,0.931,USD,72079230,https://images.financialmodelingprep.com/symbol/AREC.png,6036248,-3.72,0.0223,447773,-7210803,-11455086,"[{'period': '2023', 'revenue': 16.74, 'unit': 'M', 'net_profit': -11.46}, {'period': '2022', 'revenue': 39.47, 'unit': 'M', 'net_profit': 22.53}, {'period': '2021', 'revenue': 7.76, 'unit': 'M', 'net_profit': -36.33}, {'period': '2020', 'revenue': 1.06, 'unit': 'M', 'net_profit': -16.13}]","[{'period': ""Q3 '24"", 'revenue': 0.23544, 'unit': 'M', 'net_profit': -9.21}, {'period': ""Q2 '24"", 'revenue': 0.00409, 'unit': 'M', 'net_profit': -6.62}, {'period': ""Q1 '24"", 'revenue': 0.09401999999999999, 'unit': 'M', 'net_profit': -6.23}, {'period': ""Q4 '23"", 'revenue': 0.0664, 'unit': 'M', 'net_profit': -10.84}, {'period': ""Q3 '23"", 'revenue': 5.83, 'unit': 'M', 'net_profit': 3.48}, {'period': ""Q2 '23"", 'revenue': 1980.0, 'unit': 'K', 'net_profit': -999.92}]",-0.15,-0.15,91746164,34885493,2666638,91522320,0,18780000,18070562,2666638,-14515241,-2.5274736704303438,-1.5083879837066758,-1.441176470588235,__nan__,__nan__,__nan__,0.9975601813717248
312,ARGX,argenx SE American Depositary Shares,"argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjgren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S..R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Universit Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.","Mr. Timothy  Van Hauwermeiren EMBA, M.Sc.",Biotechnology,565.63,USD,34537140417,https://images.financialmodelingprep.com/symbol/ARGX.png,413040,34.47,3.88,429215,3394960,833040000,"[{'period': '2024', 'revenue': 2190.0, 'unit': 'M', 'net_profit': 833.04}, {'period': '2023', 'revenue': 1230.0, 'unit': 'M', 'net_profit': -295.51}, {'period': '2022', 'revenue': 410.75, 'unit': 'M', 'net_profit': -709.98}, {'period': '2021', 'revenue': 464.13, 'unit': 'M', 'net_profit': -407.63}]","[{'period': ""Q4 '24"", 'revenue': 1300.0, 'unit': 'M', 'net_profit': 835.54}, {'period': ""Q2 '24"", 'revenue': 841.96, 'unit': 'M', 'net_profit': -30.37}, {'period': ""Q4 '23"", 'revenue': 686.31, 'unit': 'M', 'net_profit': -155.63}, {'period': ""Q2 '23"", 'revenue': 468.2, 'unit': 'M', 'net_profit': -112.94}, {'period': ""Q4 '22"", 'revenue': 302.91, 'unit': 'M', 'net_profit': -255.57}, {'period': ""Q2 '22"", 'revenue': 111.35, 'unit': 'M', 'net_profit': -416.1}]",13.92,12.78,6202522000,4883103000,3378826000,704239000,909096000,8946400,669916000,1499936000,-81614184,1.0157157304807587,3.818991202354298,3.6976744186046506,__nan__,__nan__,__nan__,0.11354075003683985
313,ARKO,ARKO Corp. Common Stock,"Arko Corp. operates convenience stores in the United States. It operates through three segments: Retail, Wholesale, and GPM Petroleum. The Retail segment engages in the sale of fuel and merchandise to retail consumers. The Wholesale segment supplies fuel to third-party dealers and consignment agents. The GPM Petroleum segment supplies fuel to independent dealers, and bulk and spot purchasers. It operates approximately 3,000 locations comprising approximately 1,400 company-operated stores and approximately 1,650 dealer sites. The company is based in Richmond, Virginia.",Mr. Arie  Kotler,Specialty Retail,5.2,USD,592566000,https://images.financialmodelingprep.com/symbol/ARKO.png,821104,173.33,-0.09,1037581,256630999,20845000,"[{'period': '2024', 'revenue': 8730.0, 'unit': 'M', 'net_profit': 20.84}, {'period': '2023', 'revenue': 9410.0, 'unit': 'M', 'net_profit': 34.37}, {'period': '2022', 'revenue': 9140.0, 'unit': 'M', 'net_profit': 71.75}, {'period': '2021', 'revenue': 7420.0, 'unit': 'M', 'net_profit': 59.2}]","[{'period': ""Q1 '25"", 'revenue': 1830.0, 'unit': 'M', 'net_profit': -14.09}, {'period': ""Q4 '24"", 'revenue': 1990.0, 'unit': 'M', 'net_profit': -2.3}, {'period': ""Q3 '24"", 'revenue': 2280.0, 'unit': 'M', 'net_profit': 26.25}, {'period': ""Q2 '24"", 'revenue': 2390.0, 'unit': 'M', 'net_profit': 14.06}, {'period': ""Q1 '24"", 'revenue': 2069999.9999999998, 'unit': 'K', 'net_profit': -594.0}, {'period': ""Q4 '23"", 'revenue': 2230.0, 'unit': 'M', 'net_profit': 1.08}]",0.13,0.13,3620658000,722208000,267088000,3243792000,142239000,3009000,445490000,261758000,107944000,-0.0348008943749906,-0.39349413715848586,-0.4583333333333333,"[0.03, 0.02]","['2025-05-19', '2022-03-14']",__nan__,0.8959122899760209
314,ARKOW,ARKO Corp. Warrant,"Arko Corp. operates convenience stores in the United States. It operates through three segments: Retail, Wholesale, and GPM Petroleum. The Retail segment engages in the sale of fuel and merchandise to retail consumers. The Wholesale segment supplies fuel to third-party dealers and consignment agents. The GPM Petroleum segment supplies fuel to independent dealers, and bulk and spot purchasers. It operates approximately 3,000 locations comprising approximately 1,400 company-operated stores and approximately 1,650 dealer sites. The company is based in Richmond, Virginia.",Mr. Arie  Kotler,Specialty Retail,0.0239,USD,2723525,https://images.financialmodelingprep.com/symbol/ARKOW.png,38602.56364,0.04,-0.0015,237444,256630999,20845000,"[{'period': '2024', 'revenue': 8730.0, 'unit': 'M', 'net_profit': 20.84}, {'period': '2023', 'revenue': 9410.0, 'unit': 'M', 'net_profit': 34.37}, {'period': '2022', 'revenue': 9140.0, 'unit': 'M', 'net_profit': 71.75}, {'period': '2021', 'revenue': 7420.0, 'unit': 'M', 'net_profit': 59.2}]","[{'period': ""Q1 '25"", 'revenue': 1830.0, 'unit': 'M', 'net_profit': -14.09}, {'period': ""Q4 '24"", 'revenue': 1990.0, 'unit': 'M', 'net_profit': -2.3}, {'period': ""Q3 '24"", 'revenue': 2280.0, 'unit': 'M', 'net_profit': 26.25}, {'period': ""Q2 '24"", 'revenue': 2390.0, 'unit': 'M', 'net_profit': 14.06}, {'period': ""Q1 '24"", 'revenue': 2069999.9999999998, 'unit': 'K', 'net_profit': -594.0}, {'period': ""Q4 '23"", 'revenue': 2230.0, 'unit': 'M', 'net_profit': 1.08}]",0.13,0.13,3620658000,722208000,267088000,3243792000,142239000,3009000,445490000,261758000,107944000,-0.0348008943749906,-0.39349413715848586,-0.4583333333333333,__nan__,__nan__,__nan__,0.8959122899760209
315,ARKR,Ark Restaurants Corp. Common Stock,"Ark Restaurants Corp., through its subsidiaries, owns and operates restaurants and bars in the United States. As of December 20, 2021, it owned and operated 17 restaurants and bars, including four restaurants located in New York City; one in Washington, D.C.; five in Las Vegas, Nevada; one in Atlantic City, New Jersey; four on the east coast of Florida; and two on the gulf coast of Alabama, as well as had 17 fast food concepts and catering operations. The company was incorporated in 1983 and is based in New York, New York.",Mr. Michael  Weinstein,Restaurants,11.93,USD,43021489,https://images.financialmodelingprep.com/symbol/ARKR.png,9530,-4.07,0.63,8201,591000,-3896000,"[{'period': '2024', 'revenue': 183.54, 'unit': 'M', 'net_profit': -3.9}, {'period': '2023', 'revenue': 184.79, 'unit': 'M', 'net_profit': -5.93}, {'period': '2022', 'revenue': 183.67, 'unit': 'M', 'net_profit': 9.28}, {'period': '2021', 'revenue': 131.87, 'unit': 'M', 'net_profit': 12.89}]","[{'period': ""Q2 '25"", 'revenue': 39.73, 'unit': 'M', 'net_profit': -9.14}, {'period': ""Q1 '25"", 'revenue': 44.99, 'unit': 'M', 'net_profit': 3.16}, {'period': ""Q4 '24"", 'revenue': 43.41, 'unit': 'M', 'net_profit': -4.46}, {'period': ""Q3 '24"", 'revenue': 50400.0, 'unit': 'K', 'net_profit': 640.0}, {'period': ""Q2 '24"", 'revenue': 42.26, 'unit': 'M', 'net_profit': -1.45}, {'period': ""Q1 '24"", 'revenue': 47.49, 'unit': 'M', 'net_profit': 1.37}]",-1.08,-1.08,156041000,18225000,10273000,112400000,3771000,6550000,28884000,10273000,2189000,-0.06782334384858044,0.3427800269905533,0.3454545454545454,"[0.1875, 0.35]","['2024-05-31', '2004-10-20']",__nan__,0.7203235047199134
316,ARLP,Alliance Resource Partners L.P. Common Units representing Limited Partners Interests,"Alliance Resource Partners, L.P., a diversified natural resource company, produces and markets coal primarily to utilities and industrial users in the United States. The company operates through four segments: Illinois Basin Coal Operations, Appalachia Coal Operations, Oil & Gas Royalties, and Coal Royalties. It produces a range of thermal and metallurgical coal with sulfur and heat contents. The company operates seven underground mining complexes in Illinois, Indiana, Kentucky, Maryland, Pennsylvania, and West Virginia. In addition, it leases land and operates a coal loading terminal on the Ohio River at Mt. Vernon, Indiana; and buys and resells coal, as well as owns mineral and royalty interests in approximately 1.5 million gross acres of oil and gas producing regions primarily in the Permian, Anadarko, and Williston Basins. Further, the company offers various mining technology products and services, including data network, communication and tracking systems, mining proximity detection systems, industrial collision avoidance systems, and data and analytics software. As of December 31, 2021, it had approximately 547.1 million tons of proven and probable coal mineral reserves, as well as 1.17 billion tons of measured, indicated, and inferred coal mineral resources in Illinois, Indiana, Kentucky, Maryland, Pennsylvania, and West Virginia. The company was founded in 1971 and is headquartered in Tulsa, Oklahoma.","Mr. Joseph W. Craft III, J.D.",Coal,26.68,USD,3426459040,https://images.financialmodelingprep.com/symbol/ARLP.png,431543,12.53,0.07,192484,627009000,360855000,"[{'period': '2024', 'revenue': 2450.0, 'unit': 'M', 'net_profit': 360.86}, {'period': '2023', 'revenue': 2570.0, 'unit': 'M', 'net_profit': 630.12}, {'period': '2022', 'revenue': 2410.0, 'unit': 'M', 'net_profit': 586.2}, {'period': '2021', 'revenue': 1570.0, 'unit': 'M', 'net_profit': 182.77}]","[{'period': ""Q1 '25"", 'revenue': 540.47, 'unit': 'M', 'net_profit': 73.98}, {'period': ""Q4 '24"", 'revenue': 590.09, 'unit': 'M', 'net_profit': 16.33}, {'period': ""Q3 '24"", 'revenue': 613.57, 'unit': 'M', 'net_profit': 86.28}, {'period': ""Q2 '24"", 'revenue': 593.35, 'unit': 'M', 'net_profit': 100.19}, {'period': ""Q1 '24"", 'revenue': 651.7, 'unit': 'M', 'net_profit': 158.06}, {'period': ""Q4 '23"", 'revenue': 625.42, 'unit': 'M', 'net_profit': 115.44}]",2.81996,2.81996,2915730000,513230000,136962000,1062197000,176987000,128073000,233142000,136962000,374390000,-0.3389627874073691,-0.4273215492971158,-0.41372972972972966,"[0.7, 0.23]","['2025-05-08', '1999-10-27']",__nan__,0.3642988205355091
317,ARNA,Arena Pharmaceuticals Inc. Common Stock,"Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.",Mr. Amit Munshi,Biotechnology,99.99,USD,0,https://images.financialmodelingprep.com/symbol/ARNA.png,1472638,-9.858030168589174,0,0,-608402000,-620592000,"[{'period': '2021', 'revenue': 0.054, 'unit': 'M', 'net_profit': -620.59}, {'period': '2020', 'revenue': 0.319, 'unit': 'M', 'net_profit': -404.73}, {'period': '2019', 'revenue': 806.43, 'unit': 'M', 'net_profit': 397.56}, {'period': '2018', 'revenue': 17.97, 'unit': 'M', 'net_profit': -29.4}]","[{'period': ""Q4 '21"", 'revenue': 0.054, 'unit': 'M', 'net_profit': -156.61}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -196.31}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -146.09}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -118.42}, {'period': ""Q4 '20"", 'revenue': 0.037, 'unit': 'M', 'net_profit': -122.16}, {'period': ""Q3 '20"", 'revenue': 0.02, 'unit': 'M', 'net_profit': -97.44}]",-11.33,-11.33,784705000,569465000,550469000,111468000,0,160796000,66316000,224572000,-523004000,-0.5350003658355053,-0.5333330038988571,-0.5331529093369419,__nan__,__nan__,__nan__,0.1420508343899937
318,AROW,Arrow Financial Corporation Common Stock,"Arrow Financial Corporation, a bank holding company, provides commercial and consumer banking, and financial products and services. The company's deposit products include demand deposits, interest-bearing checking accounts, savings deposits, time deposits, and other time deposits. Its lending activities comprise commercial loans, such as term loans, time notes, and lines of credit; and commercial real estate loans to finance real estate purchases, refinancing, expansions, and improvements to commercial properties, as well as commercial construction and land development loans to finance projects. The company's lending activities also include consumer installment loans to finance personal expenditures, personal lines of credit, overdraft protection, and automobile loans; and residential real estate loans, fixed home equity loans, and home equity lines of credit for consumers to finance home improvements, debt consolidation, education, and other uses. In addition, it maintains an indirect lending program; and sells residential real estate loan originations into the secondary market. Further, the company provides retirement planning, trust, and estate administration services for individuals; and pension, profit-sharing, and employee benefit plan administration services for corporations. Additionally, it offers insurance agency services comprising group health care policies and life insurance, and property and casualty insurance products; and investment advisory services to its proprietary mutual funds, as well as holds a real estate investment trust. The company operates in the northeastern region of New York State in Warren, Washington, Saratoga, Essex, Clinton, Rensselaer, Albany, and Schenectady counties, as well as surrounding areas. It owns 26 branch banking offices; and leases 12 branch banking offices, as well as two residential loan origination offices. Arrow Financial Corporation was founded in 1851 and is headquartered in Glens Falls, New York.",Mr. David S. DeMarco,Banks - Regional,26.44,USD,440894932,https://images.financialmodelingprep.com/symbol/AROW.png,43795,15.55,-0.31,43497,42719000,29709000,"[{'period': '2024', 'revenue': 223.07, 'unit': 'M', 'net_profit': 29.71}, {'period': '2023', 'revenue': 191.68, 'unit': 'M', 'net_profit': 30.07}, {'period': '2022', 'revenue': 160.55, 'unit': 'M', 'net_profit': 48.8}, {'period': '2021', 'revenue': 147.92, 'unit': 'M', 'net_profit': 49.86}]","[{'period': ""Q1 '25"", 'revenue': 58.2, 'unit': 'M', 'net_profit': 6.31}, {'period': ""Q4 '24"", 'revenue': 55.13, 'unit': 'M', 'net_profit': 4.47}, {'period': ""Q3 '24"", 'revenue': 57.58, 'unit': 'M', 'net_profit': 8.97}, {'period': ""Q2 '24"", 'revenue': 55.83, 'unit': 'M', 'net_profit': 8.6}, {'period': ""Q1 '24"", 'revenue': 54.53, 'unit': 'M', 'net_profit': 7.66}, {'period': ""Q4 '23"", 'revenue': 51.81, 'unit': 'M', 'net_profit': 7.72}]",0,0,4306348000,617657000,617657000,3905447000,0,3502210000,3827930000,154546000,28872000,-0.03433699534336995,-0.012169576059850374,0,"[0.28, 8.2136]","['2025-05-13', '1985-01-17']",__nan__,0.9069046440278399
319,ARPO,Aerpio Pharmaceuticals Inc. Common Stock,"Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The company is headquartered in Blue Ash, Ohio and currently employs 27 full-time employees. The firm is focused on developing treatments for ocular disease. Its lead product candidate is AKB-9778. Its other two pipeline programs include AKB-4924 and ARP-1536. AKB-9778 is a small molecule activator of the Tie-2 pathway, which is being developed for the treatment of diabetic retinopathy (DR). AKB-4924 is a selective stabilizer of hypoxia-inducible factor-1 alpha (HIF-1alpha), which is being developed for the treatment of inflammatory bowel disease (IBD). ARP-1536 is a humanized monoclonal antibody directed at the same target as AKB-9778. ARP-1536 binds the extracellular domain of vascular endothelial protein tyrosine phosphatase (VE-PTP) inhibiting its ability to interact with Tie-2. As of April 14, 2017, the Company had completed a Phase II trial of AKB-9778 in 144 patients with diabetic macular edema. As of April 14, 2017, the Company had completed Phase Ia clinical trial in healthy volunteers for AKB-4924.",,Biotechnology,2.2,USD,53669220,https://images.financialmodelingprep.com/symbol/ARPO.png,401776,0,-0.01999998,826006,-67458000,-63691000,"[{'period': '2024', 'revenue': 25.98, 'unit': 'M', 'net_profit': -63.69}, {'period': '2022', 'revenue': 5.51, 'unit': 'M', 'net_profit': -36.92}, {'period': '2021', 'revenue': 4.47, 'unit': 'M', 'net_profit': -23.16}, {'period': '2020', 'revenue': 0.8230000000000001, 'unit': 'M', 'net_profit': -22.18}]","[{'period': ""Q1 '25"", 'revenue': 7.14, 'unit': 'M', 'net_profit': 73.02}, {'period': ""Q4 '24"", 'revenue': 22.98, 'unit': 'M', 'net_profit': -14.49}, {'period': ""Q3 '24"", 'revenue': 7.21, 'unit': 'M', 'net_profit': -12.55}, {'period': ""Q2 '24"", 'revenue': 6.18, 'unit': 'M', 'net_profit': -14.58}, {'period': ""Q3 '23"", 'revenue': 1.23, 'unit': 'M', 'net_profit': -31.16}, {'period': ""Q2 '23"", 'revenue': 0.98, 'unit': 'M', 'net_profit': -3.55}]",-2.36,-2.36,70319000,61287000,47237000,17841000,5903000,0,17074000,28670000,-61204000,0,0,0,__nan__,__nan__,__nan__,0.25371521210483655
320,ARQT,Arcutis Biotherapeutics Inc. Common Stock,"Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.",Mr. Todd Franklin Watanabe M.A.,Biotechnology,14.11,USD,1681940220,https://images.financialmodelingprep.com/symbol/ARQT.png,2420879,-13.57,0.48,1774802,-109625000,-140039000,"[{'period': '2024', 'revenue': 196.54, 'unit': 'M', 'net_profit': -140.04}, {'period': '2023', 'revenue': 59.61, 'unit': 'M', 'net_profit': -262.14}, {'period': '2022', 'revenue': 3.69, 'unit': 'M', 'net_profit': -321.29}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -205.9}]","[{'period': ""Q1 '25"", 'revenue': 65.85, 'unit': 'M', 'net_profit': -25.06}, {'period': ""Q4 '24"", 'revenue': 71.36, 'unit': 'M', 'net_profit': -10.79}, {'period': ""Q3 '24"", 'revenue': 44.76, 'unit': 'M', 'net_profit': -41.54}, {'period': ""Q2 '24"", 'revenue': 30.86, 'unit': 'M', 'net_profit': -52.33}, {'period': ""Q1 '24"", 'revenue': 49.57, 'unit': 'M', 'net_profit': -35.38}, {'period': ""Q4 '23"", 'revenue': 13.53, 'unit': 'M', 'net_profit': -66.28}]",-1.16,-1.16,348889000,335820000,227955000,191348000,73066000,0,81013000,71335000,-112301000,0.5179920328534872,0.46578545815213246,0.6931216931216931,__nan__,__nan__,__nan__,0.5484495068632144
321,ARRW,Arrowroot Acquisition Corp. Class A common stock,"Arrowroot Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to identify and acquire a business focusing on the enterprise software sector. The company was incorporated in 2020 and is based in Marina Del Rey, California.",Mr. Matthew J. Safaii,Shell Companies,18,USD,59292648,https://images.financialmodelingprep.com/symbol/ARRW.png,14305,-48.648648648648646,0,44582,19115000,-4407000,"[{'period': '2023', 'revenue': 420.58, 'unit': 'M', 'net_profit': -4.41}, {'period': '2022', 'revenue': 309.17, 'unit': 'M', 'net_profit': 11.47}, {'period': '2021', 'revenue': 217.87, 'unit': 'M', 'net_profit': 4.84}, {'period': '2020', 'revenue': 141.75, 'unit': 'M', 'net_profit': 6.86}]","[{'period': ""Q2 '24"", 'revenue': 135.54, 'unit': 'M', 'net_profit': -314.03}, {'period': ""Q1 '24"", 'revenue': 124.94, 'unit': 'M', 'net_profit': -4.24}, {'period': ""Q4 '23"", 'revenue': 115670.0, 'unit': 'K', 'net_profit': 949.69}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 275.54}, {'period': ""Q2 '23"", 'revenue': 195.22, 'unit': 'M', 'net_profit': -5.38}, {'period': ""Q1 '23"", 'revenue': 93980.0, 'unit': 'K', 'net_profit': -374.84}]",-0.05,-0.046,47004462,80832000,4763000,24744253,74007000,0,23170000,4763000,-16190000,0.592253227821741,-1.3843537414965987,-1.131578947368421,__nan__,__nan__,__nan__,0.5264234914549176
322,ARRWU,Arrowroot Acquisition Corp. Unit,"Arrowroot Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to identify and acquire a business focusing on the enterprise software sector. The company was incorporated in 2020 and is based in Marina Del Rey, California.",Mr. Matthew J. Safaii,Shell Companies,17,USD,137576274,https://images.financialmodelingprep.com/symbol/ARRWU.png,1553,67.46031746031746,4.66,6933,19115000,-4407000,"[{'period': '2023', 'revenue': 420.58, 'unit': 'M', 'net_profit': -4.41}, {'period': '2022', 'revenue': 309.17, 'unit': 'M', 'net_profit': 11.47}, {'period': '2021', 'revenue': 217.87, 'unit': 'M', 'net_profit': 4.84}, {'period': '2020', 'revenue': 141.75, 'unit': 'M', 'net_profit': 6.86}]","[{'period': ""Q2 '24"", 'revenue': 135.54, 'unit': 'M', 'net_profit': -314.03}, {'period': ""Q1 '24"", 'revenue': 124.94, 'unit': 'M', 'net_profit': -4.24}, {'period': ""Q4 '23"", 'revenue': 115670.0, 'unit': 'K', 'net_profit': 949.69}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 275.54}, {'period': ""Q2 '23"", 'revenue': 195.22, 'unit': 'M', 'net_profit': -5.38}, {'period': ""Q1 '23"", 'revenue': 93980.0, 'unit': 'K', 'net_profit': -374.84}]",-0.05,-0.046,47004462,80832000,4763000,24744253,74007000,0,23170000,4763000,-16190000,0.592253227821741,-1.3843537414965987,-1.131578947368421,__nan__,__nan__,__nan__,0.5264234914549176
323,ARRWW,Arrowroot Acquisition Corp. Warrant,"Arrowroot Acquisition Corp. is a blank check company. The company was incorporated in 2020 and is based in Marina Del Rey, California.",Mr. Matthew J. Safaii,Shell Companies,0.289,USD,2338797,https://images.financialmodelingprep.com/symbol/ARRWW.png,0,0,0.0296,274799,19115000,-4407000,"[{'period': '2023', 'revenue': 420.58, 'unit': 'M', 'net_profit': -4.41}, {'period': '2022', 'revenue': 309.17, 'unit': 'M', 'net_profit': 11.47}, {'period': '2021', 'revenue': 217.87, 'unit': 'M', 'net_profit': 4.84}, {'period': '2020', 'revenue': 141.75, 'unit': 'M', 'net_profit': 6.86}]","[{'period': ""Q2 '24"", 'revenue': 135.54, 'unit': 'M', 'net_profit': -314.03}, {'period': ""Q1 '24"", 'revenue': 124.94, 'unit': 'M', 'net_profit': -4.24}, {'period': ""Q4 '23"", 'revenue': 115670.0, 'unit': 'K', 'net_profit': 949.69}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 275.54}, {'period': ""Q2 '23"", 'revenue': 195.22, 'unit': 'M', 'net_profit': -5.38}, {'period': ""Q1 '23"", 'revenue': 93980.0, 'unit': 'K', 'net_profit': -374.84}]",-0.05,-0.046,47004462,80832000,4763000,24744253,74007000,0,23170000,4763000,-16190000,0.592253227821741,-1.3843537414965987,-1.131578947368421,__nan__,__nan__,__nan__,0.5264234914549176
324,ARRY,Array Technologies Inc. Common Stock,"Array Technologies, Inc. manufactures and supplies solar tracking systems and related products in the United States and internationally. Its products include DuraTrack HZ v3, a single-axis solar tracking system; and SmarTrack, a machine learning software that is used to identify the optimal position for a solar array in real time to increase energy production. The company was founded in 1989 and is headquartered in Albuquerque, New Mexico.",Mr. Kevin G. Hostetler,Solar,7.68,USD,1171560960,https://images.financialmodelingprep.com/symbol/ARRY.png,6032100,-4.13,-0.76,10422722,-162972000,-240394000,"[{'period': '2024', 'revenue': 915.81, 'unit': 'M', 'net_profit': -240.39}, {'period': '2023', 'revenue': 1580.0, 'unit': 'M', 'net_profit': 137.24}, {'period': '2022', 'revenue': 1640.0, 'unit': 'M', 'net_profit': 4.43}, {'period': '2021', 'revenue': 853.32, 'unit': 'M', 'net_profit': -50.4}]","[{'period': ""Q1 '25"", 'revenue': 302.36, 'unit': 'M', 'net_profit': 16.75}, {'period': ""Q4 '24"", 'revenue': 275.23, 'unit': 'M', 'net_profit': -126.9}, {'period': ""Q3 '24"", 'revenue': 231.41, 'unit': 'M', 'net_profit': -141.35}, {'period': ""Q2 '24"", 'revenue': 255.77, 'unit': 'M', 'net_profit': 25.7}, {'period': ""Q1 '24"", 'revenue': 153.4, 'unit': 'M', 'net_profit': 2.17}, {'period': ""Q4 '23"", 'revenue': 341.62, 'unit': 'M', 'net_profit': 23.09}]",-1.95,-1.95,1425999000,998724000,362992000,1137164000,275838000,0,437814000,362992000,146675000,-1.5900250532199904,-2.751632177207811,-3.142857142857143,__nan__,__nan__,__nan__,0.7974507696008202
325,ARTAU,Artisan Acquisition Corp. Units,"Artisan Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to search for a target with operations or prospects focusing on healthcare, consumer, and technology sectors. The company was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.",Mr. Cheng Yin Pan,Shell Companies,10.15,USD,0,https://images.financialmodelingprep.com/symbol/ARTAU.png,8262,0,0,1240,0,0,"[{'period': '2021', 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]","[{'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'T', 'net_profit': 5.56}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.1}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.54}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]",0,0,340178214,610487,102212,27888846,0,0,3278431,102212,-1372731,0,0,0,__nan__,__nan__,__nan__,0.08198304551037475
326,ARTL,Artelo Biosciences Inc. Common Stock,"Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.",Mr. Gregory D. Gorgas M.B.A.,Biotechnology,0.92,USD,3018548,https://images.financialmodelingprep.com/symbol/ARTL.png,407177,-0.3,-0.02,24336,-10285000,-9874000,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -9.87}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -7.44}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.65}, {'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.17}]","[{'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.45}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.6}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.04}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.2}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.26}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.43}]",-3.49,-3.49,20424000,18322000,17533000,1021000,0,-1495000,998000,6888000,-8008000,-0.38183528147252455,-0.32768589485007393,0.4154103852596314,__nan__,__nan__,__nan__,0.04999020759890325
327,ARTLW,Artelo Biosciences Inc. Warrant,"Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for treating breast and prostate cancer, neuropathic and nociceptive pain, and anxiety disorders, including PTSD. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.",Mr. Gregory D. Gorgas M.B.A.,Biotechnology,0.0056,USD,13069,https://images.financialmodelingprep.com/symbol/ARTLW.png,0,-0.003918824352694192,0,29400,-10285000,-9874000,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -9.87}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -7.44}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.65}, {'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.17}]","[{'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.45}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.6}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.04}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.2}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.26}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.43}]",-3.49,-3.49,20424000,18322000,17533000,1021000,0,-1495000,998000,6888000,-8008000,-0.38183528147252455,-0.32768589485007393,0.4154103852596314,__nan__,__nan__,__nan__,0.04999020759890325
328,ARTNA,Artesian Resources Corporation Class A Common Stock,"Artesian Resources Corporation, through its subsidiaries, provides water, wastewater, and other services in Delaware, Maryland, and Pennsylvania. The company distributes and sells water to residential, commercial, industrial, governmental, municipal, and utility customers, as well as for public and private fire protection in the states of Delaware, Maryland, and Pennsylvania; and offers wastewater collection, treatment infrastructure, and wastewater services to customers in Delaware. It also provides contract water and wastewater services; water, sewer, and internal service line protection plans; and wastewater management services, as well as design, construction, and engineering services. In addition, the company offers services to other water utilities, including operations and billing functions; owns real estate properties, including land for office buildings, a water treatment plant, and wastewater facility; and provides design, installation, maintenance, and repair services related to existing or proposed storm water management systems. As of December 31, 2021, it served approximately 91,700 customers in Delaware, 2,500 customers in Maryland, and 40 customers in Pennsylvania through 1,368 miles of transmission and distribution mains. Artesian Resources Corporation was founded in 1905 and is headquartered in Newark, Delaware.",Ms. Nicholle R. Taylor,Regulated Water,33.92,USD,349435971,https://images.financialmodelingprep.com/symbol/ARTNA.png,45911,16.31,0.43,29170,50117000,20394000,"[{'period': '2024', 'revenue': 107.95, 'unit': 'M', 'net_profit': 20.39}, {'period': '2023', 'revenue': 98.86, 'unit': 'M', 'net_profit': 16.7}, {'period': '2022', 'revenue': 98.9, 'unit': 'M', 'net_profit': 18.0}, {'period': '2021', 'revenue': 90.86, 'unit': 'M', 'net_profit': 16.83}]","[{'period': ""Q1 '25"", 'revenue': 25.89, 'unit': 'M', 'net_profit': 5.43}, {'period': ""Q4 '24"", 'revenue': 26.85, 'unit': 'M', 'net_profit': 3.85}, {'period': ""Q3 '24"", 'revenue': 29.14, 'unit': 'M', 'net_profit': 6.81}, {'period': ""Q2 '24"", 'revenue': 27.42, 'unit': 'M', 'net_profit': 5.33}, {'period': ""Q1 '24"", 'revenue': 24.54, 'unit': 'M', 'net_profit': 4.41}, {'period': ""Q4 '23"", 'revenue': 24.55, 'unit': 'M', 'net_profit': 3.48}]",1.98,1.98,798623000,24528000,1147000,559434000,13824000,0,25593000,1147000,-9119000,0.1896081084288732,0.2212707347745374,0.1856287425149701,"[0.3074, 0.15]","['2025-05-16', '1994-05-05']",__nan__,0.7004982325828332
329,ARTW,Art's-Way Manufacturing Co. Inc. Common Stock,"Art's-Way Manufacturing Co., Inc. manufactures and sells agricultural equipment, specialized modular science buildings, and steel cutting tools in the United States and internationally. The company operates through three segments: Agricultural Products, Modular Buildings, and Tools. The Agricultural Products segment offers various specialized farm machinery, including portable and stationary animal feed processing equipment and related attachments; hay and forage equipment, such as forage boxes, bale processors, running gears, and dump boxes; manure spreaders; sugar beet harvesting equipment; dirt work equipment; and after-market service parts. The Modular Buildings segment produces, sells, and leases swine buildings, complex containment research laboratories, and research facilities for academic research institutions, government research and diagnostic centers, public health institutions, and private research and pharmaceutical companies. This segment also designs, manufactures, delivers, installs, and rents building units. The Tools segment offers standard single point brazed carbide tipped tools, polycrystalline diamond and cubic boron nitride inserts and tools, and original equipment manufacturer (OEM) specialty tools to the automotive, aerospace, oil and gas piping, and appliances industries. The company markets and sells its products through independent farm equipment dealers, manufacturers' representatives, direct sales, and OEM sales channels. Art's-Way Manufacturing Co., Inc. was founded in 1956 and is based in Armstrong, Iowa.",Mr. Marc H. McConnell,Agricultural - Machinery,1.78,USD,9056782,https://images.financialmodelingprep.com/symbol/ARTW.png,23904,35.6,-0.02,3097,460697,307375,"[{'period': '2024', 'revenue': 24500.0, 'unit': 'K', 'net_profit': 307.38}, {'period': '2023', 'revenue': 30280.0, 'unit': 'K', 'net_profit': 266.97}, {'period': '2022', 'revenue': 28400.0, 'unit': 'K', 'net_profit': 97.8}, {'period': '2021', 'revenue': 24970.0, 'unit': 'K', 'net_profit': 212.63}]","[{'period': ""Q1 '25"", 'revenue': 5140.0, 'unit': 'K', 'net_profit': -55.76}, {'period': ""Q4 '24"", 'revenue': 6170.0, 'unit': 'K', 'net_profit': 831.93}, {'period': ""Q3 '24"", 'revenue': 5880.0, 'unit': 'K', 'net_profit': -26.2}, {'period': ""Q2 '24"", 'revenue': 6730.0, 'unit': 'K', 'net_profit': -33.34}, {'period': ""Q1 '24"", 'revenue': 5720.0, 'unit': 'K', 'net_profit': -465.04}, {'period': ""Q4 '23"", 'revenue': 6850.0, 'unit': 'K', 'net_profit': -307.88}]",0.0608,0.0608,21240684,13124309,1860,9146861,2586071,0,6632493,1860,1902021,-0.8145021825427983,0.15135090591042405,0.13857677902621715,"[0.05, 0.1]","['2015-02-10', '1989-02-01']",__nan__,0.4306293055346052
330,ARVL,Arrival Ordinary Shares,"Arrival engages in the research and development, and design of commercial electric vehicles (EVs), EVs components, robotic manufacturing processes for EVs, and associated software in the United Kingdom, the United States, Russia, and internationally. Its products portfolio includes commercial EV vans, buses, and cars. The company was formerly known as Arrival Group S.A. and changed its name to Arrival. The company was founded in 2015 and is based in Howald, Luxembourg. Arrival is a subsidiary of Kinetik S. r.l.",Mr. Igor  Torgov,Auto - Manufacturers,0.49,USD,9003799,https://images.financialmodelingprep.com/symbol/ARVL.png,174108,-0.07324364723467862,-0.249,2343693,-187182000,-1304404595,"[{'period': '2021', 'revenue': 0.0, 'unit': 'B', 'net_profit': -1.3}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.3}, {'period': '2019', 'revenue': 0.0, 'unit': 'K', 'net_profit': 31.09}]","[{'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -53.51}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -26.79}]",-95.78,-95.77,1770701523,1017542628,901092593,544484952,44199633,41116603,81634247,901092593,-585656180,-0.949690644334729,-244.98412065323978,-10.68048780487805,__nan__,__nan__,__nan__,0.3074967434813688
331,ARVLW,Arrival Warrant,,,,,,,,,,,,,,[],[],,,,,,,,,,,,,,,__nan__,__nan__,__nan__,__nan__
332,ARVN,Arvinas Inc. Common Stock,"Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.",Dr. John G. Houston Ph.D.,Biotechnology,6.49,USD,473714186,https://images.financialmodelingprep.com/symbol/ARVN.png,2950159,-9.83,0.23,1919962,-250200000,-198900000,"[{'period': '2024', 'revenue': 263.4, 'unit': 'M', 'net_profit': -198.9}, {'period': '2023', 'revenue': 78.5, 'unit': 'M', 'net_profit': -367.3}, {'period': '2022', 'revenue': 131.4, 'unit': 'M', 'net_profit': -271.9}, {'period': '2021', 'revenue': 46.7, 'unit': 'M', 'net_profit': -183.2}]","[{'period': ""Q1 '25"", 'revenue': 188.8, 'unit': 'M', 'net_profit': 82.9}, {'period': ""Q4 '24"", 'revenue': 59.2, 'unit': 'M', 'net_profit': -45.1}, {'period': ""Q3 '24"", 'revenue': 102.4, 'unit': 'M', 'net_profit': -49.2}, {'period': ""Q2 '24"", 'revenue': 76.5, 'unit': 'M', 'net_profit': -35.2}, {'period': ""Q1 '24"", 'revenue': 25.3, 'unit': 'M', 'net_profit': -69.4}, {'period': ""Q4 '23"", 'revenue': -43.1, 'unit': 'M', 'net_profit': -154.8}]",-2.77,-2.77,1091400000,1067300000,1039400000,529700000,13700000,0,229800000,100500000,-261100000,0.3662613981762918,0.4584808058807514,0.581570996978852,__nan__,__nan__,__nan__,0.4853399303646692
333,ARWR,Arrowhead Pharmaceuticals Inc. Common Stock,"Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.",Dr. Christopher R. Anzalone Ph.D.,Biotechnology,15.71,USD,2169551000,https://images.financialmodelingprep.com/symbol/ARWR.png,1800050,-12.67,0.37,1779678,-561513000,-599493000,"[{'period': '2024', 'revenue': 3.55, 'unit': 'M', 'net_profit': -599.49}, {'period': '2023', 'revenue': 240.74, 'unit': 'M', 'net_profit': -205.28}, {'period': '2022', 'revenue': 243.23, 'unit': 'M', 'net_profit': -176.49}, {'period': '2021', 'revenue': 138.29, 'unit': 'M', 'net_profit': -140.85}]","[{'period': ""Q2 '25"", 'revenue': 542.71, 'unit': 'M', 'net_profit': 370.44}, {'period': ""Q1 '25"", 'revenue': 2.5, 'unit': 'M', 'net_profit': -173.09}, {'period': ""Q4 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -170.54}, {'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -170.79}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -125.3}, {'period': ""Q1 '24"", 'revenue': 3.55, 'unit': 'M', 'net_profit': -132.86}]",-5,-5,1139802000,695471000,680961000,948739000,0,0,103168000,102685000,-604320000,-2.1963716471606176,-1.9204384362440627,-1.617801047120419,__nan__,__nan__,__nan__,0.8323717628149451
334,ARYA,ARYA Sciences Acquisition Corp III Class A Ordinary Shares,,,,,,,,,,,,,,[],[],,,,,,,,,,,,,,,__nan__,__nan__,__nan__,__nan__
335,ARYD,ARYA Sciences Acquisition Corp IV Class A Odinary Shares,"ARYA Sciences Acquisition Corp IV does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.",Mr. Adam Leo Stone,Shell Companies,6.64,USD,50042486,https://images.financialmodelingprep.com/symbol/ARYD.png,30382,-25.53846153846154,-2.46,90405,-4752270,-2133335,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.13}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.14}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -6.56}, {'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -13.54}]","[{'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -245.85}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.22}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -455.07}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 381.51}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.29}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.14}]",-0.22,-0.22,40652687,76738,20191,14969477,0,40575949,12353227,20191,-725858,-3.709559009344257,-1.6785326022998421,-2.375,__nan__,__nan__,__nan__,0.3682284765088222
336,ASAX,Astrea Acquisition Corp. Class A Common Stock,"Astrea Acquisition Corp. does not have significant operations. It intends to enter a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. The company focuses on the businesses in the food and beverage/hospitality, financial services, technology, consumer, real estate and transportation, telecom and media, and industrial sectors. The company was incorporated in 2020 and is based in Key Biscayne, Florida.",Mr. Felipe  Gonzalez,Shell Companies,10.08,USD,0,https://images.financialmodelingprep.com/symbol/ASAX.png,67834,0,0.01,7296,-1589100,-1565898,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.57}]","[{'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 218.28}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 370.83}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -207.91}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -797.81}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -291.37}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -158.19}]",-0.0783,-0.0783,172973428,412348,67689,1552178,0,0,1209988,67689,-1541075,0,0,0,__nan__,__nan__,__nan__,0.008973505456572209
337,ASAXU,Astrea Acquisition Corp. Unit,"Astrea Acquisition Corp. does not have significant operations. It intends to enter a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. The company focuses on the businesses in the food and beverage/hospitality, financial services, technology, consumer, real estate and transportation, telecom and media, and industrial sectors. The company was incorporated in 2020 and is based in Key Biscayne, Florida.",Mr. Felipe  Gonzalez,Shell Companies,10,USD,0,https://images.financialmodelingprep.com/symbol/ASAXU.png,336,0,0,0,-1589100,-1565898,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.57}]","[{'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 218.28}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 370.83}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -207.91}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -797.81}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -291.37}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -158.19}]",-0.0783,-0.0783,172973428,412348,67689,1552178,0,0,1209988,67689,-1541075,0,0,0,__nan__,__nan__,__nan__,0.008973505456572209
338,ASAXW,Astrea Acquisition Corp. Warrant,"Astrea Acquisition Corp. does not have significant operations. It intends to enter a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities. The company was founded 2020 and is based in Key Biscayne, Florida.",Mr. Felipe  Gonzalez,Shell Companies,0.0013,USD,0,https://images.financialmodelingprep.com/symbol/ASAXW.png,0,0,0,14061,-1589100,-1565898,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.57}]","[{'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 218.28}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 370.83}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -207.91}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -797.81}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -291.37}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -158.19}]",-0.0783,-0.0783,172973428,412348,67689,1552178,0,0,1209988,67689,-1541075,0,0,0,__nan__,__nan__,__nan__,0.008973505456572209
339,ASLE,AerSale Corporation Common Stock,"AerSale Corporation provides aftermarket commercial aircraft, engines, and its parts to passenger and cargo airlines, leasing companies, original equipment manufacturers, and government and defense contractors, as well as maintenance, repair, and overhaul (MRO) service providers worldwide. It operates in two segments, Asset Management Solutions and Technical Operations (TechOps). The Asset Management Solutions segment engages in the sale and lease of aircraft, engines, and airframes, as well as disassembly of these assets for component parts. The TechOps segment provides internal and third-party aviation services, including internally developed engineered solutions, heavy aircraft maintenance and modification, and component MRO, as well as end-of-life disassembly services. This segment also provides aircraft modifications, cargo and tanker conversions of aircraft, and aircraft storage; and MRO services for landing gear, thrust reversers, hydraulic systems, and other aircraft components. The company was founded in 2008 and is headquartered in Coral Gables, Florida.",Mr. Nicolas  Finazzo,"Airlines, Airports & Air Services",6.27,USD,333609771,https://images.financialmodelingprep.com/symbol/ASLE.png,591417,-57,-0.05,338658,26157000,5851000,"[{'period': '2024', 'revenue': 345.07, 'unit': 'M', 'net_profit': 5.85}, {'period': '2023', 'revenue': 334.5, 'unit': 'M', 'net_profit': -5.56}, {'period': '2022', 'revenue': 408.54, 'unit': 'M', 'net_profit': 43.86}, {'period': '2021', 'revenue': 340.44, 'unit': 'M', 'net_profit': 36.12}]","[{'period': ""Q1 '25"", 'revenue': 65.78, 'unit': 'M', 'net_profit': -5.28}, {'period': ""Q4 '24"", 'revenue': 94.74, 'unit': 'M', 'net_profit': 2.7}, {'period': ""Q3 '24"", 'revenue': 82680.0, 'unit': 'K', 'net_profit': 509.0}, {'period': ""Q2 '24"", 'revenue': 77.1, 'unit': 'M', 'net_profit': -3.64}, {'period': ""Q1 '24"", 'revenue': 90.54, 'unit': 'M', 'net_profit': 6.28}, {'period': ""Q4 '23"", 'revenue': 94.42, 'unit': 'M', 'net_profit': -2.73}]",0.0001,0.0001,604723000,284030000,4698000,149103000,36640000,0,74970000,4698000,-17846000,543.9375,2.0517706273593386,1.0006666666666666,__nan__,__nan__,__nan__,0.24656412936170777
340,ASLEW,AerSale Corporation Warrants,"AerSale Corporation provides aftermarket commercial aircraft, engines, and its parts to passenger and cargo airlines, leasing companies, original equipment manufacturers, and government and defense contractors, as well as maintenance, repair, and overhaul (MRO) service providers worldwide. It operates in two segments, Asset Management Solutions and Technical Operations (TechOps). The Asset Management Solutions segment engages in the sale and lease of aircraft, engines, and airframes, as well as disassembly of these assets for component parts. The TechOps segment provides internal and third-party aviation services, including internally developed engineered solutions, heavy aircraft maintenance and modification, and component MRO, as well as end-of-life disassembly services. This segment also provides aircraft modifications, cargo and tanker conversions of aircraft, and aircraft storage; and MRO services for landing gear, thrust reversers, hydraulic systems, and other aircraft components. The company was founded in 2008 and is headquartered in Coral Gables, Florida.",Mr. Nicolas  Finazzo,"Airlines, Airports & Air Services",6.48,USD,0,https://images.financialmodelingprep.com/symbol/ASLEW.png,0,8.307692307692308,0.15999985,48476,26157000,5851000,"[{'period': '2024', 'revenue': 345.07, 'unit': 'M', 'net_profit': 5.85}, {'period': '2023', 'revenue': 334.5, 'unit': 'M', 'net_profit': -5.56}, {'period': '2022', 'revenue': 408.54, 'unit': 'M', 'net_profit': 43.86}, {'period': '2021', 'revenue': 340.44, 'unit': 'M', 'net_profit': 36.12}]","[{'period': ""Q1 '25"", 'revenue': 65.78, 'unit': 'M', 'net_profit': -5.28}, {'period': ""Q4 '24"", 'revenue': 94.74, 'unit': 'M', 'net_profit': 2.7}, {'period': ""Q3 '24"", 'revenue': 82680.0, 'unit': 'K', 'net_profit': 509.0}, {'period': ""Q2 '24"", 'revenue': 77.1, 'unit': 'M', 'net_profit': -3.64}, {'period': ""Q1 '24"", 'revenue': 90.54, 'unit': 'M', 'net_profit': 6.28}, {'period': ""Q4 '23"", 'revenue': 94.42, 'unit': 'M', 'net_profit': -2.73}]",0.0001,0.0001,604723000,284030000,4698000,149103000,36640000,0,74970000,4698000,-17846000,543.9375,2.0517706273593386,1.0006666666666666,__nan__,__nan__,__nan__,0.24656412936170777
341,ASLN,ASLAN Pharmaceuticals Limited American Depositary Shares,"ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.","Dr. Carl Alan Jason Morton Firth EMBA, Ph.D.",Biotechnology,0.6,USD,1697010,https://images.financialmodelingprep.com/symbol/ASLN.png,102493,-0.0375,-0.0999,769822,-43387100,-44219604,"[{'period': '2023', 'revenue': 12.0, 'unit': 'M', 'net_profit': -44.22}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -51.38}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -34.71}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -17.91}]","[{'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -9.92}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -13.51}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -9.71}, {'period': ""Q2 '23"", 'revenue': 12.0, 'unit': 'M', 'net_profit': -1.89}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -19.11}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -14.48}]",-67.25,-67.25,24626525,24129992,21252058,37913456,171441,235567,13114904,21252058,-46370623,0.08865003160110863,0.13940202540491622,0.2690217391304348,__nan__,__nan__,__nan__,1.539537389055094
342,ASMB,Assembly Biosciences Inc. Common Stock,"Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.",Mr. Jason A. Okazaki J.D.,Biotechnology,13.42,USD,102495921,https://images.financialmodelingprep.com/symbol/ASMB.png,27222,-2.16,0.92,13192,-45420000,-40177000,"[{'period': '2024', 'revenue': 28.52, 'unit': 'M', 'net_profit': -40.18}, {'period': '2023', 'revenue': 7.16, 'unit': 'M', 'net_profit': -61.23}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -92.07}, {'period': '2021', 'revenue': 6.25, 'unit': 'M', 'net_profit': -129.85}]","[{'period': ""Q1 '25"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.82}, {'period': ""Q4 '24"", 'revenue': 7.36, 'unit': 'M', 'net_profit': -10.34}, {'period': ""Q3 '24"", 'revenue': 6.84, 'unit': 'M', 'net_profit': -9.61}, {'period': ""Q2 '24"", 'revenue': 8.53, 'unit': 'M', 'net_profit': -11.15}, {'period': ""Q1 '24"", 'revenue': 5.79, 'unit': 'M', 'net_profit': -9.08}, {'period': ""Q4 '23"", 'revenue': 7.16, 'unit': 'M', 'net_profit': -10.96}]",-6.69,-6.69,119168000,115503000,112079000,85809000,0,0,47803000,38344000,-51145000,0.2924792821982678,0.3438132880381525,0.5,__nan__,__nan__,__nan__,0.7200674677765844
343,ASML,ASML Holding N.V. New York Registry Shares,"ASML Holding N.V. develops, produces, markets, sells, and services advanced semiconductor equipment systems for chipmakers. It offers advanced semiconductor equipment systems, including lithography, metrology, and inspection systems. The company also provides extreme ultraviolet lithography systems; and deep ultraviolet lithography systems comprising immersion and dry lithography solutions to manufacture various range of semiconductor nodes and technologies. In addition, it offers metrology and inspection systems, including YieldStar optical metrology systems to assess the quality of patterns on the wafers; and HMI electron beam solutions to locate and analyze individual chip defects. Further, the company provides computational lithography solutions, and lithography systems and control software solutions; and refurbishes and upgrades lithography systems, as well as offers customer support and related services. It operates in Japan, South Korea, Singapore, Taiwan, China, rest of Asia, the Netherlands, rest of Europe, the Middle East, Africa, and the United States. The company was formerly known as ASM Lithography Holding N.V. and changed its name to ASML Holding N.V. in 2001. ASML Holding N.V. was founded in 1984 and is headquartered in Veldhoven, the Netherlands.",Mr. Christophe D. Fouquet,Semiconductors,748.1,USD,294152920000,https://images.financialmodelingprep.com/symbol/ASML.png,1708125,30.26,-10.26,1081026,9941200000,7571600000,"[{'period': '2024', 'revenue': 28.26, 'unit': 'B', 'net_profit': 7.57}, {'period': '2023', 'revenue': 27.56, 'unit': 'B', 'net_profit': 7.84}, {'period': '2022', 'revenue': 21.17, 'unit': 'B', 'net_profit': 5.62}, {'period': '2021', 'revenue': 18.61, 'unit': 'B', 'net_profit': 5.88}]","[{'period': ""Q1 '25"", 'revenue': 7.74, 'unit': 'B', 'net_profit': 2.35}, {'period': ""Q4 '24"", 'revenue': 9.26, 'unit': 'B', 'net_profit': 2.69}, {'period': ""Q3 '24"", 'revenue': 7.47, 'unit': 'B', 'net_profit': 2.08}, {'period': ""Q2 '24"", 'revenue': 6.24, 'unit': 'B', 'net_profit': 1.58}, {'period': ""Q1 '24"", 'revenue': 5.29, 'unit': 'B', 'net_profit': 1.22}, {'period': ""Q4 '23"", 'revenue': 7.24, 'unit': 'B', 'net_profit': 2.05}]",19.24,19.24,48589600000,30737400000,12741300000,30112800000,4880700000,903000000,20051400000,12735900000,9083100000,-0.0034883720930232558,-0.03411149381298635,-0.03267973856209161,"[1.919, 2.84]","['2025-04-28', '2007-10-01']",__nan__,0.6197375570080841
344,ASND,Ascendis Pharma A/S American Depositary Shares,"Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 /g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.",Mr. Jan Moller Mikkelsen,Biotechnology,157.6,USD,9514863600,https://images.financialmodelingprep.com/symbol/ASND.png,587815.4,-24.28,0.06,488874,-290023000,-378084000,"[{'period': '2024', 'revenue': 363.64, 'unit': 'M', 'net_profit': -378.08}, {'period': '2023', 'revenue': 266.72, 'unit': 'M', 'net_profit': -481.45}, {'period': '2022', 'revenue': 51.17, 'unit': 'M', 'net_profit': -583.19}, {'period': '2021', 'revenue': 7.78, 'unit': 'M', 'net_profit': -383.58}]","[{'period': ""Q1 '25"", 'revenue': 100.95, 'unit': 'M', 'net_profit': -94.63}, {'period': ""Q4 '24"", 'revenue': 173.92, 'unit': 'M', 'net_profit': -38.47}, {'period': ""Q3 '24"", 'revenue': 57.83, 'unit': 'M', 'net_profit': -99.2}, {'period': ""Q2 '24"", 'revenue': 36.0, 'unit': 'M', 'net_profit': -109.38}, {'period': ""Q1 '24"", 'revenue': 95.89, 'unit': 'M', 'net_profit': -131.03}, {'period': ""Q4 '23"", 'revenue': 137.7, 'unit': 'M', 'net_profit': -86.88}]",-6.53,-6.53,1179495000,1060861000,559543000,1285201000,177440000,13575000,907863000,559543000,-307624000,0.2946362557397463,0.21469237527702945,0.2362573099415205,__nan__,__nan__,__nan__,1.0896197101301828
345,ASO,Academy Sports and Outdoors Inc. Common Stock,"Academy Sports and Outdoors, Inc., through its subsidiaries, operates as a sporting goods and outdoor recreational products retailer in the United States. The company sells coolers and drinkware, camping accessories, camping equipment, sunglasses, backpacks, and sports bags; marine equipment and fishing rods, reels, baits, and equipment; firearms, ammunition, archery and archery equipment, camouflage apparel, waders, shooting accessories, optics, airguns, and hunting equipment; team sports equipment, including baseball, football, basketball, soccer, golf, racket sports, and volleyball; fitness equipment and accessories, and nutrition supplies; and patio furniture, outdoor cooking, wheeled goods, trampolines, playsets, watersports, and pet equipment, as well as electronics products, watches, consumables, batteries, etc. It also offers outdoor apparel, seasonal apparel, denim, work apparel, graphic t-shirts, and accessories; boys and girls outdoor and athletic apparel; sporting apparel and apparel for fitness; professional and collegiate team licensed apparel and accessories; casual shoes and slippers, work and western boots, youth footwear, socks, and hunting and seasonal footwear; and boys and girls athletic footwear, running shoes, athletic lifestyle and training shoes, team and specialty sports footwear, and slides. The company sells its products under the Academy Sports + Outdoors, Magellan Outdoors, BCG, O'rageous, Outdoor Gourmet, and Freely brand names. As of June 14, 2022, it operated 260 retail locations in 16 contiguous states. The company also sells merchandise to customers through the academy.com website. Academy Sports and Outdoors, Inc. was founded in 1938 and is headquartered in Katy, Texas.",Mr. Steven Paul Lawrence,Specialty Retail,45.23,USD,3008998118,https://images.financialmodelingprep.com/symbol/ASO.png,1882030,7.96,-0.26,1293902,693168000,418447000,"[{'period': '2024', 'revenue': 5930.0, 'unit': 'M', 'net_profit': 418.45}, {'period': '2023', 'revenue': 6160.0, 'unit': 'M', 'net_profit': 519.19}, {'period': '2022', 'revenue': 6400.0, 'unit': 'M', 'net_profit': 628.0}, {'period': '2021', 'revenue': 6770.0, 'unit': 'M', 'net_profit': 671.38}]","[{'period': ""Q4 '24"", 'revenue': 1680.0, 'unit': 'M', 'net_profit': 133.63}, {'period': ""Q3 '24"", 'revenue': 1340.0, 'unit': 'M', 'net_profit': 65.76}, {'period': ""Q2 '24"", 'revenue': 1550.0, 'unit': 'M', 'net_profit': 142.59}, {'period': ""Q1 '24"", 'revenue': 1360.0, 'unit': 'M', 'net_profit': 76.47}, {'period': ""Q4 '23"", 'revenue': 1790.0, 'unit': 'M', 'net_profit': 168.17}, {'period': ""Q3 '23"", 'revenue': 1400.0, 'unit': 'M', 'net_profit': 99.98}]",5.87,5.73,4900963000,1710149000,288929000,2896928000,16759000,0,960881000,288929000,328493000,-0.1548205617800798,-0.19403879119397524,-0.1480406386066763,"[0.13, 0.075]","['2025-03-25', '2022-03-16']",__nan__,0.591093627925777
346,ASPC,Alpha Capital Acquisition Company One Class A Ordinary Share,"A SPAC III Acquisition Corp. is a blank check company. The company was created for the purpose of effecting a merger, asset acquisition, share purchase, reorganization or similar business combination. The company was founded on September 3, 2021 and is headquartered in Hong Kong.",Mr. Sze Wai  Tsang CFA,Shell Companies,10.18,USD,81999900,https://images.financialmodelingprep.com/symbol/ASPC.png,15243,509,0,2470,-2650,-2650,"[{'period': '2023', 'revenue': 0.0, 'unit': 'K', 'net_profit': -2.65}, {'period': '2022', 'revenue': 0.0, 'unit': 'K', 'net_profit': -102.73}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.91}]","[{'period': ""Q1 '25"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 413.2}, {'period': ""Q4 '24"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -179.6}, {'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -38.78}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -8.0}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -2.65}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]",0,0,62075158,1718199,1598890,517334,2576,0,517334,1598890,-473887,0.9742039735615065,0.9742039735615065,0,__nan__,__nan__,__nan__,0.008333994091485036
347,ASPCU,Alpha Capital Acquisition Company Unit,"A SPAC III Acquisition Corp. is a blank check company. The company was created for the purpose of effecting a merger, asset acquisition, share purchase, reorganization or similar business combination. The company was founded on September 3, 2021 and is headquartered in Hong Kong.",Mr. Sze Wai  Tsang CFA,Shell Companies,10.31,USD,87155090,https://images.financialmodelingprep.com/symbol/ASPCU.png,955,91.24,0.02,144,-2650,-2650,"[{'period': '2023', 'revenue': 0.0, 'unit': 'K', 'net_profit': -2.65}, {'period': '2022', 'revenue': 0.0, 'unit': 'K', 'net_profit': -102.73}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.91}]","[{'period': ""Q1 '25"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 413.2}, {'period': ""Q4 '24"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -179.6}, {'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -38.78}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -8.0}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -2.65}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]",0,0,62075158,1718199,1598890,517334,2576,0,517334,1598890,-473887,0.9742039735615065,0.9742039735615065,0,__nan__,__nan__,__nan__,0.008333994091485036
348,ASPCW,Alpha Capital Acquisition Company Warrant,"Alpha Capital Acquisition Company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 2020 and is based in New York, New York.",Mr. Alec  Oxenford,Shell Companies,0.2892,USD,0,https://images.financialmodelingprep.com/symbol/ASPCW.png,0,0,-0.0108,106229,-2650,-2650,"[{'period': '2023', 'revenue': 0.0, 'unit': 'K', 'net_profit': -2.65}, {'period': '2022', 'revenue': 0.0, 'unit': 'K', 'net_profit': -102.73}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.91}]","[{'period': ""Q1 '25"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 413.2}, {'period': ""Q4 '24"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -179.6}, {'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -38.78}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -8.0}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -2.65}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]",0,0,62075158,1718199,1598890,517334,2576,0,517334,1598890,-473887,0.9742039735615065,0.9742039735615065,0,__nan__,__nan__,__nan__,0.008333994091485036
349,ASPS,Altisource Portfolio Solutions S.A. Common Stock,"Altisource Portfolio Solutions S.A. operates as an integrated service provider and marketplace for the real estate and mortgage industries in the United States, India, Luxembourg, Uruguay, and internationally. It provides property preservation and inspection services, payment management technologies, and a vendor management oversight software-as-a-service (SaaS) platform. The company also offers Hubzu, an online real estate auction platform, as well as real estate auction, real estate brokerage, and asset management services; and Equator, a SaaS-based technology to manage real estate owned, short sales, foreclosure, bankruptcy, and eviction processes. In addition, it provides mortgage loan fulfillment, certification and certification insurance services, technologies, title insurance agent, settlement, real estate valuation services, residential and commercial construction inspection and risk mitigation, foreclosure trustee, and commercial loan servicing technology services. Further, the company operates TrelixTM Connect, Vendorly, RentRange, REALSynergy, Lenders One Loan Automation, and other platform solutions. It serves financial institutions, government-sponsored enterprises, banks, asset managers, servicers, investors, originators, correspondent lenders, and mortgage bankers. Altisource Portfolio Solutions S.A. was incorporated in 1999 and is headquartered in Luxembourg City, Luxembourg.",Mr. William B. Shepro,Real Estate - Services,0.808,USD,70772316,https://images.financialmodelingprep.com/symbol/ASPS.png,140988,-0.8,0.009,106577,11523000,-35636000,"[{'period': '2024', 'revenue': 160.13, 'unit': 'M', 'net_profit': -35.64}, {'period': '2023', 'revenue': 145.07, 'unit': 'M', 'net_profit': -56.29}, {'period': '2022', 'revenue': 153.12, 'unit': 'M', 'net_profit': -52.83}, {'period': '2021', 'revenue': 178.45, 'unit': 'M', 'net_profit': 11.81}]","[{'period': ""Q1 '25"", 'revenue': 43.44, 'unit': 'M', 'net_profit': -5.34}, {'period': ""Q4 '24"", 'revenue': 41.01, 'unit': 'M', 'net_profit': -8.77}, {'period': ""Q3 '24"", 'revenue': 40.53, 'unit': 'M', 'net_profit': -9.36}, {'period': ""Q2 '24"", 'revenue': 41.34, 'unit': 'M', 'net_profit': -8.31}, {'period': ""Q1 '24"", 'revenue': 42.01, 'unit': 'M', 'net_profit': -9.2}, {'period': ""Q4 '23"", 'revenue': 36.03, 'unit': 'M', 'net_profit': -13.15}]",-1.25,-1.25,143606000,51101000,29811000,300317000,16093000,0,271273000,29811000,-5028000,2.67,0.3669213004085983,0.50199203187251,__nan__,__nan__,__nan__,2.091256632731223
350,ASPU,Aspen Group Inc. Common Stock,"Aspen Group, Inc., an education technology company, provides online higher education services in the United States. The company offers baccalaureate, master's, and doctoral degree programs in nursing and health sciences, business and technology, arts and sciences, and education fields through Aspen University and United States University. As of April 30, 2022, it had 13,334 degree-seeking students enrolled. Aspen Group, Inc. was founded in 1987 and is based in New York, New York.",Mr. Michael D. Mathews,Education & Training Services,0.145,USD,3692033,https://images.financialmodelingprep.com/symbol/ASPU.png,23467,-0.38,-0.007,10,-4802256,-13578756,"[{'period': '2024', 'revenue': 51.4, 'unit': 'M', 'net_profit': -13.58}, {'period': '2023', 'revenue': 66.32, 'unit': 'M', 'net_profit': -8.35}, {'period': '2022', 'revenue': 76.69, 'unit': 'M', 'net_profit': -9.59}, {'period': '2021', 'revenue': 67.81, 'unit': 'M', 'net_profit': -10.45}]","[{'period': ""Q3 '25"", 'revenue': 10940.0, 'unit': 'K', 'net_profit': -908.75}, {'period': ""Q2 '25"", 'revenue': 11.46, 'unit': 'M', 'net_profit': -4.15}, {'period': ""Q1 '25"", 'revenue': 11330.0, 'unit': 'K', 'net_profit': -127.86}, {'period': ""Q4 '24"", 'revenue': 10.87, 'unit': 'M', 'net_profit': -7.45}, {'period': ""Q3 '24"", 'revenue': 12.06, 'unit': 'M', 'net_profit': -3.88}, {'period': ""Q2 '24"", 'revenue': 13.83, 'unit': 'M', 'net_profit': -1.61}]",-0.53,-0.53,75947000,24594326,2619427,43670386,19686527,17533030,19641670,2619427,-4811240,-1.592565639377256,-0.6266648937030441,-0.6060606060606061,__nan__,__nan__,__nan__,0.575011336853332
351,ASRT,Assertio Holdings Inc. Common Stock,"Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate acute pain; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.",Mr. Brendan P. O'Grady,Drug Manufacturers - Specialty & Generic,0.6658,USD,63770790,https://images.financialmodelingprep.com/symbol/ASRT.png,380685,-2.08,0.0263,339584,-24476000,-21581000,"[{'period': '2024', 'revenue': 124.96, 'unit': 'M', 'net_profit': -21.58}, {'period': '2023', 'revenue': 152.07, 'unit': 'M', 'net_profit': -331.94}, {'period': '2022', 'revenue': 156.23, 'unit': 'M', 'net_profit': 109.62}, {'period': '2021', 'revenue': 111.01, 'unit': 'M', 'net_profit': -1.28}]","[{'period': ""Q1 '25"", 'revenue': 26.49, 'unit': 'M', 'net_profit': -13.05}, {'period': ""Q4 '24"", 'revenue': 32.18, 'unit': 'M', 'net_profit': -10.48}, {'period': ""Q3 '24"", 'revenue': 29.2, 'unit': 'M', 'net_profit': -2.92}, {'period': ""Q2 '24"", 'revenue': 31.13, 'unit': 'M', 'net_profit': -3.67}, {'period': ""Q1 '24"", 'revenue': 32.45, 'unit': 'M', 'net_profit': -4.51}, {'period': ""Q4 '23"", 'revenue': 32.98, 'unit': 'M', 'net_profit': -57.38}]",-0.23,-0.23,284732000,202549000,100054000,163651000,54120000,0,114688000,50588000,26408000,0.8899692960570383,0.9349856300197023,0.9507494646680942,__nan__,__nan__,__nan__,0.5747545059915992
352,ASRV,AmeriServ Financial Inc. Common Stock,"AmeriServ Financial, Inc. operates as the bank holding company for AmeriServ Financial Bank that provides various consumer, mortgage, and commercial financial products. It offers retail banking services, such as demand, savings, and time deposits; checking and money market accounts; secured and unsecured consumer loans, and mortgage loans; and safe deposit boxes, holiday club accounts, and money orders. The company also provides lending, depository, and related financial services, such as commercial real estate mortgage loans, short and medium-term loans, revolving credit arrangements, lines of credit, inventory and accounts receivable financing, real estate-construction loans, business savings accounts, certificates of deposit, wire transfers, night depository, and lock box services to commercial, industrial, financial, and governmental customers. In addition, the company offers personal trust products and services, including personal portfolio investment management, estate planning and administration, custodial services, and pre-need trusts; institutional trust products and services comprising 401(k) plans, defined benefit and defined contribution employee benefit plans, and individual retirement accounts; financial services consisting of the sale of mutual funds, annuities, and insurance products; and union collective investment funds to invest union pension dollars in construction projects that utilize union labor. Further, it engages in underwriting as reinsurer of credit life and disability insurance. The company operates through a network of 17 banking locations in Allegheny, Cambria, Centre, Somerset, and Westmoreland counties, Pennsylvania, and Washington County, Maryland; and operates 18 automated bank teller machines. AmeriServ Financial, Inc. is headquartered in Johnstown, Pennsylvania.",Mr. Jeffrey A. Stopko CPA,Banks - Regional,2.5,USD,41298250,https://images.financialmodelingprep.com/symbol/ASRV.png,22598,11.36,-0.03,53344,0,3601000,"[{'period': '2024', 'revenue': 54.02, 'unit': 'M', 'net_profit': 3.6}, {'period': '2023', 'revenue': 52.41, 'unit': 'M', 'net_profit': -3.35}, {'period': '2022', 'revenue': 57.26, 'unit': 'M', 'net_profit': 7.45}, {'period': '2021', 'revenue': 46.67, 'unit': 'M', 'net_profit': 7.07}]","[{'period': ""Q1 '25"", 'revenue': 21.14, 'unit': 'M', 'net_profit': 1.91}, {'period': ""Q4 '24"", 'revenue': 13990.0, 'unit': 'K', 'net_profit': 889.0}, {'period': ""Q3 '24"", 'revenue': 13.09, 'unit': 'M', 'net_profit': 1.18}, {'period': ""Q2 '24"", 'revenue': 16510.0, 'unit': 'K', 'net_profit': -375.0}, {'period': ""Q1 '24"", 'revenue': 14.25, 'unit': 'M', 'net_profit': 1.9}, {'period': ""Q4 '23"", 'revenue': 11.35, 'unit': 'M', 'net_profit': -5.32}]",0.22,0.22,1422362000,19377000,13891000,1315114000,5486000,0,18903000,17746000,976000,0,2.0762104004781827,2.1,"[0.03, 0.22]","['2025-05-05', '1987-02-27']",__nan__,0.924598660537894
353,ASRVP,AmeriServ Financial Inc. AmeriServ Financial Trust I - 8.45% Beneficial Unsecured Securities Series A,,None,Asset Management,27.31,USD,0,https://images.financialmodelingprep.com/symbol/ASRVP.png,2364,0,2.06,1092,-2707000,4598000,"[{'period': '2020', 'revenue': 46.88, 'unit': 'M', 'net_profit': 4.6}, {'period': '2019', 'revenue': 35.44, 'unit': 'M', 'net_profit': 6.03}, {'period': '2018', 'revenue': 35.49, 'unit': 'M', 'net_profit': 7.77}, {'period': '2017', 'revenue': 35.56, 'unit': 'M', 'net_profit': 3.29}]","[{'period': ""Q2 '21"", 'revenue': 11.84, 'unit': 'M', 'net_profit': 1.71}, {'period': ""Q4 '20"", 'revenue': 26.29, 'unit': 'M', 'net_profit': 1.48}, {'period': ""Q1 '20"", 'revenue': 8.75, 'unit': 'M', 'net_profit': 1.41}, {'period': ""Q4 '19"", 'revenue': 8960.0, 'unit': 'K', 'net_profit': 669.0}, {'period': ""Q3 '19"", 'revenue': 8.76, 'unit': 'M', 'net_profit': 1.69}, {'period': ""Q2 '19"", 'revenue': 9.06, 'unit': 'M', 'net_profit': 1.79}]",0.27,0.27,34701000,20427000,20427000,1175314000,0,0,24702000,20427000,-1373000,-1.1144076750771312,-0.23722627737226276,-0.22857142857142848,"[0.528, 0.35208]","['2021-06-28', '1998-06-25']",__nan__,33.869744387769806
